

EULAR 2026

Scientific Programme

3 – 6 June 2026


Excel Centre

London

United Kingdom

Please note that this programme is subject to change

EULAR has received funding by means of sponsorship to support the delivery of our conference from multiple sponsors. Our sponsors have had no editorial input or control over the agenda, content development, or choice of speakers, nor opportunity to influence except for the sponsored presentations.



Opening Plenary

Date: **03/06/2026**

The EULAR 2026 Opening Plenary will launch this year’s Congress with a dynamic and inspiring ceremony. It brings together a vibrant community, united in passion, purpose, and a shared drive to shape the future of rheumatology. Led by the EULAR Board, this session will provide insights into EULAR’s activities and spark fresh ideas as well as meaningful connections.

Room: **Plenary**

13:00-14:00 BST

In addition to the Abstract awards, this year’s Opening Plenary will also honour excellence across the EULAR community with the presentation of the Meritorious and Honorary Member awards, the HPR lifetime award, the PARE outstanding achievement award, the Edgar Stene Prize as well as the award for the Best Undergraduate Teaching Concept.

We invite you to join us on this collective journey and to celebrate the various award winners.

EULAR 2026 Opening Plenary

Chair:	
13:00 - 14:00	<p>Opening by the President of EULAR Speaker: Xenofon Baraliakos (Germany)</p>

What is New (WIN)

Date: **03/06/2026**

1. Understand recent developments in the pathophysiology of psoriatic arthritis
2. Review advances in the individualization of clinical management of psoriatic arthritis
3. Learn about emerging research and future directions in psoriatic arthritis

Room: **Plenary**

14:15-15:00 BST

Psoriatic Arthritis

Chair:	Oliver FitzGerald (Ireland) Hanna Johnsson (United Kingdom)
14:15 - 15:00	What is new in psoriatic arthritis? Speaker: Dennis McGonagle (Northern Ireland)

Basic and Translational Science

Date: **03/06/2026**

1. To learn that the possible origin of interferon signature observed in numbers of autoimmune diseases
2. To learn that it may be due to impaired mechanisms of regulation leading to accumulation of mt dsDNA or mt dsRNA

Room: **Connaught Room 1 & 2**

14:15-15:31 BST

The mitochondria: a new culprit for autoimmune diseases?

Chair:	Edward M. Vital (United Kingdom) Zana Brkic (Netherlands)
14:15 - 14:37	The origin of anti-dsDNA in lupus Speaker: Virginia Pascual (United States of America)

14:37 - 14:59	Accumulation of mitochondrial DNA at the origin of lupus Speaker: Eric Boilard (Canada)
14:59 - 15:20	Accumulation of mitochondrial RNA at teh origine of autoimmune diseases with anti-ribonucleoproteins Speaker: Rami Bechara (France)
15:20 - 15:30	Metabolic remodeling of Salivary Gland Epithelium links mitochondrial dysfunction to chronic inflammation in Sjögren’s Disease Speaker: Serena Colafrancesco (Italy)

Basic and Translational Science

Date: **03/06/2026**

To gain an increased understanding of mechanisms leading to rheumatoid arthritis from the perspective of different

Room: **Connaught Room 3 & 4**

14:15-15:30 BST

body compartments. Specifically, participants will learn about:

1. How changes in gut permeability and microbial composition may cause immune dysregulation and trigger arthritis
2. Pathophysiological events in lymph nodes and synovial tissue prior to arthritis onset
3. Alterations in the circulation that may reflect or contribute to the development of arthritis

Novel Insights into Pre-RA Mechanisms: What Happens Where and When?

Chair:	Cristina Maglio (Sweden) Hans Ulrich Scherer (Netherlands)
14:15 - 14:40	How the gut may trigger the onset of RA Speaker: Mario M. Zaiss (Germany)

14:40 - 15:05	What happens in lymph nodes and synovial tissue prior to RA onset? Speaker: Lisa van Baarsen (Netherlands)
15:05 - 15:30	Mechanistic lessons learned from tracking RA onset in the circulation Speaker: Kevin Deane (United States of America)

Health Professionals in Rheumatology (HPR)

Date: **03/06/2026**

Delegates will:

Room: **Victoria Room 1**

1. Identify long-term effects of green spaces on musculoskeletal health

14:15-15:15 BST

2. Learn about various ways of contributing to EULAR and HPR community's work as well as identify new networks to engage in different HPR activities

3. Identify learning opportunities for HPR in the EULAR congress programme

EULAR HPR - A welcoming environment

Chair:	Nina Brodin (Sweden) Mwidimi Ndosu (Northern Ireland)
14:15 - 14:35	How green spaces can impact joint health Speaker: Jessica Stanhope (Australia)
14:35 - 14:50	What is what we are trying to move forward when implementing our strategic action points in practice Speaker: Rikke Helene Moe (Norway)
14:50 - 15:05	What's on the menu? How to get the most from this year's Congress programme. Speaker: Erika Mosor (Austria)

15:05 - 15:15	Questions and Answers Speaker: Nina Brodin (Sweden) Co-Speaker: Mwidimi Ndosi / (Bristol, Northern Ireland)
---------------	--

Practical Skills Lecture

Date: **03/06/2026**

1. How to diagnose CTD-ILD using chest HRCT

Room: **Victoria Room 2**

2. How to avoid misdiagnosing

14:15-15:30 BST

3. How to identify different subtypes of ILD

4. How to assess severity of CTD-ILD on chest HRCT

After short introductory presentations, the audience can learn from cases prepared by the speakers.

Chest HRCT in detecting, staging and follow up of SARD-ILD

Chair:	Oliver Distler (Switzerland) Muriel Elhai (Switzerland)
14:15 - 14:25	Introductory lesson: Interpretation of HRCT findings in interstitial lung disease (pearls and pitfalls) Speaker: Gerlig Widmann (Austria)
14:25 - 14:50	Case presentations: Interpretation of HRCT findings in interstitial lung disease (pearls and pitfalls) Speaker: Gerlig Widmann (Austria)
14:50 - 15:00	Introductory lesson: Differentiating subtypes of SARD-ILD using HRCT, staging and follow up Speaker: Ann-Katrin Kaufmann-Bühler (Austria)
15:00 - 15:25	Case presentations: Differentiating subtypes of SARD-ILD using HRCT, staging and follow up Speaker: Ann-Katrin Kaufmann-Bühler (Austria)

15:25 - 15:30	Questions and Answers Speaker: Muriel Elhai (Switzerland) Co-Speaker: Oliver Distler / (Zurich, Switzerland)
---------------	---

EULAR Projects

Date: **03/06/2026**

This session addresses critical challenges and opportunities in rheumatology research dissemination, featuring expert perspectives on data quality, ethical AI use, effective visual communication, and streamlined publication workflows from the perspective of the leading research journals published by EULAR and ACR.

Room: **Victoria Room 3**

14:15-15:30 BST

ARD – A&R Perspective: Big Data, AI and Integrity in Rheumatology Publishing

Chair:	S. Louis Bridges (United States of America) Josef S. Smolen (Austria)
14:15 - 14:18	Introduction Speaker: S. Louis Bridges (United States of America)
14:18 - 14:31	Big Data from Clinical Databases in Rheumatology: Powerful Tool or Double-Edged Sword? Speaker: Kimme Hyrich (United Kingdom)
14:31 - 14:44	Artificial intelligence in research – When? How? And why not? Speaker: Jeffrey R. Curtis (United States of America)
14:44 - 14:57	Omics at Scale: Making Sense of Public Datasets Speaker: Caroline Ospelt (Switzerland)
14:57 - 15:10	Paper Mills Speaker: Tony Merriman (United States of America)

15:10 - 15:30	Roundtable Discussion and Concluding Remarks Speaker: Josef S. Smolen (Austria)
---------------	---

Practical Skills Lecture

Date: **03/06/2026**

This session will explore the clinical recognition, pathophysiology, and diagnosis of secondary osteoporosis specifically within the context of rheumatic diseases. Emphasis will be placed on practical approaches to identifying at-risk patients, the role of imaging and biomarkers, and disease- or treatment-specific bone loss patterns

Room: **Victoria Room 4**

14:15-15:30 BST

Bones Under Pressure: Diagnosing Osteoporosis in Inflammatory Rheumatic Conditions

Chair:	Nestor Avgoustidis (Greece) Radmila Matijevic (Serbia)
14:15 - 14:22	Introduction Speaker: Radmila Matijevic (Serbia) Co-Speaker: Nestor Avgoustidis / (Heraklion , Crete, Greece)
14:22 - 14:39	Inflammatory Bone Loss in Rheumatic Diseases: A Common but Silent Threat Speaker: Roland Kocijan (Austria)
14:39 - 14:56	Glucocorticoid-Induced Osteoporosis: Still Underestimated in 2026? Speaker: Giovanni Adami (Italy)
14:56 - 15:13	Rheumatic Diseases with High Bone Risk: Who Deserves More Screening? Speaker: Katie Moss (United Kingdom)

15:13 - 15:30	Imaging and Labs: How to Detect and Monitor Secondary Osteoporosis in Practice Speaker: Paula Hoff (Germany)
---------------	--

Clinical Science

Date: **03/06/2026**

This session will cover the current understanding of pathophysiology, clinical evidence—including real-world and trial data— safety considerations, and future directions for JAK inhibitors in LVV.

Room: **Victoria Room 5 & 6**

14:15-15:30 BST

JAK inhibition in large vessel vasculitis

Chair:	Ellen Margrethe Hauge (Denmark) Bernhard Hellmich (Germany)
14:15 - 14:40	Pathogenic Significance of JAK-STAT in GCA & TAK Speaker: Andrea Rubbert-Roth (Switzerland)
14:40 - 15:05	JAK Inhibitors in Giant Cell Arteritis: Clinical Trial Data and Interpretation Speaker: Daniel Blockmans (Belgium)
15:05 - 15:30	JAK Inhibition in Takayasu Arteritis: Emerging Data and Clinical Experience Speaker: David Saadoun (France)

Clinical Science

Date: **03/06/2026**

1. To understand the impact of extreme environments of the body in terms of resilience, bone and muscle and the immune system;

Room: **N1**

14:15-15:30 BST

2. to understand the connection to autoimmunity and the musculoskeletal system;

3. to learn from space for rehab on Earth.

Rheumatology: It's not Rocket Science, or is it?

Chair:	Bimba Hoyer (Germany) Marta Mosca (Italy)
14:15 - 14:40	Ground control to major Tom - how is life in space from the astronaut perspective? Speaker: John McFall
14:40 - 15:05	Ageing in a tin can - what is the impact on the immune system? Speaker: Judith-Irina Buchheim (Germany)
15:05 - 15:30	Is cartilage made for space or do we need our feet on the ground? Speaker: Anna-Maria Liphardt (Germany)

Clinical Science

Date: **03/06/2026**

- To learn how to improve the diagnosis of mixed connective tissue disease in the daily clinical practice

Room: **N2**

14:15-15:30 BST

- To discuss the complications in the context of mixed connective tissue disease and its evolution

- To provide the latest advances about the treatment of mixed connective tissue diseases

The enigma of mixed connective tissue disease in challenging the rheumatologist clinical care

Chair:	Marzena Olesinska (Poland) Ragnar Gunnarsson (Norway)
14:15 - 14:40	Dissecting the heterogeneous clinical presentation, toward an early diagnosis Speaker: Vasiliki Liakouli (Italy)

14:40 - 15:05	Monitoring the occurrence of complications and disease evolution Speaker: Gonçalo Boletto (Portugal)
15:05 - 15:30	The therapeutic management of patients with MCTD Speaker: Kevin Chevalier (France)

Clinical Science

Date: **03/06/2026**

1. Understand Strategies for Infection Prevention and Vaccination in Rheumatology Patients:

Room: **N3**

14:15-15:30 BST

2. Recognise and Diagnose Primary and Secondary Immunodeficiencies in Clinical Practice:

3. Explore the Role of the Rheumatologist in Treating Emerging infections like Zika, Dengue

4. Evaluate the Impact of Immunosuppressive Therapies on Infection Risk and Immunity

Emerging Infections: Infection Prevention, Vaccination, and Managing Immunodeficiency in Rheumatology

Chair:	Anja Strangfeld (Germany) Wafa Hamdi (Tunisia)
14:15 - 14:20	Introduction Speaker: Anja Strangfeld (Germany) Co-Speaker: Wafa Hamdi / (Ksar Said, Tunisia)

14:20 - 14:40	Vaccination Strategies in Autoimmune and Immunosuppressed Populations: Evidence and Gaps Speaker: Pedro Machado (United Kingdom)
14:40 - 15:00	The role of public health in emerging infections Speaker: Isabelle Bekeredjian-Ding (Germany)
15:00 - 15:20	How to manage emerging infections in patients with RMD Speaker: Kevin L. Winthrop (United States of America)
15:20 - 15:30	Systemic Lupus Erythematosus Is a Strong Independent Risk Factor for Severe Outcomes in Dengue Hospitalizations: a Nationwide Cross-Sectional Population Study Speaker: Ana Cristina Medeiros-Ribeiro (Brazil)

Practical Skills Lecture

Date: **03/06/2026**

To learn how capillaroscopy can be applied to detect very early abnormalities as well as advanced stages of connective tissue diseases.

Room: **George V Room 1**

14:15-15:30 BST

There will be a live demonstration with a videocapillaroscope.

Capillaroscopy

Chair:	Maurizio Cutolo (Italy) Maja Zlatanovic (Serbia)
14:15 - 15:30	Capillaroscopy Skills Session Speaker: Vanessa Smith (Belgium) Co-Speaker: Carina Mihai / (Zurich, Switzerland)

Challenges in Clinical PracticeDate: **03/06/2026**

Understand the importance of pre-conception counselling and achieving disease control before and during pregnancy in women with RMDs.

Room: **George V Room 2****14:15-15:30 BST**

Apply current evidence on the safety and effectiveness of DMARDs in managing pregnancy while minimising maternal and foetal risks.

The importance of disease activity control before and during pregnancy in patients with rheumatoid arthritis

Chair:	Roba Ghossan (France) Ian Giles (Northern Ireland)
14:15 - 14:25	Case presentation - Timing is Everything: Why control of disease activity in the periconceptual period is key in Rheumatoid Arthritis Speaker: Hieronymus TW Smeele (Netherlands)
14:25 - 14:45	Timing is Everything: Why control of disease activity in the periconceptual period is key in Rheumatoid Arthritis Speaker: Radboud J.E.M. Dolhain (Netherlands)
14:45 - 14:55	Case presentation - Keeping Disease activity in Check during Pregnancy in RA patients Speaker: Linda Rüegg (Switzerland)
14:55 - 15:15	Keeping RA Disease activity in Check during Pregnancy Speaker: Frauke Förger (Switzerland)
15:15 - 15:30	Questions and Answers Speaker: Karen Schreiber (Denmark) Co-Speaker: Roba Ghossan / (PARIS CEDEX 14, France)

PAREDate: **03/06/2026**

1. Explore what matters to young people with RMDs, including identity, autonomy, social life, and digital-first expectations in healthcare engagement.

Room: **George V Room 3**

14:15-15:30 BST

2. Reimagine communication and education by integrating youth-led content, gamification, and social media strategies to make rheumatology visible and relevant.

3. Share best practice to involve all stakeholders in making transitions from paediatric to adult care more empowering and less isolating.

Fishbowl: Young People Taking the Lead: Transforming Rheumatology Care and Research

Chair:	Michael Poelzl (Austria)
14:15 - 14:20	Introduction to the Fishbowl Speaker: Michael Poelzl (Austria)
14:20 - 14:25	Joining the Conversation: How I Found My Place in Rheumatology Research Speaker: Catherine Wright (Northern Ireland)
14:25 - 14:30	What Young People Really Want: Rethinking Rheumatology Through Their Eyes Speaker: Deniz Bayraktar (Iceland)
14:30 - 14:35	No More Lost in Transition: Youth-Led Solutions for Empowered Care Speaker: Mariana Carvalho (Portugal)
14:35 - 14:40	Guiding the Journey: Clinical Innovations in Caring for Young People with RMDs Speaker: alexandre belot (France)

14:40 - 15:30	Fishbowl Discussion
---------------	----------------------------

EULAR Joint Sessions

Date: **03/06/2026**

This session will look at the 2023 EULAR Recommendations and discuss:

Room: **George V Room 4**

14:15-15:30 BST

1. how to define pathological fatigue
2. how to measure fatigue
3. how to treat fatigue

Tired is not just a state of mind

Chair:	Christina Duesing (Germany) Elena Elefante (Italy)
14:15 - 14:20	Introduction Speaker: Christina Duesing (Germany)
14:20 - 14:40	When is "being tired" getting pathological? Speaker: Emma Dures (Northern Ireland)
14:40 - 15:00	My patient is always tired - (differential) diagnostic approach to the fatigued patient Speaker: Simona Rednic (Romania)
15:00 - 15:15	Lifestyle against fatigue - is it that easy? Speaker: Tanja Thomsen (Denmark)

15:15 - 15:25	Is there any association between comorbid fatigue in rheumatoid arthritis patients and the treatments they are receiving? A multicenter study Speaker: Rosa Morlà (Spain)
---------------	---

EULAR Debate

Date: **03/06/2026**

1. To understand the challenges associated with the diagnosis and management of PMR in primary and specialist care

Room: **Room 12**

14:15-15:30 BST

2. To understand which patients with (suspected) PMR should be referred to specialist care

3. To explore which PMR patients would qualify for (novel) glucocorticoid sparing agents

Polymyalgia Rheumatica – A Primary Care Disease or a Rheumatologist’s Domain?

Chair:	Kornelis van der Geest (Netherlands) Victoria Konzett (Austria)
14:15 - 14:35	Pro - Polymyalgia Rheumatica: A Disease Best Managed by Rheumatologists Speaker: Milena Bond (Italy)
14:35 - 14:55	Contra - Polymyalgia Rheumatica: Most Patients Don’t Need a Rheumatologist Speaker: Elisabeth Brouwer (Netherlands)
14:55 - 15:05	Rebuttal - Polymyalgia Rheumatica: A Disease Best Managed by Rheumatologists Speaker: Milena Bond (Italy)
15:05 - 15:15	Rebuttal - Polymyalgia Rheumatica: Most Patients Don’t Need a Rheumatologist Speaker: Elisabeth Brouwer (Netherlands)

15:15 - 15:30	Questions and Answers Speaker: Kornelis van der Geest (Netherlands) Co-Speaker: Victoria Konzett / (Vienna, Austria)
---------------	---

Hands-on Sessions

Date: **03/06/2026**

1. Assessment of the shoulder and elbow joints by physical examination.

Room: **Hands-on 1**

14:15-15:30 BST

2. Assessment of the shoulder and elbow joints by ultrasound.

3. How to integrate and correlate clinical and ultrasonography findings.

How to evaluate larger joints - the shoulder and elbow

Chair:	Marina Backhaus (Germany) David Kane (Albania)
14:15 - 14:20	How to access the elbow: clinical examination Speaker: Rusmir Husic (Austria)
14:20 - 14:25	How to access the elbow: ultrasonography examination Speaker: Giasna Giokits (Greece)
14:25 - 14:30	How to access the shoulder: clinical examination Speaker: Christina Duftner (Austria)
14:30 - 14:35	How to access the shoulder: ultrasonography examination Speaker: Luis Coronel (Spain)

14:35 - 14:40	Questions and Answers Speaker: Marina Backhaus (Germany) Co-Speaker: David Kane / (Dubiln, Albania)
14:40 - 15:30	Hands-on Workshop Speaker: Luis Coronel (Spain) Co-Speaker: Christina Duftner / (Innsbruck, Austria), Giasna Giokits / (Katerini, Greece), Rusmir Husic / (Graz, Austria), David Kane / (Dubiln, Albania), Marina Backhaus / (Berlin, Germany)

Hands-on Sessions <ul style="list-style-type: none"> • Practice diagnostic reasoning in rheumatology. • Compare clinical problem-solving with and without large language model (LLM) assistance. • Reflect on benefits, limitations, and pitfalls of AI in clinical practice <p>You may wish to bring your own laptop for this session.</p>	Date: 03/06/2026 Room: Hands-on 2 14:15-15:30 BST
---	--

Clinical Case Solving in Rheumatology – With and Without AI Support

Chair:	Gerd R. Burmester (Germany) Thomas Hügler (Switzerland)
14:15 - 14:50	Clinical Decision Support with Live Prompting Speaker: Thomas Hügler (Switzerland)
14:50 - 15:25	Solve Difficult Cases! Who is the best? Speaker: Gerd R. Burmester (Germany)

Year 3026 - The Last Hope

Room: **Escape Room 1**

14:30-16:30 BST

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **03/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

14:30-16:30 BST

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience

unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

How to Treat (HOT)

Date: **03/06/2026**

By the end of the session, participants will be able to:

Room: **Plenary**

Describe the current state-of-the-art in the management of spondyloarthritis, with a particular focus on axial spondyloarthritis (axSpA).

15:00-15:45 BST

Apply appropriate clinical assessment tools for the diagnosis and monitoring of spondyloarthritis in routine practice.

Address challenging clinical scenarios, including diagnostic uncertainty, presence of comorbidities, and persistently active disease despite treatment.

How to manage axial Spondyloarthritis

Chair:	Victoria Navarro-Compán (Spain) Filip Van den Bosch (Belgium)
--------	--

15:00 - 15:45	Hot to manage spondyloarthritis in 2025 Speaker: Floris A. van Gaalen (Netherlands)
---------------	---

Health Professionals in Rheumatology (HPR)

Date: **03/06/2026**

Delegates will be able to:

Room: **Victoria Room 1**

- i) Understand advances in our understanding of digital ulcers in people with systemic sclerosis
- ii) Explore new evidence on treatment strategies for digital ulcers
- iii) Consider how to apply this new evidence to practice

15:15-16:00 BST

HPR HOT Session: Digital Ulcers in Systemic Sclerosis

Chair:	Khadija El Aoufy (Italy) Rúben Duarte Fernandes (Portugal)
15:15 - 16:00	How To Treat Digital Ulcers in Systemic Sclerosis: non-pharmacological, topical, and MDT approach Speaker: Begonya Alcacer-Pitarch (United Kingdom)

Poster View Presentations

Date: **03/06/2026**

Room: **Poster View**

15:30-16:50 BST

Poster View I

Chair:	
--------	--

15:30 - 15:30	Glucocorticoid discontinuation and clinical phenotypes in patients with giant cell arteritis: A retrospective study from a fast-track clinic. Speaker: Tanja Gorlen (Denmark)
15:30 - 15:30	Small airway disease contributes to functional lung impairment in systemic sclerosis, but does not impact on interstitial lung disease prognosis and mortality. Speaker: Gesa Sauer (Switzerland)
15:30 - 15:30	"HLA-Cw6 in psoriatic arthritis: clinical phenotype and therapeutic impact" Speaker: Cristina Macia-Villa (Spain)
15:30 - 15:30	Clonal hemopoiesis of indeterminate prognosis and relapses in patients with giant cell arteritis. Speaker: Oriane Cellier (France)
15:30 - 15:30	Increased mortality rate in patients with Takayasu arteritis is predicted by pre-treatment disease activity, early damage, lower limb pulse deficit, visual impairment, heart failure, coronary artery or abdominal aorta involvement – analysis of two cohorts. Speaker: Durga Prasanna Misra (India)
15:30 - 15:30	Cost-effectiveness of pneumococcal vaccination in in 50-year-old patients with rheumatoid arthritis in Norway-A Markov modelling analysis Speaker: Gunhild Hagen (Norway)
15:30 - 15:30	Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups Speaker: Philip J. Mease (United States of America)
15:30 - 15:30	Progression and survival of systemic sclerosis-associated interstitial lung disease in a multiethnic cohort in Malaysia Speaker: Hui Jen Ding (Malaysia)
15:30 - 15:30	Clinical phenotypes and prognosis in Susac syndrome determined by unsupervised hierarchical cluster analysis at diagnosis: a national cohort study Speaker: Marie Robert (France)

15:30 - 15:30	Long-term follow-up of interleukin-6 receptor inhibition by tocilizumab in active idiopathic retroperitoneal fibrosis Speaker: Eva Baier (Germany)
15:30 - 15:30	Factors Associated with the Development of Pneumocystis Pneumonia in Patients with Systemic Dysimmune Diseases Speaker: Chloë Dumas de la Roque (France)
15:30 - 15:30	Cardiovascular Outcomes Associated with Biologic and Targeted Therapies in Inflammatory Diseases: A Systematic Review and Meta-Analysis Speaker: Juan Sebastian Theran Leon (Colombia)
15:30 - 15:30	Evaluation of the mycophenolate mofetil–rituximab combination in systemic sclerosis: a French retrospective multicenter study Speaker: François Barde (France)
15:30 - 15:30	Psoriatic Skin and Nail Outcomes With Guselkumab Treatment in Participants With Active and Erosive Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study Speaker: Joseph F. Merola (United States of America)
15:30 - 15:30	Proteomic Profiling Mediates the Association Between Degenerative Joint Diseases and Dementia Risk Speaker: Sheng-Ming Dai (China)
15:30 - 15:30	KNOWLEDGE EXCHANGE AND APPROPRIATION IN HEALTH: EXPERIENCE OF THE EMPOWERMENT MEETINGS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS Speaker: Pedro Santos-Moreno (Colombia)
15:30 - 15:30	Gaps in Post-Vision-Loss Support for GCA Patients: A Three Year Audit and Implementation of a Standardised Care Pathway Speaker: Saira Ahmed (United Kingdom)
15:30 - 15:30	Performance Validation of the 2023 American College of Rheumatology/ European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in a Chinese Systemic Lupus Erythematosus Cohort Speaker: Lanlan Ji (China)

15:30 - 15:30	<p>Biomarker-Driven Insights From the Phase 2a AFFINITY Study Evaluating Guselkumab + Golimumab Combination Therapy Versus Guselkumab Monotherapy in Psoriatic Arthritis</p> <p>Speaker: Iain B. McInnes (United Kingdom)</p>
15:30 - 15:30	<p>Disease Burden and Comorbidities in Patients with Psoriatic Arthritis and Concomitant Obesity - a Pooled Analysis of Three Clinical Trials</p> <p>Speaker: Lihi Eder (Canada)</p>
15:30 - 15:30	<p>Clinical Manifestations and Long-Term Prognosis of Juvenile- and Adult-Onset Takayasu Arteritis</p> <p>Speaker: HIDEAKI TSUJI (Japan)</p>
15:30 - 15:30	<p>Evidence-based foundations for mHealth fibromyalgia self-management: a multi-phase investigation</p> <p>Speaker: Thomas Hügler (Switzerland)</p>
15:30 - 15:30	<p>Applying the 2025 GRAPPA and EULAR Definitions in a Real-World Longitudinal Cohort of PsA: Frequency of Complex-to-Manage, Difficult-to-Manage, and Treatment-Refractory Psoriatic Arthritis</p> <p>Speaker: Gonul Hazal Koc (Netherlands)</p>
15:30 - 15:30	<p>Long-term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from Year 1 of the Open Label Period of the Phase 3 MITIGATE Trial</p> <p>Speaker: John H. Stone (United States of America)</p>
15:30 - 15:30	<p>Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor: pooled safety and adverse events of special interest in the phase 3 POETYK PsA-1 and PsA-2 trials</p> <p>Speaker: Joseph F Merola (United States of America)</p>
15:30 - 15:40	<p>Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Characterization of the STOP PsA At-Risk Cohort</p> <p>Speaker: Victoria Konzett (Austria)</p>
15:40 - 15:40	<p>The COMBo study: a randomized trial of deucravacitinib-TNF inhibitor combination therapy versus TNF inhibitor monotherapy in difficult-to-control psoriatic disease</p> <p>Speaker: Joseph F Merola (United States of America)</p>

15:40 - 15:40	Diagnostic Accuracy of Musculoskeletal Ultrasound in Glucocorticoid-Naïve Suspected Polymyalgia Rheumatica – A Cross-Country Cohort Comparison Speaker: Christoffer Våben (Denmark)
15:40 - 15:40	WINDOW OF OPPORTUNITY IN THE TREATMENT OF GIANT CELL ARTERITIS WITH TOCILIZUMAB: MULTICENTER STUDY OF 471 PATIENTS Speaker: Adrián Martín-Gutiérrez (Spain)
15:40 - 15:40	Effects of Guselkumab on Patient-Reported Outcomes in Biologic-Naïve Participants With Active and Erosive Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study Speaker: Proton Rahman (Canada)
15:40 - 15:40	A Multicenter, Double-blind, Randomized, Parallel-arm Study to Compare Efficacy and Safety of BAT2506, a Golimumab Biosimilar, with the Golimumab Reference Product in Patients with Active Psoriatic Arthritis Speaker: Yi Liu (China)
15:40 - 15:40	Does PET/CT or MRI activity at treatment stop predict risk of subsequent relapse in Large-Vessel Giant Cell Arteritis Speaker: Camila Pitasi (Switzerland)
15:40 - 15:40	Deciphering Platelet Transcriptomic Profiles in Antiphospholipid Syndrome: Insights into their Role as Immunological Players Speaker: Yaqing Yang (China)
15:40 - 15:40	Treatment adherence and disease awareness among patients with rheumatic and musculoskeletal diseases treated at the Institute Niška banja Speaker: Jelena Jenic (Serbia)
15:40 - 15:40	Comparative long-term clinical and vascular imaging outcomes of tocilizumab versus infliximab in Takayasu’s arteritis: a real-world IPTW-adjusted analysis from India Speaker: Rudra Prosad Goswami (India)
15:40 - 15:40	Reporting of exercise interventions in spondyloarthritis research: A systematic review of randomized controlled trials. Speaker: Kristine Norden (Norway)

15:40 - 15:40	Clonal hematopoiesis as a second hit driving atypical and severe manifestations in adult familial Mediterranean fever Speaker: Philippe Mertz (France)
15:40 - 15:40	Association of FABP3 with vascular calcification and angiographic progression in Takayasu's Arteritis Speaker: Sifan Wu (China)
15:40 - 15:40	Prevalence and Clinical Significance of Anti-Drug Antibodies in Patients with Psoriatic Arthritis Treated with Biologics: A Systematic Review Speaker: James Kimpton (United Kingdom)
15:40 - 15:40	Precision Prognosis in GCA: Shifting from Systemic Markers to Ultrasound-Based Risk Stratification. Speaker: Yasser El Miedany (United Kingdom)
15:40 - 15:40	Long-term work participation outcomes after initiation of biologic or targeted synthetic DMARDs in inflammatory rheumatic diseases: results from the German National Database Speaker: Johanna Callhoff (Germany)
15:40 - 15:40	Clinical Characterization of Systemic Sclerosis in Egypt: A Multicenter Study from the Egyptian EUSTAR Cohort Speaker: Rahma Ahmed Soliman Ahmed Elziaty (Egypt)
15:40 - 15:40	Assessing Vasculitis in Takayasu Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises Speaker: Alessandro Tomelleri (Italy)
15:40 - 15:40	3D Characterization of calcinosis cutis stones from patients with systemic sclerosis and dermatomyositis using microCT imaging and multimodal ex vivo analysis. A pilot study Speaker: Mette Mogensen (Denmark)
15:40 - 15:40	Prevalence of calcinosis cutis in systemic sclerosis – a systematic review and meta-analysis Speaker: Mette Mogensen (Denmark)

15:40 - 15:50	Phosphodiesterase-4 inhibition with apremilast modulates subclinical inflammation measured by MRI in psoriasis patients at risk of developing psoriatic arthritis - results from the prospective, interventional EPOS study Speaker: Arnd Kleyer (Germany)
15:50 - 15:50	Diabetes Mellitus in Patients with Giant Cell Arteritis Treated with Glucocorticoids and Interleukin-6 Receptor Inhibitors: A Prospective Cohort Study Speaker: Anne Lund Overgaard (Denmark)
15:50 - 15:50	Associations between physical activity and body composition in individuals with psoriatic arthritis - longitudinal observations in the Trøndelag Health Study Speaker: Abdirizak Ali Osman (Norway)
15:50 - 15:50	Digital activity patterns measured by wearable devices in adults with and without osteoarthritis: associations with functional impairment in the US NHANES database Speaker: Valentin Ritschl (Austria)
15:50 - 15:50	Giant Cell Arteritis-related harm: a retrospective analysis of litigation claims data from England for the Getting It Right First Time programme Speaker: Robert Sandler (Northern Ireland)
15:50 - 15:50	Achieving Sustained Low Disease Activity in Psoriatic Arthritis reduces enthesiophyte and erosion progression – A 2-year study using High Resolution Peripheral Quantitative Computed Tomography Speaker: Isaac T. Cheng (Hong Kong, China)
15:50 - 15:50	Frailty phenotypes and determinants of glucocorticoid-related adverse events in polymyalgia rheumatica at 12 months: a real-life single-center investigation Speaker: Elvis Hysa (Italy)
15:50 - 15:50	Fast-track clinic for giant cell arteritis: diagnostic performance and factors associated with corticosteroid initiation Speaker: Olivier Malaise (Belgium)
15:50 - 15:50	Oral anticoagulants do not improve the prognosis of precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study Speaker: Nicola Farina (Italy)

15:50 - 16:00	<p>Efficacy of Apremilast in Early Oligoarticular Psoriatic Arthritis by Baseline Active Joint Count: A Post Hoc Analysis of the FOREMOST Study</p> <p>Speaker: Laura C. Coates (United Kingdom)</p>
16:00 - 16:00	<p>Real-life effectiveness of selexipag treatment in systemic sclerosis-associated pulmonary arterial hypertension: long-term data from a multicentric Italian cohort.</p> <p>Speaker: Stefano Stano (Italy)</p>
16:00 - 16:00	<p>Effectiveness of adalimumab and secukinumab with and without concomitant csDMARD use in patients with psoriatic arthritis - a retrospective cohort study</p> <p>Speaker: Sophie Gerritsen (Netherlands)</p>
16:00 - 16:00	<p>Current Management of EGPA Across Europe: Insights from a Multinational Expert Survey</p> <p>Speaker: Edoardo Conticini (Italy)</p>
16:00 - 16:00	<p>Imaging for diagnosis, monitoring and outcome prediction of polymyalgia rheumatica: a systematic literature review informing an international task force</p> <p>Speaker: Victoria Konzett (Austria)</p>
16:00 - 16:00	<p>Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis and Inadequate Response/Intolerance to One Prior Tumor Necrosis Factor Inhibitor Through 1 Year of the SOLSTICE Study</p> <p>Speaker: Alice B. Gottlieb (United States of America)</p>
16:00 - 16:00	<p>Early Gastrointestinal Manifestations Predict Outcomes in Patients with Systemic Sclerosis</p> <p>Speaker: Zsuzsanna McMahan (United States of America)</p>
16:00 - 16:00	<p>Long-term follow-up of patients in the GOLimumab and Methotrexate versus placebo and methotrexate in early, untreated Psoriatic Arthritis (GOLMePsA) trial</p> <p>Speaker: Katya Meridor (United Kingdom)</p>
16:00 - 16:00	<p>From baseline eGFR to long-term outcome: the silent burden of renal dysfunction in systemic sclerosis.</p> <p>Speaker: Stefano Stano (Italy)</p>

16:00 - 16:10	<p>Efficacy of Risankizumab in Prevention of Radiographic Progression in Patients With PsA at Low and High Risk of Joint Erosive Disease: 5-Year Data From the KEEPSAKE 1 Phase 3 Trial</p> <p>Speaker: Laura C. Coates (United Kingdom)</p>
16:10 - 16:10	<p>Comparative analysis of the Psoriatic Arthritis Ratingen Score and the Modified Sharp-van der Heijde Method for longitudinal assessment of structural damage in a prospective Belgian cohort</p> <p>Speaker: Myroslava Kulyk (Ukraine)</p>
16:10 - 16:20	<p>Benefits of Achieving Early versus Late Clinical Response in the Real World: Results from the PRO-SPIRIT study</p> <p>Speaker: Laura C. Coates (United Kingdom)</p>
16:20 - 16:20	<p>Patient-Reported Outcome Measures in Incident Polymyalgia Rheumatica: Changes After Treatment Initiation, Short-Term Glucocorticoid Discontinuation, and at One-Year Follow-Up.</p> <p>Speaker: Asger Buch Bjerre (Denmark)</p>
16:20 - 16:20	<p>Reliability and Content Validity of a Definition of Severe Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis</p> <p>Speaker: Peter A Merkel (United States of America)</p>
16:20 - 16:20	<p>Real-world treatment patterns and determinants of therapy in systemic sclerosis: findings from a German multicenter cohort</p> <p>Speaker: Tim Filla (Germany)</p>
16:20 - 16:20	<p>Efficacy and Safety of Interleukin-6 Receptor Inhibitors in Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials</p> <p>Speaker: Mohamed Hamouda Elkasaby (Egypt)</p>
16:20 - 16:20	<p>Deciphering arthritis in systemic sclerosis: prevalence, clinical phenotype and prognosis in the EUSTAR cohort (CP 151)</p> <p>Speaker: Blaz Burja (Switzerland)</p>
16:20 - 16:20	<p>Lifetime Risk of Malignancy in Polymyalgia Rheumatica: A Population-Based Matched Cohort Study from Southern Norway.</p> <p>Speaker: Stig Tengedal (Norway)</p>

16:20 - 16:20	Effect of adding oral glucocorticoids to immunosuppression on lung function in systemic sclerosis-associated interstitial lung disease: a target trial emulation study from the European Scleroderma Trial and Research Group database. Speaker: Zubeyir Salis (France)
16:20 - 16:20	Enhanced Platelet Activation in Primary Antiphospholipid Syndrome Despite Therapy Speaker: Silvia Mancuso (Italy)
16:20 - 16:20	Clinical and imaging features of flares in Takayasu arteritis and Large-Vessel Giant Cell Arteritis: a comprehensive analysis of 184 cases from a single-center cohort Speaker: luigi boiardi (Italy)
16:20 - 16:20	Anthropometric, Apolipoproteins and the Risk of Giant Cell Arteritis: a Nested Case-Control Study Speaker: Carl Turesson (Sweden)
16:20 - 16:20	Identification of a subset of patients with early psoriatic arthritis who benefit most from intensive therapy: A pooled analysis of four strategy trials Speaker: Jose Manuel Lema Martinez (Northern Ireland)
16:20 - 16:20	Impact of disease-modifying therapies on metabolic liver disease in psoriatic disease. Speaker: Lija James (Northern Ireland)
16:20 - 16:20	The Use of Artificial Intelligence to Recognize Facial Features of Systemic Sclerosis(SSc) Speaker: Yossra A. Suliman (United Arab Emirates)
16:20 - 16:20	Autoimmune Targeting of Enteric Neurons and Extracellular Vesicles Defines Distinct Gastrointestinal Phenotypes in Systemic Sclerosis Speaker: Zsuzsanna McMahan (United States of America)
16:20 - 16:20	Analysis of esophageal 68Ga-FAPI-uptake and gastrointestinal symptoms in patients with diffuse cutaneous systemic sclerosis upon CD19-targeting CAR T cell therapy Speaker: Janina Auth (Germany)

16:20 - 16:20	Baseline Neutrophil-to-Lymphocyte Ratio as a Predictor of Treatment Response in Systemic Sclerosis-Associated Interstitial Lung Disease Speaker: Shiri Keret (Israel)
16:20 - 16:20	Objective Assessment of Small Bowel Involvement Identifies High-Risk Phenotypes in Systemic Sclerosis Speaker: Luis Alcala-Gonzalez (Spain)
16:20 - 16:20	DIAPS EVOLUTION AMONG ANTIPHOSPHOLIPID ANTIBODY CARRIERS: IMPACT OF SEROLOGICAL PROFILE, ASSOCIATED DISEASES AND PRIMARY THROMBOPROPHYLAXIS Speaker: Rafael Gálvez-Sánchez (Spain)
16:20 - 16:20	Interstitial lung disease in limited cutaneous systemic sclerosis: risk factors and trajectories in the EUSTAR cohort Speaker: Antonio Tonutti (Italy)
16:20 - 16:20	Serum Type I Interferon Activation as a Predictor of Diffuse Subclinical Myocardial Involvement in Systemic Sclerosis Speaker: Cristiana Sieiro Santos (Northern Ireland)
16:20 - 16:30	Efficacy and Safety of Subcutaneous Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis: Results of the Open-label, Phase 3 PSUMMIT-Jr Study Through Week 52 Speaker: Nicolino Ruperto (Italy)
16:30 - 16:30	Defining Clinical Subtypes of Pediatric IgA Vasculitis Through Cluster Analysis Speaker: Marija Jelusic (Croatia)
16:30 - 16:40	Efficacy, Safety, and Glucocorticoid-Sparing Effects of Upadacitinib in Giant Cell Arteritis: Real-World Evidence from a Prospective Cohort Speaker: Arnd Kleyer (Germany)
16:40 - 16:40	Anti-BICD2 Antibodies in Systemic Sclerosis: Insights from Advanced Autoantibody Profiling in an Italian monocentric cohort Speaker: Marco de Pinto (Italy)

16:40 - 16:40	<p>Identifying Predictors of Relapse in Pediatric IgA Vasculitis: Insights from a Multicenter Cohort Study Speaker: Marija Jelusic (Croatia)</p>
16:40 - 16:40	<p>Fibroblast activation by IFN-I-primed keratinocytes bridges UVB-induced epidermal injury to MMP9+ myeloid cell recruitment and T cell cytotoxicity in skin lupus and dermatomyositis Speaker: Mehdi Rashighi (United States of America)</p>
16:40 - 16:40	<p>Guselkumab retention rate and predictive factors of discontinuation: results from a real-world evidence study in a PsA cohort. Speaker: Mattia Costanaro (Italy)</p>
16:40 - 16:40	<p>Real-World Outcomes of Upadacitinib in Giant Cell Arteritis: A Multicenter Italian Cohort Study of the Italian Society of Rheumatology Vasculitis Study Group Speaker: Luca Iorio (Italy)</p>
16:40 - 16:40	<p>Endovascular versus Surgical Revascularization in Takayasu Arteritis: An updated Lesion- and Patient-Level Meta-Analysis Speaker: MI HYEON KIM (Korea, Republic of (South Korea))</p>
16:40 - 16:50	<p>Impact of Early Biologic Use with Secukinumab on Radiographic Progression in Psoriatic Arthritis: A Pooled Analysis of the FUTURE 1 and FUTURE 5 trials Speaker: Laura C. Coates (United Kingdom)</p>
16:50 - 16:50	<p>Structural Lesions of Sacroiliac Joints Are Crucial for Identifying Axial Involvement in Psoriatic Arthritis: Validation of the ASAS 2021 Data-Driven MRI Cut-offs Speaker: Xianfeng Yan (Hong Kong, China)</p>
16:50 - 16:50	<p>Real-world data on halting radiographic progression with antifibrotics in connective tissue disease-associated interstitial lung disease: A two-center experience from Hungary Speaker: Szilvia Szamosi (Hungary)</p>
16:50 - 16:50	<p>Longitudinal Assessment of Conventional Radiography, MRI, and PET/CT in Psoriatic Arthritis: Evaluating One-Year Imaging Changes Under Different DMARD Regimens Speaker: Nagme Renkli (Netherlands)</p>

16:50 - 16:50	Does mRSS at 6 months predict mRSS at 12 months follow-up in patients with early diffuse systemic sclerosis? A EUSTAR/RISE-SSc study Speaker: Carina Mihai (Switzerland)
16:50 - 16:50	THE IMPACT OF ANEURYSM PRESENCE ON THE COURSE OF TAKAYASU ARTERITIS: A RETROSPECTIVE TERTIARY CENTER EXPERIENCE Speaker: Fatma Alibaz (Türkiye)
16:50 - 16:50	Real-world evidence prevalence and clinical outcome of patients meeting the inclusion criteria of the Phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab in SSc) - A EUSTAR cohort study. Speaker: Lesley-Anne Bissell (Northern Ireland)
16:50 - 16:50	Early combination therapy reduces relapse risk after treatment cessation in IgG4-related disease: a retrospective cohort study with risk stratification analysis Speaker: Yifei Wang (China)
16:50 - 16:50	Juvenile systemic sclerosis with dermatomyositis-like overlap features represents a distinct clinical phenotype: updates from the Juvenile Scleroderma Inception Cohort Speaker: Ivan Foeldvari (Germany)
16:50 - 16:50	Differentiating Active vs. Chronic Systemic Sclerosis-Primary Heart Involvement: Clinical and Prognostic Implications Speaker: Beatrice Moccaldi (Italy)
16:50 - 16:50	Improvement of nailfold microvascular changes over time in patients with systemic sclerosis: a EUSTAR study Speaker: Carina Mihai (Switzerland)
16:50 - 16:50	Hemodynamic response to vasoactive therapy in Systemic Sclerosis-related Pulmonary Arterial Hypertension Speaker: Lorenzo Mattia Bianchessi (Italy)
16:50 - 16:50	Destombes-Rosai-Dorfman disease: clinical, molecular characteristics and treatment response: data from a retrospective cohort of 107 patients Speaker: Julien Haroche (France)

16:50 - 16:50	<p>Complex-, Difficult-to-Manage, and Treatment Refractory Psoriatic Arthritis: Insights from an Application of EULAR and GRAPPA Definitions to a Large Observational Cohort</p> <p>Speaker: Arabi Rasendrakumar (Canada)</p>
16:50 - 16:50	<p>A Study on Gastrointestinal Involvement in Chinese SSc patients evaluated by GIT 2.0</p> <p>Speaker: Shihan Xu (China)</p>
16:50 - 16:50	<p>Induced pluripotent stem cell (iPSC)-derived cardiac microtissues as a modeling and drug testing platform for systemic sclerosis primary heart involvement</p> <p>Speaker: Andrea-Hermina Györfi (Germany)</p>
16:50 - 16:50	<p>BIMEKIZUMAB LONG-TERM INCIDENCE OF PSORIATIC ARTHRITIS SYMPTOMS AND PSORIATIC ARTHRITIS ADVERSE EVENTS IN PATIENTS WITH PSORIASIS AND RISK FACTORS FOR DISEASE PROGRESSION</p> <p>Speaker: Joseph F. Merola (United States of America)</p>
16:50 - 16:50	<p>Objective Physiological Assessment Across the GERD Spectrum in Systemic Sclerosis: A Multicenter International Study</p> <p>Speaker: Francisco Alejandro Felix-Tellez (Spain)</p>
16:50 - 16:50	<p>Rates of adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome treated with standard of care without certolizumab pegol: comparison with the IMPACT study</p> <p>Speaker: Anne Murarasu (France)</p>
16:50 - 16:50	<p>Immunogenicity And Impact of Anti-drug Antibodies on the Efficacy and Pharmacokinetics of Inebilizumab in MITIGATE, A Phase 3 Trial in IgG4-Related Disease</p> <p>Speaker: John H. Stone (United States of America)</p>
16:50 - 16:50	<p>Distinct Serum Proteomic Signatures Associated With Gastrointestinal Symptom Severity in Systemic Sclerosis</p> <p>Speaker: Ashima Makol (United States of America)</p>
16:50 - 16:50	<p>Emulated Target Trial of Corticosteroid Pulses for Induction Therapy in ANCA-Associated Vasculitis</p> <p>Speaker: Maxime Vignac (France)</p>

16:50 - 16:50	IgG4-related lymphadenopathy as an activity-related feature rather than a poor prognostic factor: a Japanese multicentre retrospective cohort study Speaker: Hiroyuki Kawahara (Japan)
16:50 - 16:50	Living with Pulmonary Fibrosis in Systemic Sclerosis-Associated Interstitial Lung Disease : Insights from Patient-Reported Outcomes Speaker: Laura Maria Groseanu (Romania)
16:50 - 16:50	Clinical Phenotypes and Pulmonary Risk Associated With Anti-Ro52 Positivity in Systemic Sclerosis Speaker: Chia-hsuan Chang (Taiwan)
16:50 - 16:50	Using Machine Learning and Electronic Health Records for Early Identification of Antinuclear Antibody- related Connective Tissue Diseases. Speaker: Eugenia Chock (United States of America)
16:50 - 16:50	DISEASE OUTCOMES DURING THE POSTPARTUM PERIOD IN SYSTEMIC SCLEROSIS AND VEDOSS PATIENTS: A RETROSPECTIVE INTERNATIONAL MULTICENTRE STUDY Speaker: Elda Piovani (Italy)
16:50 - 16:50	Healthcare utilization before and after a diagnosis of giant cell arteritis - a population-based cohort study in Denmark Speaker: Tobias Gaster (Denmark)
16:50 - 16:50	When Should Systemic Sclerosis-Associated Interstitial Lung Disease Be Considered Early Despite Preserved Lung Volumes? Insights from Impulse Oscillometry Speaker: ibrahim Vasi (Türkiye)
16:50 - 16:50	Early diagnosis of ILD in rheumatic diseases with a short questionnaire and a structured diagnostic pathway Speaker: Anna Meinecke (Germany)
16:50 - 16:50	Clinician awareness and interpretation of VEDOSS criteria: results from an international World Scleroderma Foundation survey Speaker: Cristiana Sieiro Santos (Northern Ireland)

16:50 - 16:50	Peripheral Lymphatic Function in Patients with Systemic Sclerosis Speaker: Esben Naeser (Denmark)
16:50 - 16:50	Comparative Effectiveness of Risankizumab Versus Tumour Necrosis Factor Inhibitors or Interleukin-17 Inhibitors on Joint Outcomes in Biologic-Naïve Patients With Psoriatic Arthritis: A Global Real-World Study Speaker: Philip J. Mease (United States of America)
16:50 - 16:50	Novel genetic risk factors for systemic sclerosis-associated pulmonary arterial hypertension. Speaker: Inmaculada Rodriguez-Martin (Spain)
16:50 - 16:50	Efficacy and Safety of Tocilizumab in Systemic Sclerosis and Associated Interstitial Lung Disease: A Meta-analysis with Meta-regression and Trial Sequential Analysis Speaker: Amr Elrosasy (Egypt)
16:50 - 16:50	DLCO decline is associated with increased vascular risk in systemic sclerosis, primarily driven by pulmonary arterial hypertension: EUSTAR database analysis Speaker: Gonçalo Boletto (Portugal)
16:50 - 16:50	DIFFERENTIAL MODULATION OF CXCL4, ANTI-CXCL4 ANTIBODIES AND KL-6 DURING NINTEDANIB THERAPY IN PROGRESSIVE SSC-ILD: ASSOCIATIONS WITH BASELINE AUTOMATED QUANTITATIVE CT AND FUNCTIONAL FEATURES Speaker: Davide Mohammad Reza Beigi (Italy)
16:50 - 16:50	Joint Disease Activity Trajectories in Participants with Active Psoriatic Arthritis Treated with Guselkumab: A Bayesian Analysis of Three Phase 3, Randomized, Controlled Studies Speaker: Iain B. McInnes (United Kingdom)
16:50 - 16:50	SEX DIFFERENCES IN GLUCOCORTICOID EXPOSURE AND TOXICITY ASSESSED BY THE GLUCOCORTICOID TOXICITY INDEX IN GIANT CELL ARTERITIS Speaker: María Pilar Ortiz-Lavín (Spain)
16:50 - 16:50	Performance of two sets of PsAID12 thresholds defining disease impact severity in Psoriatic Arthritis in a clinical practice scenario Speaker: Clementina López-Medina (Spain)

16:50 - 16:50	<p>Predictors and Early Indicators for Inflammatory Bowel Disease in Patients With Psoriatic Arthritis Speaker: Andrea Rubbert-Roth (Switzerland)</p>
16:50 - 16:50	<p>CORRELATION BETWEEN CUMULATIVE GLUCOCORTICOID DOSE AND GLUCOCORTICOID TOXICITY INDEX IN GIANT CELL ARTERITIS: A REAL-WORLD LONGITUDINAL STUDY Speaker: María Pilar Ortiz-Lavín (Spain)</p>
16:50 - 16:50	<p>Mortality Risk Factors in Interstitial Lung Disease with Systemic Sclerosis–Associated Autoantibodies Speaker: Karla Chacón (Mexico)</p>
16:50 - 16:50	<p>Long-term real-world safety of mepolizumab in EGPA: a multinational cohort study comparing 100 mg vs 300 mg every 4 weeks Speaker: Federica Davanzo (Italy)</p>
16:50 - 16:50	<p>High Prevalence of Autoimmunity and Cancer in Anti-NOR90 Patients: Insights from a Multicenter Observational Study Speaker: Marina Dueñas (Spain)</p>
16:50 - 16:50	<p>Patients with Very Early Systemic Sclerosis show microvascular disease of the skin preceding fibrotic changes as assessed by Optical Coherence tomography Speaker: Duygu Temiz Karadag (Türkiye)</p>
16:50 - 16:50	<p>Prediction of future significant organ involvement in very early and mild systemic sclerosis: a EUSTAR analysis Speaker: Madeleine Venables (Switzerland)</p>
16:50 - 16:50	<p>Prevalence and Predictors of Dysphagia in Idiopathic Inflammatory Myopathies: A Cross-Sectional Study Speaker: Fulden Sari (Türkiye)</p>
16:50 - 16:50	<p>Multimodal Imaging Markers of Macroangiopathy in Polymyalgia Rheumatica and Giant Cell Arteritis: Insights from the VASCARD and POLYMYACARD cohorts. Speaker: Konstantinos Triantafyllias (Germany)</p>

16:50 - 16:50	TREATMENT OF GIANT CELL ARTERITIS WITH AORTIC INVOLVEMENT: AN EVIDENCE-BASED REVIEW OF CURRENT THERAPEUTIC STRATEGIES Speaker: Carmen Secada-Gómez (Spain)
16:50 - 16:50	Comparison of rituximab and tocilizumab for systemic sclerosis interstitial lung disease: a multicentric retrospective propensity score-weighted analysis Speaker: Stefano Rodolfi (Italy)
16:50 - 16:50	Obstetric Antiphospholipid Syndrome Identifies an Immune-Enriched Phenotype Without Modifying Thrombotic Risk Among Women With Thrombotic APS Speaker: Paula David (Israel)
16:50 - 16:50	Real-World Survival of Biologic Therapies by Mechanism of Action in Psoriatic Arthritis Speaker: Amir Haddad (Israel)
16:50 - 16:50	Ancillary baseline HRCT features predict Progressive Pulmonary Fibrosis in Systemic Sclerosis-associated Interstitial Lung Disease: A Retrospective Cohort Study Speaker: Andrea Benini (Italy)
16:50 - 16:50	Clinical Outcomes and Incidence of GCA-spectrum Events in Korean Patients with Polymyalgia Rheumatica: A Retrospective Multicenter Study Based on a Distributed Research Network Analysis Speaker: Yeon-Ah Lee (Korea, Republic of (South Korea))
16:50 - 16:50	Standardized ELISA or Multiplex Platforms? Impact on 2023 ELISA-Based Antiphospholipid Syndrome Classification Criteria and Clinical Practice Speaker: Florina Ionete (Romania)
16:50 - 16:50	COMPARATIVE EFFICACY OF IL-17 AND IL-23 PATHWAY INHIBITORS FOR ENTESITIS RESOLUTION IN PSORIATIC ARTHRITIS: A NETWORK META-ANALYSIS Speaker: Krima Patel (India)
16:50 - 16:50	Clinical Remission Despite Persistent MPO-ANCA Positivity During Avacopan-Based Therapy in Microscopic Polyangiitis and Granulomatosis with Polyangiitis: A Retrospective Observational Cohort Study Speaker: Yusuke Ushio (Japan)

16:50 - 16:50	Treatment Inefficacy in Psoriatic Arthritis: Do the New EULAR and GRAPPA Definitions Identify the Same Patients? Data from the RABBIT-SpA Register Speaker: Stephanie Lembke (Germany)
16:50 - 16:50	Data-driven clinical clusters in ACA-positive systemic sclerosis are associated with disease evolution and organ-specific prognosis: data from the EUSTAR cohort Speaker: Jelena Colic (Serbia)
16:50 - 16:50	Incidence and disease course of Polymyalgia Rheumatica in Denmark across primary and secondary healthcare over two decades Speaker: Agnete Overgaard Donskov (Denmark)
16:50 - 16:50	Healthy seniors with RMDs and stronger bridge building with Danish municipalities Speaker: Merethe Jelsbak Raundahl (Denmark)
16:50 - 16:50	BIMEKIZUMAB TREATMENT FOR PATIENTS WITH PSORIATIC ARTHRITIS IN FIVE EUROPEAN COUNTRIES: PHYSICIAN-REPORTED OUTCOMES FROM A GLOBAL REAL-WORLD STUDY Speaker: Fabian Proft (Germany)
16:50 - 16:50	Being heard matters: The value of multidisciplinary professional counselling for people with rheumatic and musculoskeletal diseases. Speaker: Nanna Bacci Hartz (Denmark)
16:50 - 16:50	Efficacy of Nintedanib with Concomitant Immunosuppressive Therapy in Progressive Pulmonary Fibrosis Associated with Systemic Autoimmune Rheumatic Diseases: A Real-World Cohort Study Speaker: Risa Wakiya (Japan)
16:50 - 16:50	A Tale of Two Wild Types - V247 vs L247 in β2GPI & Implications for Disease Severity Speaker: CHRISTOPHE LALAUURIE (Northern Ireland)
16:50 - 16:50	Age-Related Differences in Inflammatory Bone Osteitis: A Systematic Literature Review of CNO and SAPHO Syndrome Across Childhood and Adulthood Speaker: Caterina Matucci-Cerinic (Italy)

16:50 - 16:50	<p>Association between daily dose of oral glucocorticoids and infections in patients with eosinophilic granulomatosis with polyangiitis treated with anti-interleukin-5/receptor therapies</p> <p>Speaker: Peter A Merkel (United States of America)</p>
16:50 - 16:50	<p>The Association Between Serum Calprotectin Levels and Disease Activity in Large Vessel Vasculitis Patients: A Multicenter Cohort Study</p> <p>Speaker: Nilüfer Alpay Kanitez (Türkiye)</p>
16:50 - 16:50	<p>Placebo-arm response rates and adverse event rates in psoriatic arthritis clinical trials between 2005-2025: a systematic review and meta-regression</p> <p>Speaker: Mark Gibson (United Kingdom)</p>
16:50 - 16:50	<p>Serum cytokine profiling reveals persistent pro-inflammatory state in stable thrombotic primary antiphospholipid syndrome</p> <p>Speaker: Pedro Gaspar (Portugal)</p>
16:50 - 16:50	<p>Overlap of IgG4-Related Disease with Adult-Onset Asthma with Periocular Xanthogranuloma: Review of 17 cases</p> <p>Speaker: Manaswini Pujar (United States of America)</p>
16:50 - 16:50	<p>Malignancy risk in patients with vasculitis: A nationwide population-based cohort study</p> <p>Speaker: Jaejoon Lee (Korea, Republic of (South Korea))</p>
16:50 - 16:50	<p>In Utero Exposure to High Placental Transfer TNF Inhibitors is Associated with Delayed T Cell Maturation and Transient IL-12/INF-γ Immune Pathway Dysfunction in Infants</p> <p>Speaker: Yiyi Luo (Spain)</p>
16:50 - 16:50	<p>Relaps free survival in AAV patients on GC-free maintenance treatment after discontinuation of avacopan – a 2-year prospective uni-center observational study stratified into renal and non-renal manifestations</p> <p>Speaker: Gunter Assmann (Germany)</p>
16:50 - 16:50	<p>Effects on new bone formation after 12 weeks of secukinumab treatment in joints and entheses of patients with psoriatic arthritis using Sodium [18F]Fluoride PET/CT.</p> <p>Speaker: Sam Groothuizen</p>

16:50 - 16:50	<p>Risk of Herpes Zoster in Patients with Immune-Mediated Inflammatory Diseases Initiating Biologic or Targeted Synthetic Therapies: A Nationwide Cohort Study</p> <p>Speaker: Mounya Abboud (France)</p>
16:50 - 16:50	<p>Beyond Treatment Failure: How PIPsA and TR-PsA Definitions Capture Active Psoriatic Arthritis</p> <p>Speaker: Nicola Cabas (Italy)</p>
16:50 - 16:50	<p>Preliminary baseline characteristics of participants randomized into the ongoing Phase 2b CONQUEST trial for interstitial lung disease associated with systemic sclerosis</p> <p>Speaker: Dinesh Khanna (United States of America)</p>
16:50 - 16:50	<p>Cryofibrinogenemia in systemic sclerosis: novel associations with interstitial lung disease, pulmonary hypertension, and survival</p> <p>Speaker: Luca Keller Sarmiento (Italy)</p>
16:50 - 16:50	<p>Comparison of Bimekizumab efficacy in bDMARD-naïve versus IL-17i-experienced patients with Psoriatic Arthritis. A real-world prospective study.</p> <p>Speaker: George E. Fragoulis (Greece)</p>
16:50 - 16:50	<p>APS prevalence and clinical outcomes in a large young stroke cohort in the Netherlands: impact of 2023 ACR/EULAR criteria</p> <p>Speaker: Emma Tax (Netherlands)</p>
16:50 - 16:50	<p>The feasibility of outpatient lung US for screening of early interstitial lung disease in VEDOSS</p> <p>Speaker: Lucy Thornton (Northern Ireland)</p>
16:50 - 16:50	<p>A study on the implementation of the 2015 ACR/EULAR recommendations for Polymyalgia Rheumatica in clinical practice</p> <p>Speaker: Konstantin Louis Thuere (Germany)</p>
16:50 - 16:50	<p>Effectiveness and tolerability of the 2023/2024 influenza vaccine in inflammatory rheumatic disease patients: a nationwide longitudinal self-reported study in Germany</p> <p>Speaker: Nadine Al-Azem (Germany)</p>

16:50 - 16:50	BIMEKIZUMAB TREATMENT RESULTED IN RAPID RESPONSE THAT WAS ASSOCIATED WITH CLINICALLY IMPORTANT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES UP TO 3 YEARS IN PATIENTS WITH PSORIATIC ARTHRITIS Speaker: Laure Gossec (France)
16:50 - 16:50	Describing CPPD synovium: histological analysis of synovial samples from the Baricitinib in calcium pyrophosphate deposition disease (BAPTIST) phase II trial Speaker: Laura Pezzoni (Italy)
16:50 - 16:50	Meta-analysis of randomized controlled clinical trials shows significant treatment efficacy of tocilizumab on the lung, the skin and fatigue in SSc Speaker: Anna-Maria Hoffmann-Vold (Norway)
16:50 - 16:50	Can we predict ascending aortic aneurysm formation in large vessel GCA Speaker: Chamaya De Silva (New Zealand)
16:50 - 16:50	Obesity Amplifies Cardiovascular Risk in Psoriatic Arthritis More than in Psoriasis: A Pooled Prospective Analysis Speaker: Axel Svedom (Sweden)
16:50 - 16:50	BIMEKIZUMAB TIME TO MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A POST HOC ANALYSIS OF TWO POOLED PHASE 3 STUDIES Speaker: Alen Zabotti (Italy)
16:50 - 16:50	Micro- and macrovascular dissociation in Systemic Sclerosis: nailfold capillaroscopy abnormalities predict cardiovascular events independently of subclinical atherosclerosis Speaker: Carlos Valera-Ribera (Spain)
16:50 - 16:50	Nailfold Capillaroscopic status and concomitant Hand Bone Condition in Systemic Sclerosis: first pilot study Speaker: Rosanna Campitiello (Italy)
16:50 - 16:50	Central sensitization in psoriatic arthritis: prevalence, clinical correlates and association with therapeutic refractoriness in an unselected cohort excluding fibromyalgia Speaker: Esther Toledano (Spain)

16:50 - 16:50	A novel pathogenic mechanism in antiphospholipid syndrome involving hepatic, autoimmune and metabolic pathways Speaker: Beatriz Vellón-García (Spain)
16:50 - 16:50	Efficacy, safety and tolerability of home-based iloprost administration for acral vascular manifestations in Scleroderma patients: a single-centre real life study Speaker: Alice Dionisi (Italy)
16:50 - 16:50	Comparison of Mobile-Based and Supervised Artificial Intelligence Personalized Exercise Programs in Juvenile Idiopathic Arthritis: A Randomized Controlled Trial Speaker: Asena Yekdaneh (Türkiye)
16:50 - 16:50	Screening of body shape and sexual health in patients with autoimmune rheumatic diseases: a cross-sectional study. Speaker: Juan Pablo González-Morales (Mexico)
16:50 - 16:50	Survival in progressive pulmonary fibrosis associated to autoimmune diseases: Multicenter study from NEREA Registry Speaker: marta ruiz-valdepeñas almansa (Spain)
16:50 - 16:50	Real-world use of anifrolumab in genetically confirmed type I interferonopathies: the French experience Speaker: Samira Khaldi-Plassart (France)
16:50 - 16:50	Frailty in Polymyalgia Rheumatica: a longitudinal cohort study. Speaker: Patricia Harkins (Ireland)
16:50 - 16:50	Chemokine-mediated immune cell trafficking characterizes active systemic sclerosis: insights from high-dimensional immune profiling Speaker: Maria Noviani (Singapore)
16:50 - 16:50	EFFICACY OF URATE-LOWERING DRUGS FOR THE TREATMENT OF HYPERURICEMIA WITH OR WITHOUT GOUT: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Speaker: Zhuoli Zhang (China)

16:50 - 16:50	<p>Reduction of Gout Flares With Pegloticase in Patients With or Without Tophi at Baseline: a Post Hoc Analysis of the MIRROR Trial Speaker: Brian LaMoreaux (United States of America)</p>
16:50 - 16:50	<p>Clinical Characteristics and Ethnic Differences in Anti-Fibrillar Positive Systemic Sclerosis patients: An International Multicenter Cohort Study Speaker: Roberto D'Alessandro (France)</p>
16:50 - 16:50	<p>The Nor-SSCardioCare Open-Label Clinical Pilot Trial: Home-Based Monitoring of Cardiopulmonary Complications in Systemic Sclerosis Speaker: Hilde Jenssen Bjørkekjær (Norway)</p>
16:50 - 16:50	<p>MEPOLIZUMAB IMPROVES GASTROINTESTINAL INVOLVEMENT IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS AND HYPEREOSINOPHILIC SYNDROME: REAL-WORLD EVIDENCE FROM A MULTICENTRE COHORT Speaker: Alessia Gatti (Italy)</p>
16:50 - 16:50	<p>Litifilimab Improves Cutaneous Lupus Erythematosus Disease Activity: 24-Week CLASI-A Change from Baseline in AMETHYST Part A Speaker: Joseph F. Merola (United States of America)</p>
16:50 - 16:50	<p>Cytokine profiling reveals distinct inflammatory clusters and clinical correlations in antiphospholipid syndrome Speaker: Xiangjun Liu (China)</p>
16:50 - 16:50	<p>Real-World Effectiveness of Rituximab in Long-Standing, Drug-Refractory Systemic Sclerosis with Pulmonary and Cutaneous Involvement Speaker: Percival D. Sampaio-Barros (Brazil)</p>
16:50 - 16:50	<p>Is there a difference in drug survival between switching and cycling biologic therapy after TNFi failure in Psoriatic Arthritis? Speaker: Gabriela Moreira (Brazil)</p>
16:50 - 16:50	<p>A multimodal artificial intelligence model for predicting acute gout flares: a retrospective study integrating structured and unstructured clinical data from electronic health records Speaker: YanLong Yang (China)</p>

16:50 - 16:50	<p>Simultaneous multi-domain efficacy of advanced therapies in psoriatic arthritis: a systematic review and network meta-analysis of joint, skin and soft tissue outcomes</p> <p>Speaker: Mark Gibson (United Kingdom)</p>
16:50 - 16:50	<p>Early Use of Sarilumab in Patients with Glucocorticoid-Resistant PMR Improves Outcomes – Insights from Randomized Controlled Trial and Real-World Data</p> <p>Speaker: Wolfgang Schmidt (Germany)</p>
16:50 - 16:50	<p>12 months sensitivity to change of EULAR Scleroid upon immunosuppressive treatment: results of national UK cohort</p> <p>Speaker: Seda Colak (Türkiye)</p>
16:50 - 16:50	<p>Sarcopenia in patients with systemic sclerosis: assessment of incidence and potential risk factors.</p> <p>Speaker: Tetiana Karasevska (Ukraine)</p>
16:50 - 16:50	<p>Microvasculopathy-related hemorrhagic tissue deposition of iron in the pathogenesis of systemic sclerosis</p> <p>Speaker: Nikolaos Vlachogiannis (Greece)</p>
16:50 - 16:50	<p>Results of a Phase II study (VITALISScE) with the soluble guanylate cyclase activator avenciguat</p> <p>Speaker: Oliver Distler (Switzerland)</p>
16:50 - 16:50	<p>Renal involvement in anti-U1-RNP-associated connective tissue disease: a retrospective cohort study</p> <p>Speaker: Dewi Marina De Vries (Germany)</p>
16:50 - 16:50	<p>AI-Based Quantitative HRCT Scoring for Predicting Disease Progression in Scleroderma-Associated Interstitial Lung Disease</p> <p>Speaker: Yolanda Braun-Moscovici (Israel)</p>
16:50 - 16:50	<p>Non-Invasive Microcirculatory Profiling for Differentiating Vasculitic Conditions from Severe Asthma: a pilot study</p> <p>Speaker: Barbara Ruaro (Italy)</p>
16:50 - 16:50	<p>Higher articular disease activity score is associated with deterioration of capillary pattern in a five-Year Follow-Up study in Patients with Systemic Sclerosis</p> <p>Speaker: Gabriella Nagy (Hungary)</p>

16:50 - 16:50	EPIDEMIOLOGY OF ADULT-ONSET SYSTEMIC AUTOINFLAMMATORY DISEASES: DATA FROM NORTHERN SPAIN Speaker: Rafael Gálvez-Sánchez (Spain)
16:50 - 16:50	Sex-Specific Inflammation-Pain Mismatch in Chinese Psoriatic Arthritis: a high-resolution Ultrasound-Based Study Speaker: Bofan Lu (China)
16:50 - 16:50	Use of Medicinal Plants in Patients with Rheumatoid Arthritis: An Ethnobotanical Survey and Clinical Implications Speaker: Imane Bensaghir (Morocco)
16:50 - 16:50	ANTI-PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) AUTOANTIBODIES IN THE ASSESSMENT OF PATIENTS WITH SYSTEMIC SCLEROSIS Speaker: Marco Binda (Italy)
16:50 - 16:50	Incidence, timing, and predictors of new onset gastrointestinal involvement in systemic sclerosis: a longitudinal cohort study from the EUSTAR database Speaker: Francesco Bonomi (Italy)
16:50 - 16:50	Effects of Structured Versus Exergaming-Based Core Stabilization Training on Pain and Physical Function in Children with Juvenile Idiopathic Arthritis: A Randomized Controlled Trial Speaker: Nilay Arman (Türkiye)
16:50 - 16:50	Systematic review and integrative analysis of monogenic immune-mediated inflammatory arthritis Speaker: Chrissy Bolton (United Kingdom)
16:50 - 16:50	U3P study- Upadacitinib in Psoriatic arthritis Pain Processing Speaker: Jürgen Rech (Germany)
16:50 - 16:50	Association of HALP Score with Disease Phenotype and Organ Involvement in Systemic Sclerosis: A Multicenter Cohort Study Speaker: Gulsah Yamancan (Türkiye)

16:50 - 16:50	Early phenotyping of arterial wall damage identifies predictors of aortic dilatation and/or aneurysm formation in Giant Cell Arteritis Speaker: Ourania D. Argyropoulou (Greece)
16:50 - 16:50	Healthcare Utilization and Clinical Features in the Five Years Preceding Systemic Sclerosis Diagnosis: A Population-Based Case–Control Study Speaker: Helana Jeres (Israel)
16:50 - 16:50	A Randomized Controlled Trial To Compare The Efficacy And Safety OF Baricitinib With Mycophenolate Mofetil In Systemic Sclerosis Speaker: Joban Preet Singh Deol (India)
16:50 - 16:50	MRI-detected axial inflammation in newly diagnosed psoriatic arthritis. Speaker: Linde Steenvoorden (Norway)
16:50 - 16:50	Safety and Efficacy of the BCMAxCD3 bispecific T cell Engager Teclistamab in Severe Diffuse Cutaneous Systemic Sclerosis Speaker: Elise Siegert (Germany)
16:50 - 16:50	Development and Evaluation of a Virtual Reality-Based Mindfulness Intervention Program for Reducing Depressive Symptoms Among Patients with Autoimmune Arthritis: Application of a Five-Stage Framework of Digital Mental Health Implementation in Hong Kong Speaker: Chung Ming Timothy Wu (Hong Kong, China)
16:50 - 16:50	Clinical Characteristics and Predictors of Treatment-Refractory Psoriatic Arthritis in a Real-Life Cohort Speaker: Matteo Molfese (Italy)
16:50 - 16:50	Incidence, timing, and factors associated with aortic aneurysm in patients with giant cell arteritis Speaker: Jorge Esteban-Sampedro (Spain)
16:50 - 16:50	Comparative effectiveness and predictors of discontinuation of second-line immunosuppressive therapies for psoriatic arthritis: a GISEA Registry cohort study Speaker: Stefano Gentileschi (Italy)

16:50 - 16:50	Difficult-to-Manage Psoriatic Arthritis: Real-World characterisation from a large UK Centre Speaker: Muhammad K Nisar (United Kingdom)
16:50 - 16:50	Cutaneous panniculitis as a presenting manifestation of immune-mediated diseases: a multidisciplinary real-world cohort study. Speaker: claudia Campos Fabre (Spain)
16:50 - 16:50	Contrast-enhanced ultrasound for defining disease activity in Takayasu arteritis Speaker: evandro klumb (Brazil)
16:50 - 16:50	Modern Management of Necrotizing ANCA-Associated Vasculitis Beyond Cyclophosphamide: Clinical Outcomes with Rituximab plus Avacopan Speaker: Javohir Mullokulov (Uzbekistan)
16:50 - 16:50	Does Microbiological Documentation Impact the Prognosis of Infectious Spondylodiscitis? A Comparative Study of 131 Patients Speaker: Olfa Jomaa (Tunisia)
16:50 - 16:50	Are there any correlation between ultrasonography presence of halo and the positron emission tomography findings in large vessel vasculitis? Speaker: Pierluigi Macchioni (Italy)
16:50 - 16:50	CORRELATION BETWEEN LUNG ULTRASOUND FEATURES AND HRCT SCORE IN INTERSTITIAL LUNG DISEASE: A CROSS SECTIONAL STUDY FROM A TERTIARY CARE CENTRE IN INDIA Speaker: Anusree seetha (India)
16:50 - 16:50	Impact of Disease Duration on the Treatment Effect of Secukinumab in the Prevention of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A 5-year Pooled Analysis of the ERASURE, FIXTURE and SCULPTURE Studies Speaker: Diamant Thaçi (Germany)
16:50 - 16:50	Avacopan-target C5AR1 is increased in crescentic glomeruli in ANCA vasculitis kidney biopsies Speaker: Hanna Schebet (Germany)

16:50 - 16:50	Fatigue severity relates to esophageal manometric patterns beyond gastrointestinal symptoms in Systemic Sclerosis Speaker: Silvia Bellando-Randone (Italy)
16:50 - 16:50	Predictors of Drug Retention in Psoriatic Arthritis: the Role of Musculoskeletal Ultrasound Speaker: Giacomo Cozzi (Italy)
16:50 - 16:50	Clinical Outcomes in Polyarteritis Nodosa With and Without Hepatitis C Virus Infection: A Propensity-Matched Analysis From the TriNetX Global Collaborative Network Speaker: Chukwuemelie Okeke (United States of America)
16:50 - 16:50	Quantitative Assessment of Nailfold Microvascular Perfusion Using Ultra-Micro-Angiography in Systemic Sclerosis Speaker: Ibrahim Vasi (Türkiye)
16:50 - 16:50	Inflammatory Signals in Subclinical Psoriatic Arthritis Predict Severe and Polyarticular Disease at Diagnosis Speaker: Valentino Paci (Italy)
16:50 - 16:50	Radiographic Sacroiliitis and predictors of Spinal Radiographic Progression in Psoriatic Arthritis in an Indian Cohort Speaker: Subin Philip (India)
16:50 - 16:50	Burden of Glucocorticoid-Related Events in Polymyalgia Rheumatica: Insights from Italian Real-World Data Speaker: Dario Camellino (Italy)
16:50 - 16:50	Serum IFN score predicts clinically significant events in Systemic Sclerosis independently of disease subset and duration: results from a national observational cohort. Speaker: Veronica Batani (Northern Ireland)
16:50 - 16:50	Echocardiographic Features and Frequency of Cardiac Involvement in AA Amyloidosis Speaker: Burak Karakaya (Türkiye)

16:50 - 16:50	Distinct extracellular vesicle signatures are associated with autoantibody profiles and organ involvement in Systemic Sclerosis Speaker: Precious Bonney (Germany)
16:50 - 16:50	Clinical Correlates of Anterior Uveitis in Psoriatic Arthritis: Insights from a Multicenter TRASD-Network Study Speaker: Nesrin Sen (Türkiye)
16:50 - 16:50	High Retention Rates and Sustained Effectiveness Over 5 Years in Patients With Moderate-to-severe Plaque Psoriasis Regardless of Disease Duration: Real-world Evidence From the SERENA Study Speaker: Matthias Augustin (Germany)
16:50 - 16:50	Preliminary Records from FMFTrackR: A Prospective, Real-Time Study Using a Purpose-Built Web-Based Mobile Application to Capture Patient-Reported FMF Attacks and Triggering Factors Speaker: Bengisu Menentoglu (Türkiye)
16:50 - 16:50	Atypical IgG4-Related Disease: Re-Examining the Entry Criteria of the 2019 ACR/EULAR Classification Criteria Speaker: Guy Katz (United States of America)
16:50 - 16:50	Impact of Individualised Nursing Education on Illness Perceptions and Medication Adherence in Systemic Lupus Erythematosus: A Preliminary Prospective Self-Controlled Study Speaker: Tamar Stern Lavee (Israel)
16:50 - 16:50	Autoimmunity-associated Chronic Fatigue Syndrome in patients with Systemic Sclerosis: Autoantibodies targeting G-protein coupled receptors as diagnostic biomarkers and potential pathophysiological contributors Speaker: Hanna Grasshoff (Germany)
16:50 - 16:50	First non-Raynaud's phenomenon sign/symptom predicts MACE occurrence in systemic sclerosis: a monocentric long-term analysis Speaker: Eugenio Capparelli (Italy)
16:50 - 16:50	Beyond Cardiac Complications: Long-Term Atopic and Rheumatic Disease Risk Following Kawasaki Disease in Children Speaker: Mohammad Hamad saied (Netherlands)

16:50 - 16:50	Effectiveness and safety of Neridronate in Chronic Nonbacterial Osteomyelitis: insight from the CAMELOT registry Speaker: Achille Marino (Italy)
16:50 - 16:50	From recognition to actionable change: a co-designed framework to hyperlocally address adverse Social Determinants of Health in lupus care Speaker: Daniel Guimarães de Oliveira (Portugal)
16:50 - 16:50	Cancer in systemic sclerosis: clinical and treatment-related associations Speaker: Veronica Batani (Northern Ireland)
16:50 - 16:50	Bridging with Calcium Disodium Edetate (CaNa₂EDTA) to Potentiate Autologous Tandem CD19-BCMA CAR-T Therapy in Refractory Diffuse Systemic Sclerosis: A Pilot "Microenvironment-Remodeling" Study Speaker: Yajing Zhang (China)
16:50 - 16:50	Vaccination Practices During Biologic Therapy Speaker: Boudokhane Manel (Tunisia)
16:50 - 16:50	Patient Partnership to Enhance Independent Living for People with Arthritis Speaker: Laurie Proulx (Canada)
16:50 - 16:50	Five-Year Follow-Up of Anakinra Treatment in Familial Mediterranean Fever: A Retrospective Single-Center Study Speaker: Yigit Çamur (Türkiye)
16:50 - 16:50	Iron Restriction Phenotypes and Their Impact on Clinical Outcomes in Familial Mediterranean Fever: A Prospective Study of 161 Adults. Speaker: Cristina Lavilla (Spain)
16:50 - 16:50	Multi-omics profiling reveals selective CD16⁺ NK-cell collapse and TNF-driven apoptotic rewiring during Familial Mediterranean Fever flares Speaker: ZHICHENG ZHOU (France)
16:50 - 16:50	Determinants of complementary and alternative medicine use in osteoarthritis: longitudinal analyses from the Osteoarthritis Initiative Speaker: Valentina Schmolik (Austria)

16:50 - 16:50	Comprehensive Immunological Reset in Systemic Sclerosis: Dual Depletion of B Cells and Plasma Cells via CD19/BCMA CAR-T Therapy Eradicates Pathogenic Autoimmunity Speaker: Yajing Zhang (China)
16:50 - 16:50	Exercise-Induced Cytokine Modulation in Psoriatic Arthritis: Results From a Randomized Controlled Trial on Blood Flow Restriction Training Speaker: Claus Juergen Bauer (Germany)
16:50 - 16:50	Long-Term Incidence of SARS-CoV-2 Infection According to COVID-19 Vaccine Acceptance in Chronic Inflammatory Rheumatic Diseases: The COVID-RIC III Study Speaker: Jacques Morel (France)
16:50 - 16:50	Rethinking skin assessment: analysis of individual Rodnan skin sites scores in early diffuse systemic sclerosis using the EUSTAR cohort Speaker: Tânia Santiago (Portugal)
16:50 - 16:50	Recognizing JAK1-Associated Autoinflammatory Disease in Rheumatology Practice: A Systematic Literature Review of 36 cases. Speaker: Sara Benchekroun-Jolicoeur (France)

Poster Tour Presentations

Date: **03/06/2026**

Room: **Poster Tour I**

15:30-16:30 BST

Basic Poster Tours: Basic Science Insights into Systemic Sclerosis

Chair:	Jelena Colic (Serbia) Jerome Avouac (France)
15:30 - 15:36	Single-Cell RNA Sequencing of Skin Tissue Reveals Prominent Fibroblast–T Cell Crosstalk in Pre-Stages of Systemic Sclerosis Speaker: Lumeng Li (Switzerland)

15:36 - 15:42	Multi-Omics Reveals a Vascular-Immune Niche Characterizing Regressive Skin Fibrosis in Systemic Sclerosis Speaker: Astrid Hofman (Switzerland)
15:42 - 15:48	Spatial transcriptomics identifies phenotypic shifts in fibroblasts upon CD19-CAR T-cell therapy in systemic sclerosis skin Speaker: Yi-Nan Li (Germany)
15:48 - 15:54	High-Definition Spatial Transcriptomics Reveals Altered T Cell States and Epithelial Stress Responses in the Small Intestine of Systemic Sclerosis Patients Speaker: Laura Much (Switzerland)
15:54 - 16:00	Niche-specific Phenotypes of Immune Cells in Immune Cell Aggregates in Systemic Sclerosis Skin Speaker: Dennis Bleck (Germany)
16:00 - 16:06	Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity-driven fibrosis Speaker: Jaime Marty Lobo (Spain)
16:06 - 16:12	Spatial Profiling of Scleroderma Renal Crisis Reveals Fibrotic Remodeling and Complement Activation in the Kidney Speaker: Minrui Liang (China)
16:12 - 16:18	Distinct HLA risk landscapes in female and male patients with systemic sclerosis Speaker: Inmaculada Rodriguez-Martin (Spain)
16:18 - 16:24	PATHOGENIC EFFECTS OF IMMUNE COMPLEXES CONTAINING SCLERODERMA-SPECIFIC ANTIBODIES IN A DYNAMIC 3D MULTICELLULAR IN VITRO MODEL Speaker: Cecilia Chighizola (Italy)

Poster Tour Presentations

Date: **03/06/2026**

Room: **Poster Tour II**

15:30-16:30 BST

Clinical Poster Tours: New clinical developments in Large Vessel Vasculitis and Polymyalgia Rheumatica

Chair:	Kornelis van der Geest (Netherlands) Valerie Devauchelle-Pensec (France)
15:30 - 15:36	Secukinumab in patients with polymyalgia rheumatica: Subgroup analyses of Week 52 results of a Phase 3, multicentre, randomised, double-blind, placebo-controlled trial (REPLENISH) Speaker: Frank Buttgereit (Germany)
15:36 - 15:42	Clinical Characteristics of Flares of Giant Cell Arteritis: Two-Year Outcomes From the SELECT-GCA Phase 3 Trial Speaker: Christian Dejaco (Italy)
15:42 - 15:48	Tocilizumab versus Methotrexate for Glucocorticoid Sparing in Giant Cell Arteritis: A Nationwide Target Trial Emulation Speaker: Maxime Beydon (France)
15:48 - 15:54	A Comprehensive Prognostic Architecture for Takayasu Arteritis: From Data-Driven Phenotypes to an Individualized Risk Prediction Tool Speaker: Gokce Kenar Artin (Türkiye)
15:54 - 16:00	Identifying Difficult-to-Treat Giant Cell Arteritis: Results from a French Large Vessel Vasculitis Study Group Cohort Speaker: Omar Dhrif (Tunisia)
16:00 - 16:06	Methotrexate for Remission Maintenance Following Tocilizumab and Glucocorticoid Induction in Giant Cell Arteritis: The Randomized Phase II METEORITICS Trial Speaker: Valentin S. Schäfer (Germany)
16:06 - 16:12	Characteristics of VEXAS syndrome associated with UBA1 splice-site variants: a multicenter comparative study with Met41 variants Speaker: Côme Le Liepvre (France)
16:12 - 16:18	Risk of digestive perforation among patients with polymyalgia rheumatica and giant cell arteritis treated with anti-IL6-receptor therapies Speaker: Alain Saraux (France)

16:18 - 16:24	<p>Prednisolone tapering in patients with polymyalgia rheumatica using a structured, nurse-led, hospital-based taper versus usual care tapering in general practice: A randomised, open-label, parallel-group, multicentre, superiority trial</p> <p>Speaker: Christoffer Våben (Denmark)</p>
---------------	--

Poster Tour Presentations

Date: **03/06/2026**

Room: **Poster Tour III**

15:30-16:30 BST

Basic and Clinical Poster Tours: Infection and prevention in RMDs

Chair:	<p>George E. Fragoulis (Greece)</p> <p>Kevin L. Winthrop (United States of America)</p>
15:30 - 15:36	<p>Incidence of herpes zoster in rheumatoid arthritis patients treated with biologic/targeted synthetic disease modifying anti-rheumatic drugs and in biologic naïve patients: a Swedish nationwide study</p> <p>Speaker: Meliha C Kapetanovic (Sweden)</p>
15:36 - 15:42	<p>Incidence of infections in patients with rheumatoid arthritis treated with JAK inhibitors (including subtypes), TNF inhibitors and other bDMARDs : results from the JAK-pot collaboration</p> <p>Speaker: Kim Lauper (Switzerland)</p>
15:42 - 15:48	<p>Disparities in Severe Infection Risk Associated With Systemic Lupus Erythematosus: Evidence From a Causal Forest Analysis</p> <p>Speaker: Kai Zhao (Canada)</p>
15:48 - 15:54	<p>Osteoarticular involvement in infectious endocarditis: post hoc analysis of a prospective cohort</p> <p>Speaker: Baptiste de Maleprade (France)</p>
15:54 - 16:00	<p>Baseline Immunity and it's natural course against Respiratory Syncytial Virus in Rheumatic Patients while starting vaccination program</p> <p>Speaker: Christoph Pohl (Germany)</p>

16:00 - 16:06	What is the probability of benefit of tuberculosis preventive therapy in rheumatic diseases? A Bayesian meta-analysis Speaker: Gabriela Moreira (Brazil)
16:06 - 16:12	Prevalence and Infection Risks of Combination Advanced Therapy Exposures in Immune-Mediated Inflammatory Diseases Speaker: Timothy Kwok (Canada)
16:12 - 16:18	Single cell RNA sequencing and autoantibody screening reveal novel immune biomarkers in knee joint-fluid for early clinical stratification of septic and autoimmune arthritis in children Speaker: Prithvi Raj (United States of America)
16:18 - 16:24	Cost-effectiveness of herpes zoster vaccination in patients with rheumatoid arthritis Speaker: Gunhild Hagen (Norway)

Poster Tour Presentations

Date: **03/06/2026**

Room: **Poster Tour IV**

15:30-16:30 BST

Clinical Poster Tours: Clots, clues, and care

Chair:	Maria G. Tektonidou (Greece) Kevin Chevalier (France)
15:30 - 15:36	Antiphospholipid antibody negativization is characterized by restoration of immune homeostasis and reversal of thrombogenicity in thrombotic primary antiphospholipid syndrome Speaker: Pedro Gaspar (Portugal)
15:36 - 15:42	The single-cell multi-omic profiling of placental trophoblast differentiation in obstetric antiphospholipid syndrome Speaker: Rui Gao (China)

15:42 - 15:48	Effect of Hydroxychloroquine on adverse pregnancy outcomes in antiphospholipid syndrome without systemic lupus erythematosus: a propensity score-adjusted analysis from the French GR2 study Speaker: Anne Murarasu (France)
15:48 - 15:54	Less pronounced interferon signature in primary antiphospholipid syndrome compared with other autoimmune diseases Speaker: Dionysis Nikolopoulos (Sweden)
15:54 - 16:00	Proteomic profiling reveals a thromboinflammatory dichotomy between thrombotic and obstetric antiphospholipid syndrome Speaker: Dorien Salet (Netherlands)
16:00 - 16:06	Predictors of Thrombotic Recurrence in Antiphospholipid Syndrome: The Role of aPL Profile and aGAPSS score Speaker: Vasileios Lainis (Greece)
16:06 - 16:12	Development of Clinical Manifestations in Antiphospholipid Antibodies Carriers According to the 2023 ACR/EULAR Serological Domains Speaker: Rafael Gálvez-Sánchez (Spain)
16:12 - 16:18	Effectiveness and safety of primary thromboprophylaxis in antiphospholipid antibody carriers by serological 2023 ACR/EULAR domains Speaker: Rafael Gálvez-Sánchez (Spain)

Poster Tour Presentations

Date: **03/06/2026**

Room: **Poster Tour V**

15:30-16:30 BST

Clinical Poster Tours: From skin to joint

Chair:	Maria-Antonietta D'Agostino (Italy) Gizem Ayan (Türkiye)
15:30 - 15:36	Persistence, Effectiveness, Safety, and Patient Reported Impact of Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: Full Population Results of the PsABIONd Global Observational Study Over 12 Months Speaker: Laure Gossec (France)

15:36 - 15:42	Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: A GRAPPA-OMERACT systematic review and network meta-analysis Speaker: Tommy Kok Annfeldt (Denmark)
15:42 - 15:48	Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPSAKE 1 Trial Speaker: Frank Behrens (Germany)
15:48 - 15:54	BIMEKIZUMAB INHIBITED RADIOGRAPHIC PROGRESSION REGARDLESS OF BASELINE CHARACTERISTICS IN BDMARD-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 3 STUDY AND ITS OPEN-LABEL EXTENSION Speaker: Philipp Sewerin (Germany)
15:54 - 16:00	Tofacitinib for axial psoriatic arthritis: Clinical and MRI outcomes of a randomised, double-blind, placebo-controlled trial Speaker: Hildrun Haibel (Germany)
16:00 - 16:06	Concurrent Initiation of Tirzepatide and Biologics in Obese Patients with Psoriatic Arthritis: A Propensity Score-Matched Comparative Study Speaker: Vincenzo Venerito (Italy)
16:06 - 16:12	Characteristics Influencing the Prevention of Psoriatic Arthritis With Secukinumab in Patients With Moderate to Severe Plaque Psoriasis: 5-Year Real-World Results From the SERENA Study Speaker: Uta Kiltz (Germany)
16:12 - 16:18	Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials Speaker: Iain B. McInnes (United Kingdom)

PARE Poster Tour I: Experience, Innovation and Partnership

Chair:	Sara Badreh Wirström (Belgium) Sofia Sotiria Marantidou (Greece)
15:30 - 15:36	Act on Axial SpA to reduce the time to diagnosis: Supporting initial implementation of the Playbook Speaker: Jill Hamilton (United Kingdom)
15:36 - 15:42	Health-related quality of life in Patients with Systemic Lupus Erythematosus in China: A Cross-Sectional Survey of Patient-Reported and Caregiver-Reported Outcomes Speaker: Can Huang (China)
15:42 - 15:48	Snapshots of Sjögren's: A Photovoice Study of Living with Sjögren's Disease in Ireland Speaker: Alanna Drury (Ireland)
15:48 - 15:54	Barriers to App-Based Remote Monitoring in Rheumatoid Arthritis: Findings from the REMORA2 Study Speaker: Josh Behan-Devlin (United Kingdom)
15:54 - 16:00	Bridging the Gap: Co-Designing Menopause Support for Women with Rheumatoid Arthritis Speaker: Donagh Stenson (United Kingdom)
16:00 - 16:06	Webinar on sex and lupus – a case study on Youth Group–clinician co-creation Speaker: Marina Pietri (Greece)
16:06 - 16:12	Making Sense of Fibromyalgia: Developing an Expert-Led Digital Learning Programme for Patients Speaker: Anna Fryxelius (Norway)
16:12 - 16:18	No one size that fits all- Developing a tailor made strategy for monitoring and evaluating Patient Research Partner involvement in the HIPPOCRATES translational consortium Speaker: Hillary Collins (United Kingdom)

16:18 - 16:24	Development and evaluation of a stakeholder involvement strategy for complex multinational and interdisciplinary projects: the SQUEEZE experience over three years Speaker: Estíbaliz Loza (Spain)
---------------	--

Meet the EULAR Expert Date: **03/06/2026**

Room: **Meet the EULAR Expert 1**

15:45-16:15 BST

Immunological impacts of our environment

Chair:	
15:45 - 16:15	Immunological impacts of our environment Speaker: Eicke Latz (Germany)

PARE Meet the EULAR Expert Date: **03/06/2026**

To learn about the reasons surgery may be offered Room: **Meet the EULAR Expert 2**

To share the risk factors and complications associated with joint surgery **15:45-16:15 BST**

To spell out the options and alternatives to surgery

To educate on the prehab, surgery and rehab required for success

Is slicing too dicey? When is surgery the right choice? When is it the only option?

Chair:	
--------	--

15:45 - 16:15	<p>Is slicing too dicey? When is surgery the right choice? When is it the only option? Speaker: Anders Odgaard</p>
---------------	--

Meet the EULAR Expert

Date: **03/06/2026**

Room: **Meet the EULAR Expert 3**

15:45-16:15 BST

Myositis

Chair:	
15:45 - 16:15	<p>Myositis Speaker: Hector Chinoy (United Kingdom)</p>

Meet the EULAR Expert

Date: **03/06/2026**

Juvenile idiopathic arthritis (JIA) is a heterogenous group of inflammatory disease with childhood arthritis. The classification that is currently used worldwide was proposed in 1995 by ILAR; new PRINTO JIA classification criteria have been proposed and are now validated in a study including more than 1000 patients, to try to identify homogeneous entities.

Room: **Meet the EULAR Expert 4**

15:45-16:15 BST

It is time to re-classify JIA

Chair:	
15:45 - 16:15	<p>It is time to re-classify Juvenile Idiopathic Arthritis criteria Speaker: Nicolino Ruperto (Italy)</p>

Oral Abstract PresentationsDate: **03/06/2026**Room: **Plenary****16:30-17:45 BST****Abstract Plenary**

Chair:	
16:30 - 16:40	Treat-to-target continuation of urate-lowering therapy versus a urate-lowering therapy discontinuation attempt strategy in gout patients in remission (GO TEST Finale): a pragmatic open label randomised superiority trial. Speaker: Iris Rose Peeters (Netherlands)
16:40 - 16:50	Anifrolumab treatment in patients with Sjögren's disease: Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase IIa proof-of-mechanism trial (ANISE-II) Speaker: Hendrika Bootsma (Netherlands)
16:50 - 17:00	Microenvironmental hypoxia and HIF-1α activity segregate across skin, synovium and enthesis in psoriatic disease and associate with compartment-specific CD8 exhaustion. Speaker: Daniele Mauro (Italy)
17:00 - 17:10	Multi-omics analysis elucidates the trajectory of progression from the antibody-positive phase to established Systemic Sclerosis Speaker: Hanlin Yin (China)
17:10 - 17:20	Cost-effectiveness of digital patient education for newly diagnosed patients with rheumatoid arthritis: An economic evaluation from a randomised controlled trial Speaker: Line Raunsbæk Knudsen (Denmark)
17:20 - 17:30	Lupus nephritis histological activity and response are linked to specific immune, metabolic, and remodeling pathways: a per-protocol kidney biopsy study. Speaker: Andrea Fava (United States of America)

17:30 - 17:40	Presence and impact of involvement in Arthritis UK funded research Speaker: Gemma Winsor (United Kingdom)
17:40 - 17:50	CD19 CAR T-Cell Therapy in ACPA-Positive, Treatment-Refractory, Active Rheumatoid Arthritis - Data from the Phase 1 of the Prospective, Interventional COMPARE Trial Speaker: Fredrik N. Albach (Germany)

Oral Abstract Presentations

Date: **03/06/2026**

Room: **Connaught Room 1 & 2**

16:30-17:45 BST

Clinical Abstract Sessions: New Trends in Global Health

Chair:	Laurent Arnaud (France) Delphine Courvoisier (Switzerland)
16:30 - 16:40	Increasing lifetime smoking exposure among male rheumatoid arthritis patients despite declining current use in Switzerland Speaker: Eve Caroline Berthouzoz (Switzerland)
16:40 - 16:50	COVID-19 Amplifies Cardiovascular Risk in Idiopathic Inflammatory Myopathies: Updated Whole-Population Data from England Speaker: max lyon (United Kingdom)
16:50 - 17:00	Castleman Disease Hospitalizations in Spain (2018-2023): Nationwide Epidemiology, Epidemiological Subtypes, and Outcomes Speaker: Jorge Esteban Sampedro (Spain)
17:00 - 17:10	GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients with Rheumatic and Muskuloskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry Speaker: Jeffrey R Curtis (United States of America)

17:10 - 17:20	Fourteen-Year Longitudinal Impact of an Integrated Rheumatology–Primary Care Model on Healthcare Efficiency Speaker: Ligia Gabrie (Spain)
17:20 - 17:30	Socioeconomic Deprivation and Access to Care Correlate with Regional Disparities in Premature Mortality from Systemic Connective Tissue Disorders in Spain Speaker: Halbert Hernández-Negrin (Spain)
17:30 - 17:40	Post-Acute COVID-19 Outcomes in Patients With Rheumatologic Disease: A Large Real-World Cohort Study Speaker: Maya Khasho (United States of America)

Oral Abstract Presentations

Date: **03/06/2026**

Room: **Connaught Room 3 & 4**

16:30-17:50 BST

Basic Abstract Sessions: The Many Paths of Arthritis

Chair:	Javier Rodríguez-Carrio (Spain) Valentina Pucino (Italy)
16:30 - 16:40	Network analysis of the serum proteome in a prospective cohort of immune checkpoint inhibitor recipients highlights interferon-γ as a pivotal mediator of immune-related adverse events. Speaker: Joe Berry (United Kingdom)
16:40 - 16:50	Immune exhaustion protects against checkpoint inhibitor toxicity caused by activation and migration of cytotoxic T-cells to synovial tissue Speaker: Arthur Pratt (United Kingdom)
16:50 - 17:00	Plasma proteomic profile of Rheumatoid Arthritis: insights into shared inflammatory pathways with Psoriatic Arthritis Speaker: Maria Kyriakidi (Greece)

17:00 - 17:10	CCR2-Guided Treg Exosome–Gas6 Hybrid Synergistically Reprograms Macrophage Inflammation and Immune Tolerance in Gouty Arthritis Speaker: 芳芳 陈 (China)
17:10 - 17:20	JAK-dependent regulation of CXCL10, a known nociceptive chemokine, identifies a potential target underlying pain reduction in an in vitro model of enthesitis Speaker: Francesca Trunfio (Italy)
17:20 - 17:30	Fenestrated capillaries as the structural basis of the blood–joint barrier Speaker: Tetsuo Hasegawa (United Kingdom)
17:30 - 17:40	Early intervertebral bone formation in recent-onset arthritis revealed by X-ray phase-contrast imaging: evidence for parallel, non-sequential bone and inflammatory processes Speaker: Frank Verhoeven (France)
17:40 - 17:50	Transcriptomic Profiles Differentiate Resolving from Chronic Reactive Arthritis Speaker: Avarna Agarwal (India)

Health Professionals in Rheumatology (HPR)

Date: 03/06/2026

Room: **Victoria Room 1**

16:30-17:50 BST

HPR Abstract Sessions: Listening to Lived Experience - Health Literacy, Self-Management, and Partnership in Care

Chair:	Mwidimi Ndosu (United Kingdom) Tuva Moseng (Norway)
16:30 - 16:40	How the Conversational Health Literacy Assessment Tool for inflammatory Rheumatic Diseases (CHAT-iRD) can help to address health literacy in practice: a qualitative study Speaker: Jelle Pergens (Belgium)

16:40 - 16:50	Health literacy needs of patients with migrant backgrounds and inflammatory rheumatic diseases - a qualitative exploration Speaker: Laura Treacy (Norway)
16:50 - 17:00	Patients' Perspectives on SPINCODE: A Qualitative Evaluation of an Interdisciplinary Physiotherapist-Coordinated Rehabilitation Intervention Speaker: Kirsten Lykke Knak (Denmark)
17:00 - 17:10	Development of a Patient Reported Experience Measure (PREM) for interdisciplinary care in immune mediated inflammatory diseases with skin manifestations (skIMIDs) Speaker: Diederik De Cock (Belgium)
17:10 - 17:20	Sexual Health, Pleasure, Justice, and Well-Being in People with Rheumatic and Musculoskeletal Diseases: A Systematic Scoping Review Speaker: Benedetto Giardulli (Italy)
17:20 - 17:30	Person-Centered Care at Risk in Clinical Practice: Fragmentation, Access, and Partnership - A Qualitative Secondary Analysis Speaker: Luise Lindgren (Denmark)
17:30 - 17:40	Caregiving in Inflammatory Arthritis: A Phenomenological Study Speaker: Valentina Bressan (Italy)
17:40 - 17:50	Patients' experience of their partners' influence on their ability to self-manage inflammatory arthritis - a qualitative study Speaker: Charlotte Werdal Hansen (Denmark)

PARE

Date: **03/06/2026**

Encourage rheumatologists and HPRs to be open with their patients and be more conformable in engaging in a dialog

Room: **Victoria Room 2**

16:30-17:45 BST

Explore various tools that can be used to enhance patient doctor communication

Emphasise that responsibility for patient doctor communication is a two way street leading to

successful shared decision making

Building Bridges: Enhancing Patient-Doctor Communication

Chair:	Elena Nikiphorou (United Kingdom) Marcos Séneca García Rodríguez (Spain)
16:30 - 16:45	Foundations of successful communication in clinic Speaker: Anna Fryxelius (Norway)
16:45 - 17:00	Adding the structure of shared decision making to the foundations of successful communication Speaker: Oliver Hendricks (Denmark)
17:00 - 17:15	The right tool to pull the (green) threads of communication together Speaker: Corinna Elling-Audersch (Germany)
17:15 - 17:25	Using the Manga Cells at Work! to Improve Health Literacy and Patient Communication in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Speaker: Takako Miyamae (Japan)
17:25 - 17:35	Beyond “Dr Google”: Performance of Large Language Models in Patient Counselling for Connective Tissue Diseases Speaker: Phillip Kremer (Germany)
17:35 - 17:45	Questions and Answers Speaker: Elena Nikiphorou (United Kingdom)

Oral Abstract Presentations

Date: **03/06/2026**

Room: **Victoria Room 3**

16:30-17:50 BST

Basic and Clinical Abstract Sessions: New Routes in Osteoarthritis

Chair:	Francis Berenbaum (France) Ufuk Ilgen (Türkiye)
16:30 - 16:40	DURABLE EFFICACY AT 6 MONTHS USING AN INNOVATIVE INTRA-ARTICULAR APOPTOTIC CELL THERAPY IN KNEE OSTEOARTHRITIS: DATA FROM A PHASE IIA RCT Speaker: Philip G. Conaghan (United Kingdom)
16:40 - 16:50	Investigating the Role of TRPM8-positive Neurons in Δ^9-Tetrahydrocannabinol-mediated Analgesia of Osteoarthritis Pain Speaker: Maham Zain (Canada)
16:50 - 17:00	Phase II study of the NLRP3 inhibitor DFV890 as anti-inflammatory principle for the treatment of pain in osteoarthritis Speaker: Franziska Saxer (Switzerland)
17:00 - 17:10	The Cilia-Wnt Axis as a Therapeutic Target for Sox9 mRNA-LNP in Osteoarthritis Speaker: Yoonhee Kim (Korea, Republic of (South Korea))
17:10 - 17:20	ASAP2 facilitates osteoarthritis progression by promoting macrophage M1 polarization via hnRNPA1-mediated stabilization of NFKB3 mRNA Speaker: Tao Meng (China)
17:20 - 17:30	Risk factors for structural progression of knee osteoarthritis: data from the KHOALA cohort Speaker: Augustin Latourte (France)
17:30 - 17:40	SGLT2 inhibition is a potential therapeutic strategy for treating osteoarthritis Speaker: Junyu Zhu (China)
17:40 - 17:50	Comparing Joint Safety Outcomes from Phase 2 RCTs of Two Different Neurotrophin Modulators: LEVI-04 (P75NTR-FC, NT-3 Inhibitor) and Fasinumab (Anti-NGF) Speaker: Philip G. Conaghan (United Kingdom)

Basic and Clinical Abstract Sessions: Insights in other diseases

Chair:	Rik Lories (Belgium) Augusta ORTOLAN (Italy)
16:30 - 16:40	Natural History of IgG4-RD: Patterns of Organ Involvement and Flare-associated Biomarker Changes in the MITIGATE Trial Speaker: John H. Stone (United States of America)
16:40 - 16:50	T peripheral helper 2 cells reflect disease activity and predict relapse in IgG4-related disease Speaker: Kanako Shimanuki (Japan)
16:50 - 17:00	Outcome and risk factors for progression of the watchful waiting strategy for IgG4-related disease: a retrospective cohort study in China Speaker: Jialing Jiang (China)
17:00 - 17:10	Serum IgG4:IgG ratio in participants with and without flare: an exploratory analysis of a phase 2a study of rilzabrutinib in participants with IgG4-related disease Speaker: Matthew Baker (United States of America)
17:10 - 17:20	Serum IgG4 Elevation in IgG4-Related Disease: A Marker of Disease Phenotype and Organ Involvement Speaker: Guy Katz (United States of America)
17:20 - 17:30	An Investigation into the proteomic differences between Haemophagocytic Lymphohistiocytosis and Sepsis in adult patient cohorts. Speaker: Keira Iouden (United Kingdom)
17:30 - 17:40	Impact of Disease Modifying Anti-Rheumatic Drugs vs. glucocorticoids on Overall survival and Progression free survival in patients with checkpoint-inhibitor-induced arthritis or Polymyalgia Rheumatica Speaker: Matina Liapi (Sweden)
17:40 - 17:50	CD6 as a dynamic serum biomarker of immune-related adverse events, involved in JAK/STAT-mediated CD4⁺ T cell activation Speaker: Xu Jiang (China)

Oral Abstract PresentationsDate: **03/06/2026**Room: **Victoria Room 5 & 6****16:30-17:45 BST****Clinical Abstract Sessions: Mind the spine - imaging in Spondyloarthritis**

Chair:	Olivier Fogel (France) Olivier Fogel (France)
16:30 - 16:40	Defining an MRI Indicative of Axial Spondyloarthritis in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: A Data-Driven and Consensus-Based Framework of Recommendations by The Spondyloarthritis Research and Treatment Network and The Society of Skeletal Radiology Speaker: Walter P Maksymowych (Canada)
16:40 - 16:50	Impact of Sex on Clinical Outcomes, Treatment Exposure, and Spinal Radiographic Progression Over a 10-Year Follow-Up in Axial Spondyloarthritis Speaker: Didem Sahin (Germany)
16:50 - 17:00	Structural progression of the sacroiliac joints on MRI in patients with axial spondyloarthritis: 10-year data from the DESIR cohort Speaker: Laura Pina Vegas (France)
17:00 - 17:10	Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort Speaker: Liese de Bruin (Netherlands)
17:10 - 17:20	One-year changes of spinal new bone formation in axial spondyloarthritis assessed by low-dose CT and MRI-based synthetic CT – a descriptive evaluation Speaker: Simone Tromborg Willesen (Denmark)
17:20 - 17:30	Enhancing Diagnostic Accuracy in Axial Spondyloarthritis through Centralized Imaging and Clinical Evaluation: Final Results from a Prospective Multicentre Project (IMPROVE-axSpA) Speaker: Denis Poddubnyy (Canada)
17:30 - 17:40	Real-World Data Comparing the Safety and Adverse Event Profiles of Biologic Therapies and Targeted Synthetic DMARDs in Ankylosing Spondylitis Speaker: Marina Magrey (United States of America)

17:40 - 17:50	Immediate TNF Blockade Outperforms Step-Up csDMARDs in Early Peripheral Spondyloarthritis: 24-Week Results from the SPARTACUS Trial. Speaker: Phillippe Carron (Belgium)
---------------	--

Oral Abstract Presentations

Date: **03/06/2026**

Room: **N1**

16:30-17:45 BST

Clinical Abstract Sessions: Next Generation Treatment in Large Vessel Vasculitis

Chair:	Jens Thiel (Austria) Nils Venhoff (Germany)
16:30 - 16:40	Secukinumab in polymyalgia rheumatica: Results of the phase 3 REPLENISH trial Speaker: Christian Dejaco (Italy)
16:40 - 16:50	Response to Upadacitinib in New-Onset Versus Relapsing Giant Cell Arteritis: Two-Year Outcomes From the SELECT-GCA Phase 3 Trial Speaker: Anisha B Dua (United States of America)
16:50 - 17:00	International recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica Speaker: Christian Dejaco (Italy)
17:00 - 17:10	Methotrexate versus Tocilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial. Speaker: Maxime Samson (France)
17:10 - 17:20	Mosaic Loss of the Y Chromosome Differentiates Giant Cell Arteritis from Polymyalgia Rheumatica Across the GCA–PMR Spectrum. Speaker: Simon M. Petzinna (Germany)

17:20 - 17:30	Glucocorticoids in giant cell arteritis: changes in treatment regimens and associated toxicity in real life: a national study based on the French Health Insurance database Speaker: Maxime Beydon (France)
17:30 - 17:40	Head-to-head comparison of secukinumab and adalimumab combined with glucocorticoids in active Takayasu arteritis: a 2-year prospective study Speaker: Xiufang Kong (China)
17:40 - 17:50	Rituximab as a glucocorticoid-sparing therapy in newly diagnosed polymyalgia rheumatica: A randomized controlled trial (REDUCE PMR 1) Speaker: Pauline Bovens (Netherlands)

Oral Abstract Presentations

Date: **03/06/2026**

Room: **N2**

16:30-17:50 BST

Clinical Abstract Sessions: Advanced therapies across rheumatic diseases

Chair:	Theodoros Dimitroulas (Greece) Rodrigo Garcia Salinas (Argentina)
16:30 - 16:40	Management of relapses after autologous CD19 CAR T-cell therapy in SLE, SSc and IIM – a case series Speaker: Andreas Wirsching (Germany)
16:40 - 16:50	SAFETY AND EARLY EFFICACY OF RAPCABTAGENE AUTOLEUCEL (YTB323), AN AUTOLOGOUS CD19 DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN SEVERE REFRACTORY IDIOPATHIC INFLAMMATORY MYOPATHIES AND DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: PRELIMINARY ANALYSIS OF THE OPEN-LABEL AUTOGRAPH-IIM AND -SSC STUDIES Speaker: Dinesh Khanna (United States of America)
16:50 - 17:00	BCMA targeted T-cell engager Teclistamab as rescue therapy for severe refractory Autoimmunediseases Speaker: Sebastian Boeltz (Germany)

17:00 - 17:10	Does Having Preexisting Rheumatologic Disease Increase the Risk of Immune Related Adverse Events While on Immune Checkpoint Inhibitor Therapy? Speaker: Pallavi Velagapudi (United States of America)
17:10 - 17:20	Survival-progression dissociation in connective tissue disease-associated interstitial lung disease: real-world data from the INSIGHTS-ILD registry Speaker: Torsten Witte (Germany)
17:20 - 17:30	Long-Term Safety of Upadacitinib in Clinical Trial and Clinical Practice Settings: Risk of Infection, Malignancy, Cardiovascular Events, and Thromboembolism in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Speaker: Gerd R. Burmester (Germany)
17:30 - 17:40	A single-cell atlas reveals shared fibroblast signature in pauci-immune arthritis across different chronic arthritides Speaker: Marija Lugar (Switzerland)

Oral Abstract Presentations

Date: **03/06/2026**

Room: **N3**

16:30-17:45 BST

Clinical Abstract Sessions: Positive Clinical Trials - a new era in Sjögren's Disease

Chair:	Benjamin A. Fisher (United Kingdom) Simon Bowman (United Kingdom)
16:30 - 16:40	The smoking paradox in Sjögren's syndrome: epidemiological, histological, and in vitro evidence Speaker: Edoardo Simoncelli (Italy)
16:40 - 16:50	The Sjögren's Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 15 recent RCTs in Sjögren's disease Speaker: Raphaële Seror (France)
16:50 - 17:00	Efficacy and Safety of the Ianalumab Global Phase 3 Studies (NEPTUNUS-1 and NEPTUNUS-2) and Their Extension Study in Patients With Sjögren's Disease Speaker: Xavier Mariette (France)
17:00 - 17:10	Efficacy and safety of Telitacicept in patients with Sjogren's disease: results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study Speaker: Dong Xu (China)
17:10 - 17:20	Iscalimab (CFZ533) in patients with Sjögren's disease (TWINSS): histopathological and transcriptomic findings from a salivary gland biopsy sub-study Speaker: Saba Nayar (United Kingdom)
17:20 - 17:30	AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab was Highly Effective in Severe Sjögren Disease: Experience in First Patient Treated Speaker: Norman Gaylis (United States of America)
17:30 - 17:40	Long-Term Efficacy and Safety of Efgartigimod in Sjögren's Disease: Findings from the RHO+ Open-Label Extension Study Speaker: Isabelle Peene (Belgium)
17:40 - 17:50	Biomarker-Driven Insights to Clinical Response in DAHLIAS: a Nipocalimab Trial for Sjögren's Disease Speaker: R Hal Scofield (United States of America)

Oral Abstract Presentations

Date: 03/06/2026

Room: George V Room 1

Clinical Abstract Sessions: Diagnostic Tools in Lupus

Chair:	Marta Mosca (Italy) Aggelos Banos (Greece)
16:30 - 16:40	Multiparametric renal magnetic resonance imaging: a promising noninvasive biomarker of disease activity in lupus nephritis Speaker: Can Huang (China)
16:40 - 16:50	Brain MRI Phenotypes in Neuropsychiatric Systemic Lupus Erythematosus: Associations with Clinical Manifestions, Serological Features, and Prognostic Implications Speaker: Yufei Liu (China)
16:50 - 17:00	North American Expert Consensus on Atherosclerotic Cardiovascular Disease Risk Screening and Management in Patients with Lupus Nephritis Speaker: SHIVANI GARG (United States of America)
17:00 - 17:10	Significance of residual proteinuria in the management of lupus nephritis - insights from a prospective multi-national, longitudinal cohort study Speaker: Jun Kikuchi (Japan)
17:10 - 17:20	Genome-Wide Methylation Profiling Identifies Epigenetic Signatures of Pain, Fatigue, and Health Scores in Women with Systemic Lupus Erythematosus Speaker: Amin Ravaei (Sweden)
17:20 - 17:30	Baseline proteomic profiling identifies a subclinical inflammatory-organ damage state preceding disease worsening in systemic lupus erythematosus Speaker: Lydia Formanti Alonso (Spain)
17:30 - 17:40	Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort Speaker: Marco Martínez-Martínez (Mexico)
17:40 - 17:50	Toward a “virtual biopsy”: in vivo LC-OCT characterization of acute, subacute, and chronic cutaneous lupus erythematosus and differential diagnosis with rosacea: a pilot study Speaker: Rebecca Ventura (Italy)

Oral Abstract Presentations

Date: 03/06/2026

Room: George V Room 2

16:30-18:00 BST

Clinical Abstract Sessions: Comorbidities in Rheumatoid Arthritis

Chair:	Emre Bilgin (Türkiye) Maya Buch (United Kingdom)
16:30 - 16:40	Risk factors for interstitial lung disease in patients with rheumatoid arthritis: results from the international ANCHOR-RA study Speaker: Jeffrey A. Sparks (United States of America)
16:40 - 16:50	Venous thromboembolism with Janus kinase inhibitors and other immunomodulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis Speaker: Maxime Raffray (Sweden)
16:50 - 17:00	Subtype-specific cancer risk with JAK inhibitors and biologic DMARDs in rheumatoid arthritis: comparative analysis within the JAK-pot collaboration Speaker: Kim Lauper (Switzerland)
17:00 - 17:10	Cancer polygenic scores and cancer risk in rheumatoid arthritis Speaker: Virva Kuusi (Finland)
17:10 - 17:20	Contribution of Rare Deleterious Variants in Telomere-Related Genes to the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease Speaker: Pierre-Antoine Juge (France)
17:20 - 17:30	Safety in Continuing and Restarting Biologics in Rheumatoid Arthritis Patients with New-Onset Cancer – A Retrospective Multi-Center Study from the National Database of Rheumatic Diseases in Japan Speaker: Yanakawee Siripongvutikorn (Japan)
17:30 - 17:40	Clinical outcomes of patients with rheumatoid arthritis and lung cancer and according to treatment with immune checkpoint inhibitors: a nationwide Danish register-based cohort study Speaker: Bergur Magnussen (Denmark)

17:40 - 17:50	Assessment of stroke risk and stroke-related mortality in rheumatoid arthritis: A retrospective population based cohort study Speaker: Sarah Pimple (United States of America)
---------------	--

Health Professionals in Rheumatology (HPR)

Date: **03/06/2026**

By the end of the session, delegates will be able to:

Room: **George V Room 3**

- Recognise key digital tools used in rheumatology care across age groups
- Understand how apps support symptoms management, healthy behaviours and monitoring
- Reflect on the promises and limitations of digital health in improving lives of people with RMDs
- Explore how digital tools can enhance shared decision-making and personalise care in rheumatology
- Discuss ways to collaborate across disciplines and with patients in digital innovation

16:30-17:45 BST

Digital Dialogues: A Fishbowl on Tech-enabled Clinical Practice

Chair:	Simone Battista (United Kingdom)
16:30 - 16:35	Introduction to Fishbowl Speaker: Simone Battista (United Kingdom)
16:35 - 16:40	Can technology improve not just how we live, but how long we live? Hype or hope? Speaker: Rafael Prieto Moreno (Spain)
16:40 - 16:45	Self-managing hand osteoarthritis is in the palm of your hand: the Happy Hands app Speaker: Anne Therese Tveter (Norway)

16:45 - 16:50	No gym, no problem: bringing digital exercise to young people with RMDs Speaker: Nilay Arman (Türkiye)
16:50 - 16:55	Click, choose, decide: digital tools for shared decision-making and tailored self-management Speaker: Maartje Stutvoet (Netherlands)
16:55 - 17:45	Fishbowl Discussion

Oral Abstract Presentations

Date: **03/06/2026**

Room: **George V Room 4**

16:30-17:45 BST

Basic and Clinical Abstract Sessions: Unconventional targets in Psoriatic Arthritis

Chair:	Dennis McGonagle (United Kingdom) Josefina Marin (Spain)
16:30 - 16:40	Detection of Subclinical Synovial Angiogenesis in Psoriatic Arthritis Using 68Ga-RGD PET/CT: A Pilot Study Speaker: Muskan Arora (India)
16:40 - 16:50	Ixekizumab and Concomitant Tirzepatide Achieved Early Disease Control in Adults with Psoriatic Arthritis and Obesity/Overweight: Phase 3b TOGETHER-PsA Trial Speaker: Laura C. Coates (United Kingdom)
16:50 - 17:00	Dietary interventions in Psoriatic Arthritis (DIPSA): A Randomized controlled clinical trial Speaker: Lihi Eder (Canada)

17:00 - 17:10	From disease-centred to tissue-centred care in psoriatic arthritis: clinical impact of synovial biopsy-driven therapeutic stratification Speaker: Simone Parisi (Italy)
17:10 - 17:20	Interception of psoriatic arthritis in psoriasis: real-world evidence across biologic classes from a long-term clinical cohort Speaker: Nikolaos Kougkas (Greece)
17:20 - 17:30	Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients With Active Psoriatic Arthritis: Week 52 Results From a Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 2b/3 Study Speaker: Philip J. Mease (United States of America)
17:30 - 17:40	Treatment with Glucagon-like Peptide-1 Receptor Agonists is associated with Lower Disease Activity and Pain in Psoriatic Arthritis Independent of Weight Change Speaker: Pankti Mehta (Canada)
17:40 - 17:50	Structural Damage Progression and Clinical Response to Guselkumab in Participants With Active and Erosive Psoriatic Arthritis: Post hoc Analysis at Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study Speaker: Christopher T. Ritchlin (United States of America)

Oral Abstract Presentations

Date: **03/06/2026**

Room: **Room 12**

16:30-17:45 BST

Basic and Clinical Abstract Sessions: Biomarkers in RMDs

Chair:	Diane van der Woude (Netherlands) Costantino Pitzalis (United Kingdom)
16:30 - 16:40	Diagnostic performance of serum and urine levels of CD163, CD25, CD206 and MCP-1 as biomarkers for detecting disease activity in ANCA-associated vasculitis Speaker: Laurie Baas (Netherlands)

16:40 - 16:50	Improving remission rates in early rheumatoid arthritis: Targeting predicted poor methotrexate responders, based on naïve CD4+ T-cell frequency, with additional etanercept: the TEEMS trial, a pilot proof of concept study. Speaker: Kulveer Mankia (United Kingdom)
16:50 - 17:00	Autoantibodies and risk for clinical rheumatoid arthritis-associated interstitial lung disease: A case-control study Speaker: Rathnam Venkat (United States of America)
17:00 - 17:10	Circulating proteomic biomarkers predict flare during biologic tapering in rheumatoid arthritis Speaker: Lucía Lourido (Spain)
17:10 - 17:20	Ex vivo immune-derived molecular signatures of JAK and TNF inhibitors predict treatment response in biologic- and targeted synthetic DMARD-naïve Rheumatoid Arthritis patients Speaker: Sagrario Corrales-Díaz Flores (Spain)
17:20 - 17:30	Superior Correlation with Clinical Activity and Unique Detection Patterns: A Prospective Study of FAPI versus FDG-PET in Polymyalgia Rheumatica and Giant Cell Arteritis Speaker: Weiqian Chen (China)
17:30 - 17:40	Proteomic Biomarkers of Clinical Endpoints in CTD-ILD Speaker: Justin Oldham (United States of America)
17:40 - 17:50	Autoantibody Reactome Analysis Reveals Novel Biomarkers for Idiopathic Retroperitoneal Fibrosis Speaker: Xi He

EULAR Culture

Date: 03/06/2026

Year 3026 - The Last Hope

Room: Escape Room 1

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the

16:30-18:30 BST

hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **03/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

16:30-18:30 BST

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

What is New (WIN)

Date: **04/06/2026**

1. Gain a comprehensive understanding of how Bi-specific T-cell Engagers function
2. Review existing evidence on efficacy and safety of BiTEs in treatment of RMDs
3. Discuss the role of BiTEs as a novel therapeutic strategy in RMDs

Room: **Plenary**

08:15-09:00 BST

BiTE me - Bi-specific T-cell Engagers in RMDs

Chair:	Hans Ulrich Scherer (Netherlands) Melanie Hagen (Germany)
08:15 - 09:00	Bi-specific T-cell Engagers in RMDs Speaker: Wolfgang Merkt (Germany)

Basic and Clinical Abstract Sessions: What's new in juvenile idiopathic arthritis?

Chair:	Jordi Antón (Spain) Petra Hissink Muller (Netherlands)
08:15 - 08:25	Distinct roles of IL-1 and IFN-gamma in recruitment of lung macrophage populations in the TLR9-induced model of macrophage activation syndrome Speaker: Grant Schulert (United States of America)
08:25 - 08:35	High-resolution spatial mapping of the JIA synovium uncovers disease-relevant cellular landscape and niche Speaker: Jun Inamo (Japan)
08:35 - 08:45	Long-term Outcomes of Juvenile Idiopathic Arthritis in Adulthood: a Population-Based Matched Comparator Study from Norway. Speaker: Imane Bardan (Norway)
08:45 - 08:55	Baseline Characteristics of the Prospective, Multicentre, International Cohort for the New Classification Criteria of Juvenile Idiopathic Arthritides Speaker: Saverio La Bella (Italy)
08:55 - 09:05	Components of JIA-ACR (Wallace) inactive disease criteria after initiation of TNF inhibitors: Results from the MyJIA trial Speaker: Alexander Nima Sharami (Norway)
09:05 - 09:15	Low Concordance Between Adult and Pediatric OMERACT Ultrasound Definitions of Synovitis in Transitional Juvenile Idiopathic Arthritis Speaker: Silvia Magni-Manzoni (Italy)
09:15 - 09:25	Therapeutic goals of the EULAR/PRES recommendations for systemic juvenile idiopathic arthritis are often achieved in clinical practice Speaker: Gerd Horneff (Germany)

09:25 - 09:35	Distinct Subgroups of Early Juvenile Psoriatic Arthritis Identified using Machine Learning: Results from a Multinational Collaboration of Inception Cohorts Speaker: Stephanie Shoop-Worrall (United Kingdom)
---------------	---

Oral Abstract Presentations

Date: **04/06/2026**

Room: **Connaught Room 3 & 4**

08:15-09:30 BST

Basic and Clinical Abstract Sessions: Insights into bone health - what are the drivers?

Chair:	Björn Bühring (Germany) Magda Osipyan (Armenia)
08:15 - 08:25	Romosozumab versus denosumab in glucocorticoid-induced osteoporosis: an extended observation of a randomized controlled trial at 48 months Speaker: Chi Chiu Mok (Hong Kong, China)
08:25 - 08:35	Changes in Bone Mineral Density and Fractures During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis Speaker: Frank Buttgereit (Germany)
08:35 - 08:45	Osteosarcopenia and musculoskeletal phenotypes in different idiopathic inflammatory myopathies: a cross-sectional DXA study Speaker: Federico Aldegheri (Italy)
08:45 - 08:55	Spp1+ Macrophages Are Specifically Enriched in Arthritic Joints and Associated with Abnormal Bone Metabolism in Collagen-Induced Arthritis Mice Speaker: Chenjia He (China)
08:55 - 09:05	An Proteogenomic Study in UK and China Kadoorie Biobank pinpoints 14 Causal Biomarkers for Bone health and disease Speaker: Li Chen (China)

09:05 - 09:15	Do Glucagon-like peptide-1 Based Therapies Increase the Risk of Adverse Effects in Those Taking Oral Bisphosphonates for Osteoporosis? Speaker: Pallavi Velagapudi (United States of America)
09:15 - 09:25	Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women Speaker: Maxime Auroux (France)

Health Professionals in Rheumatology (HPR)

Date: 04/06/2026

Room: Victoria Room 1

08:15-09:35 BST

HPR Abstract Sessions: Evidence Into Action - Multidisciplinary Approaches to Improve Outcomes in RMD Care

Chair:	
08:15 - 08:25	Feasibility of COMFI: a COMBined Fatigue Intervention for people with inflammatory arthritis Speaker: Astrid Damgaard (Denmark)
08:25 - 08:35	Co-developing a Flexible Care Delivery Model for Inflammatory Arthritis in Canada (FlexCAre): Results from Focus Groups with Patients and Health Care Providers Speaker: Susan J. Bartlett (Canada)
08:35 - 08:45	An Interdisciplinary Model to Improve Access to Rheumatology Care and Promote Early Identification for Axial Spondyloarthritis: Preliminary Results of the FASTRAX Study Speaker: Laura Passalent (Canada)
08:45 - 08:55	A three wide-level behavioral change recommendation guide to support clinicians in routinely using methods to assess glucocorticoid toxicity: A multimethod study Speaker: Vasilis Vasiliou (United Kingdom)

08:55 - 09:05	Course of Itch from Systemic Sclerosis Onset: a Scleroderma Patient-centered Intervention Network Cohort Study Speaker: Meira Golberg (Canada)
09:05 - 09:15	Work participation trajectories before and after multidisciplinary rehabilitation across occupational groups in people with RMDs: a multicentre cohort study Speaker: Mari Nilsen Skinnes (Norway)
09:15 - 09:25	Unravelling complex relationships between Health Literacy and Shared Decision Making: A cross-sectional study in patients attending rheumatology rehabilitation Speaker: Lisbeth Skovly Nielsen (Denmark)
09:25 - 09:35	Measuring what matters: development of the OMERACT core domain set for foot and ankle disorders in rheumatic and musculoskeletal diseases Speaker: Lara Chapman (United Kingdom)

Oral Abstract Presentations

Date: **04/06/2026**

Room: **Victoria Room 3**

08:15-09:30 BST

Basic Abstract Sessions: Digging deep into Lupus

Chair:	George Tsokos (United States of America) Anne Trolborg (Denmark)
08:15 - 08:25	Platelets activate remigrating neutrophils in systemic lupus erythematosus and represent a therapeutic target Speaker: Yakai Fu (China)
08:25 - 08:35	Clonally expanded dural CD8+ T cells drive pathological lymphatic remodeling via macrophage crosstalk in neuropsychiatric SLE Speaker: Yi Feng (China)
08:35 - 08:45	Autoantibody Signatures for Risk Stratification of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus Speaker: Junjie Peng (United Kingdom)

08:45 - 08:55	Single-cell analysis of interferon blockade uncovers B cell repertoire remodeling in Systemic lupus erythematosus Speaker: Keigo Terada (Japan)
08:55 - 09:05	Immune Reset and Microbial Shifts: Gut Microbiota Dynamics After CD19 CAR T-Cell Therapy in Autoimmune Disease Speaker: Yuichi Maeda (Japan)
09:05 - 09:15	12-Lipoxygenase regulates inflammatory cell recruitment in lupus nephritis Speaker: Mélina Monteil (Canada)
09:15 - 09:25	Oxidative stress-associated PLA2 activation drives lysophospholipid dysregulation linked to B cell hyperactivity in systemic lupus erythematosus Speaker: JUNXIA HUANG (China)
09:25 - 09:35	Early Disruption of B cell Tolerance Pathways and Immune Regulatory Circuits in Preclinical Systemic Autoimmune Disease Speaker: Aleksandra Bylinska (United States of America)

Oral Abstract Presentations

Date: **04/06/2026**

Room: **Victoria Room 4**

08:15-09:35 BST

Case Reports: Diagnostic Challenges

Chair:	Francisca Sivera (Spain) Predrag Ostojic (Serbia)
08:15 - 08:25	Introduction Speaker: Predrag Ostojic (Serbia)
08:25 - 08:35	A Genetic Mimic in Rheumatology: Type II Collagenopathy Masquerading as Treatment-Resistant Seronegative Arthritis Speaker: zeynep yagbasan (Türkiye)

08:35 - 08:45	Rare Report of a Non-Thrombotic Venous Aneurysm Related to Inferior Vena Cava Stenosis in a Patient with Takayasu's Arteritis Speaker: Markus Bredemeier (Brazil)
08:45 - 08:55	Suprasellar Neurosarcoidosis Masquerading as Meningioma: A Multisystem Diagnostic Challenge with Non-Biopsy Confirmation Speaker: Mani Rajendran (India)
08:55 - 09:05	Spondyloepiphyseal Dysplasia Tarda Mimicking Rheumatoid Arthritis: Importance of Recognising a Non-Inflammatory Mimicker Speaker: Burcu Yagiz (Türkiye)
09:05 - 09:15	Bile Acid-Associated Systemic Inflammatory Syndrome (BASIS): A Novel Autoinflammatory Disorder Linked to Impaired Bile Acid Absorption Speaker: Ahmet Gül (Türkiye)
09:15 - 09:25	Never Too Old for Genetic Testing: Two Cases of Adult-Onset Deficiency of Adenosine Deaminase 2 Speaker: Nikolas Bublitz (Germany)
09:25 - 09:35	Voting Speaker: Predrag Ostojic (Serbia)

Oral Abstract Presentations

Date: **04/06/2026**

Room: **Victoria Room 5 & 6**

08:15-09:30 BST

Clinical Abstract Sessions: Clinical manifestations and disease course in Systemic Sclerosis

Chair:	Marco Matucci-Cerinic (Italy) Cristiana Sieiro Santos (United Kingdom)
--------	---

08:15 - 08:25	Clinical Spectrum and Prognosis of Interstitial Lung Disease in Patients with Systemic Sclerosis–Related Autoantibodies: Systemic Sclerosis, IPAF, or Unclassifiable Disease? Speaker: Karla Chacón (Mexico)
08:25 - 08:35	Deciphering survival determinants in systemic sclerosis-associated pulmonary arterial hypertension: insights from a multicenter and multidisciplinary real-world study. Speaker: Stefano Stano (Italy)
08:35 - 08:45	Validation of the ILD-RISC score in special populations from the EUSTAR registry: tailored cut-off values for non-Caucasian ethnicities, patients with pulmonary hypertension and very early pre-disease Speaker: Maria Iacovantuono (Italy)
08:45 - 08:55	Clinical value of modified EUSTAR disease activity index to stratify for clinical outcome: A longitudinal Observational Analysis of the EUSTAR Database Speaker: Tânia Santiago (Portugal)
08:55 - 09:05	Longitudinal patterns of vascular, immune and fibrotic manifestations throughout the course of systemic sclerosis: Evidence from the German National Systemic Sclerosis Registry DNSS Speaker: Tim Filla (Germany)
09:05 - 09:15	Primary Cardiac Involvement in Early Systemic Sclerosis: Baseline Profile of the patients in the SOLAR Registry Speaker: Shirkhan Amikishiyev (Azerbaijan)
09:15 - 09:25	The involvement of the temporomandibular joint in patients with Systemic Sclerosis: a clinical and ultrasound study Speaker: Alessia Laneri (Italy)
09:25 - 09:35	Features of pulmonary Veno-Occlusive Disease complicate the course of precapillary pulmonary hypertension in Systemic Sclerosis: A EUSTAR Cohort Study Speaker: Nicola Farina (Italy)

Clinical Abstract Sessions: Advanced Management in Rheumatoid Arthritis

Chair:	Serena Bugatti (Italy) Ruxandra Ionescu (Romania)
08:15 - 08:25	Rosnilimab, a Selective and Potent Depletor of Pathogenic T Cells, Demonstrates Efficacy, Safety and Translational Proof of Mechanism in RENOIR, a Phase 2B Trial in Moderate-to-Severe Rheumatoid Arthritis Speaker: Paul Emery (United Kingdom)
08:25 - 08:35	“Immune dimming” with low-dose blinatumomab reverses the treatment-resistant state in rheumatoid arthritis Speaker: Laura Bucci (Germany)
08:35 - 08:45	Better After CHOosing in rheumatoid arthritis (The BACH Study): Rheumatoid Arthritis patients choose a JAK inhibitor over anti-TNF and patients who may choose their treatment are more satisfied, have a better drug survival and less adverse events in comparison to randomly allocated treatment Speaker: reinhard bos (Netherlands)
08:45 - 08:55	Subcutaneous tocilizumab versus abatacept in rheumatoid arthritis with inadequate response to one or two prior b/tsDMARDs: results of the SUNSTAR head-to-head, multicentre, open-label, randomised superiority trial Speaker: Tristan Pascart (France)
08:55 - 09:05	Oral Split-Dose vs. Subcutaneous Methotrexate in Active Rheumatoid Arthritis (SCOOT study): A Multicentric Randomized Controlled Trial Speaker: Varun Dhir (India)
09:05 - 09:15	Dietary Fiber Supplementation Improves Methotrexate-Associated Clinical Response and Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibres Randomized Trial Speaker: Claire Immediato Daien (France)
09:15 - 09:25	A Randomized Double-Blind Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of LNK01001 (zemprocitinib) in Patient with Moderate-to-Severe Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs (COURAGE-RA) Speaker: Xiaofeng Zeng (China)

09:25 - 09:35	Efficacy and Safety of the Oral TNFR1 Signal Inhibitor, Balinatunfib, in Patients With Moderate-to-Severe Rheumatoid Arthritis: Results From the SPECIFI-RA Phase 2b Study Speaker: Iain B. McInnes (United Kingdom)
---------------	--

Oral Abstract Presentations

Date: **04/06/2026**

Room: **N2**

08:15-09:30 BST

Clinical Abstract Sessions: DORIS and the wolf - outcome measures in SLE

Chair:	Thomas Dörner (Germany) Alessia Alunno (Italy)
08:15 - 08:25	Evaluation of Candidate Definitions of Severe Refractory Systemic Lupus Erythematosus Using Clinical Outcomes: Real-World Data Exploration Study Speaker: Rangi Kandane-Rathnayake (Australia)
08:25 - 08:35	DORIS Remission and LLDAS Attainment After up to 12 Months of Real-world Anifrolumab Treatment: Interim Results From the ASTER Study Speaker: Marta Mosca (Italy)
08:35 - 08:45	The association of physical function with patient-reported outcomes in people with systemic lupus erythematosus Speaker: Mrinalini Dey (United Kingdom)
08:45 - 08:55	Association of the Treatment Response Measure for SLE (TRM-SLE) renal response thresholds with long-term outcomes in patients with lupus nephritis Speaker: Yanjie Hao (Australia)
08:55 - 09:05	Proteinuria underestimates intrarenal inflammation after 12 months of therapy in lupus nephritis: interim results from the ReBioLup study Speaker: Ioannis Parodis (Sweden)
09:05 - 09:15	Risk-stratified use of triple therapy in lupus nephritis based on EULAR 2025 prognostic factors Speaker: Hironari Hanaoka (Japan)

09:15 - 09:25	Poor air quality is associated with increased risk of systemic lupus erythematosus onset Speaker: Sharon Dowell (United States of America)
09:25 - 09:35	Risk of cancer induced by human papillomavirus in patients with immune mediated inflammatory diseases: a nationwide matched cohort study Speaker: Clothilde Gros (France)

Oral Abstract Presentations

Date: **04/06/2026**

Room: **N3**

08:15-09:43 BST

Basic and Clinical Abstract Sessions: Optimising care in Psoriatic Arthritis

Chair:	Gaëlle Varkas (Belgium) Gizem Ayan (Türkiye)
08:15 - 08:25	The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis Speaker: Lihi Eder (Canada)
08:25 - 08:35	Impact of Biologic Therapies and Targeted Synthetic DMARDs on Major Adverse Cardiovascular Events in Psoriatic Arthritis Speaker: Milad Heydari-Kamjani (United States of America)
08:35 - 08:45	Enthesophyte Development in Psoriatic Arthritis: Role of Disease Activity and Biomechanical Factors Speaker: Pankti Mehta (Canada)
08:45 - 08:55	Clinical and Imaging Features of Subclinical and Early Psoriatic Arthritis Reveal Synovio-Enthesial Inflammation as a Marker of Psoriatic Arthralgia Progression Speaker: Alen Zabotti (Italy)
08:55 - 09:05	Phase 2b trial of the selective TYK2 inhibitor zasocitinib (TAK-279) in active psoriatic arthritis: biomarkers associated with pathway modulation, disease activity and clinical responses Speaker: Iain B. McInnes (United Kingdom)

09:05 - 09:15	Treatment retention and clinical remission in 787 real-world patients with psoriatic arthritis treated with bimekizumab: results from 12 registries in the European Spondyloarthritis Research Collaboration Network Speaker: Louise Majormoen Nielung (Denmark)
09:15 - 09:25	Effect of Guselkumab and Golimumab Combination Therapy on Magnetic Resonance Imaging-Detected Inflammation and Damage in Phalangeal Joints of the Hands and Feet and Entheses of the Heels Among Participants With Active Psoriatic Arthritis: Findings From the Phase 2a AFFINITY Study Speaker: Mikkel Østergaard (Denmark)
09:25 - 09:35	Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial Speaker: Alexandre Garaïman (United Kingdom)

Oral Abstract Presentations

Date: 04/06/2026

Room: George V Room 1

08:15-09:30 BST

Clinical Abstract Sessions: New insights in Small Vessel Vasculitis and Behcet's Disease

Chair:	Jens Thiel (Austria) Luca Quartuccio (Italy)
08:15 - 08:25	Very early mepolizumab treatment in EGPA is associated with higher remission and glucocorticoid-free status through 24 months: results from the MEPEARL study Speaker: Roberto Padoan (Italy)
08:25 - 08:35	Behcet's Syndrome Might Have Distinct Clinical Subgroups: Result of A Cluster Analysis Speaker: Hasan Kocaayan (Türkiye)
08:35 - 08:45	Lenalidomide in Refractory Mucosal Behçet's Syndrome: A Prospective Study of Efficacy, Safety, and Immunomodulatory Mechanisms Speaker: Jingwen Wu (China)

08:45 - 08:55	In patients with ANCA-associated vasculitides, low-dose glucocorticoids added to maintenance treatment, does not reduce the risk of major flares and is associated with an increased risk for chronic damage and hospitalization Speaker: Katerina Chavatza (Greece)
08:55 - 09:05	Inside the Heterogeneity of Primary Central Nervous System Vasculitis: a single-centre 40-year experience Speaker: Carlo Salvarani (Italy)
09:05 - 09:15	COMBINED ANTI-IL-5/IL-5R AND DUPILUMAB THERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A EUROPEAN RETROSPECTIVE STUDY Speaker: Miriam Guerini (Italy)
09:15 - 09:25	A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis Speaker: Mark McClure (United Kingdom)
09:25 - 09:35	Mepolizumab 100 vs 300 mg/4 weeks for eosinophilic granulomatosis with polyangiitis (EGPA): a 24-month retrospective cohort study by the European EGPA Study Group Speaker: Alessandra Bettiol (Italy)

Oral Abstract Presentations

Date: **04/06/2026**

Room: **George V Room 2**

08:15-09:30 BST

Clinical Abstract Sessions: This is a woman's world

Chair:	Antonia Mazzucato-Puchner (Austria) Dina Zucchi (Italy)
08:15 - 08:25	Disease activity during and after pregnancy in women with rheumatoid arthritis: a prospective multientre study from Norway Speaker: Ingunn Sagberg (Norway)

08:25 - 08:35	Menopausal status influences disease severity and remission in women with rheumatoid arthritis starting biologic DMARDs: a real-world evidence study from the multicenter prospective BIOlogic aPULian REgistry (BIOPURE). Speaker: Simone Perniola (Italy)
08:35 - 08:45	Pregnancy Outcomes in Women with Autoinflammatory Diseases - Data from the German Rhekiss Registry Speaker: Ann-Christin Pecher (Germany)
08:45 - 08:55	Fertility and pregnancy outcomes in Axial Spondyloarthritis: A multinational study of 500 patients from 15 Arab countries. Speaker: Farid Abou Abdallah (Lebanon)
08:55 - 09:05	Perimenopause is associated with increased disease activity in psoriatic arthritis Speaker: Lihi Eder (Canada)
09:05 - 09:15	Pregnancy Outcomes in Maternal Exposure to Guselkumab: Review of Cases Reported to the Company Global Safety Database Speaker: Laura C. Coates (United Kingdom)
09:15 - 09:25	Association of Pregnancy with Disease Activity and Medication Use in Rheumatoid Arthritis: Analysis of a Japanese National Registry Speaker: Tatsunori Shizuku (United States of America)
09:25 - 09:35	Pregnancy rates and outcomes in early arthritis over a 12-year follow-up: an analysis of the ESPOIR cohort Speaker: Roba Ghossan (France)

Oral Abstract Presentations

Date: **04/06/2026**

Room: **George V Room 3**

08:15-09:30 BST

Basic and Clinical Abstract Sessions: Advances in Inflammatory Myopathies

Chair:	Jiri Vencovsky (Czechia) Vasiliki Liakouli (Italy)
--------	---

08:15 - 08:25	Impact of Anti-Cytosolic Nucleotidase 1A Antibody Status on Disease Phenotype and Therapeutic Response to Ulviprubarb in Inclusion Body Myositis Speaker: Pedro Machado (United Kingdom)
08:25 - 08:35	Integrated genomics and cross-tissue single-cell transcriptomics define monocyte-driven tissue injury in myositis Speaker: Shinji Izuka (Japan)
08:35 - 08:45	Rapid, Clinically Meaningful Improvement in Skin Disease with Brepocitinib in Dermatomyositis: Results from the Phase 3 VALOR Trial Speaker: Ruth Vleugels (United States of America)
08:45 - 08:55	Immune-Exhausted, High-Inflammation Phenotype Defines Rituximab Non-Responders in Refractory Myositis: Results From the MYOPROSP Study Speaker: Xia Lyu (China)
08:55 - 09:05	Quantitative Nailfold Videocapillaroscopy Outperforms Muscle Enzymes for Assessing Disease Activity in Inflammatory Myopathies Speaker: Jorge Álvarez Troncoso (Spain)
09:05 - 09:15	Mosaic Chromosomal Alterations in Sex Chromosomes in Inclusion Body Myositis Speaker: Luke Tomlinson (United Kingdom)
09:15 - 09:25	Safety and Efficacy of Rese-cel (Resecabtagene Autoleucel) in Severe, Refractory Idiopathic Inflammatory Myopathy: Results from the Phase 1/2 cohorts of the RESET-IIM Clinical Trial Speaker: Erin Wilfong (United States of America)
09:25 - 09:35	Immune Checkpoint Inhibitor Myositis, Myocarditis and Myasthenia Gravis: a comparison of overall survival using real world data Speaker: Deanna Jannat-Khah (United States of America)

Oral Abstract Presentations

Date: **04/06/2026**

Room: **George V Room 4**

08:15-09:30 BST

Clinical Abstract Sessions: Optimising Care in Spondyloarthritis

Chair:	Alexandre Sepriano (Portugal) Zineb Ez-Zaitouni (Netherlands)
08:15 - 08:25	Filgotinib significantly improves disease activity in patients with active axial spondyloarthritis: Primary results from the Phase 3 OLINGUITO trial Speaker: Xenofon Baraliakos (Germany)
08:25 - 08:35	No superiority of IL-17A inhibitors compared with TNF inhibitor cycling after failure of a first TNF inhibitor in axial spondyloarthritis: results from the ROC-SpA study Speaker: Hubert Marotte (France)
08:35 - 08:45	The 2025 Assessment of SpondyloArthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of AxSpA Inception Cohort Study Speaker: Walter P Maksymowych (Canada)
08:45 - 08:55	Ivarmacitinib, a selective JAK1 inhibitor, in active non-radiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial Speaker: Xuan Zhang (China)
08:55 - 09:05	Risk of Cancer according to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study from the French Health Insurance Database Speaker: Karine Tankovic (France)
09:05 - 09:15	High specificity but modest sensitivity of the 2025 ASAS-SPARTAN revised axial spondyloarthritis classification criteria in early axial spondyloarthritis: data from the SPACE cohort Speaker: Liese de Bruin (Netherlands)
09:15 - 09:25	Efficacy and safety of gecacitinib, a novel pan-JAK inhibitor, in patients with active radiographic axial spondyloarthritis: Results from a randomised, double-blind, placebo-controlled, multicentre phase 3 clinical trial Speaker: Chunde Bao (China)

09:25 - 09:35	Tofacitinib in early active axial spondyloarthritis: results from the randomised, double-blind, placebo-controlled, multicentre Phase IV study, FASTLANE Speaker: Valeria Rios Rodriguez (Germany)
---------------	--

Oral Abstract Presentations

Date: **04/06/2026**

Room: **Room 12**

08:15-09:30 BST

Basic Abstract Sessions: New therapeutic targets in Rheumatoid Arthritis and Sjögren's

Chair:	Inger Gjertsson (Sweden) Torsten Witte (Germany)
08:15 - 08:25	Off-the-Shelf Dual-CAR T-Cell Therapy: Targeting B and T Cells in Autoimmune Disease Without Preconditioning Speaker: Natalie J. Shiff (United States of America)
08:25 - 08:35	KT502, a novel CD19-directed T cell engager, leads to rapid and deep B cell depletion with transient and low cytokine release Speaker: Min Bao (United States of America)
08:35 - 08:45	Calcium phosphate-associated extracellular vesicles in rheumatoid arthritis Speaker: Caroline Schmidt (Germany)
08:45 - 08:55	Multimodal analysis identifies altered brain connectivity signature and related psychological and molecular patterns in difficult-to-treat rheumatoid arthritis Speaker: Lilla Gunkl-Tóth (Hungary)
08:55 - 09:05	Enhanced TYK2 inhibition signature is associated with severity of clinical domains and laboratory measures in Sjögren's disease Speaker: Divi Cornec (France)

09:05 - 09:15	Accumulation of mitochondrial dsRNA due to defective m⁶A-dependent RNA regulation in epithelial cells may explain the Interferon signature in Sjögren's disease Speaker: Alejandro Arco-hierves (France)
09:15 - 09:25	Direct inhibition of salivary gland organoid maturation by IgG from Sjögren disease patients Speaker: Tobit D. Steinmetz (Netherlands)
09:25 - 09:35	EVIDENCE OF THE DUAL MECHANISM OF ACTION OF IANALUMAB (VAY736) IN THE CIRCULATION AND SALIVARY GLAND TISSUE OF PATIENTS WITH SJÖGREN'S DISEASE: RESULTS FROM A PHASE 2 MECHANISTIC STUDY Speaker: Divi Cornec (France)

HPR Meet the EULAR Expert

Date: **04/06/2026**

Delegates will:

Room: **Meet the EULAR Expert 1**

- Identify the long-term impact of green spaces on musculoskeletal health.

08:30-09:00 BST

- Discuss how outdoor physical activity supports better health perception, energy levels, and sustained participation.

Nature in prevention and RMD management

Chair:	
08:30 - 09:00	Nature in prevention and RMD management Speaker: Jessica Stanhope (Australia)

Meet the EULAR Expert

Date: **04/06/2026**

Room: **Meet the EULAR Expert 2**

08:30-09:00 BST

Artificial Intelligence in RMDs

Chair:	
08:30 - 09:00	Artificial Intelligence in RMDs Speaker: Oliver Hendricks (Denmark)

Meet the EULAR Expert

Date: **04/06/2026**

1. Review recent advances in the diagnosis and management of spondyloarthritis.
2. Clarify challenging clinical scenarios through focused expert discussion.
3. Apply practical strategies to individualise treatment across SpA phenotypes.

Room: **Meet the EULAR Expert 3**

08:30-09:00 BST

Spondyloarthritis

Chair:	
08:30 - 09:00	Spondyloarthritis Speaker: Helena Marzo-Ortega (United Kingdom)

PARE Meet the EULAR Expert

Date: **04/06/2026**

1. Describe how AI tools, such as LupusGPT, are being used to deliver accurate, patient-centered information to individuals living with RMDs.

Room: **Meet the EULAR Expert 4**

08:30-09:00 BST

2. Evaluate the opportunities and limitations of AI-powered communication tools in promoting health literacy and shared decision-making.

3. Identify practical and ethical challenges in applying AI for patient support, including trust, transparency, data quality, bias, and accessibility.

AI as a Partner in Care: Empowering the RMD Community with Information

Chair:	
08:30 - 09:00	AI as a Partner in Care: Empowering the RMD Community with Information Speaker: Zoe Karakikla Mitsakou (Belgium)

EULAR Culture

Date: **04/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

08:30-10:30 BST

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **04/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

08:30-10:30 BST

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

Oral Abstract PresentationsDate: **04/06/2026**Room: **Victoria Room 2****08:45-10:15 BST****PARE Abstract Session: Evidence meets Experience**

Chair:	Fitim Sadiku (Kosovo) Eszter Rozán (Hungary)
08:45 - 08:55	Stene Prize - Is it all in the genes, or not? How rheumatic and musculoskeletal diseases shape and reshape family connections Speaker: Yusra Momade (Portugal)
08:55 - 09:05	Increasing Access in General Health System for Physiotherapy treatments for people with RMDs Speaker: Stalo PAPAMICHAEL (Cyprus)
09:05 - 09:15	Patient-Reported Prevalence and Functional Impact of Digestive and Bowel Symptoms in Sjögren's Disease: Findings from a Global Survey Speaker: Ellen Wang (Canada)
09:15 - 09:25	Chronic Competence - see the resources, not the restrictions Speaker: Ingeborg Dybvig (Norway)
09:25 - 09:35	Make lupus visible Speaker: Ingrid Hennes (Belgium)
09:35 - 09:45	Development and evaluation of a self-management website to support everyday well-being of people living with RMDs Speaker: Sanni Huttunen (Finland)
09:45 - 09:55	Engagement of Patient Research Partners (PRPs) in a 7 years clinical research project: points to consider and lessons learned! Speaker: Coralie Bouillot (France)

09:55 - 10:05	Turning Guidelines to Answers: Patient Evaluation of AI-Based Guideline Chatbots in Rheumatology Speaker: Johannes Knitza (Germany)
---------------	---

How to Treat (HOT)

Date: **04/06/2026**

After attending this session, participants will be able to:

Room: **Plenary**

09:00-09:45 BST

Recognise the spectrum of rheumatic immune-related adverse events (irAE) associated with immune checkpoint inhibitor (ICI) therapy.

Formulate evidence-based treatment strategies for managing rheumatic irAEs while balancing oncological priorities.

Understand the role of multidisciplinary collaboration between rheumatologists and oncologists in the care of patients receiving ICI therapy.

Apply practical decision-making principles for when to initiate, taper, or withhold immunosuppressive therapy in patients with rheumatic irAEs.

Immune checkpoint inhibitor induced rheumatic irAE

Chair:	Katerina Chatzidionysiou (Sweden) Eden Sebbag (France)
09:00 - 09:45	Treatment of immune checkpoint inhibitor induced rheumatic irAE Speaker: Hendrik Schulze-Koops (Germany)

Poster View PresentationsDate: **04/06/2026**Room: **Poster View****09:30-23:40 BST****Poster View II**

Chair:	
09:30 - 09:40	3H-1,2-Dithiole-3-Thione Ameliorates Lupus Nephritis in Imiquimod-Induced Lupus-prone Mice via Modulation of Th1 and Th17 Responses Speaker: Kai-Chun Wang (Taiwan)
09:40 - 09:50	Circulating miR-1285-3p promotes pathogenic B-cell differentiation via suppression of the OXPPOS–IKZF2 axis in systemic lupus erythematosus Speaker: Satoshi Akao (Japan)
09:50 - 10:00	Real-world Evidence on the Long-term Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study Speaker: SHIVANI GARG (United States of America)
10:00 - 10:10	Multidisciplinary Care and Clinical Outcomes in Spondyloarthritis: Evidence from a Colombian Real-World Cohort Speaker: Julián Arias-Aponte (United Kingdom)
10:10 - 10:20	Evaluating the causal associations between Clonal Hematopoiesis and its subtypes and Rheumatoid Arthritis: A Bidirectional Mendelian Randomization Study Speaker: Nan Li (China)
10:20 - 10:30	Partners' experience of inflammatory arthritis impact on their lives: A qualitative study Speaker: Charlotte Werdal Hansen (Denmark)
10:30 - 10:40	IFI44L Promoter Methylation as a Biomarker Across the Spectrum of SLE: From Genetic Predisposition to Diagnosis and Disease Activity Monitoring Speaker: Xiaohui Zhang (China)

10:40 - 10:50	Sema4A is elevated in patients with psoriatic arthritis and induces inflammation in vitro and in vivo Speaker: Jaime Marty Lobo (Spain)
10:50 - 11:00	The Impact of Advanced Practice Nursing on Patient Satisfaction in Rheumatology: A Pre-Post-Study in a Hospital Setting Speaker: Kendra Rohleder (Germany)
11:00 - 11:10	Delineation of Pathogenic IgG4-secreting Cellular Networks in IgG4-Related Disease by Spatial Transcriptomic and Proteomic Profiling Speaker: Min-Gang Kim (Korea, Republic of (South Korea))
11:10 - 11:20	BIOLOGICAL AGE ACCELERATION AS A RISK FACTOR FOR ARTHRITIS: EVIDENCE FROM COLOMBIA Speaker: julian arias (United Kingdom)
11:20 - 11:30	Safety and Efficacy of Allogeneic anti-CD19 STAR-T cell in Severe/Refractory Autoimmune Diseases: A phase I trial Speaker: Huji Xu (China)
11:30 - 11:40	Complete and partial renal response to voclosporin in difficult-to-treat patients with lupus nephritis: data from the VoRLiSS (Voclosporin in Real Life Setting Study). Speaker: Aurora Di Gregorio (Italy)
11:40 - 11:50	Antimalarials in Lupus Nephritis: The Untold Story Speaker: Fadi Kharouf (Israel)
11:50 - 12:00	Utilization and In-Hospital Outcomes of Plasma Exchange in Systemic Lupus Erythematosus and Vasculitis: A National Inpatient Analysis Speaker: Naina Kumari (United States of America)
12:00 - 12:10	Inflammasome-related polymorphisms as biomarkers to accurately diagnose interstitial lung disease associated with autoimmune diseases? Speaker: Joao Carlos Batista-Liz (Spain)
12:10 - 12:20	Maternal and neonatal outcomes in systemic lupus erythematosus: comparison of 430 pregnancies from the French GR2 prospective study with 1,720 pregnancies from French perinatal surveys Speaker: AMANDINE DERNONCOURT (France)

12:20 - 12:30	<p>Operational and Recruitment Challenges Across the Lupus Clinical Trial Lifecycle: Insights from the LuCIN Network Speaker: Brandon Jackson (United States of America)</p>
12:30 - 12:40	<p>GLUCOCORTICOID-SPARING MAINTENANCE OF DISEASE CONTROL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: 48-WEEK RESULTS FROM A PHASE 3 TRIAL OF DAPIROLIZUMAB PEGOL Speaker: Eric Morand (Australia)</p>
12:40 - 12:50	<p>Voclosporin Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death: A Post-Hoc Analysis of the AURORA 1 Phase 3 Study Speaker: Amit Saxena (United States of America)</p>
12:50 - 13:00	<p>Treatment with Anifrolumab Prevents Organ Damage Accrual Compared With Real-world Standard of Care in Patients With Systemic Lupus Erythematosus: Analysis of the LASER Study Over 4 Years Speaker: Zahi Touma (Canada)</p>
13:00 - 13:10	<p>Anifrolumab Treatment is Associated With DORIS Remission in Adults With Systemic Lupus Erythematosus: Real-World Outcomes From an Academic Lupus Registry Speaker: Amanda Eudy (United States of America)</p>
13:10 - 13:20	<p>Variation in Demographics and Clinical Features Among Adults With Moderate-to-Severe Systemic Lupus Erythematosus by US Insurance Type Speaker: Anca Dinu Askanase (United States of America)</p>
13:20 - 13:30	<p>Real-World Use of Voclosporin in UK Lupus Nephritis Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR) Speaker: Ian Bruce (Ireland)</p>
13:30 - 13:40	<p>From Consideration to Enrollment: Characteristics and Barriers to Participation in Advanced B-Cell-Targeted Therapy Trials in Systemic Lupus Erythematosus Speaker: Iftach Sagy (Israel)</p>

13:40 - 13:50	IFN-α-mediated neuronal damage in SLE: Association with neurofilament light chain in SLE and in vitro inhibition by anifrolumab Speaker: Ioanna Giannakou (Sweden)
13:50 - 14:00	Clinical Spectrum and Survival Outcomes of SLE Patients with Evans Syndrome: A Multicenter Experience; TR-LUPUS Study Group Speaker: GUL SANDAL UZUN (Türkiye)
14:00 - 14:10	Novel serum biomarkers for early prediction of structure bone damage in psoriatic arthritis Speaker: Yingzhao Jin (Hong Kong, China)
14:10 - 14:20	The Threshold Phenomenon and Distinct Radiologic-Serologic Phenotypes in Lupus Lymphadenopathy: A Multimodal Cluster Analysis Speaker: Yesim Erez (Türkiye)
14:20 - 14:30	Health inequalities in systemic lupus erythematosus: comorbidities, infections, and treatment patterns in a multi-ethnic UK population Speaker: Sarah Dyball (United Kingdom)
14:30 - 14:40	Real-world Effectiveness of Anifrolumab in Systemic Lupus Erythematosus: 12-month Multicenter Data Speaker: Daliya Pencheva (Bulgaria)
14:40 - 14:50	Does Timing Matter? Biologic Initiation in SLE Speaker: Pablo Martínez Calabuig (Spain)
14:50 - 15:00	Interleukin-18-secreting autologous CAR T-Cells targeting CD19 and BCMA for refractory systemic lupus erythematosus Speaker: QIAN WANG (China)
15:00 - 15:10	Longitudinal association between organ damage and health-related quality of life in patients with systemic lupus erythematosus: a multinational prospective cohort study Speaker: Rangi Kandane-Rathnayake (Australia)
15:10 - 15:20	The Impact of Obinutuzumab on Remission and Low Disease Activity in Active Systemic Lupus Erythematosus: Additional Results of the Phase III ALLEGORY Trial Speaker: Richard A. Furie (United States of America)

15:20 - 15:30	Impact of Rurality on Disease Severity and Social Outcomes in Systemic Lupus Erythematosus: A Regional Cohort Study Speaker: Ginevra De Marchi (Italy)
15:30 - 15:40	Lupus patients with concurrent inflammatory activity and symptom burdens have the lowest medication adherence and experience distinct adherence barriers Speaker: Kai Sun (United States of America)
15:40 - 15:50	Pharmacokinetics and Exposure-Response Relationship of the Anti-TLR7 Monoclonal Antibody DS-7011a in Patients with Systemic Lupus Erythematosus Speaker: Li Zhang (United States of America)
15:50 - 16:00	Lifestyle changes in people with established rheumatoid arthritis are challenging in clinical practice - a longitudinal, observational study from the BARFOT cohort Speaker: Maria Andersson (Sweden)
16:00 - 16:10	Memantine Improves Neuropsychological Function in Systemic Lupus Erythematosus: Results from a phase II randomized, double-blind, placebo-controlled trial Speaker: Leslie Crofford (United States of America)
16:10 - 16:20	Obinutuzumab in Systemic Lupus Erythematosus: A Secondary Safety Analysis of Infusion-Related Reactions, Infections, Neutropenia and Immunoglobulin G in the Phase III ALLEGORY Trial Speaker: Anca Dinu Askanase (United States of America)
16:20 - 16:30	Safety and Efficacy of Rese-cel (Resecabtagene Autoleucel) in Severe, Refractory SLE and Lupus Nephritis: Results from the RESET-SLE Clinical Trial Phase 1/2 Cohorts Speaker: Christopher Palma (United States of America)
16:30 - 16:40	EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice – 2025 update Speaker: Peter Mandl (Austria)

16:40 - 16:50	ORELABRUTINIB, A HIGHLY SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE(BTK), FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS(SLE): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIB STUDY Speaker: Zhanguo Li (China)
16:50 - 17:00	Computational Insights of Inflammation-Induced Remodeling and Atrial Arrhythmias in Systemic Lupus Erythematosus Speaker: Karla Arévalo Ruales (Spain)
17:00 - 17:10	Deficiency of Serum Short-Chain Fatty Acid is Associated with Promoting Plasmablast Differentiation in Systemic Lupus Erythematosus Speaker: Ryuichiro Kanda (Japan)
17:10 - 17:20	An Allogenic CD19 CAR NK Cells (SNC-103) in patients with Severe, Refractory Systemic Lupus Erythematosus: Preliminary efficacy and safety results Speaker: Yakai Fu (China)
17:20 - 17:30	Physiotherapy as a multimodal intervention is effective to treat adults with recurrent or chronic low back pain: a systematic review with meta-analysis Speaker: Stéphane LE CAM (France)
17:30 - 17:40	Resting T regulatory cells as biomarkers for disease activity in Systemic Lupus Erythematosus patients: results from a monocentric cohort. Speaker: Valeria Moretti (Italy)
17:40 - 17:50	Patient Preferences for Hydroxychloroquine Dosing in Lupus Care Speaker: April Jorge (United States of America)
17:50 - 18:00	USP46 mediates polyubiquitination, aggregation and activation of NLRP3 inflammasome in lupus nephritis Speaker: Heng Cao (China)
18:00 - 18:10	Age at Onset and Its Association with Damage Accrual in Systemic Lupus Erythematosus (SLE): Insights from 5 Registries in the Lupus Federated Data Network (LupusNet) Speaker: Kaleb Michaud (United States of America)

18:10 - 18:20	Experiences with high-intensity training among patients with inflammatory disease Speaker: Christine Hestevik (Norway)
18:20 - 18:30	Pathway-Based Molecular Stratification Identifies Patient Subgroups with Differential In-silico Response Rates to Biologic Therapies in Systemic Lupus Erythematosus Speaker: Ana Brescia Zapata (Spain)
18:30 - 18:40	Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Antibody, for Active Lupus Nephritis: 104-Week Results of a Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled Trial Speaker: Zhanguo Li (China)
18:40 - 18:50	IgG4 drives TGF-β+ macrophages to facilitate fibrosis in IgG4-Related Disease Speaker: qihua Dai (China)
18:50 - 19:00	Alignment Between 2025 EULAR Lupus Nephritis Guidelines and Real-World Practice in Europe: Current Use of Early Quadruple Therapy and Anticipated Impact of Obinutuzumab Approval Speaker: Sawyer May (United States of America)
19:00 - 19:10	Single-Cell and Spatial Transcriptomic Profiling Reveals Systemic and Tissue Immune Remodeling in SLE Treated with Anifrolumab Speaker: Cristina Solé-Marcé (Spain)
19:10 - 19:20	IFNλ1 Mediated Modulation of Dendritic Cell Activation and its role in pathogenesis of SLE Speaker: Sarit Sekhar Pattanaik (India)
19:20 - 19:30	Advanced Practice Physiotherapy-led inflammatory back pain pathway - diagnostic yield, referral source outcomes and consultant time savings in Axial Spondyloarthritis Speaker: Kathryn Rigler (United Kingdom)
19:30 - 19:40	Deep immunophenotyping reveals novel B cell subsets and trajectories in IgG4-related disease Speaker: Lena Teichert (Germany)

19:40 - 19:50	Periaortitis (retroperitoneal fibrosis): Impact of IgG4-related disease classification and immunosuppressive treatment on the clinical trajectory Speaker: Mustafa Ekici (Türkiye)
19:50 - 20:00	Reliability of a New Automated Knee Inflammation MRI Scoring Grid Placement and Bone Marrow Lesion Detection Algorithm ("iKIMRISS") Speaker: Stephanie Wichuk (Canada)
20:00 - 20:10	Digital fast-track pathway for connective tissue diseases via eConsultation in a tertiary hospital: a four-year real-world evaluation Speaker: Irene Alvarez Losada (Spain)
20:10 - 20:20	Comparison of Molecular Responses to Autologous and Allogeneic CD19 CAR-T Cell Therapy in Systemic Lupus Erythematosus Speaker: Evan Maestri (United States of America)
20:20 - 20:30	Predictors of Sustained Drug-Free Remission in Systemic Lupus Erythematosus (SLE). Data from the SLICC (Systemic Lupus International Collaborating Clinics) inception cohort Speaker: Manuel Ugarte-Gil (Peru)
20:30 - 20:40	A BAFF/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a 36-month, observational, real-world study Speaker: Yi Wei (China)
20:40 - 20:50	Extended follow up on safety and clinical efficacy from first eight SLE patients receiving autologous CD19-directed CAR-T cell therapy. Speaker: Jule Bachl (Germany)
20:50 - 21:00	Cenerimod, a selective S1PR1 modulator, induces changes in BCR and TCR repertoire in systemic lupus erythematosus: post-hoc analysis from the placebo-controlled Phase 2b CARE trial Speaker: Mark Murphy (Switzerland)
21:00 - 21:10	Long-Term Remission Achieved with ICG318, a BCMA-CD19 Armored Compound CAR T-cell Therapy, in Refractory Systemic Lupus Erythematosus/Lupus Nephritis with Follow-Up Approaching 6 years Speaker: Jennifer Chow (United States of America)

21:10 - 21:20	Sharp.AI: Longitudinal AI-Based Evaluation of Radiographic Progression in Psoriatic Arthritis Speaker: Zijun Gao (United States of America)
21:20 - 21:30	Long-term trends in the burden and sex-specific patterns of gout in the European Union, 1990-2023: Findings from the Global Burden of Disease Study 2023 Speaker: Xue Wang (China)
21:30 - 21:40	Autoimmune Comorbidity Burden and Risk of Death in Systemic Lupus Erythematosus: A Single Centre Cohort from the United Kingdom Speaker: Javier del Cid Lemus (Spain)
21:40 - 21:50	Single-cell transcriptome profiling uncovers type I interferon activation and sex-dimorphic IFIT1hi neutrophil expansion in psoriatic arthritis Speaker: Yan Geng (China)
21:50 - 22:00	Conventional and plasmacytoid dendritic cells (DC) are highly activated in blood and skin of patients with scleromyxedema Speaker: Theresa Graalman (Germany)
22:00 - 22:10	Clinical features and conventional radiography assessments are not adequate for the diagnosis of MRI confirmed osteitis condensans ilii Speaker: Gözde Sevgi Kart Bayram (Türkiye)
22:10 - 22:20	Rare Autoimmune SELF-management (RAISE) programme development: a national survey to determine support needs of people with rare autoimmune rheumatic diseases in the United Kingdom Speaker: Sadia Janjua (United Kingdom)
22:20 - 22:30	Characteristics of Difficult-To-Manage AxSpA patients: Data From ATTRA Registry Speaker: Kristyna Bubova (Czechia)
22:30 - 22:40	Sex and regional inequities in osteoarthritis across Europe: findings from the Global Burden of Disease study 2023 Speaker: Qifan Feng (China)

22:40 - 22:50	Long-term disease control in SLE using LLDAS and DORIS criteria: integrated post hoc analyses from the PAISLEY SLE and LTE trials Speaker: Eric Morand (Australia)
22:50 - 23:00	Survival continues to improve in the 21st century in patients with systemic lupus erythematosus (SLE) - a meta-regression analysis Speaker: Anselm Mak (Singapore)
23:00 - 23:10	Dysphagia in Patients with Systemic Sclerosis: Clinical Characteristics, Patient-Reported Outcomes, and Associated Factors Speaker: Fulden Sari (Türkiye)
23:10 - 23:20	Histological Evolution and Clinical Impact of Repeat Renal Biopsy in Lupus Nephritis Speaker: Sriyanka Mohapatra (India)
23:20 - 23:30	Serologically active clinically quiescent systemic lupus erythematosus: a prospective study on the role of IgG anti-dsDNA and C3 Speaker: Silvia Piunno (Italy)
23:30 - 23:40	An Immunological Reset is Not Enough: A Prospective Study of Dual CD19/BCMA CAR-T in SLE Defines a Histological "Point of No Return" for Organ Recovery Speaker: Yajing Zhang (China)
23:40 - 23:40	Is Lower Better? A Comparative Study of LLDAS, LLDAS5, and DORIS on Disease Stability and Organ Damage in Systemic Lupus Erythematosus Speaker: Dai Gao (China)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour I**

09:30-10:30 BST

Basic Poster Tours: New routes to Osteoarthritis

Chair:	Antonios Psarras (United Kingdom) Frédéric Cailotto (France)
--------	---

09:30 - 09:36	Thrombospondin-4 (TSP-4) is a key mediator of pain in osteoarthritis (OA) and is related to treatment response Speaker: Andisheh Niakan (Iran, Islamic Republic of)
09:36 - 09:42	Nicotinamide, derived from the gut microbiome, suppresses mechanoflammation and is disease modifying in murine osteoarthritis Speaker: Tonia Vincent (United Kingdom)
09:42 - 09:48	Plasma Proteomics Identifies FABP4 as a Key Biomarker for Obesity-related Knee Osteoarthritis Speaker: Yimiao Zhao (Canada)
09:48 - 09:54	Mechanism of Action of the Neurotrophin-3 Inhibitor, LEVI-04, a Novel Osteoarthritis Treatment: in vitro Pharmacology and Efficacy in Animal Models Speaker: Simon Westbrook (United Kingdom)
09:54 - 10:00	Discovery of a Small-Molecule Enhancer promoting SOX9 Condensation for the Treatment of Osteoarthritis Speaker: Hongwon Lee (Korea, Republic of (South Korea))
10:00 - 10:06	The role of osmolarity and LRRC8A channel in cartilage homeostasis and osteoarthritis Speaker: yasmine SEDJAI (France)
10:06 - 10:12	IMI-APPROACH study: Blood-based Biomarkers (C3M, PRO-C4, & ARGS) Associate with Distinct Pain Profiles in Knee Osteoarthritis Patients Speaker: Joscha Rombach (Denmark)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour II**

09:30-10:30 BST

Clinical Poster Tours: Comorbidities in Rheumatoid Arthritis

Chair:	Axel Finckh (Switzerland) Olena Zimba (Ukraine)
--------	--

09:30 - 09:36	Leflunomide Exposure Duration and Dose Are Not Associated with Incident or Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Longitudinal CT Study Speaker: Merve Erkek (Türkiye)
09:36 - 09:42	Time-trends of malignant lymphoma risk in rheumatoid arthritis Speaker: Johan Askling (Sweden)
09:42 - 09:48	Real-world cancer incidence in rheumatoid arthritis patients receiving b/tsDMARDs: findings from the GISEA registry Speaker: Fabiola Atzeni (Italy)
09:48 - 09:54	Risk factors for interstitial lung disease in rheumatoid arthritis Speaker: Anna-Maria Hoffmann-Vold (Norway)
09:54 - 10:00	Opportunistic CT-based detection of RA-associated lung involvement among b/tsDMARDs-treated rheumatoid arthritis: a single-center real-world study in Taiwan Speaker: CHI JUNG CHIANG (Taiwan)
10:00 - 10:06	ROTEM and platelet aggregometry identify differential hypercoagulable states in rheumatoid arthritis patients actively treated with JAK or TNF-alpha inhibitors Speaker: Lorenzo Di Luozzo (Italy)
10:06 - 10:12	Low-dose aspirin, NSAIDs, DOACs and the risk of venous thromboembolism among patients with RA treated with JAKis or bDMARDs - A population-level clinical validation of recent experimental findings Speaker: Maxime Raffray (Sweden)
10:12 - 10:18	Immune-Related Adverse Events and Survival in Patients Treated with Immune Checkpoint Inhibitors: A Nationwide Matched Cohort Study with Cancer-Type Subgroup Analyses Speaker: Yu-Seon Jung (Korea, Republic of (South Korea))
10:18 - 10:24	Infection rate by severity and site on janus kinase inhibitors versus biologic disease modifying antirheumatic drugs for rheumatoid arthritis -- a nationwide cohort study accounting for informative censoring at treatment discontinuation Speaker: Jacob Granfors (Sweden)

Poster Tour PresentationsDate: **04/06/2026**Room: **Poster Tour III****09:30-10:30 BST****Clinical Poster Tours: From pathway to patient - therapeutic advances in Lupus**

Chair:	Georg Schett (Germany) Laura Bucci (Germany)
09:30 - 09:36	Efficacy of enpatoran on arthritis outcomes in participants with active cutaneous manifestations of SLE: A post-hoc analysis of Cohort B of the phase II WILLOW study Speaker: Eric Morand (Australia)
09:36 - 09:42	IMC-002 (IMM0306), a bispecific CD20-CD47 fusion protein, demonstrates improvements in active Systemic Lupus Erythematosus (SLE) patients in a phase Ib/II study Speaker: Haihong Yao (China)
09:42 - 09:48	Anifrolumab versus belimumab in active systemic lupus erythematosus: a propensity score matched analysis. Speaker: Filippo Vesentini (Italy)
09:48 - 09:54	Obinutuzumab Demonstrates Consistent Efficacy in Lupus Nephritis Independent of Baseline Type 1 Interferon Gene Signature: Post-Hoc Exploratory Analyses of the Phase III REGENCY Trial Speaker: Edward M. Vital (United Kingdom)
09:54 - 10:00	Efficacy of Subcutaneous Anifrolumab Across Multiple Organ Systems in Patients With Moderate to Severe Systemic Lupus Erythematosus: A Post Hoc Analysis of the Phase 3 TULIP-SC Trial Speaker: Richard A. Furie (United States of America)
10:00 - 10:06	Kidney Function Preservation with Belimumab in Patients with Lupus Nephritis Receiving MMF Induction Therapy in BLISS-LN: eGFR Slope for Belimumab Versus Placebo Speaker: Richard A. Furie (United States of America)

10:06 - 10:12	Five-Year Safety of Belimumab in SLE: Insights from the Global, Prospective, Observational SABLE Registry Speaker: Ronald F. van Vollenhoven (Netherlands)
10:12 - 10:18	In Vivo CD19 CAR T-cell therapy Induces tissue B-cell depletion in Systemic Lupus Erythematosus Speaker: Zhu Chen (China)
10:18 - 10:24	Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Discharge Speaker: Jennifer Medlin (United States of America)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour IV**

09:30-10:30 BST

Basic Poster Tours: Cracking the immune code in PsA and SpA

Chair:	Rik Lories (Belgium) Omar Dhrif (Tunisia)
09:30 - 09:36	TNF drives iron-sensitive activation of ligament fibroblasts and pathological ossification in r-axSpA Speaker: Jing Liu (China)
09:36 - 09:42	TL1A inhibition is efficacious in mouse models of collagen-induced arthritis (CIA) and imiquimod-induced (IMQ) psoriasis Speaker: Andy Spencer (United States of America)
09:42 - 09:48	Cytometry by Time of Flight (CyTOF) identifies sexual dimorphism in monocyte populations in patients with active axial spondyloarthritis (AxSpA) Speaker: Claudia Worth (United Kingdom)
09:48 - 09:54	Peripheral immune-cell signatures predict clinical response in psoriatic arthritis: integrated flow cytometry and single-cell RNA sequencing from the COLIPSO cohort Speaker: Shannon Gunawardana (United Kingdom)

09:54 - 10:00	Axial–Peripheral Immune Divergence at Human Enteseal Sites Revealed by Single-Cell Transcriptomics Speaker: Ala Altaie (United Kingdom)
10:00 - 10:06	Can glia-targeting autoantibodies differentiate axial spondyloarthritis patients from control subjects and are they linked to comorbid fibromyalgia? Results from the SPARTAKUS cohort Speaker: Khosiyat Makhmudova (Sweden)
10:06 - 10:12	Investigating the role of IL-23 biology between peripheral and axial entheses Speaker: Yaaseen Hamid (United Kingdom)
10:12 - 10:18	A Genome-Wide Association Study of Treatment Response to Tumour-Necrosis Factor Inhibitor (TNFi) in Psoriatic Arthritis Patients Speaker: Moshiur Rahman Khasru (United Kingdom)
10:18 - 10:24	Genetic Determinants and Polygenic Risk Scores for Predicting Psoriatic Arthritis Onset in Patients with Psoriasis Speaker: Proton Rahman (Canada)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour V**

09:30-10:30 BST

Basic and Clinical Poster Tours: From Treatment to outcome in Other Diseases

Chair:	Robert Landewé (Netherlands) Ioanna Katsigianni (Greece)
09:30 - 09:36	Long-term Inebilizumab Treatment Results in Mild Immunoglobulin Reduction but No Increase in Infection Risk Speaker: Emanuel Della Torre (Italy)
09:36 - 09:42	Single-cell transcriptomic analysis reveals the pivotal role of the CXCL12-CXCR4 axis in mediating fibrotic-immune interactions and its therapeutic potential in IgG4-related disease Speaker: Difei Lian (China)

09:42 - 09:48	Radiologic Abnormalities Persist in the Majority of Patients Treated for Chronic Periaortitis: A Single-Center Retrospective Study Speaker: Sofia Flouda (Greece)
09:48 - 09:54	Defining the Immunometabolic Landscape of Haemophagocytic Lymphohistiocytosis (HLH) using Integrated Multi-Omics Speaker: Alexandra Oppong (United Kingdom)
09:54 - 10:00	Effects of colony stimulating-factor 1 receptor inhibitors in an in vitro cell culture model using synovial fluids from tenosynovial giant cell tumor patients Speaker: Manon Bauerheim (France)
10:00 - 10:06	Baseline Peripheral Eosinophilia Identifies a Distinct and High-Risk Subset of IgG4-Related Disease: A Multicentre Study Speaker: Carson Chun Yin Yip (Hong Kong, China)
10:06 - 10:12	Ultrasound-assessed enthesitis and disease severity in SAPHO syndrome. Speaker: Adrián Navarro Sánchez (Spain)
10:12 - 10:18	Whole-blood Epstein-Barr virus DNA positivity during active disease is associated with relapse and early mortality in Still's disease Speaker: Kohei Yo (Japan)
10:18 - 10:24	The Potential of Albumin-Fused IL-10 as a Therapeutic Agent for Macrophage Activation Syndrome Speaker: Wataru Fujii (Japan)

Meet the EULAR Expert

Date: 04/06/2026

Room: Meet the EULAR Expert 1

09:45-10:15 BST

Scleroderma

Chair:	
09:45 - 10:15	Scleroderma Speaker: Francesco Del Galdo (United Kingdom)

HPR Meet the EULAR Expert

Date: **04/06/2026**

Delegates will be able to:

Room: **Meet the EULAR Expert 2**

i) Explore common and challenging clinical scenarios related to foot involvement in inflammatory arthritis through discussion

09:45-10:15 BST

ii) Gain practical insights into the diagnosis and differentiation of inflammatory foot disease from other causes of foot pain, including overlapping mechanical pathology

iii) Discuss real-world strategies for managing persistent foot symptoms, including when and how to escalate care or involve podiatry, orthotics, or surgery.

The foot and ankle in inflammatory arthritis

Chair:	
09:45 - 10:15	The foot and ankle in IA Speaker: Christopher Joyce (United Kingdom)

Meet the EULAR Expert

Date: **04/06/2026**

Room: **Meet the EULAR Expert 3**

09:45-10:15 BST

Managing Vascular Behçet's: What to Do (and What Not to Do)

Chair:	
09:45 - 10:15	Managing Vascular Behçet's: What to Do (and What Not to Do) Speaker: Gulen Hatemi (Türkiye)

Meet the EULAR Expert

Date: **04/06/2026**

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of inflammatory disease with childhood arthritis. The classification that is currently used worldwide was proposed in 1995 by ILAR; new PRINTO JIA classification criteria have been proposed and are now validated in a study including more than 1000 patients, to try to identify homogeneous entities.

Room: **Meet the EULAR Expert 4**

09:45-10:15 BST

It is time to re-classify JIA

Chair:	
09:45 - 10:15	It is time to re-classify Juvenile Idiopathic Arthritis criteria Speaker: Nicolino Ruperto (Italy)

What is New (WIN)

Date: **04/06/2026**

1. Learn the relationship between nutrition and inflammation in rheumatic diseases
2. Nutritional recommendations for patients with

Room: **Plenary**

10:30-11:15 BST

inflammatory rheumatic diseases

Nutrition and inflammation

Chair:	Claire Immediato Daien (France) Elena Philippou (Cyprus)
10:30 - 11:15	Nutrition and inflammation in rheumatic diseases Speaker: Konstantinos Gkikas

EULAR Projects

Date: **04/06/2026**

Understand the importance of robust epidemiological and health-system data for RMDs in Europe.

Room: **Connaught Room 1 & 2**

10:30-11:45 BST

Learn methodological approaches to collect and harmonise such data across diverse countries and health systems.

Explore successful models (e.g., ESC Atlas) and their impact on research and advocacy.

Discover how RheumaFacts will support EULAR's strategy in advocacy, funding allocation, and visibility of RMDs at the European level.

RheumaFacts: Building the Epidemiological Backbone for Advocacy and Policy in Europe

Chair:	Annelies Boonen (Belgium) Loreto Carmona (Spain)
--------	---

10:30 - 10:45	Why epidemiological and population-level data are crucial for RMDs in Europe Speaker: Sofia Ramiro (Netherlands)
10:45 - 11:00	Learning from existing models: the ESC Atlas of Cardiology Speaker: Radu Huculeci
11:00 - 11:15	RheumaFacts: EULAR's project to map the epidemiology and health system capacity of RMDs Speaker: Anna Molto (France)
11:15 - 11:30	From data to advocacy: how to leverage epidemiological insights to put RMDs back on the European health agenda Speaker: Margreet Kloppenburg (Netherlands)
11:30 - 11:45	Question and Answers Speaker: Annelies Boonen (Belgium) Co-Speaker: Loreto Carmona / (Madrid, Spain)

Basic and Translational Science

Date: **04/06/2026**

1. Understand the role of gut dysbiosis on hyperuricemia and gout

Room: **Connaught Room 3 & 4**

10:30-11:45 BST

2. Recognise relevant biomarkers that predict gout flares

3. Appreciate role of metabolomics in identifying risk of developing gout

Insights from 'Omics in Gout: Microbiome, Proteome, and Metabolome

Chair:	Nicola Dalbeth (New Zealand) Tristan Pascart (France)
--------	--

10:30 - 10:50	Gout and the Gut: the role of the Microbiome Speaker: Dylan Dodd (United States of America)
10:50 - 11:10	Identification of gout flare biomarkers through proteomics and metabolomics Speaker: Hang Korng Ea (France)
11:10 - 11:30	Insights from metabolomics on risk of developing gout Speaker: Natalie McCormick (United States of America)
11:30 - 11:40	Characterization of giant multinucleated cells phenotype and formation in gouty tophus Speaker: Charles Leroy (France)
11:40 - 11:45	Questions and Answers Speaker: Tristan Pascart (France) Co-Speaker: Nicola Dalbeth / (Auckland, New Zealand)

EULAR Projects

Date: **04/06/2026**

Room: **Victoria Room 1**

10:30-11:45 BST

The FOREUM dive into mechanisms of RMDs

Chair:	Rik Lories (Belgium) Diane van der Woude (Netherlands)
10:30 - 10:40	Introduction
10:40 - 10:55	Harnessing cell energy metabolism to suppress salivary gland inflammation in Sjögren Syndrome Speaker: SERENA COLAFRANCESCO (Italy)

10:55 - 11:10	Deciphering synovitis in systemic sclerosis Speaker: Muriel Elhai (Switzerland)
11:10 - 11:25	Unravelling the cellular phenotypes in subclinically inflamed synovium and tenosynovium in Clinically Suspect Arthralgia related to Rheumatoid Arthritis development Speaker: Hanna van Steenberg (Netherlands)
11:25 - 11:40	When autoimmunity gets more than skin deep Speaker: Jolien Suurmond (Netherlands)
11:40 - 11:45	Q&A

PARE

Date: **04/06/2026**

1. Identify structural barriers to equitable care for underserved populations living with RMDs.

Room: **Victoria Room 2**

10:30-11:45 BST

2. Showcase potentially scalable community-based and cross-sectoral solutions that improve early diagnosis, treatment access, and long-term care for underserved communities.

3. Inspire policy and advocacy action by sharing how patient organisations can influence systemic change to reduce inequities in rheumatology.

Bridging the Gap: Expanding Rheumatology Access for Underserved and Underrepresented Communities

Chair:	Mrinalini Dey (United Kingdom) Franklin Hiagbe (Ghana)
--------	---

10:30 - 10:45	No Exceptions: Building Universal Access to Rheumatology Services Speaker: Gonzalo Tobar (Chile)
10:45 - 11:00	Portuguese patient panel pilot Rheumatology Care Speaker: Zoe Karakikla Mitsakou (Belgium)
11:00 - 11:15	Equity Is Not Equality: Tackling Ethnic Disparities in Rheumatology Access Speaker: Arumugam Moorthy
11:15 - 11:25	Make Rheum for Youth: Identifying Barriers to Medication Access and Healthcare for Young People with Rheumatic Diseases Speaker: Natasha Trehan (Canada)
11:25 - 11:45	Questions and Answers Speaker: Mrinalini Dey (United Kingdom) Co-Speaker: Franklin Hiagbe / (Accra, Ghana)

EMEUNET Presents

Date: **04/06/2026**

Back to the drawing board.

Room: **Victoria Room 3**

10:30-11:45 BST

After attending this session, participants will be able to:

1. Explain key immunological pathways relevant to the mechanism of action of biologic and targeted synthetic DMARDs.
2. Describe the cellular basis of therapeutic strategies in rheumatology, including T cell and B cell–targeted therapies.
3. Translate complex immunological concepts into simple, visual explanations that support everyday clinical decision-making.
4. Recognise how immunology guides treatment

selection and monitoring in immune-mediated inflammatory diseases.

Drawn by Immunology - The basics for the busy clinician

Chair:	Ertugrul Cagri Bolek (Türkiye) Alessia Alunno (Italy)
10:30 - 11:00	The normal immune response Speaker: Armando Hasudungan Faigl (Australia)
11:00 - 11:20	Autoimmunity Speaker: Megan Hanlon (United States of America)
11:20 - 11:40	Immunology meets targeted DMARDs Speaker: Tue Wenzel Kragstrup (Denmark)

From Bench to Bedside

Date: **04/06/2026**

1. To provide results of the recent phase 2 and phase 3 positive trials in Sjögren's disease,

Room: **Victoria Room 4**

10:30-11:47 BST

2. To discuss how these positive trials inform about the role of the targets of these trials in pathophysiology of the disease

What do recent positive trials in Sjogren disease tell about pathophysiology of the disease?

Chair:	Elena Pontarini (United Kingdom)
--------	----------------------------------

10:30 - 10:52	BAFF-R targeting and B-cell depletion and Sjogren Speaker: Divi Cornec (France)
10:52 - 11:14	CD40 - CD40 ligand targeting and Sjogren Speaker: Michele Bombardieri (United Kingdom)
11:14 - 11:35	Plasma-cell and IgG targeting in Sjögren's Disease Speaker: Gaetane Nocturne (France)
11:35 - 11:45	From histology to phenotype: a National Multicenter study identifying salivary gland pathotypes in Sjögren's Disease Speaker: Serena Colafrancesco (Italy)

Clinical Science

Date: **04/06/2026**

Recognise the importance of addressing fertility and family planning with RMD patients from the time of diagnosis and throughout follow-up.

Room: **Victoria Room 5 & 6**

10:30-11:45 BST

Understand how RMDs and their treatments may affect fertility, conception, and reproductive outcomes in both women and men.

Evaluate when and how fertility preservation should be discussed and offered to patients with RMDs, considering disease context, treatment exposure, and patient values.

Integrate multidisciplinary approaches (rheumatology, reproductive medicine, patient perspectives) into clinical care pathways.

From Diagnosis to Family Building: Navigating Fertility in RMDs

Chair:	Laura Andreoli (Italy) Roba Ghossan (France)
10:30 - 10:45	Starting the Conversation Early: Fertility and Family Planning from Diagnosis to Long-Term Care Speaker: Karen Schreiber (Denmark)
10:45 - 11:00	How RMDs and Their Treatments Influence Fertility and Reproductive Outcomes Speaker: Isabell Haase (Germany)
11:00 - 11:15	Beyond the Present: Fertility Preservation Pathways in RMDs Speaker: Mathilde Bourdon (France)
11:15 - 11:30	The Other Half of the Story: Male Fertility in RMDs Speaker: Luis Fernando Perez (Netherlands)
11:30 - 11:45	Questions and Answers Speaker: Laura Andreoli (Italy) Co-Speaker: Roba Ghossan / (PARIS CEDEX 14, France)

Clinical Science

Date: **04/06/2026**

By the end of this session, participants will:

Room: **N1**

- Recognise clinical presentations of difficult-to-treat SLE, particularly involving joints, skin, and the nervous system.

10:30-11:45 BST

- Assess and confirm when a case truly qualifies as difficult-to-treat, and identify the underlying reasons.

- Evaluate treatment adherence and distinguish between therapeutic resistance and poor adherence.

Difficult to treat SLE: joint, skin, nervous system and beyond

Chair:	Ian N. Bruce (United Kingdom) Martin Aringer (Germany)
10:30 - 10:48	D2T joint involvement in SLE Speaker: Edward M. Vital (United Kingdom)
10:48 - 11:06	D2T skin involvement in SLE Speaker: Miriam Wittmann (Germany)
11:06 - 11:24	D2T neurological involvement in SLE Speaker: Antonis Fanouriakis (Greece)
11:24 - 11:42	And beyond (Adherence) Speaker: Nathalie Costedoat-Chalumeau (France)

EULAR Joint Sessions

Date: **04/06/2026**

1. How physical activity may improve quality of life in patients with systemic connective tissue diseases (CTD)

Room: **N2**

10:30-11:45 BST

2. Learn how psychosocial interventions may improve treatment results in patients with systemic CTD

3. Become familiar EULAR recommendations for non-pharmacological treatment of SLE and SSc

4. Are non-pharmacological interventions important for patients with systemic CTD

Non-pharmacological interventions to improve quality of life in patients with connective tissue diseases

Chair:	Tanja Stamm (Austria) Ilaria Galetti (Italy)
10:30 - 10:45	Exercise and physical therapy for patients with connective tissue diseases Speaker: Sophie Liem (Netherlands)
10:45 - 11:00	Importance of psychosocial support in management of connective tissue diseases Speaker: Tijana Vranes (United Kingdom)
11:00 - 11:15	EULAR recommendations for personalized non-pharmacological management of SLE and SSc Speaker: Ioannis Parodis (Sweden)
11:15 - 11:30	Are non-pharmacological interventions important for patients with systemic connective tissue diseases. Let's hear the patient's voice Speaker: Jeanette Andersen (Denmark)
11:30 - 11:45	Questions and Answers Speaker: Tanja Stamm (Austria) Co-Speaker: Ilaria Galetti / (Milan, Italy)

Clinical Science

Date: **04/06/2026**

- To understand the heterogeneity and the distinct
physiopathogenesis of RA-ILD

Room: **N3**

- To identify high-risk patients for RA-ILD

10:30-11:45 BST

- To optimise the therapeutic management of
patients with RA-ILD

Catching your breath: Unravelling Rheumatoid-Associated Interstitial Lung Disease

Chair:	Philippe Dieudé (France) Kastriot Kastrati (Austria)
--------	---

10:30 - 10:55	RA-ILD: One disease or multiple diseases? Speaker: Pierre-Antoine Juge (France)
10:55 - 11:20	How to best identify RA patients eligible for screening? Speaker: Jeffrey A. Sparks (United States of America)
11:20 - 11:45	How do the new EULAR/ERS guidelines impact therapeutic management of RA-ILD? Speaker: Anna-Maria Hoffmann-Vold (Norway)

From Bench to Bedside

Date: **04/06/2026**

1. to learn about the pathophysiology of giant cell arteritis (GCA) and Takayasu arteritis
2. to discuss whether GCA and Takayasu arteritis could be part of the same disease spectrum
3. to understand commonalities and differences in clinical presentation, course, prognosis and outcome
4. to learn about differences in the management of these diseases

Room: **George V Room 1**

10:30-11:45 BST

Giant Cell Arteritis and Takayasu Arteritis: Shared Pathways, Different Ages?

Chair:	Elisabeth Brouwer (Netherlands) Alojzija Hocevar (Slovenia)
10:30 - 10:55	Shared and distinct pathways in large vessel vasculitis Speaker: Cornelia Weyand (United States of America)
10:55 - 11:20	Clinical Evolution and Outcomes in Takayasu and Giant Cell Arteritis: Insights from Both Ends of the Spectrum outcomes Speaker: Alessandro Tomelleri (Italy)

11:20 - 11:45	Treating the Spectrum: Shared and Distinct Approaches in Takayasu and Giant Cell Arteritis Speaker: Haner Direskeneli (Türkiye)
---------------	---

Innovation Date: **04/06/2026**

Many clinical trial do not reach their primary endpoint
 - therefore regarded as failed Room: **George V Room 2**

10:30-11:45 BST

in this session we will

- analyse common pitfalls/reasons why trials have failed
- learn what are the clinical implications and learning from trials that didn't meet the endpoints
- discuss how unsuccessful trials could shape industry research
- receive insights from regulators how failed trials could shape regulatory guidelines and policies

Learning from Setbacks: The Hidden Value of Unsuccessful Trials

Chair:	Arwen van de Stadt (Netherlands) Maya Buch (United Kingdom)
10:30 - 10:45	Analysing the Pitfalls: Common Reasons for Clinical Trial Failures Speaker: Andrew Cope (United Kingdom)
10:45 - 11:00	The Take home of Failure : Learnings for clinicians Speaker: Gaëlle Varkas (Belgium)

11:00 - 11:15	From Failure to Innovation: How Unsuccessful Trials Shape Industry Speaker: Mark C. Genovese (United States of America)
11:15 - 11:30	The Regulator Perspective on Failure Speaker: Markus Zeitlinger
11:30 - 11:45	Questions and Answers Speaker: Arwen van de Stadt (Netherlands) Co-Speaker: Maya Buch / (Manchester, United Kingdom)

Clinical Science

Date: **04/06/2026**

1. Understand new approaches to scleroderma diagnosis and stratification.

Room: **George V Room 3**

10:30-11:45 BST

2. Recognise utility of novel biomarkers

3. Appreciate impact on clinical trial design and outcome measures

New approaches to scleroderma diagnosis and stratification

Chair:	Chiara Bellocchi (Italy) Oliver Distler (Switzerland)
10:30 - 10:50	Scleroderma disease stratification with mechanistic insights Speaker: Shervin Assassi (United States of America)
10:50 - 11:10	Novel approach to assessing scleroderma skin involvement using SFDI -- potential outcome measure for clinical trials Speaker: Andreea Bujor (United States of America)

11:10 - 11:30	Imagine and soluble biomarkers to track disease activity in scleroderma Speaker: Francesco Del Galdo (United Kingdom)
11:30 - 11:45	Clinical implications: diagnostic work-up and application of EULAR recommendations Speaker: Christopher Denton (United Kingdom)

EULAR Joint Sessions

Date: **04/06/2026**

This joint session with PARE will explore the biopsychosocial impact of inflammatory arthritis, including mechanistic links between inflammation and mood disorders, the real-life psychological burden on patients, and practical approaches to integrating mental health care into rheumatology practice.

Room: **George V Room 4**

10:30-11:45 BST

Inflammatory arthropathies and Mental Health: Bridging the Gap

Chair:	Christoph Baerwald (Germany) Elena Nikiphorou (United Kingdom)
10:30 - 10:55	The Science of the Connection: Inflammation and Mental Health Speaker: Leonard Calabrese (United States of America)
10:55 - 11:20	The Lived Experience: What Mental Health Struggles Look Like for Patients Speaker: Caroline Kirsten (Germany)
11:20 - 11:45	What Can We Do? Screening, Support, and Integrated Care Models Speaker: Bente Appel Esbensen (Denmark)

Basic and Translational Science

Date: **04/06/2026**

Advances in diagnosis, treatment, and management for children with juvenile idiopathic arthritis (JIA) have been limited by a poor understanding of the disease process in the synovial tissue. New insights offer a better understanding of disease-associated features of the synovial tissue and identify potential research avenues for application in JIA.

Room: **Room 12**
10:30-11:45 BST

Disentangling synovial inflammation in JIA

Chair:	Lucy Wedderburn (United Kingdom) Marco Gattorno (Italy)
10:30 - 10:48	Synovial tissue atlas in juvenile idiopathic arthritis Speaker: Adam P. Croft (United Kingdom)
10:48 - 11:07	Abnormal B- and T-cells driving synovitis Speaker: Henner Morbach (Germany)
11:07 - 11:25	Interferon-driven gene signature as a predictor of response Speaker: Chris Wallace (United Kingdom)
11:25 - 11:44	Interleukin-6 in synovial fluid drives immune cell conversion in inflammatory arthritis Speaker: I. Jolanda M. de Vries

Hands-on Sessions

Date: **04/06/2026**

1. Assessment of the shoulder and elbow joints by physical examination.

Room: **Hands-on 1**

10:30-11:45 BST

2. Assessment of the shoulder and elbow joints by ultrasound.

3. How to integrate and correlate clinical and ultrasonography findings.

How to evaluate larger joints - the shoulder and elbow

Chair:	Marina Backhaus (Germany) David Kane (Albania)
10:30 - 10:35	How to access the elbow: clinical examination Speaker: Rusmir Husic (Austria)
10:35 - 10:40	How to access the elbow: ultrasonography examination Speaker: Giasna Giokits (Greece)
10:40 - 10:45	How to access the shoulder: clinical examination Speaker: Christina Duftner (Austria)
10:45 - 10:50	How to access the shoulder: ultrasonography examination Speaker: Luis Coronel (Spain)
10:50 - 10:55	Questions and Answers Speaker: Marina Backhaus (Germany) Co-Speaker: David Kane / (Dubiln, Albania)
10:55 - 11:45	Hands-on Workshop Speaker: David Kane (Albania) Co-Speaker: Luis Coronel / (Barcelona, Spain), Christina Duftner / (Innsbruck, Austria), Giasna Giokits / (Katerini, Greece), Rusmir Husic / (Graz, Austria), Marina Backhaus / (Berlin, Germany)

HPR Hands-on Sessions

Date: **04/06/2026**

A workshop for HPRs and physicians to learn/refresh clinical examinations in rheumatic conditions.

Room: **Hands-on 2**

10:30-11:45 BST

1) To understand remission criteria and scoring systems used in psoriatic arthritis

2) To be able to apply practical skills required to perform assessments of disease activity, nail and skin

involvement in psoriasis arthritis

Assessment of disease activity in Psoriatic Arthritis

Chair:	Clementina López-Medina (Spain) Annette de Thurah (Denmark)
10:30 - 10:55	DAPSA scoring – how to assess number of tender and swollen joints in people with Psoriatic arthritis? Speaker: Michael Zauner (Austria)
10:55 - 11:20	Dermatological Assessment of patients with Psoriasis: Nails and Skin Speaker: Luis Puig (Spain)
11:20 - 11:45	Assessment of enthesitis and dactylitis – and collecting the overall picture Speaker: Laura C. Coates (United Kingdom)

EULAR Culture

Date: **04/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

10:30-12:30 BST

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **04/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

10:30-12:30 BST

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	
--------	--

--	--

How to Treat (HOT)

Date: **04/06/2026**

By the end of this session, participants will:

Room: **Plenary**

- Understand how obesity impacts disease activity, treatment response, and outcomes in patients with rheumatic diseases.

11:15-12:00 BST

- Learn how to optimize rheumatologic therapies in obese patients to improve efficacy and tolerability.

- Explore the emerging role of GLP-1 receptor agonists and their potential benefits beyond weight management in rheumatology.

Lean on Me? Persons with Obesity, RMDs, and the Promise of GLP-1s

Chair:	Jérémie Sellam (France) Hannah den Braanker (Netherlands)
11:15 - 12:00	Lean on Me? Persons with Obesity, RMDs, and the Promise of GLP-1s Speaker: Catherine Bakewell (United States of America)

Health Professionals in Rheumatology (HPR)

Date: **04/06/2026**

The "EULAR Move Together Session: Moving Science into Practice" at the EULAR 2026 Congress offers a unique and interactive experience for attendees to embed evidence-based practice in exercise and physical activity recommendations for rheumatic and musculoskeletal diseases (RMDs). This session is designed for both people with RMDs and all members of the multi-professional healthcare team. It aims to

Room: **HPR Move Together**

12:15-13:15 BST

bridge the gap between scientific knowledge and practical strategies for promoting physical activity in rheumatology.

Attendees will participate in hands-on activities and learn how to integrate evidence-based exercise programmes into their daily lives and patient care. This will ultimately improve the understanding and management of RMDs.

This session will include Pilates and Therapeutic Dance

Thomas Davergne is a physiotherapist specialised in the treatment of inflammatory arthritis. He has been practising urban and contemporary dance for several years and uses this practice to rehabilitate his patients when appropriate. In this session, you'll take part in a guided dance experience, combining physical appropriation and gentle body movement.

Mikel Achek is a physical therapist specialized in pain management and rehabilitation, using a mind-body approach to treat patients with chronic pain conditions. In this session entitled "Move Together: Rewiring Protection Through Shared Movement," participants explore how shared movement, attention, language, breath, and coordination reshape perceptions of safety and effort, culminating in clinical insights on fear-avoidance, central sensitization, and practical rheumatology care.

EULAR HPR Move Together Session: Moving Science into Practice

Chair:	
12:15 - 13:15	EULAR HPR Move Together Co-Speaker: Mikhael El Achek / (Beirut, Lebanon), Thomas Davergne / (Paris, France)

EULAR Culture

Date: **04/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

12:30-14:30 BST

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **04/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

12:30-14:30 BST

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants

move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

Hands-on Sessions

Date: **04/06/2026**

1. How to perform ultrasound-guided synovial biopsies

Room: **Hands-on 1**

13:30-14:45 BST

2. How to perform ultrasound-guided peri-articular procedures

3. How to perform ultrasound-guided joint aspirations and injections

4. Preparation and aftercare, dos and don'ts of these rheumatology procedures

Musculoskeletal ultrasound guided procedures

Chair:	Daniela Fodor (Romania) Aurelie Najm (United Kingdom)
13:30 - 13:35	Ultrasound-guided synovial biopsy Speaker: Peter Mandl (Austria)
13:35 - 13:40	Ultrasound-guided joint aspirations and injections Speaker: PLAMEN Todorov (Bulgaria)
13:40 - 13:45	Ultrasound-guided peri-articular procedures Speaker: Nemanja Damjanov (Serbia)
13:45 - 13:50	Questions and Answers Speaker: Aurelie Najm (United Kingdom) Co-Speaker: Daniela Fodor / (Cluj-Napoca, Romania)
13:50 - 14:45	Hands-on Practice Speaker: Aurelie Najm (United Kingdom) Co-Speaker: Daniela Fodor / (Cluj-Napoca, Romania), Peter Mandl / (Vienna, Austria), Nemanja Damjanov / (Belgrade, Serbia), PLAMEN Todorov / (Plovdiv, Bulgaria)

HPR Hands-on Sessions

Date: **04/06/2026**

A workshop for HPRs and physicians to learn/refresh clinical examinations in rheumatic conditions.

Room: **Hands-on 2**

13:30-14:45 BST

- 1) To understand remission criteria and scoring systems used in psoriatic arthritis
- 2) To be able to apply practical skills required to perform assessments of disease activity, nail and skin involvement in psoriasis arthritis

Assessment of disease activity in Psoriatic Arthritis

Chair:	Clementina López-Medina (Spain) Annette de Thurah (Denmark)
--------	--

13:30 - 13:55	DAPSA scoring – how to assess number of tender and swollen joints in people with Psoriatic arthritis? Speaker: Michael Zauner (Austria)
13:55 - 14:20	Dermatological Assessment of patients with Psoriasis: Nails and Skin Speaker: Luis Puig (Spain)
14:20 - 14:45	Assessment of enthesitis and dactylitis – and collecting the overall picture. Speaker: Laura C. Coates (United Kingdom)

Meet the EULAR Expert

Date: **04/06/2026**

1. Understand the evidence behind treat-to-target in gout, including target thresholds and clinical benefits
2. Recognise novel insights regarding gout pathogenesis, including gut dysbiosis, innate immune mechanisms, and genetics
3. Appreciate how comorbidities impact therapeutic approaches and how gout may in turn influence comorbidity outcomes

Room: **Meet the EULAR Expert 1**

13:30-14:00 BST

Gout

Chair:	
13:30 - 14:00	Gout Speaker: Nicola Dalbeth (New Zealand)

Meet the EULAR Expert

Date: **04/06/2026**

Room: **Meet the EULAR Expert 2**

13:30-14:00 BST

Lupus and pregnancy

Chair:	
13:30 - 14:00	Lupus and pregnancy Speaker: Karen Schreiber (Denmark)

Meet the EULAR Expert

Date: **04/06/2026**

What is the current state-of-the art strategy in the management of patients with JDM? What is the evidence for T2T strategies? What is the approach in light of the lack of approved drugs? What is the patient outcome?

Room: **Meet the EULAR Expert 3**

13:30-14:00 BST

State-of-the-art in juvenile dermatomyositis

Chair:	
13:30 - 14:00	State-of-the art strategies in the management of JDM Speaker: Clarissa Pilkington (United Kingdom)

Meet the EULAR Expert

Date: **04/06/2026**

Room: **Meet the EULAR Expert 4**

13:30-14:00 BST

Difficult skin manifestations with myositis

Chair:	
13:30 - 14:00	Difficult skin manifestations with myositis Speaker: Hanna Brauner

Poster View Presentations

Date: **04/06/2026**

Room: **Poster View**

13:30-01:10 BST

Poster View III

Chair:	
13:30 - 13:40	Infection Risk in VEXAS Syndrome: A Cohort Analysis of twenty patients and Comparison with Rheumatoid Arthritis and ANCA-Associated Vasculitis Speaker: Sara Bindoli (Italy)
13:40 - 13:50	What role for coaching in the development of Patient experts Speaker: Alain Cornet (Belgium)
13:50 - 14:00	The Benefit of Carotid Ultrasound in Patients with Inflammatory Joint Diseases Speaker: Eli J. Platou Sollerud (Norway)
14:00 - 14:10	Real-world safety of adalimumab biosimilar-to-biosimilar switching in >1,200 patients with inflammatory arthritis: results from the nationwide DANBIO registry Speaker: Kasper Yde Jensen (Denmark)
14:10 - 14:20	Trends over eight years in seronegative rheumatoid arthritis treated with biologic and targeted synthetic DMARDs Speaker: Alessandro Giollo (Italy)

14:20 - 14:30	Dual Immunomodulation with Tofacitinib and Mycophenolate Mofetil in Autoimmune Orbital Inflammatory Disease: A Retrospective Cohort Study Speaker: Madhulika Kaushik (United Kingdom)
14:30 - 14:40	Beyond DAS28 Scores: Defining Success in Inflammatory Arthritis - Longitudinal Outcomes of Remission versus Low Disease Activity. Speaker: Yasser El Miedany (United Kingdom)
14:40 - 14:50	Building Patient Partner Leadership Through Community, Training, and Mentorship Speaker: Laurie Proulx (Canada)
14:50 - 15:00	Peripheral Blood UBA1 Variant Allele Frequency Predicts Poor Outcomes in VEXAS Syndrome: A Nationwide Prospective Study Speaker: Yohei Kirino (Japan)
15:00 - 15:10	Isolated Tracheal Chondritis as an Under-recognized Entity of Relapsing Polychondritis: A Retrospective Study Speaker: Qiong Fu (China)
15:10 - 15:20	The Newcastle Combined Rheumatology Gastroenterology Clinic: A Retrospective Service Evaluation Speaker: Ejaz Pathan (United Kingdom)
15:20 - 15:30	Histopathological synovial biopsy findings and their clinical correlates in rheumatologic diseases: a multicenter experience from Türkiye Speaker: Rabia Deniz (Türkiye)
15:30 - 15:40	The diagnosis and characteristics of early unidentified arthritis one year after methotrexate therapy Speaker: Ichiro Yoshii (Japan)
15:40 - 15:50	From digital clinical footprints to early rheumatologic diagnosis: a real-world multi-label machine learning approach Speaker: Monserrat Robustillo-Villarino (Spain)
15:50 - 16:00	Comparative Real-World Risk of Candidiasis in Ankylosing Spondylitis Treated with Secukinumab Versus Ixekizumab Speaker: Mohammed Moutaz Alshaghel (United Kingdom)

16:00 - 16:10	Scavenger Receptor MSR1+ Monocytes Trigger Macrophage Activation Syndrome/Haemophagocytic Lymphohistiocytosis by Unleashing Mitochondrial ROS to Activate the NLRP3 inflammasome Speaker: Jianfen Meng (China)
16:10 - 16:20	Beyond NLRP3: Expanding the Spectrum of NLR-Associated Autoinflammatory Diseases Speaker: Rabia Deniz (Türkiye)
16:20 - 16:30	Improving early inflammatory arthritis referrals through integrated education and pathway redesign delivered by the Rheumatology Academy and Collaborative Network (RheumACaN) Speaker: Antoni Chan (United Kingdom)
16:30 - 16:40	Real-World Evidence on JAK Inhibitors in Rheumatology Practice: Comparative Safety, Efficacy, and Outcomes Between JAK Inhibitors Speaker: Rabia Deniz (Türkiye)
16:40 - 16:50	Clinical and Phenotypic Differences Between MEFV-Positive and MEFV-Negative Familial Mediterranean Fever: Are They Really Same? Speaker: Hatice Kübra Yerisenoglu Demir (Türkiye)
16:50 - 17:00	Impact of MEFV Mutations on the Efficacy and Safety of Colchicine and Interleukin-1 Inhibitors in Familial Mediterranean Fever: A Real-World Cohort Study Speaker: Miraç Günaydın (Türkiye)
17:00 - 17:10	Anakinra for Idiopathic Recurrent Pericarditis: Real-life Insights on Long-term Effectiveness, Initiation Timing and Tapering Speaker: Theodoros Dimitroulas (Greece)
17:10 - 17:20	Burden, Timing and Risk Factors of Rheumatologic Manifestations in Inflammatory Bowel Disease: A Cohort Study Speaker: Panagiotis Garantziotis (Germany)
17:20 - 17:30	Cost Effectiveness of Prescribing and Administration of Biologic Infusions in patients with Rheumatological disorders Speaker: Andrea Hall (United Kingdom)

17:30 - 17:40	Role of rheumatologic arthroscopy in the assessment of diagnosis and synovitis severity in patients with chronic arthritis Speaker: Joshua Peñafiel-Sam (Spain)
17:40 - 17:50	FIT FOR WORK 2.0 Speaker: Silvia Tonolo (Italy)
17:50 - 18:00	PERSONALIZZAZIONE DELLE CURE NEI MALATI REUMATOLOGICI Speaker: Silvia Tonolo (Italy)
18:00 - 18:10	Musculoskeletal Ultrasound Phenotyping of Shoulder Pain After Immune Checkpoint Inhibitor Therapy Speaker: Elizabeth Wang (United States of America)
18:10 - 18:20	Patient- and Public-Led Research: A Scoping Review with Implications for Rheumatic and Musculoskeletal Disease Research Speaker: Ellen Wang (Canada)
18:20 - 18:30	Prescribing Patterns After First TNF Inhibitor Failure in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: A Real-World Cohort Study Speaker: Elen Roblin (United Kingdom)
18:30 - 18:40	Work Impairment in Young Adults with Early Inflammatory Arthritis: results from a large UK cohort Speaker: Maryam Adas (United Kingdom)
18:40 - 18:50	Clinical and Ultrasound Characteristics of a Difficult-to-Treat Population with Chronic Arthritis Speaker: Oriana Omaña Iglesias (Spain)
18:50 - 19:00	Gout and rheumatoid arthritis are associated with adverse body fat distribution and muscle composition Speaker: Lyn D. Ferguson (United Kingdom)
19:00 - 19:10	Sex differences in the safety of biologic and targeted synthetic DMARDs in rheumatoid arthritis: real-world data from BIOBADASER III Speaker: Blanca Varas de Dios (Spain)

19:10 - 19:20	Longitudinal Serum Proteomics Reveals Complement Pathway Diversity in Rheumatoid Arthritis Speaker: Benoit Marchand (Canada)
19:20 - 19:30	Validation of the Health Assessment Questionnaire Disability Index in immune checkpoint inhibitor-induced inflammatory arthritis. Speaker: Shahin Jamal (Canada)
19:30 - 19:40	SGLT2 Inhibitors as Adjunct Therapy in FMF-related Renal AA Amyloidosis: Filling an Unmet Clinical Gap? Speaker: Burak Karakaya (Türkiye)
19:40 - 19:50	Breaking the cytokine cascade: targeting inflammation upstream with small molecules for the treatment of autoimmune diseases Speaker: Candela Veloso de Simón (Spain)
19:50 - 20:00	Rehabilitation and Physical Activity in Rheumatological Diseases Speaker: Antonella Celano (Italy)
20:00 - 20:10	Single-cell transcriptomics, immune and metabolic profiling reveals monocyte and T-cell alteration in Familial Mediterranean Fever Speaker: Laura Merlo Pich (Italy)
20:10 - 20:20	Impact of Gender on Treatment Response and Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis: A Prospective Observational Study Speaker: Karen Buch Lauridsen (Denmark)
20:20 - 20:30	The UK HLH Network; Real World Data From The UK National Service For Adults With Haemophagocytic Lymphohistiocytosis Speaker: Hina Javed (United Kingdom)
20:30 - 20:40	IMP761, a novel immunosuppressive LAG-3 agonist antibody in the clinic. Speaker: Frederic Triebel (France)
20:40 - 20:50	JAK Inhibitor Treatment Is Associated with a Reduction in Liver Fibrosis, Assessed by FIB-4 Index, in Rheumatoid Arthritis Speaker: Takaichi Okano (Japan)

20:50 - 21:00	Knee and Hip Joint Replacement in Patients with Seropositive Rheumatoid Arthritis Treated with b/tsDMARDs Speaker: Melike Köle (Türkiye)
21:00 - 21:10	Artificial intelligence for identifying and grading microcrystalline deposits in knee ultrasound images: a semantic segmentation approach. Results of an OMERACT Ultrasound Working Group Project. Speaker: Marco Davide Dal Fabbro (Italy)
21:10 - 21:20	Risk of disease flare during pregnancy and postpartum in inflammatory arthritis and association with therapy discontinuation: results from a prospective nationwide multicenter study Speaker: Dina Zucchi (Italy)
21:20 - 21:30	Sacroiliitis in Familial Mediterranean Fever: Coexistence or a Distinct Disease Phenotype? Speaker: Nune Manukyan (Armenia)
21:30 - 21:40	Role of Joint Space Analysis by High-resolution Peripheral Quantitative Computed Tomography in Predicting Inflammatory Arthritis among Patients with Arthralgia Speaker: Jiawei Zhao (Hong Kong, China)
21:40 - 21:50	Flipping The Switch: Complement activation in Still's disease Speaker: Freya Huijsmans (Netherlands)
21:50 - 22:00	Comparative effectiveness and Safety of Janus Kinase Inhibitors Versus Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease: An Emulated Target Trial Speaker: Po-Cheng Shih (Taiwan)
22:00 - 22:10	Subclinical Aortic Dysfunction in Ankylosing Spondylitis : A Case Control Study Speaker: Bhuwan Jain (India)
22:10 - 22:20	SURVIVAL ON THERAPY OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND SPONDYLOARTHRITIS: 8-YEAR DATA FROM AN ITALIAN MULTICENTER REGISTER Speaker: Maria Manara (Italy)

22:20 - 22:30	Completed Suicide with Colchicine in Familial Mediterranean Fever: Demographic, Clinical, and Post-Mortem Features Speaker: Berkay Aktas (Türkiye)
22:30 - 22:40	Real-World Outcomes of GLP-1 Receptor Agonists in Inflammatory Rheumatology Patients: A Single-Centre Retrospective Cohort. Speaker: M. Retuerto-Guerrero (Spain)
22:40 - 22:50	Machine Learning–Based Identification of Key Patient-Reported Domains in Inflammatory Arthritis Speaker: Seda Nur Aydogdu (Türkiye)
22:50 - 23:00	Mitochondrial alterations in Still Disease: insights from mtDNA copy number and TFAM expression Speaker: Ludovica Manisera (Italy)
23:00 - 23:10	m6A epitranscriptomic analysis in treated inflammatory rheumatic patients: global RNA methylation and regulatory gene expression Speaker: Arianna D'Antonio (Italy)
23:10 - 23:20	Performance of large language models in diagnosing rare endemic autoinflammatory diseases Speaker: Norman Michael Drzeniek (Germany)
23:20 - 23:30	Real-word persistence of Bimekizumab in Spondyloarthritis and Psoriatic Arthritis: results from the multicentric observational study BIMPACT in Spain Speaker: Cristina Valero-Martínez (Spain)
23:30 - 23:40	Establishing the efficacy of depressive screening tools in inflammatory arthritis (IA): A systematic review Speaker: Conall Mac Gearailt (Ireland)
23:40 - 23:50	Metabolomic analysis revealed characteristic inflammatory and non-inflammatory pain signatures in inflammatory arthritis Speaker: Lilla Gunkl-Tóth (Hungary)
23:50 - 00:00	Evolution and prediction of therapeutic adherence over 1 year in a bicentric cohort of 507 patients followed for chronic inflammatory rheumatism Speaker: Cécile Gaujoux-Viala (France)

00:00 - 00:10	Efficacy of Colchicine in Palindromic Rheumatism: Evidence from Drug withdrawal. Speaker: Rashwith Umesh (India)
00:10 - 00:20	Compliance with Cardiovascular Risk Assessment and Management in Inflammatory Arthritis: A Retrospective Audit in a UK Secondary-Care Rheumatology Service Speaker: Lee Benson (United Kingdom)
00:20 - 00:30	Real-World Cardiovascular and Mortality Outcomes of Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Speaker: Hanieh Akbari (United States of America)
00:30 - 00:40	Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: safety in Routine Clinical Practice in Spain (BIMPACT) Speaker: Cristina Valero-Martínez (Spain)
00:40 - 00:50	Non-HLA susceptibility polygenic risk score is associated with Earlier Disease Onset and Longitudinal Joint Damage in Rheumatoid Arthritis Speaker: Seema Sharma (United Kingdom)
00:50 - 01:00	Multi-omics stratification of FMF attacks distinguishes bi-allelic from heterozygous patients through IL-18/S100 biomarkers Speaker: ZHICHENG ZHOU (France)
01:00 - 01:10	Fibromyalgia Attenuates Treatment Escalation Despite Objective Ultrasound Inflammation in Rheumatoid Arthritis and Spondyloarthritis Speaker: Paula David (Israel)
01:10 - 01:10	Prevalence and Clinical Associations of Suboptimal Vitamin D Levels in Patients Referred to a Community Rheumatology Clinic in Canada Speaker: Anton Lisnevski (Slovakia)

Poster Tour Presentations

Date: 04/06/2026

Room: Poster Tour I

13:30-14:30 BST

Basic and Clinical Poster Tours: Updates on autoinflammatory diseases

Chair:	
13:30 - 13:36	VEXAS Patient Neutrophils Display a Dysregulated Immune Response and an Increase in Immature Neutrophil Populations. Speaker: Thomas Young (United Kingdom)
13:36 - 13:42	Mortality in Familial Mediterranean Fever: Comparison with the General Population and Identification of Independent Predictors of Survival Speaker: Ozgur Can Kilinc (Türkiye)
13:42 - 13:48	What happens to patients with FMF after the age of 50? A re-evaluation of the aging course Speaker: Busra Firlatan Yazgan (Türkiye)
13:48 - 13:54	Unraveling heterogeneity in Undifferentiated Systemic Autoinflammatory Disease (USAID): a cluster-based study in a French cohort of 150 adult patients Speaker: Jeanne Chauffier (France)
13:54 - 14:00	Diagnostic yield and clinical impact of multigene autoinflammatory panels in adult routine care (2018–2025): the role of pre-test clinical suspicion. Speaker: Javier Manzaneque Sánchez (Spain)
14:00 - 14:06	Increased Risk of Multiple Sclerosis Among Patients with Familial Mediterranean Fever: A Nationwide Cohort Study Speaker: Niv Ben-Shabat (Israel)
14:06 - 14:12	Novel NOD2 Variants in Yao Syndrome Drive Aberrant Th17 Expansion via Spontaneous Monocyte Activation and Enhanced RIPK2-MAPK/NF-κB Signaling Speaker: Jingyuan Zhang (China)
14:12 - 14:18	ADENOSINE DEAMINASE 2 DEFICIENCY: CLINICAL FEATURES, ENZYMATIC ACTIVITY, OUTCOME, AND DISEASE SEVERITY: RESULTS FROM THE EUROFEVER REGISTRY Speaker: Chiara Conti (Italy)

14:18 - 14:24	Low-level MYD88 somatic mosaicism in patients with Schnitzler syndrome Speaker: Willem Roosens (Belgium)
---------------	--

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour II**

13:30-14:30 BST

Case Reports Poster Tour

Chair:	Axel Hueber (Germany) Lilla Gunkl-Tóth (Hungary)
13:30 - 13:36	Non-systemic Vasculitic Neuropathy (NSVN): a biopsy-confirmed case series highlighting pathology-treatment response correlations Speaker: Stefano Rizzetto (Italy)
13:36 - 13:42	Somatic NLRP3 Mosaicism Identified After 44 Years of Unexplained Inflammation Speaker: Gauravi Khatu (United Kingdom)
13:42 - 13:48	IgG4-Related Disease Presenting as a Tumor-Like Choroid Plexus Lesion of the Central Nervous System Speaker: MARCELA PATIÑO ARBOLEDA (Colombia)
13:48 - 13:54	RF-Driven Immune Complex Glomerulonephritis Mimicking Seronegative Lupus Nephritis: A Diagnostic Pitfall Speaker: Kei Tomura (Japan)
13:54 - 14:00	Beyond drug toxicity: acute hepatitis E in a patient with granulomatosis with polyangiitis during treatment with Rituximab and Avacopan Speaker: Konstantinos Tsafis (Greece)
14:00 - 14:06	Segmental Arterial MEdiolysis Mimicking Medium-Vessel VASculitis in a Renal Transplant Recipient: The Diagnostic VAlue of PET-CT. Speaker: Muhammad Mujtaba Hashir (United Kingdom)

14:06 - 14:12	Missed red flags of monogenic immune dysregulation: a case report of late-onset STAT3 gain-of-function-related disease Speaker: Ewa Wiesik-Szewczyk (Poland)
14:12 - 14:18	Sarcoidosis Following Disseminated Tuberculosis: A case of Granulomatous Renal Involvement Mimicking Infectious Recurrence Speaker: Sebastián Herrera (Colombia)
14:18 - 14:24	Successful Treatment of Refractory MAS in Still's Disease Using MAS825, a Bispecific Antibody Targeting IL-1β and IL-18 Speaker: Anne Pankow (Germany)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour III**

13:30-14:30 BST

Basic Poster Tours: What's up your SLEeve?

Chair:	Marc Scherlinger (France) Aleksandra Bylinska (United States of America)
13:30 - 13:36	Mitochondrial Expansion and Interferon-Driven Bioenergetic Reprogramming Define CD4⁺ T Cell Dysfunction in Systemic Lupus Erythematosus Speaker: Chris Wincup (United Kingdom)
13:36 - 13:42	Inflammation-driven ferroportin suppression links functional iron deficiency to monocyte bioenergetic failure in systemic lupus erythematosus Speaker: Chris Wincup (United Kingdom)
13:42 - 13:48	Spatial transcriptomics identifies fibroblast proximity as a driver of profibrotic SPP1+ macrophage polarisation in lupus nephritis Speaker: Kunal Mishra (Singapore)
13:48 - 13:54	Anti-CD47/CD20 Bispecific Antibody Enhanced B Cell Depletion and Restored Macrophages Efferocytosis in Patients with Lupus Nephritis Speaker: Chunyi Zhang (China)

13:54 - 14:00	Unveiling the role of abnormal copper metabolism in systemic lupus erythematosus Speaker: Linyi Peng (China)
14:00 - 14:06	Chidamide Reprograms the GATA1-HES1 Dysregulation to Restore Megakaryopoiesis in SLE-Associated Immune Thrombocytopenia Speaker: Yue Hou (China)
14:06 - 14:12	Ultrasensitive digital ELISA-based interferon profiling integrated with large-scale proteomics reveals immune cell-cytokine/chemokine dynamics in systemic lupus erythematosus Speaker: Tatsuki Abe (Japan)
14:12 - 14:18	Differentiation and Pathological Significance of Tissue-Resident Memory-Like CD8+ T Cells in Systemic Lupus Erythematosus Speaker: YUYA FUJITA (Japan)
14:18 - 14:24	Deciphering the Alleviation Mechanism of Lupus Nephritis by Umbilical Cord Blood Mesenchymal Stem Cells: Targeting MiT-TFE/CCL8-Mediated CCL8+ Macrophage-CCR5+ Neutrophil Crosstalk Speaker: Lingyun Sun (China)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour IV**

13:30-14:30 BST

Clinical Poster Tours: New frontiers in Small Vessel Vasculitis and Behcet's

Chair:	Gulen Hatemi (Türkiye) Luca Quartuccio (Italy)
13:30 - 13:36	Induction of remission therapy in Primary Central Nervous System Vasculitis: A single-centre 40-year experience Speaker: Carlo Salvarani (Italy)

13:36 - 13:42	One Year Real-World Effectiveness and Safety with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in Two Large Healthcare Systems Speaker: Naomi Patel (United States of America)
13:42 - 13:48	Colchicine Use Reduces Major Cardiovascular Events in Behçet's Disease Speaker: Maria Morrone (Italy)
13:48 - 13:54	Post-operative outcomes of cardiovascular surgery in patients with Behçet's disease: a nationwide population-based study Speaker: Eun Hye Park (Korea, Republic of (South Korea))
13:54 - 14:00	Impact of Glucocorticoid Regimen on Adverse Events in ANCA-Associated Vasculitis: Post-Hoc Analysis of the PEXIVAS Trial Speaker: Yuan Qi (Canada)
14:00 - 14:06	Predictors of Hypogammaglobulinaemia in Patients with ANCA-Associated Vasculitis treated with Rituximab Speaker: Jan H. Schirmer (Germany)
14:06 - 14:12	Management of Major Organ Involvement in Behçet's Syndrome: Updated Evidence from a Systematic Literature Review to Inform the 2025 EULAR Recommendations Speaker: Yesim Ozguler (Türkiye)
14:12 - 14:18	Effect of mepolizumab add-on therapy on remission rates, disease activity, and glucocorticoid withdrawal during induction of remission in severe EGPA: data from the EGPA Study Group Speaker: Marco Fornaro (Italy)
14:18 - 14:24	MPO-ANCA titre trajectories are differentially associated with relapse and survival in microscopic polyangiitis: The multicentre REVEAL cohort study Speaker: Mayu Shiomi (Japan)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour V**

Clinical Poster Tours: Extinguishing the fires of Inflammatory Arthritis

Chair:	Valentina Pucino (Italy) Stephanie Shoop-Worrall (United Kingdom)
13:30 - 13:36	Risks of breast or prostate cancer recurrence and a second cancer in patients with inflammatory arthritis following treatment with biologic and targeted synthetic DMARDs - A nationwide cohort study Speaker: Karin Hellgren (Sweden)
13:36 - 13:42	Defining Difficult-to-Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late D2T-RA Phenotypes Speaker: Rahaf Attar (Saudi Arabia)
13:42 - 13:48	Impact of Body Mass Index on Response to JAK Inhibitors in Rheumatoid Arthritis: An Individual Patient Data Meta-Analysis Speaker: Katie Bechman (United Kingdom)
13:48 - 13:54	Predicting Early Structural Joint Damage in Rheumatoid Arthritis: Clinical and Serological Insights Speaker: Victoria Lundgren (Sweden)
13:54 - 14:00	Predicting the outcomes of immune checkpoint inhibitor-induced inflammatory arthritis and arthralgia: Development of multivariable models to predict disease persistence Speaker: Kate Harnden (United Kingdom)
14:00 - 14:06	Robot-assisted arthrosonography (ARTHUR) with AI analysis (DIANA) for the initial diagnosis and follow-up of rheumatoid arthritis: Real-world data from 255 patients with suspected arthritis Speaker: Sebastian Klapa (Germany)
14:06 - 14:12	Transarterial periarticular embolization (TAPE) in the treatment of inflammatory rheumatic joint disease - concept of proof study Speaker: Carolin Pflug (Germany)
14:12 - 14:18	Rethinking Biologic Use in Pregnancy: Real-World Outcomes in Inflammatory Arthritis Speaker: Srishti Taneja (United States of America)

14:18 - 14:24	A pre-trained model TRAIN incorporating a million-scale multi-omics data matrix for comprehensive rheumatoid arthritis management Speaker: Yingtong Zhou (China)
---------------	--

Poster Tour Presentations

Date: **04/06/2026**

Room: **PARE Poster Tour**

13:30-14:30 BST

PARE Poster Tour II: Access, Equity and Empowerment

Chair:	Maranda van Dam (South Africa) Fitim Sadiku (Kosovo)
13:30 - 13:36	Preliminary results from a national campaign to reduce time to diagnosis in axial spondyloarthritis Speaker: Dale Webb
13:36 - 13:42	Spotting the Gaps: Geographic Inequalities in Rheumatic Rehabilitation Speaker: Lene Mandrup Thomsen (Denmark)
13:42 - 13:48	Patient awareness and perception of cardiovascular risk burden and management in rheumatic and musculoskeletal diseases: results from an international survey Speaker: Alessia Alunno (Italy)
13:48 - 13:54	The Patient's Voice in the Commission for Reimbursement of Medicine Speaker: Veerle De Pourcq (Belgium)
13:54 - 14:00	Patient perspectives of care for immune mediated inflammatory diseases in Scotland Speaker: Sadé Asker (United Kingdom)
14:00 - 14:06	Osteoporosis in Norway: Increasing Access to Safe and Evidence-Based Exercise Program Speaker: Julie Hillesland (Norway)

14:06 - 14:12	Building Bridges in Health:A Festival for Multi-morbidity awareness Principal Author: Machi Salamaliki-Spanou**Hellenic League Against Rheumatism Speaker: Machi Spanou Salamaliki (Greece)
14:12 - 14:18	Health literacy profiles of people living with inflammatory arthritis: application of the Ophelia process in a UK cohort Speaker: Mrinalini Dey (United Kingdom)
14:18 - 14:24	Leveraging Artificial Intelligence to Empower People with axSpA in India: A Multilingual, Patient-led Advocacy Initiative. Speaker: Prachee Bhosle (United Kingdom)

EULAR Culture

Date: **04/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

14:30-16:30 BST

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	
--------	--

--	--

EULAR Culture

Date: **04/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

14:30-16:30 BST

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

What is New (WIN)

Date: **04/06/2026**

1. Understand how to manage challenging cases of CPPD, including consideration of data regarding immunosuppressants

Room: **Plenary**

14:45-15:30 BST

2. Recognise the clinical relevance of the overlap in OA and CPPD

3. Identify important clinical mimics of CPPD, including seronegative RA and elderly onset RA

(Crystal Related Disorders) Diagnosis and Management of Difficult-to-Treat CPPD

Chair:	Georgios Filippou (Italy) Geraldine McCarthy (Ireland)
14:45 - 15:30	Diagnosis and Management of Difficult-to-Treat CPPD Speaker: Tristan Pascart (France)

EULAR Projects

Date: **04/06/2026**

- Define key concepts of implementation science and their relevance to rheumatology.

Room: **Connaught Room 1 & 2**

14:45-16:00 BST

- Describe common barriers and facilitators to translating evidence-based interventions into routine rheumatology practice.

- Evaluate strategies and frameworks for effective implementation of clinical guidelines and innovations in rheumatology care.

Implementation in rheumatology: bridging evidence and practice

Chair:	Mwidimi Ndosi (United Kingdom) Annelies Boonen (Belgium)
--------	---

14:45 - 14:50	Introduction Speaker: Mwidimi Ndosì (United Kingdom) Co-Speaker: Annelies Boonen / (Maastricht, Belgium)
14:50 - 15:05	From Bench to Bedside: which implementation model should I choose? Speaker: Dieuwke Schiphof (Netherlands)
15:05 - 15:20	From Evidence to Practice: the role of implementation strategy Speaker: Loreto Carmona (Spain)
15:20 - 15:40	Implementing EULAR recommendations at a national level - the EULAR perspective Speaker: Uta Kiltz (Germany)
15:40 - 15:55	Can you tell me how to implement? - educational insights Speaker: Krysia Dziedzic (United Kingdom)
15:55 - 16:00	Questions and Answers Speaker: Annelies Boonen (Belgium) Co-Speaker: Mwidimi Ndosì / (Bristol, United Kingdom)

Basic and Translational Science

Date: **04/06/2026**

1. Explain the basic concepts of epigenetic modifications, including DNA methylation, histone modification, and RNA-associated silencing

Room: **Connaught Room 3 & 4**

14:45-16:00 BST

2. Analyse how epigenetic modifications can influence treatment strategies

3. Identify potential biomarkers from epigenetic studies that could be integrated into clinical practice

Epigenetic Modulation - new horizon in RMDs

Chair:	Michael Bonelli (Austria) Kerstin Klein (Switzerland)
14:45 - 15:10	Epigenetics for Clinicians: how to unfold the complexity Speaker: Caroline Ospelt (Switzerland)
15:10 - 15:30	Chromatin conformation und potential drug target identification Speaker: Gisela Orozco (United Kingdom)
15:30 - 15:50	Epigenetic Inflammatory tissue priming Speaker: Markus Hoffmann (Germany)
15:50 - 16:00	Insulin inhibits inflammation and epigenetically supports T cell phenotype transition in rheumatoid arthritis Speaker: Venkataragavan Chandrasekaran (Sweden)

Health Professionals in Rheumatology (HPR)

Date: **04/06/2026**

By the end of this session, delegates will be able to:

Room: **Victoria Room 1**

1. Understand the role of implementation science in translating evidence into practice.
2. Use frameworks (e.g., ERIC taxonomy) to tailor strategies to local contexts.
3. Learn how to strategically use use facilitators to overcome barriers to local implementation

14:45-16:00 BST

Please mind the gap: Approaches to Implementing Research into Rheumatology Practice

Chair:	Anthony Woolf (United Kingdom) Tuva Moseng (Norway)
--------	--

14:45 - 15:00	Bridging the Gap: An Introduction to Implementation Science Speaker: Sabina De Geest (Switzerland)
15:00 - 15:15	More Than the Intervention: Understanding Implementation Strategies and the ERIC Taxonomy Speaker: Estíbaliz Loza (Spain)
15:15 - 15:30	The role of Patient Research Partners in Implementation Speaker: Ria Brokken (Netherlands)
15:30 - 15:45	De-implementing low value care Speaker: Leti van Bodegom-Vos (Netherlands)
15:45 - 15:55	Development of the SQUEEZE eHealth-Facilitated Integrated Care Model to Improve DMARD Adherence in Adults with Rheumatoid Arthritis: An Implementation Science-Informed Intervention Speaker: Agnes Kocher (Switzerland)
15:55 - 16:00	Questions and Answers Speaker: Anthony Woolf (United Kingdom)

PARE

Date: **04/06/2026**

To explore how personalised treatment can help identify the right medicine for the right patient, including managing resistance and addressing treatment failure

Room: **Victoria Room 2**

14:45-16:00 BST

To highlight the role of lifestyle factors, gender differences, and patient-specific needs in shaping effective care.

To discuss strategies for achieving and maintaining remission, while reflecting current research and EU-level focus on women's health.

Tailor-Made Treatment: The Future of Personalised and Holistic RMD management

Chair:	Peter Böhm (Germany) Ana Vieira (Portugal)
14:45 - 15:00	Rheumatology beyond the joints: embracing holistic and personalised care Speaker: Marta Mosca (Italy)
15:00 - 15:15	Whole person healing: Why your emotions deserve care too Speaker: Karen Lawson (United States of America)
15:15 - 15:30	Treating me not just my disease: Why personalised, holistic care matters Speaker: Connie Ziegler (Denmark)
15:30 - 15:40	Understanding the Sexual Health and Well-Being of People Living with Rheumatic and Musculoskeletal Diseases: a Cross-Sectional Analysis Speaker: Hannah Maher (United States of America)
15:40 - 16:00	Questions and Answers Speaker: Peter Böhm (Germany) Co-Speaker: Ana Vieira / (Lisbon, Portugal)

EULAR Projects

Date: **04/06/2026**

To learn about proceedings in 4 ongoing studies in
Pediatric Rheumatology:

Room: **Victoria Room 3**

14:45-16:00 BST

1) Performance of Kobayashi and Kawanet IVIg resistance scores in a multi-centric European and North Indian cohort of Kawasaki disease;

2) Applicability of standardised ultrasound examination to estimate disease activity in combination with JADAS and inflammation markers in JIA patients;

3) Effectiveness, safety and cost-effectiveness of intravenous versus oral corticosteroid induction regimens;

4) Real life clinical practice strategies from worldwide physicians taking care of the following 5 medical conditions.

Proceedings in paediatric rheumatology

Chair:	Jordi Antón (Spain) Seza Ozen (Türkiye)
14:45 - 15:03	Strategies in Kawasaki disease: The KIWI study Speaker: Maria Vincenza Mastrolia (Italy)
15:03 - 15:22	Strategies in JIA: The DAISY Study Speaker: Dragana Lazarevic (Serbia)
15:22 - 15:40	How to optimize steroid use: The STAR-JIA project Speaker: Clare Pain (United Kingdom)
15:40 - 15:58	Inhomogeneous Management strategies: CLIPS Speaker: Michael Hofer (Switzerland)

Innovation

Date: **04/06/2026**

Spotlight consultation:

Room: **Victoria Room 4**

- To discuss potential complications of long-term treatment with anti-resorptive drugs

14:45-16:00 BST

- To discuss potential combination treatments of anti-osteoporotic drugs

- To discuss potential recycling of osteoanabolic drugs

- To discuss further treatment of patients with osteoporosis and jaw necrosis

When Bone Strength Meets Clinical Uncertainty: Challenges in Osteoporosis Management

Chair:	Giovanni Adami (Italy) Roland Kocijan (Austria)
14:45 - 15:05	Case Presentations Speaker: Judith Everts-Graber (Switzerland)
15:05 - 15:50	Discussions on Case Presentations Speaker: Barbara Hauser (United Kingdom) Co-Speaker: Kenneth Saag / (Birmingham, United States of America), Frank Buttgerit / (Berlin, Germany)

Clinical Science

Date: 04/06/2026

- To learn about the diverse manifestations of vascular inflammation in different age groups.

Room: Victoria Room 5 & 6

- Primary focus is on insights from AAV and IgA-Vasculitis affecting both children and adults in different phenotypes.

14:45-16:00 BST

- On the other hand, insights into vasculitis syndromes that are more age-restricted, such as GCA in elderly or Kawasaki disease in infants and young children.

Vasculitis across ages: Commonalities and Differences

Chair:	Ulf Müller-Ladner (Germany) Marija Jelusic (Croatia)
14:45 - 15:10	ANCA-associated and IgA-vasculitis in children Speaker: David Cabral (Canada)
15:10 - 15:35	ANCA-associated and IgA-vasculitis in adults Speaker: Bernhard Hellmich (Germany)
15:35 - 16:00	Vasculitis with peculiar pattern in the very young: Kawasaki disease Speaker: Paul Brogan (United Kingdom)

Clinical Science

Date: **04/06/2026**

1. Describe the clinical spectrum and organ manifestations of IgG4-related disease and recognize its heterogeneous presentations across specialties.

Room: **N1**

14:45-16:00 BST

2. Explain current diagnostic approaches, including serological, histopathological, and imaging criteria used to identify IgG4-related diseases

3. Differentiate IgG4-related disease from other rheumatologic, autoimmune, and fibrotic disorders that may present with similar clinical or pathological features.

4. Discuss evidence-based treatment strategies, including glucocorticoid and immunomodulatory therapies, and evaluate emerging therapeutic options.

New perspectives in IgG4-associated diseases

Chair:	Tobias Alexander (Germany) Maria Maslinska (Poland)
--------	--

14:45 - 15:06	Clinical Spectrum and diagnostic Approaches in IgG4-related diseases Speaker: Emanuel Della Torre (Italy)
15:06 - 15:28	Differential Diagnosis: Distinguishing IgG4-related disease from other rheumatologic and fibrotic disorders Speaker: Arezou Khosroshahi (United States of America)
15:28 - 15:50	Treatment Strategies and Outcomes in IgG4 related disease Speaker: John H. Stone (United States of America)
15:50 - 16:00	Obexelimab, a B Cell Inhibitor, in IgG4-Related Disease: Results From the Phase 3 INDIGO Trial Speaker: Emanuel Della Torre (Italy)

EULAR Joint Sessions

Date: **04/06/2026**

1. Identify and Understand Inequities: Define underserved and marginalised populations in rheumatology and present evidence of disparities in access, diagnosis, treatment, and outcomes

Room: **N2**

14:45-16:00 BST

2. Examine Root Causes: Explore structural, social, and systemic barriers—such as racism, poverty, stigma, and limited health literacy—that drive inequities

3. Showcase Solutions and Collaboration: Highlight innovative community, digital, and policy interventions; promote inclusive research; and foster global partnerships to improve equity

4. Drive Action and Accountability: Empower the workforce, influence policy, and establish frameworks to monitor progress and inspire collective commitment to equitable rheumatologic care.

Healing Beyond Borders: Transforming Lives Through Inclusive Rheumatology Care

Chair:	Simone Battista (United Kingdom) KENZA BOUAYED (Morocco)
14:45 - 15:10	The Growth of Paediatric Rheumatology in LMICs-A Case Study of Rwanda Speaker: Nzabonimpa Clarisse (Rwanda)
15:10 - 15:35	Diversity, Equity and Inclusivity in Rheumatology Speaker: Franklin Hiagbe (Ghana)
15:35 - 16:00	Promoting Inclusive Research in Rheumatology Speaker: Jessica Perfetto (United States of America)

EULAR Joint Sessions

Date: **04/06/2026**

1. How often are sarcopenia and osteoporosis associated in the elderly

Room: **N3**

14:45-16:00 BST

2. Prevalence and causes of malnutrition in the elderly

3. What are the specificities of treatment of sarcopenia and osteoporosis in the elderly

Sarcopenia, malnutrition, and osteoporosis in older adults

Chair:	Sandra Meisalu (Estonia) Boryana Boteva (Bulgaria)
--------	---

14:45 - 15:00	Loss of muscle mass and function related to aging Speaker: Lars Larsson (Sweden)
15:00 - 15:15	Prevalence and causes of malnutrition in the elderly Speaker: Kristina Norman (Germany)
15:15 - 15:30	The role of nutrition in prevention and treatment of sarcopenia and osteoporosis in older adults Speaker: Fernando Pimentel-Santos (Portugal)
15:30 - 15:45	Treatment Considerations for osteoporosis and sarcopenia in older adults Speaker: Harnish Patel (United Kingdom)
15:45 - 16:00	Questions and Answers Speaker: Sandra Meisalu (Estonia) Co-Speaker: Boryana Boteva / (Sofia, Bulgaria)

EMEUNET Presents

Date: **04/06/2026**

Join the RheumaVision Final Round. Vote for your favourite.

Room: **George V Room 1**

14:45-16:00 BST

Here, you will see presentations from winners of the RheumaVision virtual semifinals.

You will learn rheumatology from young peers. There will also be a focus on presentation skills with a closing by RheumaVision jury (EULAR faculty).

The RheumaVision research knowledge transfer contest

Chair:	Cristiana Sieiro Santos (United Kingdom) Alexandros Panagiotopoulos (Greece) Predrag Ostojic (Serbia) Peter Boyd (Ireland) Mike Backhouse (United Kingdom)
--------	--

	Christophe Richez (France)
14:45 - 14:50	Introduction to RheumaVision 2026! Speaker: Cristiana Sieiro Santos (United Kingdom) Co-Speaker: Alexandros Panagiotopoulos / (Athens, Greece)
14:50 - 14:58	Netherlands Speaker: Kabir Budlender (South Africa)
14:58 - 15:06	Greece Speaker: Anastasia Chatzistamati (Greece)
15:06 - 15:14	France
15:14 - 15:22	Norway Speaker: Vilde Øverlien Dåstøl (Norway)
15:22 - 15:30	Israel Speaker: Shai Shtrozberg (Israel)
15:30 - 15:38	Ukraine Speaker: Mariia Sobchenko (Ukraine)
15:38 - 15:42	Voting for the winner of RheumaVision 2026!
15:42 - 15:52	How to win RheumaVision (how to give an effective flash talk) Speaker: Loreto Carmona (Spain)

15:52 - 16:00	Closing and Prize Giving! Speaker: Cristiana Sieiro Santos (United Kingdom) Co-Speaker: Alexandros Panagiotopoulos / (Athens, Greece)
---------------	--

Clinical Science	Date: 04/06/2026
Understand updates in measurement for arthritis in lupus	Room: George V Room 2
Understand updates in measurement for lupus trials	14:45-16:00 BST
Understand updates in remission definitions for advanced therapies	

Measurement of disease activity in SLE clinical trials

Chair:	Laurent Arnaud (France) Jeanette Andersen (Denmark)
14:45 - 15:10	LAMDA - a new measure for arthritis in SLE Speaker: Elizabeth Hensor (United Kingdom)
15:10 - 15:35	TRM-SLE: a new integrated outcome measure for lupus trials Speaker: Kathryn Connelly (Australia)
15:35 - 16:00	DORIS 2.0 - a new definition for deep remission Speaker: Ronald F. van Vollenhoven (Netherlands)

From Bench to Bedside	Date: 04/06/2026
Treatment of ILD in RMD, learn about newest clinical evidence of treatment, potential novel therapeutic targets and future direction of treatment	Room: George V Room 3
	14:45-16:00 BST

Rheumatic Disease–Associated ILD: Barriers, Breakthroughs, and Beyond

Chair:	Kastriot Kastrati (Austria) Simona Rednic (Romania)
14:45 - 15:05	From molecules and cells to therapeutic targets (Preclinical and early Phase clinical trials of ILD across rheumatic diseases) Speaker: Andreas Ramming (Germany)
15:05 - 15:25	From Guidelines to Clinical Practice: Clinical Implications of the 2025 ERS/EULAR guidelines of CTD-ILD Speaker: Anna-Maria Hoffmann-Vold (Norway)
15:25 - 15:45	What is on the horizon: Update on clinical trials Speaker: Andreina Manfredi (Italy)
15:45 - 16:00	Panel Discussion Speaker: Simona Rednic (Romania) Co-Speaker: Kastriot Kastrati / (Vienna, Austria)

Challenges in Clinical Practice

Date: **04/06/2026**

- To learn how to improve the diagnosis of catastrophic antiphospholipid syndrome in the daily clinical practice

Room: **George V Room 4**

14:45-16:00 BST

- To discuss the haematological features and alternate diagnoses of catastrophic antiphospholipid syndrome

- To provide the latest advances about the treatment of catastrophic antiphospholipid syndrome

Complex presentation and treatment of catastrophic antiphospholipid syndrome, from diagnostic dilemmas to therapeutic challenges

Chair:	Ricard Cervera Segura (Spain) Bahar Artim Esen (Türkiye)
--------	---

14:45 - 14:50	Introduction Speaker: Bahar Artim Esen (Türkiye)
14:50 - 15:00	Case 1 - The diagnostic dilemma of catastrophic antiphospholipid syndrome Speaker: Lucas Jacobs (Belgium)
15:00 - 15:20	Case Discussion - The diagnostic dilemma of catastrophic antiphospholipid syndrome Speaker: Maxime Taghavi (Belgium)
15:20 - 15:30	Case 2 - The precipitating factors of catastrophic antiphospholipid syndrome Speaker: Ana-Luisa Stefanski (Germany)
15:30 - 15:50	Case Discussion - The precipitating factors of catastrophic antiphospholipid syndrome Speaker: Thomas Dörner (Germany)
15:50 - 16:00	Questions and Answers Speaker: Ricard Cervera Segura (Spain)

Basic and Translational Science

Date: **04/06/2026**

1. Describe the role of stromal cells (fibroblasts, endothelial cells, entheses niches) in shaping chronic inflammation across rheumatic diseases.

Room: **Room 12**

14:45-16:00 BST

2. Explain mechanisms of stromal-immune crosstalk revealed by single-cell and microenvironmental studies.

3. Identify translational opportunities where stromal biology informs biomarkers, prognosis, and novel

therapeutic targets.

Stromal Immunology: fibroblasts, endothelial cells and inflammatory niches

Chair:	Stefano Di Donato (Switzerland) Costantino Pitzalis (United Kingdom)
14:45 - 15:00	Macrophages and stromal cells in joint pathology: from single-cell maps to targets Speaker: Stefano Alivernini (Italy)
15:00 - 15:15	Endothelial dysfunction and vascular niches in systemic sclerosis Speaker: Marie-Elise Truchetet (France)
15:15 - 15:30	Stromal-immune crosstalk in health and disease Speaker: Madhvi Menon (United Kingdom)
15:30 - 15:45	Stromal cells at the enthesis: microenvironments driving spondyloarthritis Speaker: Dirk Elewaut (Belgium)
15:45 - 16:00	Question and Answers Speaker: Stefano Di Donato (Switzerland) Co-Speaker: Costantino Pitzalis / (London, United Kingdom)

How to Treat (HOT)

Date: **04/06/2026**

- To discuss the paediatric perspective in the transition to the adult care of patients with autoinflammatory disease

Room: **Plenary**

15:30-16:15 BST

- To discuss the adult perspective in the transition from the paediatric care of patients with autoinflammatory disease

- To learn how to improve the in the transition from paediatric to adult care of patients with

autoinflammatory disease

Transitioning young patients with autoinflammatory disease to adult care, implications for daily clinical management

Chair:	Sophie Georgin-Lavialle (France) Marco Gattorno (Italy)
15:30 - 16:15	Transitioning young patients with autoinflammatory disease to adult care Speaker: Eugen Feist (Germany)

Poster View Presentations

Date: **04/06/2026**

Room: **Poster View**

16:00-17:00 BST

Poster View IV

Chair:	
16:00 - 16:00	Effect of Monosodium Urate on Angiogenesis in gouty arthritis Speaker: Ziyi Chen (China)
16:00 - 16:00	GLP-1 Receptor Agonists in Rheumatoid Arthritis and Psoriatic Arthritis: A Systematic Review of Disease Activity, Inflammatory Markers, and Cardiometabolic Outcomes Speaker: Juan Sebastian Theran Leon (Colombia)
16:00 - 16:00	The Association of the Triglyceride-Glucose Index with Disease Activity and Lymphocyte-Subset Profiles in Inflammatory Arthritis Speaker: Sheng-Xiao Zhang (China)

16:00 - 16:00	Current practices and views on family planning, contraception and prescribing in patients with rheumatic disease; a national survey Speaker: Nabeedah Moollan (Ireland)
16:00 - 16:00	Assessment of activity in adult IgA vasculitis Speaker: Alojzija Hocevar (Slovenia)
16:00 - 16:00	Multicomponent Non-Pharmacological Interventions Demonstrate Superior Efficacy for Pain and Function in Fibromyalgia: Systematic Review of 40 Randomized Controlled Trials (2020-2025) Speaker: Juan Sebastian Theran Leon (Colombia)
16:00 - 16:00	Global Diversity Among Editorial Journal Boards in Rheumatology Publishing: A Call for Equitable Representation Speaker: Rodolfo Martinez-Canales (Mexico)
16:00 - 16:00	Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review Speaker: Jiha Lee (United States of America)
16:00 - 16:00	Associations of Composite Dietary Antioxidant Index and Dietary Inflammation Index with Rheumatoid Arthritis in Adults Speaker: Sheng-Xiao Zhang (China)
16:00 - 16:00	Low-dose Interleukin-2 Promotes Regulatory T Cell Activity and Monocytes Anti-inflammatory Reprogramming in Systemic Lupus Erythematosus Speaker: Sheng-Xiao Zhang (China)
16:00 - 16:00	How quickly do pain, global functioning and health improve? A real-world Evaluation of the Symptom Amelioration in Patients with Axial Spondyloarthritis Treated with Upadacitinib Speaker: Uta Kiltz (Germany)
16:00 - 16:00	Baseline vascular involvement and male sex might predict incident deep vein thrombosis during follow-up in Behçet's syndrome. Speaker: Hasan Kocaayan (Türkiye)

16:00 - 16:00	Glucocorticoid exposure and long-term outcomes in ANCA-associated vasculitis: The multicentre REVEAL cohort study Speaker: Mayu Shiomi (Japan)
16:00 - 16:00	Concomitant use of canakinumab may lead to steroid-free dosing of pegloticase Speaker: Jeff Peterson (United States of America)
16:00 - 16:00	Analytical Evaluation a Fully Automated Multiplex Microarray Immunoassay for Simultaneous Detection of Anti-MPO, Anti-PR3, and Anti-GBM Autoantibodies in Two Clinical Laboratories in the Netherlands Speaker: Gerber Gomez (Switzerland)
16:00 - 16:00	Calcium Phosphate Crystals Lack Association to Pain and Inflammation in Individuals with Knee Osteoarthritis: A cross-sectional study based on the INKA trial Speaker: Asbjørn Poulsen (Denmark)
16:00 - 16:00	Induction of Remission in People with Newly-Diagnosed Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Simulation Modeling Approach Speaker: Naomi Patel (United States of America)
16:00 - 16:00	Clinical Outcomes by Glucocorticoid Duration in Individuals with Granulomatosis with Polyangiitis and Microscopic Polyangiitis Treated with Avacopan in a Real-World Setting in Two Large Healthcare Systems Speaker: Naomi Patel (United States of America)
16:00 - 16:00	A comparison of the Performance of Lung Ultrasound, Pulmonary Function Tests and KL-6 in Connective Tissue Disease-Associated Interstitial Lung Disease Speaker: Yukai Wang (China)
16:00 - 16:00	Incidence of first onset uveitis in patients newly diagnosed with ankylosing spondylitis, Behcet's disease, and juvenile idiopathic arthritis using national claims data Speaker: Bo Young Kim (Korea, Republic of (South Korea))
16:00 - 16:00	Evolution of treatment patterns and influence on prognosis in Erdheim-Chester disease: a 20-year experience Speaker: Chiara Bellino (Italy)

16:00 - 16:00	Can serum Neurofilament Light Chains be used to monitor Vasculitic Neuropathy? Speaker: Sofia Acabado (Switzerland)
16:00 - 16:00	Structural lesions of the sacroiliac joints in early axSpA versus non-axSpA chronic back pain: 2-year results from the SPACE cohort Speaker: Haluk Cinakli (Türkiye)
16:00 - 16:00	The clinical potential of serum autotaxin levels at diagnosis as a biomarker for current activity and subsequent complications in patients with microscopic polyangiitis and granulomatosis with polyangiitis Speaker: Sang-Won Lee (Korea, Republic of (South Korea))
16:00 - 16:00	Circulating IL-17A Accumulation Reflects Effective Target Blockade with Secukinumab in Spondyloarthritis Speaker: Adrián Llamas Urbano (Spain)
16:00 - 16:00	Impact of filgotinib on MRI inflammatory and structural lesions in the sacroiliac joint of patients with axial spondyloarthritis: 52-week results from the Phase 3 OLINGUITO trial Speaker: Xenofon Baraliakos (Germany)
16:00 - 16:00	Hospitalizations in Still's Disease: Incidence, Drivers, and Management in a Real-World Cohort Speaker: Chiara Bellino (Italy)
16:00 - 16:00	Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors vs. ACE inhibitors/angiotensin II receptor blockers for primary gout prevention among patients with heart failure: target trial emulation studies Speaker: Natalie McCormick (United States of America)
16:00 - 16:00	Early and prolonged response to Mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA): a cohort study by the European EGPA Study Group Speaker: Alessandra Bettiol (Italy)
16:00 - 16:00	MALIGNANCY PATTERNS IN ANCA-ASSOCIATED VASCULITIS: CLINICAL AND TREATMENT FACTORS IN A TWO-CENTRE COHORT Speaker: Serdar Sezer (Türkiye)

16:00 - 16:00	<p>Sex Differences in Medication Use and Healthcare Costs in Radiographic Axial Spondyloarthritis: A Nationwide Claims Study Speaker: Yu-Seon Jung (Korea, Republic of (South Korea))</p>
16:00 - 16:00	<p>The effect of pulmonary nodule presence on disease severity and course in ANCA-associated vasculitis: A Multicenter Cohort Study Speaker: Ayse Elif Boncukcuoglu (Türkiye)</p>
16:00 - 16:00	<p>Mepolizumab as first line treatment for eosinophilic granulomatosis with polyangiitis (EGPA): a retrospective cohort study by the European EGPA Study Group Speaker: Irene Mattioli (Italy)</p>
16:00 - 16:00	<p>AI-assisted screening for Systematic Reviews in Rheumatology Speaker: Dina Husum (Denmark)</p>
16:00 - 16:00	<p>Enthesitis in a mouse disease model: lessons learned from an inflammatory knee joint laxity model Speaker: Donna Vegt (Netherlands)</p>
16:00 - 16:00	<p>Altered circulating B-cell subsets in axial spondyloarthritis and their association with anti-TNF treatment response Speaker: Beatriz Nieto-Carvalho (Spain)</p>
16:00 - 16:00	<p>Clinical spectrum and imaging features in intracranial vasculitis: a single-center experience Speaker: Esra Firat Senturk (Türkiye)</p>
16:00 - 16:00	<p>Validation of MRI Structural Lesions Versus Computed Tomography in the Sacroiliac Joints of Patients with Axial Spondyloarthritis in the EchoSpA Inception Cohort Speaker: Natalya Horbal (Ukraine)</p>
16:00 - 16:00	<p>Differences in Gout Management and Outcomes in Patients Referred From Primary Care to Rheumatology Speaker: Alexis Woods (United States of America)</p>

16:00 - 16:00	Adult primary central nervous system vasculitis with small vessel involvement: a case-control study Speaker: Carlo Salvarani (Italy)
16:00 - 16:00	The Impact of Elevated Serum Urate Levels and Tophi on HRQOL and Daily Functioning in Patients with Uncontrolled Gout Speaker: Angelo Gaffo (United States of America)
16:00 - 16:00	What Defines an MRI Considered Indicative of Axial Spondyloarthritis in the Sacroiliac Joints: A Systematic Literature Review by the Spondyloarthritis Research and Treatment Network and the Skeletal Society of Radiology Speaker: Mohamad Bittar (United States of America)
16:00 - 16:00	Association of Gout Remission With Patient-Reported Quality of Life Outcomes After Pegloticase Treatment: MIRROR Randomized Controlled Trial Speaker: Alexis Woods (United States of America)
16:00 - 16:00	Body-mass index predicts remission and treatment retention in EGPA patients treated with IL5 inhibitors: results from the European EGPA Study Group Speaker: Alvise Berti (Italy)
16:00 - 16:00	Osteoclast-derived Del1 promotes pathological bone formation of AS via regulating RUNX2 expression in osteoblast Speaker: Seunghun Lee (Korea, Republic of (South Korea))
16:00 - 16:00	Time to renal replacement therapy determinants in ANCA-associated vasculitis-data from Polish Vasculitis Registry (POLVAS) Speaker: Katarzyna Wawrzycka-Adamczyk (Poland)
16:00 - 16:00	Real-world safety of rasburicase in patients with refractory chronic gouty arthritis : a retrospective observations study Speaker: Qian-Hua Li (China)
16:00 - 16:00	High-Dimensional Immunophenotyping Reveals Divergent Immune Profiles in Axial Spondyloarthritis and Psoriatic Arthritis Speaker: Natalie Frede (Germany)
16:00 - 16:00	Renal Function Trajectory in AAV Using FAIRVASC Data Speaker: Alessandra Bettioli (Italy)

16:00 - 16:00	Disentangling causality and pleiotropy between osteoporosis and ankylosing spondylitis using genome-wide genetic analyses Speaker: Sizheng S. Zhao (United Kingdom)
16:00 - 16:00	EFFECT OF NINTEDANIB ASSOCIATED WITH ABATACEPT IN RHEUMATOID ARTHRITIS–ASSOCIATED INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 526 PATIENTS. Speaker: Ana Serrano-Combarro (Spain)
16:00 - 16:00	Mortality Trends in Vasculitis, Giant Cell Arteritis, and ANCA-Associated Vasculitis in the United States between 1999 and 2024 Based on CDC WONDER Speaker: Meryem Pamuk (United States of America)
16:00 - 16:00	Longitudinal impact of menopause on bone health and osteoporosis in women with spondyloarthritis: results from the DESIR cohort Speaker: Roba Ghossan (France)
16:00 - 16:00	Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study Speaker: Nils Venhoff (Germany)
16:00 - 16:00	A Biomarker-guided decision-support algorithm for precision therapy in pregnant patients with autoimmune rheumatic diseases Speaker: Braulio Rafael Avalos García (Mexico)
16:00 - 16:00	Safety of IL-6 receptor inhibition in pregnancy: A mendelian randomization study Speaker: Benjamin Zuckerman (United Kingdom)
16:00 - 16:00	Mepolizumab Improves Remission Achievement and Duration, and OCS Sparing in Patients With EGPA with Comorbid Chronic Rhinosinusitis with Nasal Polyps: A Post Hoc Analysis of the MIRRA Study Speaker: Maria C. Cid (Spain)
16:00 - 16:00	Pathogenetic role of CPP and BCP crystals in osteoarthritis: association with inflammation, matrix remodeling and disease severity Speaker: Chiara Baggio (Italy)

16:00 - 16:00	Sensitivity to change of an automated MRI bone marrow oedema scoring system for the spine and sacroiliac joints in axial spondyloarthritis: analysis of three phase 3 trials Speaker: Saad Ahmed (United Kingdom)
16:00 - 16:00	Sustained and Consistent Improvements in Disease Activity, Functional Status, and Quality of Life with the Digital Therapeutic Axia in Axial Spondyloarthritis: Results of a 26-week randomised controlled crossover trial (Bechterew-App Trial) Speaker: Patrick-Pascal Strunz (Germany)
16:00 - 16:00	Thymic downregulation of the IFN/STAT1 pathway precedes Th17 polarization in HLA-B27 transgenic rat (B27-rat) model of spondyloarthritis (SpA) Speaker: Chiara Bonini (Italy)
16:00 - 16:00	REAL-WORLD EVIDENCE OF THE ANTIFIBROTIC NINTEDANIB IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 94 PATIENTS FROM CLINICAL PRACTICE Speaker: Ana Serrano-Combarro (Spain)
16:00 - 16:00	Renal outcomes in ankylosing spondilitis: a retrospective, population-based cohort study Speaker: Kinga Tyczynska (Poland)
16:00 - 16:00	Unsupervised segmentation of joint ultrasound images using Vision Transformer and spectral clustering method: a single-center study Speaker: Viktor Korendovych (Germany)
16:00 - 16:00	Non-lysosomal trafficking of CD71/SIgA complexes raises new questions on gut–entheses communication in Spondyloarthritis Speaker: Juliette De Avila (Colombia)
16:00 - 16:00	Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature review Speaker: Dafne Capelusnik (Israel)

Poster Tour Presentations

Date: 04/06/2026

Room: Poster Tour I

Clinical Poster Tours: An RMD pick-n-mix

Chair:	Thomas Hügle (Switzerland) Axel Finckh (Switzerland)
16:00 - 16:06	Using longitudinal ePROMs trajectories to inform outpatient appointments planning in patients with rheumatoid arthritis Speaker: Iuliia Biliavska (Ukraine)
16:06 - 16:12	Evaluating Machine Learning Tools to assist Title and Abstract Screening in Systematic Literature Reviews: A report from the EULAR RA management recommendations Task Force Speaker: Victoria Konzett (Austria)
16:12 - 16:18	EULAR AI-Driven Screening: Evaluating ASReview for Systematic Literature Reviews Informing EULAR Recommendations and Points-to-Consider Speaker: Lea Bischof (Austria)
16:18 - 16:24	Diagnostic accuracy and clinical relevance of automated AI-based capillaroscopy in connective tissue diseases: preliminary data Speaker: Georgi Gerganov (Bulgaria)
16:24 - 16:30	Inter-Operator Reliability of Shear Wave Elastography for Tendon Stiffness Assessment Speaker: Reem Jari (United Kingdom)
16:30 - 16:36	Beyond Inflammation: Functional Disability and Pain Perception Drive the Patient-Physician Discordance Gap in Rheumatology Speaker: Hakan Babaoglu (Türkiye)
16:36 - 16:42	Pulmonary Outcomes in Mycophenolate Mofetil Treated Patients: An HRCT-Based Cohort Study Speaker: Hasan Yardimci (Türkiye)
16:42 - 16:48	Cardiac Arrhythmias and Conduction Disorders in Autoimmune Diseases: A Systematic Review and Meta-Analysis Speaker: Juan Sebastian Theran Leon (Colombia)

16:48 - 16:54	Diagnostic Accuracy and Safety of Large Language Models in Autoimmune Rheumatic Diseases: A Blinded Comparative Evaluation Speaker: Juan Sebastian Theran Leon (Colombia)
---------------	---

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour II**

16:00-17:00 BST

Basic and Clinical Poster Tours: Advances in Gout and Crystal Disease

Chair:	Anne-Kathrin Tausche (Germany) Caroline van Durme (Belgium)
16:00 - 16:06	Assessing the reliability of the ultrasound semiquantitative scoring system for gout - a patient-based reliability study by the OMERACT Ultrasound Working Group Speaker: Peter Mandl (Austria)
16:06 - 16:12	COMPARATIVE EFFICACY AND SAFETY OF DOTINURAD AND FEBUXOSTAT IN GOUT PATIENTS WITH UNDEREXCRETION-TYPE HYPERURICEMIA: A POST-HOC ANALYSIS OF THE MULTICENTER, DOUBLE-BLIND, PHASE 3 TRIAL NCT05007392 Speaker: Zhuoli Zhang (China)
16:12 - 16:18	Association between gout and atrial fibrillation in young adults: a nation-wide study Speaker: Jae Hyun Jung (Korea, Republic of (South Korea))
16:18 - 16:24	Urate is associated with both calcification and total atherosclerotic burden in coronary arteries: results from the SCAPIS study. Speaker: Panagiota Drivelegka (Sweden)
16:24 - 16:30	A randomised controlled trial investigating the impact of disease labels on illness perceptions in calcium pyrophosphate deposition disease Speaker: Vicky Tai (New Zealand)

16:30 - 16:36	Do people with tophaceous gout require more allopurinol for good clinical outcomes? Analysis of two randomized controlled trials with allopurinol dose escalation. Speaker: Lisa Stamp (New Zealand)
16:36 - 16:42	Development and validation of an artificial intelligence algorithm for the identification and quantification of chondrocalcinosis and osteoarthritis on knee radiographs Speaker: Danila Madonna (Italy)
16:42 - 16:48	Metabolic Syndrome and Liver Fibrosis Risk in South Asian Gout Patients: A Cross-Sectional Analysis of Insulin Resistance and NAFLD Burden Speaker: Binit Vaidya (Nepal)
16:48 - 16:54	Baseline Predictors of Gout Remission During Intensive Urate-Lowering With Pegloticase: Post Hoc Analysis of the MIRROR Randomized Trial Speaker: Alexis Woods (United States of America)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour III**

16:00-17:00 BST

Basic Poster Tours: Emerging drivers of Rheumatoid Arthritis

Chair:	Cristina Maglio (Sweden) Pierre-Antoine Juge (France)
16:00 - 16:06	Synovium-on-a-chip - a patient-derived rheumatoid arthritis model that mimics disease, biological heterogeneity, and real-world TNF inhibitor treatment response Speaker: Theresa Wampler Muskardin (United States of America)
16:06 - 16:12	Elevation of Circulating Proliferative Tph Cells and Activated Naïve B Cells Precedes Development of Clinical Rheumatoid Arthritis in CCP-Positive At-Risk Individuals Speaker: Hideto Takada (Japan)

16:12 - 16:18	Peripheral blood single-cell programs mirror synovial inflammatory networks and track CTLA-4–Ig-mediated modulation in rheumatoid arthritis Speaker: Tai-Ming Ko (Taiwan)
16:18 - 16:24	Immunological Reprogramming: Harnessing Small Molecules to Induce Resistance to Inflammation in Rheumatoid Arthritis Speaker: Martin Kotrlev (Spain)
16:24 - 16:30	Twist1-mediated induction of AEBP1 in fibroblast-like synoviocytes activates TGF-β signaling to drive angiogenesis and promote rheumatoid arthritis Speaker: Zhenyu Li (China)
16:30 - 16:36	Species-level shotgun metagenomic analysis reveals gut microbiome alterations in individuals at-risk for rheumatoid arthritis Speaker: Ryo Motoyama (Japan)
16:36 - 16:42	Unsupervised multi-omics analysis reveals distinct molecular programmes associated with progression to rheumatoid arthritis in CCP-positive at-risk individuals Speaker: Leon Chang (United Kingdom)
16:42 - 16:48	Primary cilia modulate inflammatory and fibrotic responses in synovial and skin fibroblasts Speaker: Masoumeh Mirrahimi (Switzerland)
16:48 - 16:54	The Transcription Factor PU.1 Governs Immunosuppressive CD45⁺ Erythroid Progenitor Cells to Ameliorate Rheumatoid Arthritis Speaker: Weihang Zhu (China)

Poster Tour Presentations

Date: **04/06/2026**

Room: **Poster Tour IV**

16:00-17:00 BST

Clinical Poster Tours: Real-world evidence and disease-specific trajectories in RMDs

Chair:	Raphaèle Seror (France) Bruno Fautrel (France)
16:00 - 16:06	The EspAnde Project: A Multidisciplinary Health Services Intervention to Reduce Diagnostic Delay in Axial Spondyloarthritis. Real-World Evidence from Northern Spain Speaker: Ligia Gabrie (Spain)
16:06 - 16:12	Incidence of cancer across the spectrum of autoinflammatory diseases: A systematic review and meta-analysis Speaker: Berkay Kilic (Türkiye)
16:12 - 16:18	On the sidelines – how do we best support partners of elderly people with RMDs Speaker: Mette Saaby Bro (Denmark)
16:18 - 16:24	Closing the gap between narrative and structure: A workflow-integrated clinical documentation improvement tool for enhancing SNOMED CT- coded problem lists in rheumatology practice. Speaker: Ilse Hoffman (Belgium)
16:24 - 16:30	Socioeconomic disparities in mother-reported joint symptoms from birth to 18 years: a population-based study Speaker: Catarina Pires (Portugal)
16:30 - 16:36	Associations of Frailty Status and Trajectories with Incident Arthritis in Older Adults: Findings from the Health and Retirement Study and the English Longitudinal Study of Ageing Speaker: Huayong Zhang (China)
16:36 - 16:42	Gap in the Collection of Social Determinants of Health in Immune-Mediated Inflammatory Diseases: A Cross-Network Collaboration of Registries Speaker: Ana Triguero-Martinez (Spain)
16:42 - 16:48	Uptake of Recombinant Zoster Vaccination in Patients with Inflammatory Arthritis Receiving Biologic Therapy Speaker: Lozan Zangana (United Kingdom)
16:48 - 16:54	Prevalence and Incidence of Spondyloarthritis in Catalonia, Spain: Findings from the Population-Based CAPTURED Study Speaker: José A. Gomez-Puerta (Spain)

Poster Tour PresentationsDate: **04/06/2026**Room: **Poster Tour V****16:00-17:00 BST****Clinical Poster Tours: SpArking new research in Spondyloarthritis**

Chair:	Ana Bento da Silva (Portugal) Mirjam de Vries (Sweden)
16:00 - 16:06	Bath Ankylosing Spondylitis Metrology Index (BASMI) and Corrected AxSpA Metrology Index (CASMI) discrimination assessment in individuals with mobility impairment: Analyses from 10 RCTs. Speaker: Dafne Capelusnik (Israel)
16:06 - 16:12	Posterior Element Lesions in Axial Spondyloarthritis: 10-Year Follow-Up from the DESIR cohort Speaker: Manouk de Hooge (Luxembourg)
16:12 - 16:18	Performance of the 2025 revised ASAS-SPARTAN classification criteria and the 2009 ASAS classification criteria in axSpA - an analysis from the RABBIT-SpA registry registry Speaker: Anne Regierer (Germany)
16:18 - 16:24	Early diagnosis of axial spondyloarthritis is associated with less long-term spinal structural damage: a longitudinal analysis of the Swiss Clinical Quality Management registry Speaker: Annik Steimer (Switzerland)
16:24 - 16:30	Cost-effectiveness of a high-intensity exercise program for axial spondyloarthritis: a modelling study Speaker: Gunhild Hagen (Norway)
16:30 - 16:36	Difference in inflammatory lesions on MRI of the sacroiliac joints at baseline and after 2 years between patients with axSpA and non-axSpA chronic back pain Speaker: Senem Tekeoglu (Türkiye)
16:36 - 16:42	Impact of GLP-1 agonists on DMARD persistence and clinical outcomes in psoriatic arthritis and axial spondyloarthritis: a global real-world study (TriNetX) Speaker: Raquel Almodóvar (Spain)

16:42 - 16:48	PARADIGM-AS: Unsupervised Clustering identifies Distinct Pain Phenotypes beyond Inflammatory burden in Difficult-to-Manage Axial Spondyloarthritis (PARADIGM: Pathway for axSpA Refractory cases Addressing Difficult-to-manage inflammation and Guiding Management) Speaker: Prakashini Mruthyunjaya (India)
16:48 - 16:54	Risk factors for progression of sacroiliac joint structural lesions on MRI in early axial spondyloarthritis Speaker: Haluk Cinakli (Türkiye)

Hands-on Sessions

Date: **04/06/2026**

1. How to perform ultrasound-guided synovial biopsies
2. How to perform ultrasound-guided peri-articular procedures
3. How to perform ultrasound-guided joint aspirations and injections
4. Preparation and aftercare, dos and don'ts of these rheumatology procedures

Room: **Hands-on 1**

16:15-17:30 BST

Musculoskeletal ultrasound guided procedures

Chair:	Daniela Fodor (Romania) Aurelie Najm (United Kingdom)
16:15 - 16:20	Ultrasound-guided synovial biopsy Speaker: Peter Mandl (Austria)

16:20 - 16:25	Ultrasound-guided joint aspirations and injections Speaker: PLAMEN Todorov (Bulgaria)
16:25 - 16:30	Ultrasound-guided peri-articular procedures Speaker: Nemanja Damjanov (Serbia)
16:30 - 16:35	Questions and Answers Speaker: Aurelie Najm (United Kingdom) Co-Speaker: Daniela Fodor / (Cluj-Napoca, Romania)
16:35 - 17:30	Hands-on Workshop Speaker: Daniela Fodor (Romania) Co-Speaker: Aurelie Najm / (Glasgow, United Kingdom), Peter Mandl / (Vienna, Austria), João Dias / (Torres Novas, Portugal), Nemanja Damjanov / (Belgrade, Serbia)

Hands-on Sessions

Date: **04/06/2026**

1. How to perform fast ultrasonography scans in daily clinical practice

Room: **Hands-on 2**

16:15-17:30 BST

2. Using handheld portable ultrasound devices.

3. Examples in different anatomical areas and pathologies using portable ultrasound devices.

Fast ultrasound protocols in Rheumatology: Point of Care

Chair:	Hilde Berner Hammer (Norway) Marion Kortekaas (Netherlands)
16:15 - 16:20	Point of Care lung scan in patients with suspected interstitial lung disease Speaker: ANDREA DELLE SEDIE (Italy)

16:20 - 16:25	Point of Care salivary gland scan in suspected sjögren's disease Speaker: Alojzija Hocevar (Slovenia)
16:25 - 16:30	Point of Care vessel scan in suspected vasculitis Speaker: Wolfgang Schmidt (Germany)
16:30 - 16:35	Point of Care joint scan in suspected arthritis Speaker: Carlo Perricone (Italy)
16:35 - 16:40	Questions and Answers Speaker: ANDREA DELLE SEDIE (Italy) Co-Speaker: Marion Kortekaas / (Leiden, Netherlands)
16:40 - 17:30	Hands-on Workshops Speaker: Hilde Berner Hammer (Norway) Co-Speaker: Alojzija Hocevar / (LJUBLJANA, Slovenia), Wolfgang Schmidt / (Berlin, Germany), Carlo Perricone / (Perugia, Italy), Marion Kortekaas / (Leiden, Netherlands), ANDREA DELLE SEDIE / (Pisa, Italy)

Meet the EULAR Expert

Date: **04/06/2026**

1. Review recent advances in the diagnosis and management of spondyloarthritis.

Room: **Meet the EULAR Expert 1**

16:15-16:45 BST

2. Clarify challenging clinical scenarios through focused expert discussion.

3. Apply practical strategies to individualise treatment across SpA phenotypes.

Spondyloarthritis

Chair:	
--------	--

16:15 - 16:45	Spondyloarthritis Speaker: Helena Marzo-Ortega (United Kingdom)
---------------	---

Meet the EULAR Expert

Date: **04/06/2026**

Room: **Meet the EULAR Expert 2**

16:15-16:45 BST

Lupus and pregnancy

Chair:	
16:15 - 16:45	Lupus and pregnancy Speaker: Karen Schreiber (Denmark)

Meet the EULAR Expert

Date: **04/06/2026**

Room: **Meet the EULAR Expert 3**

16:15-16:45 BST

Artificial Intelligence in RMDs

Chair:	
16:15 - 16:45	Artificial Intelligence in RMDs Speaker: Oliver Hendricks (Denmark)

Meet the EULAR Expert

Date: **04/06/2026**

Room: **Meet the EULAR Expert 4**

16:15-16:45 BST

ICI induced rheumatic irAE

Chair:	
16:15 - 16:45	ICI induced rheumatic irAE Speaker: Hendrik Schulze-Koops (Germany)

EULAR Culture

Date: **04/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

16:30-18:30 BST

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	
--------	--

--	--

EULAR Culture

Date: **04/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

16:30-18:30 BST

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

What is New (WIN)

Date: **05/06/2026**

1. to identify and describe the latest evidence-based guidelines and medication safety profiles for managing fertility and pregnancy in patients with rheumatic and musculoskeletal diseases.

Room: **Plenary**

08:15-09:00 BST

2, To describe individualized treatment plans that balance disease control with reproductive safety for RMD patients planning pregnancy or currently pregnant.

3. to critically evaluate emerging research findings and make evidence-based clinical decisions for pregnant patients with RMDs while considering both maternal and foetal outcomes.

Managing fertility and pregnancy in patients with RMDs

Chair:	Karen Schreiber (Denmark) Luis Fernando Perez (Netherlands)
08:15 - 09:00	Managing pregnancy fertility and pregnancy in patients with RMDs Speaker: Laura Andreoli (Italy)

Oral Abstract Presentations

Date: **05/06/2026**

Room: **Connaught Room 1 & 2**

08:15-09:30 BST

Basic Abstract Sessions: Understanding how the vessel burns

Chair:	Alessandro Tomelleri (Italy) Georgina Espígol-Frigolé (Spain)
08:15 - 08:25	NR2C1 Downregulation Impairs Regulatory T Cell Differentiation and Contributes to Immunodysregulation in Behçet's Disease Speaker: Yeling Liu (China)

08:25 - 08:35	VSMCs-derived IL-33 induces a Th1-like phenotype in CD4+ stem-like T cells and contributes to arterial wall inflammation in Takayasu's Arteritis Speaker: Chenglong Fang (China)
08:35 - 08:45	Impact of IL-17A on synovial fibroblast from subacromial bursae Speaker: André Ramon (France)
08:45 - 08:55	Single-Cell Transcriptomic and Proteomic Profiling Highlights the Role of GZMK+ CD8+ T Cells in Severe Vascular Behçet's Syndrome Speaker: Jiachen Li (China)
08:55 - 09:05	GM-CSF- and IFN-γ-producing T cells in polymyalgia rheumatica Speaker: Anqi Zhang (Netherlands)
09:05 - 09:15	B Cell Receptor Isotypes of Circulating PR3-Specific Autoreactive B Cells in ANCA-Associated Vasculitis Speaker: Giulia Boscato Sopetto (Italy)
09:15 - 09:25	Single-Cell Analysis Reveals Glycosylation-Dysregulated Naïve B Cells in IgA Vasculitis Speaker: Joao Carlos Batista-Liz (Spain)
09:25 - 09:35	Apremilast Suppresses Monocyte-Driven Inflammation by Targeting BACH1 in Behçet's Disease Speaker: Yeling Liu (China)

Oral Abstract Presentations

Date: **05/06/2026**

Room: **Connaught Room 3 & 4**

08:15-09:45 BST

Basic Abstract Sessions: Decoding the Immune System - OMICS and beyond

Chair:	Lisa Christ (Switzerland) Maria G. Tektonidou (Greece)
--------	---

08:15 - 08:25	Spatial transcriptomics reveals mechanism of autoimmunity driven by internalized autoantibodies Speaker: Iago Pinal-Fernandez (United States of America)
08:25 - 08:35	Longitudinal serum proteomic signatures associated with durable remission versus relapse after CAR-T therapy in autoimmune diseases Speaker: Futoshi Iwata (Germany)
08:35 - 08:45	Shared and Disease-Specific Molecular Signatures in Rheumatoid Arthritis and Systemic Lupus Erythematosus Revealed by Multi-Omics Integration Speaker: Ismael Sanchez-Pareja (Spain)
08:45 - 08:55	Associations of Clinical Biomarker- and Proteomic-Based Biological Aging with Autoimmune Disease Incidence and Life Expectancy Speaker: Minkyong Song (United States of America)
08:55 - 09:05	Stimulated emission depletion (STED) microscopy for ANA pattern identification: first dataset and machine learning comparison with fluorescence microscopy Speaker: Krzysztof Wójcik (Poland)
09:05 - 09:15	Immunometabolic changes associated with sustained remission in patients with cSLE and JDM treated with anti-CD19 CAR T cells Speaker: Emiliano Marasco (Italy)
09:15 - 09:25	Dynamics of the immune cell signature associated with the development of immune-related adverse event: results from longitudinal immune profiling Speaker: Huaxia Yang (China)
09:25 - 09:35	Multi-tissue transcriptomics analysis of early CTD-ILD reveals consistent molecular signatures pointing to interferon response mechanisms Speaker: Philip Stauffer (Switzerland)

Health Professionals in Rheumatology (HPR)

Date: 05/06/2026

By the end of this session, delegates will be able to:

Room: **Victoria Room 1**

- Define the human microbiome and explain its role in maintaining health and regulating immune function

08:15-09:30 BST

and inflammation

- Describe the current scientific understanding of how the microbiome may influence the onset, progression, and treatment response in rheumatic and musculoskeletal diseases (RMDs)
- Recognise the potential clinical implications of microbiome research for rheumatology care, including opportunities for multidisciplinary health professional involvement
- Discuss future directions for integrating microbiome-based approaches into clinical practice and patient education

The Microbiome: A Primer for Health Professionals in Rheumatology

Chair:	Bente Appel Esbensen (Denmark) Khadija El Aoufy (Italy)
08:15 - 08:33	The Microbiome Explained: A Foundation for Health Speaker: Borja Martinez Tellez (Spain)
08:33 - 08:51	The Microbiome in Rheumatic and Musculoskeletal Diseases: State of the Art 2026 Speaker: Christopher Martey (United Kingdom)
08:51 - 09:09	Bringing the Microbiome to the Clinic: Implications for Care in Rheumatology Speaker: Jose U. Scher (United States of America)
09:09 - 09:30	Panel Discussion

Basic Abstract Sessions: Hidden circuits in Psoriatic Arthritis and Spondylarthritis

Chair:	Helena Marzo-Ortega (United Kingdom) Dennis McGonagle (United Kingdom)
08:15 - 08:25	Dynamic orchestration of Th17, TRM, and MAIT cells links the gut–joint axis during spondyloarthritis development in the SKG model Speaker: Frank Verhoeven (France)
08:25 - 08:35	Single-cell profiling of skin and synovial fibroblasts identifies opposing IFN alpha/beta pathway regulation in Psoriasis with Arthralgia and Psoriatic Arthritis. Speaker: Aleksandra Khmelevskaia (Switzerland)
08:35 - 08:45	Uncovering a critical role for MALT1 in TNF-driven arthritis and ileitis Speaker: Dirk Elewaut (Belgium)
08:45 - 08:55	A T cell-driven CCL20+ macrophage circuit drives TNF pathology and Th17 cell recruitment in axial spondyloarthritis synovium Speaker: Liye Chen (United Kingdom)
08:55 - 09:05	The Hexosamine Biosynthesis Pathway Drives Ligament Heterotopic Ossification via Protein O-GlcNAcylation in r-axSpA Speaker: kunhai tang (China)
09:05 - 09:15	Circulating pre-osteoclasts are primed for osteoclast fate and synovial tissue homing in psoriatic arthritis. Speaker: Joe Hutton (United Kingdom)
09:15 - 09:25	An IL-7–Driven Glucose–Aiolos Metabolic Circuit Licenses Pathogenic CD8⁺ T Cells in Spondyloarthritis Speaker: Mitsuhiro Akiyama (Japan)

09:25 - 09:35	NSD1, H3K36me1/2 methyltransferase as a potential therapeutic target in TH17 cell-mediated autoinflammatory disease Speaker: Sung Eun Wang (Korea, Republic of (South Korea))
---------------	---

Oral Abstract Presentations

Date: **05/06/2026**

Room: **Victoria Room 4**

08:15-09:30 BST

Case Reports: Treatment Challenges

Chair:	Christian Dejaco (Italy) Carlo Francesco Selmi (Italy)
08:15 - 08:25	Introduction Speaker: Christian Dejaco (Italy)
08:25 - 08:35	Sustained glucocorticoid-free remission 12 months after mosunetuzumab (CD20xCD3) T cell engager induction and rituximab consolidation therapy in refractory granulomatosis with polyangiitis: A case follow-up Speaker: Ayla Stütz (Germany)
08:35 - 08:45	Eosinophilic granulomatosis with polyangiitis and eosinophilic fasciitis – two diseases treated with one targeted drug - benralizumab Speaker: Piotr Wawryka (Poland)
08:45 - 08:55	Obinutuzumab in Systemic sclerosis: a multicentre retrospective case series Speaker: Roberto D'Alessandro (France)
08:55 - 09:05	First in human application of [177Lu]Lu-FAPi as a therapeutic approach in difficult-to-treat inflammatory arthritis Speaker: Peter Mandl (Austria)
09:05 - 09:15	Phenotypic Changes of the Peripheral B Cell Compartment Precede the First Case of Relapsed SLE after CD19 CAR-T Cell Therapy Speaker: Danae-Mona Nöthling (Germany)

09:15 - 09:25	Response to benralizumab in adult-onset Still's lung disease associated with eosinophilic complications: is it true DRESS or a biologics-induced cytokine imbalance syndrome? Speaker: Florian Kim Kollert (Germany)
09:25 - 09:35	Voting Speaker: Christian Dejaco (Italy)

Oral Abstract Presentations

Date: **05/06/2026**

Room: **Victoria Room 5 & 6**

08:15-09:35 BST

Clinical Abstract Sessions: Imaging innovation in Rheumatoid Arthritis

Chair:	Victoria Konzett (Austria) Torsten Diekhoff
08:15 - 08:25	Artificial Intelligence-Based Thermographic Detection of Joint Inflammation in Rheumatoid Arthritis Speaker: York Kiat Tan (Singapore)
08:25 - 08:35	Artificial Intelligence-Based Analysis of 20-Year Radiographic Progression in the ESPOIR Rheumatoid Arthritis inception Cohort Speaker: Alain Saraux (France)
08:35 - 08:45	Performance of Lung Ultrasound in Diagnosing and Screening Patients with Rheumatoid Arthritis Compared with Risk Scoring Systems Speaker: Julia Recalde-Reyes (Colombia)
08:45 - 08:55	Modified Dixon MRI or ultrasound for detecting tenosynovitis in arthralgia at risk for rheumatoid arthritis: a comparative study Speaker: Daniek van der Kaaij (Netherlands)
08:55 - 09:05	MRI tenosynovitis predicts progression to inflammatory arthritis in CCP-positive at-risk individuals but has limited additional value in those who are ultrasound-negative. Speaker: Andrea Di Matteo (United Kingdom)

09:05 - 09:15	Altered Body Fat Composition and Reduced Muscle Quality in Rheumatoid Arthritis: Insights from a Large CT-Based Study Speaker: Upasana Agrawal (United States of America)
09:15 - 09:25	Pericoronary fat attenuation is higher and associates with atherosclerosis in rheumatoid arthritis but not controls: a matched cohort study Speaker: George Karpouzas (United States of America)
09:25 - 09:35	Neuroimaging Signatures of Rheumatoid Arthritis in the UK Biobank with Ongoing Mechanistic Profiling in a CIA Rat Model Speaker: Zhao Dai (China)

Oral Abstract Presentations

Date: **05/06/2026**

Room: **N1**

08:15-09:30 BST

Clinical Abstract Sessions: Taming the wolf - new treatments in Systemic Lupus

Chair:	Anne Trolborg (Denmark) Nathalie Costedoat-Chalumeau (France)
08:15 - 08:25	SAFETY AND EFFICACY OF SUBCUTANEOUS IANALUMAB (VAY736) POST-B CELL RECOVERY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: END OF STUDY RESULTS FROM A PHASE 2 STUDY Speaker: Edward M. Vital (United Kingdom)
08:25 - 08:35	Obinutuzumab Induces Histological Remission and Deep Kidney Parenchymal B-Cell Depletion in Patients With Lupus Nephritis: Exploratory Analyses of the Phase III REGENCY Trial Speaker: Richard A. Furie (United States of America)

08:35 - 08:45	Safety and efficacy of enpatoran in lupus: Results from the first 48 weeks of the phase II WILLOW long-term extension study Speaker: Eric Morand (Australia)
08:45 - 08:55	Longitudinal analysis of kidney function decline in systemic lupus erythematosus: Correlation with low disease activity and patient characteristics Speaker: Yi Li (Hong Kong, China)
08:55 - 09:05	Clinical Characteristics of patients with Systemic Lupus Erythematosus and positive Anti-Interferon-α autoantibodies Speaker: Georgia-Savina Moysidou (France)
09:05 - 09:15	Safety and Efficacy of Daratumumab in Treatment-Refractory Systemic Lupus Erythematosus: Results from the Long-term Extension of a Phase 2 Trial Speaker: Lennard Ostendorf (Germany)
09:15 - 09:25	Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (srSLE): initial safety, preliminary efficacy, pharmacokinetics, and biomarker results from the Phase I CARLYSLE study Speaker: Maria Leandro (United Kingdom)
09:25 - 09:35	Improved SLE Disease Activity Across Multiple Organ Systems After up to 12 Months of Real-World Treatment With Anifrolumab: Interim Results From the ASTER Study Speaker: Zahir Amoura (France)

Oral Abstract Presentations

Date: **05/06/2026**

Room: **N2**

08:15-09:30 BST

Basic and Clinical Abstract Session: Beyond Hyperuricemia - New Insights into Gout Detection

Chair:	Tristan Pascart (France) Till Uhlig (Norway)
--------	---

08:15 - 08:25	Musculoskeletal ultrasound findings in asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semi-quantitative scoring system Speaker: Nicola Dalbeth (New Zealand)
08:25 - 08:35	Association between recent gout flare and tachyarrhythmia in people with gout in England and Sweden. Nested case-control and self-controlled case-series analyses Speaker: Edoardo Cipolletta (Italy)
08:35 - 08:45	Estradiol facilitates urate excretion by reducing GLUT9 expression via ERβ/TMEM106B/PI3K/AKT1 pathway in renal tubular epithelial cells Speaker: Liu Haijun (China)
08:45 - 08:55	Presence of crystal depositions in the first metatarsophalangeal joint is closely related to local erosions; results from the 5-year NOR-Gout study Speaker: Hilde Berner Hammer (Norway)
08:55 - 09:05	Association between Sodium-glucose Cotransporter-2 Inhibitors Treatment and Kidney Impairment in Gout and Type 2 Diabetes Speaker: Jie Wei (China)
09:05 - 09:15	A Phase 4, randomized, double-blind, multicenter non-inferiority trial evaluating the efficacy and safety of intravenous pegloticase administered every 4 weeks vs every 2 weeks with weekly methotrexate Speaker: Brian LaMoreaux (United States of America)
09:15 - 09:25	Polystyrene Microplastic Exposure: A Novel Link to Gouty Arthritis Speaker: Manli Wang (China)
09:25 - 09:35	Effects of causal beliefs about gout on views about gout management: A randomised experimental study Speaker: Nicola Dalbeth (New Zealand)

Oral Abstract Presentations

Date: 05/06/2026

Room: N3

Basic and Clinical Abstract Sessions: From A(PS) to C(TD)

Chair:	Zahir Amoura (France) Laurent Arnaud (France)
08:15 - 08:25	Anti-Myosin Va Antibodies: A Novel Pathogenic Autoantibody in Antiphospholipid Syndrome Speaker: Haiyue Jiang (China)
08:25 - 08:35	Further Validation of the EULAR Antiphospholipid Syndrome Disease Activity Score (EAPSDAS): Criterion validity Speaker: Maria G. Tektonidou (Greece)
08:35 - 08:45	Exosomal IKBKE-AS1/miR-125 Family Axis Regulates BCL9L/BCL3-Mediated Endothelial Dysfunction: A Novel Mechanism Driving Thrombosis in Antiphospholipid Syndrome Speaker: wenhao wang (China)
08:45 - 08:55	THE EFFECT OF ANTIPHOSPHOLIPID ANTIBODIES ON HEART VALVE INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS Speaker: Betül Dikkanoglu Demirok (Türkiye)
08:55 - 09:05	Clinical presentation, treatment and long-term outcomes of patients with juvenile onset versus adult onset mixed connective tissue disease: a multicenter retrospective cohort Speaker: Kevin Chevalier (France)
09:05 - 09:15	Consensus development of the ERN ReCONNET training framework for pediatric-to-adult healthcare transition for rare connective tissue diseases Speaker: Mojca Zajc Avramovic (Slovenia)
09:15 - 09:25	Prevalence and incidence of polyautoimmunity in patients with systemic lupus erythematosus and according to hydroxychloroquine treatment: a Danish nationwide register-based cohort study Speaker: Rasmus Westermann (Denmark)
09:25 - 09:35	Morbidity and Mortality in Primary Versus Secondary Antiphospholipid Syndrome: A Single-Center Study Using the 2023 ACR/EULAR Criteria Speaker: Roni Meidan (Israel)

Oral Abstract PresentationsDate: **05/06/2026**Room: **George V Room 1****08:15-09:30 BST****Clinical Abstract Sessions: The Inflamed Joint**

Chair:	Roberto F. Caporali (Italy) Licia Mota (Brazil)
08:15 - 08:25	Treat-to-target in inflammatory arthritis: a recommended strategy, an incomplete practice Speaker: Giorgia Trignani (Italy)
08:25 - 08:35	Long-term Real-World Outcomes of Double Targeted Therapy in Refractory Spondyloarthritis: A Multicenter Observational Study Speaker: Cristina Calomarde-Gomez (Spain)
08:35 - 08:45	Development and Validation of a Palindromic Rheumatism Severity Score (PRSS) Speaker: Rashwith Umesh (India)
08:45 - 08:55	Point-of-Care Musculoskeletal Ultrasound in the evaluation of suspected arthritis: a data-driven algorithm from the RADIAL Study Speaker: Antonella Adinolfi (Italy)
08:55 - 09:05	Efficacy and safety of tetrandrine in patients with rheumatoid arthritis (TRAL): a multicenter randomized, double-blind, placebo-controlled trial Speaker: Miao Shao (China)
09:05 - 09:15	Monitoring disease activity in arthritis patients using optical spectral transmission: a longitudinal comparison with clinical parameters Speaker: Konstantinos Triantafyllias (Germany)
09:15 - 09:25	Automatic Deep learning-based MRI analysis of Inflammatory signs in RA (ADMIRA): a validity study of AI-based MRI interpretation in early arthritis Speaker: Dennis A. Ton (Netherlands)

09:25 - 09:35	Maximum prednisone dose above 20 mg to treat rheumatologic side effects of immune checkpoints is associated with shorter cancer survival Speaker: Eleonore Mourre (France)
---------------	--

Oral Abstract Presentations

Date: **05/06/2026**

Room: **George V Room 2**

08:15-09:30 BST

Basic and Clinical Abstract Sessions: New targets in Systemic Sclerosis

Chair:	Ulf Müller-Ladner (Germany) Latika Gupta (United Kingdom)
08:15 - 08:25	Multiorgan single-cell profiling identifies shared interferon and alternative complement activation across tissues in systemic sclerosis. Speaker: Cristian Iperi (Switzerland)
08:25 - 08:35	Longitudinal Multi-omic Analysis of CD19 CAR-T Cell Therapy in Systemic Sclerosis Demonstrates Coordinated Immune and Stromal Modulation Speaker: Hanlin Yin (China)
08:35 - 08:45	Human Lung Organoids as a model of SSc-ILD Speaker: Alexandru-Emil Matei (Germany)
08:45 - 08:55	Proteome-wide Autoantibody Landscape and Pathogenic Role of Anti-C-C Motif Chemokine Receptor 8 Autoantibodies in Systemic Sclerosis: Post-hoc Analysis of a B-cell Depletion Trial Speaker: Kazuki Matsuda (Japan)
08:55 - 09:05	Single-Cell Profiling Identifies PDE4B as a Disease-Relevant Target in Systemic Sclerosis Across Tissues and Cell Subsets Speaker: Astrid Hofman (Switzerland)
09:05 - 09:15	CD19-CAR T-Cell Therapy Induces Regenerative Skin Remodelling in Diffuse Cutaneous Systemic Sclerosis Speaker: Christina Bergmann (Germany)

09:15 - 09:25	Clinical Efficacy Angle – Sustained Remission in Refractory Systemic Sclerosis with Dual-Target CAR-T Therapy Speaker: Yajing Zhang (China)
09:25 - 09:35	Universal CAR-T 19 Therapy for Relapsed or Refractory Autoimmune Diseases: An Early Exploratory Clinical Study – Results from the Systemic Sclerosis Cohort Speaker: FEI SUN (China)

Oral Abstract Presentations

Date: 05/06/2026

Room: George V Room 3

08:15-09:30 BST

Basic and Clinical Abstract Sessions: No pain is THE gain

Chair:	Jasminka Milas-Ahic (Croatia) Lars Arendt-Nielsen (Denmark)
08:15 - 08:25	Efficacy of low-dose naltrexone for fibromyalgia: A randomised, double-blind, placebo-controlled trial with 12 months of follow-up Speaker: Juan Luciano (Spain)
08:25 - 08:35	MICE ADMINISTERED IgG FROM A SUBSET OF FIBROMYALGIA PATIENTS WITH CIDP DEMONSTRATE PET / CT EVIDENCE OF WIDESPREAD IgG DEPOSITION Speaker: Xavier Caro (United States of America)
08:35 - 08:45	Sex Differences in Cannabinoid-Mediated Analgesia in an Osteoarthritis Mouse Model: Role of CaMK II α Neurons in the Medial Prefrontal Cortex Speaker: Zhenhua Jiang (China)
08:45 - 08:55	Is failure to reach early remission linked to future non-inflammatory pain? Results from a post-hoc study of the multicentre NORD-STAR trial of newly diagnosed rheumatoid arthritis Speaker: Annie Brink (Sweden)
08:55 - 09:05	Impact of Neuropathic-like and Nociceptive Pain on Mental Health and Sleep in Inflammatory Arthritis: Results from the NEUPIA Study Speaker: Iulia - Simona Chirica (Romania)

09:05 - 09:15	Integrative population proteogenomics and circuit neurophysiology implicate CA14 as a shared, druggable and transdiagnostic biology marker between neuropathic and nociplastic pain phenotypes Speaker: Li Chen (China)
09:15 - 09:25	TNX-102 SL, cyclobenzaprine HCl sublingual tablets, demonstrates pain reduction and favorable tolerability in patients with fibromyalgia Speaker: ERNEST CHOY (United Kingdom)
09:25 - 09:35	Increasing metamizole prescription in high risk groups of methotrexate-treated patients with inflammatory rheumatic diseases: nationwide German claims data from 2006 to 2024 Speaker: Johanna Callhoff (Germany)

Oral Abstract Presentations

Date: **05/06/2026**

Room: **George V Room 4**

08:15-09:30 BST

Basic and Clinical Abstract Sessions: Novelties in Autoinflammatory Diseases

Chair:	Martin Krusche (Germany) Charlotte Girard-Guyonvarc'h (Switzerland)
08:15 - 08:25	Recurrent somatic mutations in KRAS drive a specific autoinflammatory phenotype associated with myeloid neoplasms Speaker: Peter Chen (France)
08:25 - 08:35	Cytokine-Defined Endotypes in Adult-Onset Still's Disease Validated by Integrated Immune Profiling with Implications for Targeted Therapy Speaker: Ruru Guo (China)
08:35 - 08:45	Prevalence, Patterns, and Predictors of Damage in Autoinflammatory Diseases through the ADDI score: Insights from the Eurofever Registry Speaker: Paola Baldassarre (Italy)

08:45 - 08:55	A CDC42 variant reveals a novel autoinflammatory disease and the mechanism of Pyrin inflammasome activation. Speaker: Philippe Mertz (France)
08:55 - 09:05	Association of NOD2 Variants with Clinical Phenotypes in Autoinflammatory Disease: Insights from a Cohort through a Validated Next-Generation Sequencing Panel Speaker: Marta Schermi (Italy)
09:05 - 09:15	Bone Marrow Single-Cell Multiomics Sheds Light on the Etiology of Schnitzler Syndrome Speaker: Stanislas Riescher (France)
09:15 - 09:25	Assessment of Liver Fibrosis in Familial Mediterranean Fever Using Shear Wave Elastography: Role of Cumulative Colchicine Exposure, Metabolic and Genetic Factors Speaker: AYSE TUGÇENUR TEMİZ GENÇOĞLU (Türkiye)
09:25 - 09:35	Exploring genetic variants associated with monogenic autoinflammatory diseases using next-generation sequencing with a targeted gene panel in Still's disease Speaker: Erdem Bektas (Türkiye)

Oral Abstract Presentations

Date: **05/06/2026**

Room: **Room 12**

08:15-09:30 BST

Basic Abstract Sessions: Novel Mechanisms in Rheumatoid Arthritis development and progression

Chair:	Jan Piet Van Hamburg (Netherlands) Mario M. Zaiss (Germany)
08:15 - 08:25	Enrichment of T peripheral helper cells in both organized and diffuse immune infiltrates in RA-ILD lung explants. Speaker: Amara Seng (United States of America)

08:25 - 08:35	Piezo2 Drives Rab11FIP1-Dependent Vesicular Trafficking of RANKL in Fibroblast-like Synoviocytes: A Novel Mechano-Immunological Axis Driving Bone Destruction in Rheumatoid Arthritis Speaker: Ye Lu (China)
08:35 - 08:45	Rheumatoid arthritis modulates immune cell trajectories across pregnancy Speaker: Bethan Goulden (United Kingdom)
08:45 - 08:55	The emergence of distinct CD8⁺ T Cell effector phenotypes is associated with subclinical synovitis when rheumatoid arthritis is imminent Speaker: Kerem Abacar (United Kingdom)
08:55 - 09:05	Recent Thymic Emigrants Define a Therapeutically Modifiable Immunometabolic State in Rheumatoid Arthritis Speaker: Zhihua Yang (Germany)
09:05 - 09:15	Rosnilimab Selectively Depletes Pathogenic T Cells and Downregulates Clinically Relevant Immune Pathways in Rheumatoid Arthritis: A Translational Analysis of Blood and Synovial Tissue from the RENOIR Phase 2B Trial Speaker: Costantino Pitzalis (United Kingdom)
09:15 - 09:25	Genetic Risk Variants Reveal Cytokine-Responsive Modules Driving Pathogenic Programs in Rheumatoid Arthritis Synovial Fibroblasts Speaker: Ege Ezen (Switzerland)
09:25 - 09:35	POPULATION-SCALE T-CELL RECEPTOR SEQUENCING IN RHEUMATOID ARTHRITIS CONTROLS HLA POLYMORPHISM AND IDENTIFIES DISEASE-ASSOCIATED CLONOTYPES Speaker: Takahiro Nishino (Japan)

HPR Meet the EULAR Expert

Date: 05/06/2026

Delegates will be able to:

Room: **Meet the EULAR Expert 1**

i) Explore common and challenging clinical scenarios related to foot involvement in inflammatory arthritis through discussion

08:30-09:00 BST

ii) Gain practical insights into the diagnosis and

differentiation of inflammatory foot disease from other causes of foot pain, including overlapping mechanical pathology

iii) Discuss real-world strategies for managing persistent foot symptoms, including when and how to escalate care or involve podiatry, orthotics, or surgery.

The foot and ankle in inflammatory arthritis

Chair:	
08:30 - 09:00	The foot and ankle in IA Speaker: Christopher Joyce (United Kingdom)

Meet the EULAR Expert

Date: **05/06/2026**

Room: **Meet the EULAR Expert 2**

08:30-09:00 BST

Myositis

Chair:	
08:30 - 09:00	Myositis Speaker: Hector Chinoy (United Kingdom)

Meet the EULAR Expert

Date: **05/06/2026**

Room: **Meet the EULAR Expert 3**

08:30-09:00 BST

Managing Vascular Behçet's: What to Do (and What Not to Do)

Chair:	
08:30 - 09:00	Managing Vascular Behçet's: What to Do (and What Not to Do) Speaker: Gulen Hatemi (Türkiye)

Meet the EULAR Expert

Date: **05/06/2026**

Room: **Meet the EULAR Expert 4**

08:30-09:00 BST

Rheumatoid Arthritis

Chair:	
08:30 - 09:00	Rheumatoid Arthritis Speaker: Iain B. McInnes (United Kingdom)

EULAR Culture

Date: **05/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come

08:30-10:30 BST

in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **05/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

08:30-10:30 BST

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

PARE

Date: **05/06/2026**

1. Clarify the concept of primary, secondary, and tertiary prevention in RMDs.

Room: **Victoria Room 2**

08:45-10:00 BST

2. Highlight community-led initiatives that demonstrate how prevention-focused policies and practices can be integrated into daily life, health systems, and rheumatology care pathways.

3. Address prevention gaps by discussing barriers to implementation in diverse populations.

Prevention Power-Up: Stopping RMDs in Their Track

Chair:	Igor Medojevic (Montenegro) Alessia Alunno (Italy)
08:45 - 09:00	Primary Prevention in Motion: Targeting Cartilage Health to Halt Osteoarthritis Before it Starts Speaker: Ali Mobasheri (Finland)
09:00 - 09:15	Catching It Early: How Patient Advocacy Powers Timely Diagnosis and Better Outcomes Speaker: Sina Bugeja (Malta)
09:15 - 09:30	Axia in Action: Digital Coaching to Reduce axSpA Disease Activity Speaker: Patrick-Pascal Strunz (Germany)

09:30 - 09:40	"Fall Prevention for Better Ageing" project for adults over 65 who have rheumatic and musculoskeletal conditions. Principal author:Machi Salamaliki-Spanou, Hellenic League Against Rheumatism Speaker: Machi Spanou Salamaliki (Greece)
09:40 - 10:00	Questions and Answers Speaker: Igor Medojevic (Montenegro) Co-Speaker: Alessia Alunno / (L'Aquila, Italy)

How to Treat (HOT)

Date: **05/06/2026**

1. Understand the pathophysiological basis of systemic sclerosis (SSc), including vasculopathy, fibrosis, and immune activation, and how these processes guide management strategies

Room: **Plenary**

09:00-09:45 BST

2. Recognise the organ-based approach to treatment, incorporating the use of biologic and antifibrotic therapies and targeted management of complications such as Raynaud's phenomenon and pulmonary arterial hypertension

3. Gain awareness of emerging therapeutic options and advances in the contemporary management of SSc.

Systemic sclerosis

Chair:	Theresa Graalman (Germany) Jacob M. van Laar (Netherlands)
09:00 - 09:45	Systemic Sclerosis: deciphering pathogenesis, unveiling comorbidities, and paving the way for targeted treatment Speaker: Oliver Distler (Switzerland)

Poster View Presentations

Date: **05/06/2026**

Poster View V

Chair:	
09:30 - 09:30	No microorganism triggers the systemic and local lymph node inflammation at disease onset in sarcoidosis patients Speaker: Marie Robert (France)
09:30 - 09:30	MONOCYTE EPIGENETIC SIGNATURE IN SARCOIDOSIS Speaker: Marie Robert (France)
09:30 - 09:30	Degrading VAV1 Inhibits T-cell Function and Antibody Production in Mice After KLH Challenge Speaker: Yuanfeng Xia (China)
09:30 - 09:30	A combined score of syndesmophytes and facet joint ankylosis improves sensitivity to spinal structural damage progression in axial spondyloarthritis Speaker: Ana Bento da Silva (Portugal)
09:30 - 09:30	A combined score of facet joint ankylosis and syndesmophyte development correlates well with spinal mobility in axial spondyloarthritis Speaker: Ana Bento da Silva (Portugal)
09:30 - 09:30	Elevated faecal calprotectin, but not CRP, predicts future need for biologic or targeted synthetic DMARD therapy in established axial spondyloarthritis – results from the SPARTAKUS cohort Speaker: Johan K Wallman (Sweden)
09:30 - 09:30	Impact of Depression on Patient-Reported Outcome and Clinical Disease Assessment in Rheumatoid Arthritis: A Cross-Sectional Study from a Japanese National Registry Speaker: Tatsunori Shizuku (United States of America)
09:30 - 09:30	THE PREVALENCE OF FIBROMYALGIA IN A COHORT OF PATIENTS WITH PAINFUL HAND OSTEOARTHRITIS Speaker: Annemiek Olde Meule (Netherlands)

09:30 - 09:30	Impact of Secukinumab Dose Escalation on MRI-Detected Inflammation and Structural Damage in Axial Spondyloarthritis: An Investigator-Initiated, Treat-to-Target Study (TRACE) Speaker: Nora Vladimirova (Denmark)
09:30 - 09:30	Diagnostic Performance of Radiography, Low-Dose CT, and MRI in Early and non-Early Axial Spondyloarthritis Speaker: Lusi Ye (China)
09:30 - 09:30	Metformin and the Risk of Arthroplasty in Osteoarthritis: A Reconstructed Individual Patient Data Meta-analysis Speaker: Gabriela Moreira (Brazil)
09:30 - 09:30	Evaluation of the placebo and treatment effect overtime in randomized clinical trials evaluating the efficacy of biologics in axial spondyloarthritis : systematic review and meta-analysis Speaker: Lea Perrot (France)
09:30 - 09:30	Multi-ancestry GWAS of radiographic progression in axial spondyloarthritis Speaker: Sizheng S. Zhao (United Kingdom)
09:30 - 09:30	A systematic literature review informing the 2025 update of the EULAR recommendations for the use of imaging in the diagnosis and management of peripheral spondyloarthritis in clinical practice Speaker: Clara Watschinger (Austria)
09:30 - 09:30	Predictors of treatment-refractory psoriatic arthritis using different definitions Speaker: Carina Borst (Austria)
09:30 - 09:30	From mild to severe dysautonomia: identifying fibromyalgia subgroups via cluster analysis Speaker: Sergio del Vescovo (Italy)
09:30 - 09:30	Should We Change the Mechanism of Action After TNFi Failure in axSpA? A Reconstructed Individual Patient Data Meta-analysis Speaker: Gabriela Moreira (Brazil)

09:30 - 09:30	The interaction of HLA-B27 and other hereditary risk factors on ankylosing spondylitis risk among Finnish biobank participants Speaker: Johanna Paltta (Finland)
09:30 - 09:30	Investigating the immune signature of interstitial lung disease across rheumatoid arthritis Speaker: Maana Layeghi (United Kingdom)
09:30 - 09:30	The pathological role of a novel autoantibody biomarker in therapy response in a mouse model of arthritis. Speaker: Pieter Ruytinx (Belgium)
09:30 - 09:30	The effectiveness of lumbar belts for non-specific low back pain: A multi-centre randomized clinical trial. Speaker: LAURENT GRANGE (France)
09:30 - 09:30	Pathogenic citrullination of serine proteases in Rheumatoid Arthritis Speaker: Liam J. O'Neil (Canada)
09:30 - 09:30	Preliminary Efficacy and Safety of Roconkibart (JS005) Subcutaneous Injection in Chinese Participants with Active Ankylosing Spondylitis: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Speaker: Ling Zhou (China)
09:30 - 09:30	Chronic widespread pain and fibromyalgia phenotypes in rheumatoid arthritis: A discriminatory test accuracy study of muscle histopathology and intraepidermal nerve fibre density. Speaker: Philip Rask Lage-Hansen (Denmark)
09:30 - 09:30	Revisiting osteoarthritis as an inflammatory disease: characterization of synovitis grading and synovial pathotypes in surgical specimens Speaker: Jacopo Ciaffi (Italy)
09:30 - 09:30	Autoantibodies against chemokine receptor CXCR3 are associated with disease outcomes and atherosclerosis risk across rheumatoid arthritis stages Speaker: Daniel Miranda-Prieto (Spain)

09:30 - 09:30	<p>Patient-initiated follow-up is more cost-effective than remote monitoring or usual care in axial spondyloarthritis, results from the ReMonit randomized controlled trial</p> <p>Speaker: Inger Jorid Berg (Norway)</p>
09:30 - 09:30	<p>Nasal epithelial PADI expression driven by airborne pollutants: Implications for local citrullination in Rheumatoid arthritis</p> <p>Speaker: Joanna Sarnik (Poland)</p>
09:30 - 09:30	<p>BIMEKIZUMAB-TREATED PATIENTS WITH AXIAL SPONDYLOARTHRITIS MAINTAINED STRINGENT CLINICAL RESPONSES OVER 3 YEARS: RESULTS FROM TWO PHASE 3 STUDIES AND THEIR OPEN-LABEL EXTENSION</p> <p>Speaker: Fabian Proft (Germany)</p>
09:30 - 09:30	<p>Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial.</p> <p>Speaker: Phillippe Carron (Belgium)</p>
09:30 - 09:30	<p>Tofacitinib is as effective in non-radiographic axial spondyloarthropathy as in radiographic axial spondyloarthritis :A prospective observational short term study</p> <p>Speaker: SAISUNIL BAVIRIPUDI (India)</p>
09:30 - 09:30	<p>Circulating Transitional B cells are elevated in Clinically Suspect Arthralgia and further expand during progression to Inflammatory Arthritis</p> <p>Speaker: Beatriz Nieto-Carvalho (Spain)</p>
09:30 - 09:30	<p>Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index</p> <p>Speaker: Dafne Capelusnik (Israel)</p>
09:30 - 09:30	<p>Comparative Analysis of Instruments Measuring Peripheral Arthritis Activity in Spondyloarthritis: A Measurement Properties Study in 13 RCTs.</p> <p>Speaker: Dafne Capelusnik (Israel)</p>
09:30 - 09:30	<p>BIMEKIZUMAB WAS EFFICACIOUS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS REGARDLESS OF AGE, BMI, CRP, OR HLA-B27 STATUS: 1-YEAR RESULTS FROM TWO PHASE 3 STUDIES</p> <p>Speaker: Marina Magrey (United States of America)</p>

09:30 - 09:30	Distinct anatomical patterns, shared mechanometabolic drivers: determinants of enthesitis in psoriatic arthritis versus axial spondyloarthritis Speaker: Felix Doll (Switzerland)
09:30 - 09:30	Long-term progression of structural changes in peripheral entheses in radiographic axial spondyloarthritis is predicted by elevated C-reactive protein and is most pronounced in the Achilles tendon Speaker: Magnus Hallström (Sweden)
09:30 - 09:30	Latent profile analysis identifies four pain phenotypes in Rheumatoid Arthritis; mechanisms and clinical markers Speaker: Zoe Rutter-locher (United Kingdom)
09:30 - 09:30	RHEUMATOID FACTORS (RFs) DO NOT BIND FC-FREE CERTOLIZUMAB PEGOL, BUT DO BIND TO FC-CONTAINING BIOLOGICAL DMARDS, DRIVING IMMUNE COMPLEX FORMATION WHICH INDUCE CYTOKINE RELEASE FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) IN VITRO Speaker: David Humphreys (United Kingdom)
09:30 - 09:30	The IgA AMPA repertoire stratifies response to abatacept and methotrexate treatment in rheumatoid arthritis Speaker: Léna Le Goaréguer (France)
09:30 - 09:30	PLASMAPHERESIS BENEFITS SYMPTOMS AND INCREASES EPIDERMAL NERVE FIBER DENSITY IN A SUBSET OF FIBROMYALGIA PATIENTS DIAGNOSED WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY Speaker: Xavier Caro (United States of America)
09:30 - 09:30	CD8+ follicular activated T cells, Cit-vimentin-reactive effector T cells re-expressing CD45RA and CD39+ effector and regulatory CD4+ T cells expand sequentially before flare in rheumatoid arthritis patients withdrawing from conventional DMARDs Speaker: Jia Yi Hee (Australia)
09:30 - 09:30	Primary versus secondary failure of the first tumor necrosis factor inhibitor: impact on effectiveness of the subsequent biologic disease-modifying antirheumatic drug in 1534 real-world patients with axial spondyloarthritis Speaker: Lykke Midtbøll Ørnbjerg (Denmark)

09:30 - 09:30	Development of AZD5492, a pioneering CD8-guided CD20 T cell engager, advancing in clinical trials for autoimmune indications Speaker: Naresh Kumar (United States of America)
09:30 - 09:30	Over-investigated yet Underdiagnosed: Reframing Fibromyalgia Care Pathways Speaker: Rosemary Hollick (United Kingdom)
09:30 - 09:30	Moderate-to-severe disease severity is associated with higher motor vehicle collision risk in a combined group of people with osteoarthritis and rheumatoid arthritis: data from the Candrive Older Driver study Speaker: Mark Campbell (Canada)
09:30 - 09:30	The relationship between osteoarthritis and bone mineral density of young, active men with and without lower limb loss in the ADVANCE cohort Speaker: Fraje Watson (United Kingdom)
09:30 - 09:30	Clinically Meaningful Improvements in Pain and Physical Function Across a Range of OA Outcomes, Including the OMERACT-OARSI Responder Criteria, with LEVI-04, a Novel Neurotrophin-3 Inhibitor Speaker: Philip G. Conaghan (United Kingdom)
09:30 - 09:30	Timing Matters Beyond Early Windows: A Comprehensive Longitudinal and Landmark Analysis of Disease Duration, Treatment Response, and First Biologic Drug Survival in Axial Spondyloarthritis Speaker: Semih Gulle (Türkiye)
09:30 - 09:30	Risk of major cardiovascular events (MACEs) in patients with psoriasis, psoriatic arthritis and/or ankylosing Spondylitis: a cohort 72,291 biologic new-users Speaker: Laetitia Penso (France)
09:30 - 09:30	Targeting an IgA-CD89-Neutrophil Axis as a Therapeutic Strategy in Severe Rheumatoid Arthritis Patients Speaker: Connor Rosen (United States of America)
09:30 - 09:30	Long-term or recurrent antibiotic use in childhood is associated with doubled risk of axial spondyloarthritis among HLA-B27-positive individuals Speaker: Sizheng S. Zhao (United Kingdom)

09:30 - 09:30	Large-scale multicohort blood transcriptomic analysis identifies a diagnostic rheumatoid arthritis signature associated with disease activity Speaker: Andreas Kerschbaumer (United States of America)
09:30 - 09:30	NON-INVASIVE BROAD-BEAM ULTRASOUND NEUROIMMUNOMODULATION IN HEALTHY VOLUNTEERS AND ADULTS WITH INFLAMMATORY ARTHRITIS: RESULTS OF PHASE 1 SINGLE-BLIND, SHAM-CONTROLLED CROSSOVER STUDY Speaker: Nishant Doctor (United States of America)
09:30 - 09:30	Sarcoidosis in Rheumatology Practice: Early initiation of immunosuppressives may prevent relapses during long term follow-up Speaker: Fatma Alibaz (Türkiye)
09:30 - 09:30	Identification of Sex-Differentiated Clinical-Molecular Cardiovascular Risk Signatures in Rheumatoid Arthritis Patients Speaker: Chary Lopez-Pedrerera (Spain)
09:30 - 09:30	QEL-005: A CD-19 Directed CAR Regulatory T cell Therapy for the Treatment of Complex Autoimmune Diseases Including Rheumatoid Arthritis and Systemic Sclerosis Speaker: Jenny McGovern (United Kingdom)
09:30 - 09:30	Sensory and inflammatory correlates of pain-specific outcomes in refractory rheumatoid arthritis: a cross-sectional cohort study Speaker: Lucy Zhao (United Kingdom)
09:30 - 09:30	Integrated lipidomic, proteomic and hepatic functional profiling reveals a reversible inflammatory-metabolic axis in Rheumatoid Arthritis Speaker: Laura Muñoz-Barrera (Spain)
09:30 - 09:30	Loss of expression of the ubiquitous co-stimulatory CD27 and CCR7 characterizes a population of RA associated migratory CD4+ T effector cells Speaker: Laurin Braune (Germany)
09:30 - 09:30	Prognostic Value of Hormonal–Genetic Interactions in Rheumatoid Arthritis Among Women of Reproductive Age: Development of a Multifactorial Risk Stratification Model Speaker: Gulmira Salimova (Uzbekistan)

09:30 - 09:30	Pain beyond inflammation: underdiagnosed neuropathic and neuroplastic pain in systemic connective tissue diseases Speaker: Olga Brzezinska (Poland)
09:30 - 09:30	Targeting NAD+ Metabolism in Inflammatory Rheumatic Diseases: Impact of Anti-TNF Therapy and NAD+ Supplementation Speaker: Beatriz Vellón-García (Spain)
09:30 - 09:30	Steady-state population pharmacokinetic modeling and simulation of a sublingual formulation of cyclobenzaprine (CBP) HCl (TNX-102 SL): comparison to simulations of oral immediate-release CBP Speaker: Gregory Sullivan (United States of America)
09:30 - 09:30	Phenotypes of Chronic Overlapping Pain Multimorbidity in Rheumatology: A Population-Based Claims Study Speaker: Titilola Falasinnu (United States of America)
09:30 - 09:30	The use of artificial intelligence in rheumatoid arthritis diagnosis: a scoping review Speaker: Ana Filipa Águeda (Portugal)
09:30 - 09:30	Fibromyalgia in Men Speaker: Magnus Blom Petersen (Denmark)

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour I**

09:30-10:30 BST

Clinical Poster Tours: A spotlight on SpA

Chair:	Astrid van Tubergen (Netherlands) Ann-Sophie De Craemer (Belgium)
09:30 - 09:36	The performance of T2* Mapping as an erosion-sensitive magnetic resonance imaging sequence in the evaluation of the sacroiliac joints in axial spondyloarthritis Speaker: Servet Akar (Türkiye)

09:36 - 09:42	Performance of MRI-based synthetic CT in detecting spinal new bone formation: a comprehensive comparison with T1-weighted MRI, low-dose CT, and radiography Speaker: Simone Tromborg Willesen (Denmark)
09:42 - 09:48	The digital therapeutic Axia improves spinal mobility and strength, impairment of insomnia, and disease related sexual dysfunction in patients with axial spondyloarthritis: Results of a 24-week pre-post interventional trial (Bechterew-App Trial II) Speaker: Patrick-Pascal Strunz (Germany)
09:48 - 09:54	Deep Learning for Assessment of Disease Activity in Patients with Axial Spondyloarthritis Using Combined Sacrum and Spine MRI Speaker: Seulkee Lee (Korea, Republic of (South Korea))
09:54 - 10:00	Effectiveness and Safety of Sequential Therapy of Infliximab and Tofacitinib in Axial Spondyloarthritis Speaker: Sarthak Verma (India)
10:00 - 10:06	Low-dose CT, MRI or radiographs: which imaging modality best captures spinal structural progression in axial spondyloarthritis? Speaker: Gizem Ayan (Türkiye)
10:06 - 10:12	Clinical Characteristics of Chronic Back Pain Associated with the Anatomical Variations of the Sacroiliac Joint: How inflammatory may it seem? Speaker: Aysegul Avcu (Türkiye)
10:12 - 10:18	Performance of Structural Lesion MRI Cut-offs for an MRI Indicative of Axial Spondyloarthritis in The Spondyloarthritis Research and Treatment Network Classification of Axial Spondyloarthritis Inception Cohort Study Speaker: Walter P Maksymowych (Canada)
10:18 - 10:24	IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM A PHASE 3 STUDY AND ITS OPEN-LABEL EXTENSION Speaker: Walter P Maksymowych (Canada)

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour II**

09:30-10:30 BST

Basic Poster Tours: Decoding novel pathogenic mechanisms in Rheumatoid Arthritis

Chair:	Stephanie Ling (United Kingdom) Javier Rodríguez-Carrio (Spain)
09:30 - 09:36	Integration of Synovial Pathotypes and Serum Proteomic Modules Reveals Differential clinical profiles and Treatment Response in Early Rheumatoid Arthritis Speaker: Sagrario Corrales-Díaz Flores (Spain)
09:36 - 09:42	Targeting the NETs-PPIA Axis: A Novel Therapeutic Strategy to Suppress Pathological Synovial Angiogenesis in Rheumatoid Arthritis Speaker: Huayong Zhang (China)
09:42 - 09:48	CD8+CCR4+CD25+ T cells predict abatacept treatment response in rheumatoid arthritis Speaker: Yasuo Nagafuchi (Japan)
09:48 - 09:54	DigiTREAT: A Digital Twin Framework for Rheumatoid Arthritis Integrating a Multicellular Agent-Based Synovial Model with Experimental and Clinical Data to predict response to biologics Speaker: Anna Niarakis (France)
09:54 - 10:00	Targeting FGF/FGFR signalling in synovial fibroblasts from difficult-to-treat Rheumatoid Arthritis patients Speaker: Luisa Marques (United Kingdom)
10:00 - 10:06	Central Nervous System (CNS)-derived proteins in rheumatoid arthritis: evidence for a blood-detectable neuroinflammatory burden Speaker: James Brock (United Kingdom)

10:06 - 10:12	Interactions between MAIT cells and the microbiome in rheumatoid arthritis Speaker: Manon Lesturgie Talarek (France)
10:12 - 10:18	Polystyrene microplastics enhance monocyte infiltration and accelerate rheumatoid arthritis progression Speaker: Xia Meng (China)
10:18 - 10:24	Bacteroides. sp A1C1 impaired CLA+Tregs and exacerbated the development of rheumatoid arthritis via molecular mimicry Speaker: danxue zhu (China)

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour III**

09:30-10:30 BST

Clinical Poster Tours: Ouch! Pain in RMDs

Chair:	Elena Rezus (Romania) Philipp Bosch (Austria)
09:30 - 09:36	Fibromyalgia prevalence and autonomic dysfunction in 3,000 Italian subjects: a population-based study. Speaker: Sergio del Vescovo (Italy)
09:36 - 09:42	Neurophysiology of chronic widespread pain: time-series classification of resting-state EEG in pain discordant twin pairs from TwinsUK. Speaker: Jordan Tsigarides (United Kingdom)
09:42 - 09:48	Direct Regulation of NGF Signaling by Baricitinib: A Novel Mechanism for Pain Modulation Speaker: Matthias Seidel (Switzerland)
09:48 - 09:54	Pain neuroscience knowledge and attitudes among Rheumatology professionals and their role in clinical decision-making in axial spondyloarthritis Speaker: Yvonne M. van der Kraan (Netherlands)

09:54 - 10:00	Trajectory of Neuropathic-like and Nociceptive Pain Over Time in Inflammatory Arthritis: Results from the NEUPIA Study Speaker: Iulia - Simona Chirica (Romania)
10:00 - 10:06	Autistic and ADHD traits and their associations with sensory processing and pain-specific outcomes in refractory rheumatoid arthritis: a cross-sectional cohort study Speaker: Lucy Zhao (United Kingdom)
10:06 - 10:12	fAI-BRO: Multimodal AI Sentiment Analysis for Fibromyalgia Diagnosis - A Proof-of-Concept Study Speaker: Vincenzo Venerito (Italy)
10:12 - 10:18	Central Sensitization and Pain-Related Outcomes in Systemic Sclerosis: A Monocentric Observational Study Speaker: Giulia Lanaia (Italy)
10:18 - 10:24	Central mechanisms drive persistent pain from diagnosis in inflammatory arthritis: two-year prospective study Speaker: Zoe Rutter-locher (United Kingdom)

Poster Tour Presentations

Date: 05/06/2026

Room: Poster Tour IV

09:30-10:30 BST

Clinical Poster Tours: Different faces of Sarcoidosis

Chair:	James Galloway (United Kingdom) Rifat Medjedovic (Montenegro)
09:30 - 09:36	Trends of incidence, prevalence, and mortality of sarcoidosis in Taiwan: a population-based study, 2003-2023 Speaker: Hsin-Hua Chen (Taiwan)
09:36 - 09:42	Real-world effectiveness and drug survival of infliximab in refractory multisystem sarcoidosis: a multicentre cohort study Speaker: Chun Chan (United Kingdom)

09:42 - 09:48	Prevalence and determinants of fatigue, depression, and anxiety in patients with sarcoidosis: a systematic review Speaker: Christina Duftner (Austria)
09:48 - 09:54	Osteoporosis as a common comorbidity in sarcoidosis : results from a transversal prospective study on 101 patients with treated sarcoidosis. Speaker: Léna Eberhart (France)
09:54 - 10:00	Elderly-Onset Sarcoidosis and the Influence of Age on Clinical Phenotype at Diagnosis: A Multicentre Analysis from the SARCOGEAS Registry Speaker: María García-González (Spain)
10:00 - 10:06	Unsuspected extrapulmonary involvement detected by PET/CT in newly diagnosed sarcoidosis Speaker: Judith Vidal-Ripoll (Spain)
10:06 - 10:12	Risk of Malignancy in Sarcoidosis: Short- and Long-Term Associations in a Nationwide Registry Speaker: Yonatan Shneor Patt (Israel)
10:12 - 10:18	Does Sarcoidosis increase the risk of developing Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance? Speaker: Pallavi Velagapudi (United States of America)
10:18 - 10:24	Microvascular Alterations in Sarcoidosis: Insights and Their Association with Disease Severity Speaker: Barbara Ruaro (Italy)

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour V**

09:30-10:30 BST

Clinical Poster Tours: Osteoarthritis - Cracking the Joint

Chair:	
--------	--

09:30 - 09:36	IS SYNOVITIS, AS MEASURED BY EFFUSION MORPHOMETRY OR HOFFA RADIOMICS, RELATED TO OSTEOARTHRITIS PROGRESSION Speaker: Felix Eckstein (Germany)
09:36 - 09:42	Reduction in Knee Osteoarthritis Bone Marrow Lesions Using the Novel Neurotrophin Modulator LEVI-04 in a Phase 2 RCT Speaker: Simon Westbrook (United Kingdom)
09:42 - 09:48	Cross-sectional and longitudinal association between biological aging acceleration and the risk of osteoarthritis: A cohort study from UK Biobank Speaker: Sisi Liu (China)
09:48 - 09:54	Aligning drug mode of action with molecular endotypes to improve trial precision Speaker: Monica Toft Hannani (Denmark)
09:54 - 10:00	Predicting knee replacement from 12-month changes in pain and function from the Osteoarthritis Initiative: a PROACTIVE consortium project Speaker: Peter Mesenbrink (United States of America)
10:00 - 10:06	THE RELATIONSHIP BETWEEN MENISCAL EXTRUSION AND BONE SHAPE (B-SCORE) IN KNEE OSTEOARTHRITIS Speaker: Philip G. Conaghan (United Kingdom)
10:06 - 10:12	Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study Speaker: Denis Poddubnyy (Canada)
10:12 - 10:18	Knee Replacement Outcomes With GLP-1 Receptor Agonists Versus Metformin in Older Adults With Type 2 Diabetes and Obesity Speaker: Chukwuemerie Okeke (United States of America)
10:18 - 10:24	Characterization of DFV890 effect on synovitis activity measured by dynamic-contrast-enhanced (DCE)-MRI in patients with inflammatory knee osteoarthritis Speaker: Didier Laurent (France)

Meet the EULAR ExpertDate: **05/06/2026**Room: **Meet the EULAR Expert 1****09:45-10:15 BST****Meet the ARD and ERO Editors**

Chair:	
09:45 - 10:15	<p>Meet the ARD and ERO Editors - What you always wanted know about publishing</p> <p>Co-Speaker: Gerd R. Burmester / (Berlin, Germany), Josef S. Smolen / (Vienna, Austria)</p>

HPR Meet the EULAR ExpertDate: **05/06/2026**

Delegates will:

Room: **Meet the EULAR Expert 2**

- Identify the long-term impact of green spaces on musculoskeletal health.

09:45-10:15 BST

- Discuss how outdoor physical activity supports better health perception, energy levels, and sustained participation.

Nature in prevention and RMD management

Chair:	
09:45 - 10:15	<p>Nature in prevention and RMD management</p> <p>Speaker: Jessica Stanhope (Australia)</p>

Meet the EULAR ExpertDate: **05/06/2026**

Room: **Meet the EULAR Expert 3**

09:45-10:15 BST

Psoriatic Arthritis

Chair:	
09:45 - 10:15	Psoriatic arthritis Speaker: Laura C. Coates (United Kingdom)

Meet the EULAR Expert

Date: **05/06/2026**

Room: **Meet the EULAR Expert 4**

09:45-10:15 BST

ICI induced rheumatic irAE

Chair:	
09:45 - 10:15	ICI induced rheumatic irAE Speaker: Hendrik Schulze-Koops (Germany)

What is New (WIN)

Date: **05/06/2026**

Describe drug repurposing efforts in AO.

Room: **Plenary**

10:30-11:15 BST

Appraise late-stage DMOAD developments and judge which agents could obtain approval within the next decade.

Describe emerging gene-based therapies and outline

the regulatory steps toward clinical uptake

Osteoarthritis

Chair:	Ida K. Haugen (Norway) Zoran Velickovic (Serbia)
10:30 - 11:15	Emerging therapies in OA Speaker: Henning Bliddal (Denmark)

Basic and Translational Science

Date: **05/06/2026**

By the end of this session, participants will:

Room: **Connaught Room 1 & 2**

- Recognise the role of non-immune cells, such as podocytes, platelets, and fibroblasts, in the pathogenesis of autoimmune and inflammatory diseases.

10:30-11:45 BST

- Understand how these cells interact with the immune system to perpetuate or modulate inflammation.

- Explore emerging evidence on the therapeutic potential of targeting non-immune cells or their crosstalk with immune components.

Beyond the Immune Cell: Non-Immune Players in Chronic Inflammation

Chair:	Iain B. McInnes (United Kingdom) Anne Trolborg (Denmark)
10:30 - 10:55	The Role of Podocytes in Lupus Pathology Speaker: George Tsokos (United States of America)

10:55 - 11:20	Participation of platelets in the inflammatory response Speaker: Marc Scherlinger (France)
11:20 - 11:45	Role of fibroblast subsets in autoimmune diseases Speaker: Caroline Ospelt (Switzerland)

Basic and Translational Science

Date: 05/06/2026

By the end of this session, participants will:

Room: **Connaught Room 3 & 4**

- Understand how human evolution has shaped genetic susceptibility to autoinflammatory and autoimmune diseases.

10:30-11:45 BST

- Explore the expanding role of somatic mutations in adult-onset autoinflammatory syndromes beyond VEXAS.

- Learn how artificial intelligence can assist in the diagnosis and classification of complex autoinflammatory disorders.

Decoding Autoinflammation: Evolution, Somatic Mutations, and Artificial Intelligence

Chair:	Dennis McGonagle (United Kingdom) Ertugrul Cagri Bolek (Türkiye)
10:30 - 10:55	How Evolution Shaped Human Immunity and Autoimmunity Speaker: Mark Coles (United Kingdom)
10:55 - 11:20	Somatic Mutations in Autoinflammatory Diseases: Beyond VEXAS Syndrome Speaker: Sinisa Savic (United Kingdom)

11:20 - 11:45	Leveraging Artificial Intelligence to Understand Immunological Diseases: Insights from Neuroinflammation Speaker: Adam Handel (United Kingdom)
---------------	--

Health Professionals in Rheumatology (HPR)

Date: **05/06/2026**

Get an overview of different theoretical foundations for patient education in accordance with the EULAR recommendations for patient education

Room: **Victoria Room 1**

10:30-11:45 BST

Learn about different theoretical approaches and how to support exercise, adherence and behaviour change

Discussion of opportunities and challenges for applying patient education in people with inflammatory RMDs.

Redefining patient education: linking knowledge, adherence and change

Chair:	Mwidimi Ndosi (United Kingdom) Heidi Zangi (Norway)
10:30 - 10:50	New EULAR and WHO definitions of patient education and theoretical backgrounds Speaker: Catherine Beauvais (France)
10:50 - 11:10	Patient education and physical activity counselling Speaker: Jet Veldhuijzen van Zanten (United Kingdom)
11:10 - 11:30	Supporting adherence and sustained behaviour change Speaker: Keegan Knittle (Finland)
11:30 - 11:40	Optimizing implementation of digital patient education using e-health literacy profiles in a rheumatoid arthritis cohort Speaker: Line Raunsbæk Knudsen (Denmark)

PAREDate: **05/06/2026**

1. To identify possible side-effects of RMD medication and how to manage them

Room: **Victoria Room 2****10:30-11:45 BST**

2. To understand mechanisms of adverse events across RMD drugs, promote awareness of patient-centred side effect reporting

3. To discuss the patient's perspective on managing side effects

Side Effects Suck: Minimising and Managing Treatment Risks

Chair:	Michael Poelzl (Austria) Sofia Sotiria Marantidou (Greece)
10:30 - 10:35	Introduction Speaker: Michael Poelzl (Austria) Co-Speaker: Sofia Sotiria Marantidou / (Kilkis, Greece)
10:35 - 10:45	What we don't always talk about: Facing side effects together Speaker: Marie Kostine (France)
10:45 - 10:55	When the medicine heals but hurts :My experience with side effects Speaker: Kyriaki Spanidou (Greece)
10:55 - 11:05	Protecting patients from side -effects: Actions taken by the EMA Speaker: Thorsten Olski
11:05 - 11:15	'Side effects and the Mind': CBT to the rescue Speaker: Beatrice Mirela Craciun (Romania)
11:15 - 11:25	Exploration of the impact of Glucocorticoids in Children and Young People; Patient and Parent Involvement in shaping the study design Speaker: Emily Barnes (United Kingdom)

11:25 - 11:45	Discussion Speaker: Sofia Sotiria Marantidou (Greece) Co-Speaker: Michael Poelzl / (Graz, Austria)
---------------	---

EULAR Projects

Date: **05/06/2026**

Room: **Victoria Room 3**

10:30-11:45 BST

Implementing the European Health Data Space: the role of stakeholder engagement

Chair:	Margreet Kloppenburg (Netherlands) Elena Nikiphorou (United Kingdom)
10:30 - 10:35	Introduction
10:35 - 10:45	EHDS & the Stakeholder Forum: Policy Context Speaker: Marieke Meijer (Belgium)
10:45 - 10:55	Lessons learned from the Stakeholder Forum Speaker: Irene Schluender (Germany)
10:55 - 11:05	TBD Speaker: Sina Bugeja (Malta)
11:05 - 11:10	Q&A for all presentations

11:10 - 11:40	Moderated Panel Discussion Co-Speaker: Sina Bugeja / (Marsaxlokk, Malta), Marieke Meijer / (Brussels, Belgium)
---------------	--

From Bench to Bedside

Date: **05/06/2026**

1. To learn about the new autoantibodies and the new mechanisms at the origin of the immune-linked foetal auriculo-ventricular block

Room: **Victoria Room 4**

10:30-11:45 BST

2. To learn how managing pregnancies in women with anti-SSA antibodies

News in origin and management of immune-linked foetal atrio-ventricular block

Chair:	Laura Andreoli (Italy) Philip Carlucci (United States of America)
10:30 - 10:51	New autoantibodies associated with foetal atrio-ventricular block Speaker: Robert Hamilton (Canada)
10:51 - 11:13	The role of interferon in the induction of foetal atrio-ventricular block Speaker: Gregoire Martin de Fremont (Sweden)
11:13 - 11:35	Current management of pregnancies in women with anti-SSA antibodies Speaker: Frauke Förger (Switzerland)
11:35 - 11:45	Impaired glycosylation of anti-Ro52-IgG and total IgG is associated with autoimmune congenital heart block Speaker: Ana-Luisa Stefanski (Germany)

EMEUNET PresentsDate: **05/06/2026**

What can we learn about education from those that really innovated? This is an opportunity at individual level to learn how to communicate medical knowledge in written and verbal format and organise effective educational activities/resources at a local or international level.

Room: **Victoria Room 5 & 6****10:30-11:45 BST****The funny thing about education: it is serious business**

Chair:	Anastasia Madenidou (United Kingdom) Victoria Konzett (Austria)
10:30 - 10:45	RheumMadness: tournament-style evidence gamification Speaker: David Leverenz (United States of America)
10:45 - 11:00	The PANLAR Cup: the football inspired rheumatology competition Speaker: Carlos Enrique Toro-Gutierrez (Canada)
11:00 - 11:15	RheumaVision: community co-creation Speaker: Cristiana Sieiro Santos (United Kingdom)
11:15 - 11:35	RheumNow: what is on the rheumatology news? Speaker: John Cush (United States of America)

Practical Skills LectureDate: **05/06/2026**

1. Explore novel Antibodies in Connective Tissue Disease and Inflammatory Joint Diseases

Room: **N1**

2. Understand the Role of Antibodies in RMDs

10:30-11:45 BST

3. Evaluate Clinical Implications

Unveiling Novel Antibodies and Their Practical Implication in RMDs

Chair:	Martin Stradner (Austria) Claudia Mauri
10:30 - 10:35	Introduction Speaker: Claudia Mauri Co-Speaker: Martin Stradner / (Graz, Austria)
10:35 - 10:55	Novel Antibodies in Connective Tissue Disease Speaker: Reinhard Voll (Germany)
10:55 - 11:15	Novel Antibodies in Inflammatory Joint Disease Speaker: Diane van der Woude (Netherlands)
11:15 - 11:45	Clinical Insights: Timing, Application, and Impact of Novel Antibodies in RMDs Speaker: May Y. Choi (Canada)

Challenges in Clinical Practice

Date: **05/06/2026**

- To learn the possible severe extra-glandular disease manifestations in Sjögren's disease

Room: **N2**

10:30-11:45 BST

- To discuss representative cases of Sjögren's disease with severe extra-glandular manifestations

- To provide the latest advances about a tailored therapeutic approach for Sjögren's disease

The clinical challenge of managing severe manifestations of Sjögren's disease

Chair:	Hendrika Bootsma (Netherlands) Pilar Brito-Zerón (Spain)
--------	---

10:30 - 10:40	Case 1 - Patient with Sjögren's Disease and associated MALT lymphoma Speaker: Loukas Chatzis (Greece)
10:40 - 11:00	Case Discussion - Patient with Sjögren Disease and associated MALT lymphoma Speaker: Andreas V Goules (Greece)
11:00 - 11:10	Case 2 - Patient with Co-Occurrence of Anti-Synthetase Syndrome and Sjögren Disease Speaker: Onorina Berardicurti (Italy)
11:10 - 11:30	Case Discussion - Patient with Co-Occurrence of Anti-Synthetase Syndrome and Sjögren Disease Speaker: Roberto Giacomelli (Italy)
11:30 - 11:45	Question and Answers Speaker: Pilar Brito-Zerón (Spain) Co-Speaker: Hendrika Bootsma / (Groningen, Netherlands)

EULAR Debate

Date: **05/06/2026**

Debate motion: Combining targeted therapies in inflammatory arthritis should be implemented as a treatment option in routine clinical practice today.

Room: **N3**

10:30-11:45 BST

After attending this session, participants will be able to:

- 1) Describe the current evidence supporting or opposing the use of combination targeted therapies in inflammatory arthritis.
- 2) Understand the potential benefits and risks of combining biologic and/or targeted synthetic DMARDs.
- 3) Critically assess practical, ethical and economic considerations of combination strategies in routine

care.

4) Formulate an informed position on whether combination targeted therapy should be integrated into treatment algorithms now or in the future.

Combination of targeted therapies in inflammatory arthritis - is the time now?

Chair:	Fabian Proft (Germany) Sytske Anne Bergstra (Netherlands)
10:30 - 10:40	Introduction and voting Speaker: Fabian Proft (Germany) Co-Speaker: Sytske Anne Bergstra / (Leiden, Netherlands)
10:40 - 10:55	Round 1 - For the motion Speaker: Jacques-Eric Gottenberg (France)
10:55 - 11:10	Round 1 - Against the motion Speaker: Maya Buch (United Kingdom)
11:10 - 11:15	Voting
11:15 - 11:25	Round 2 - For the motion Speaker: Jacques-Eric Gottenberg (France)
11:25 - 11:35	Round 2 - Against the motion Speaker: Maya Buch (United Kingdom)

11:35 - 11:45	Closing and discussion Speaker: Sytske Anne Bergstra (Netherlands) Co-Speaker: Fabian Proft / (Berlin, Germany)
---------------	--

Practical Skills Lecture	Date: 05/06/2026
Key points:	Room: George V Room 1
<p>How to apply ASAS/OMERACT scoring in a pragmatic way.</p> <p>Common scoring pitfalls (with audience polls).</p> <p>Audience works through cases with Berlin case viewer.</p>	10:30-11:45 BST

Imaging in axial spondyloarthritis, including new techniques

Chair:	Bayram Farisogullari (United Kingdom) Miranda van Lunteren (Netherlands)
10:30 - 10:55	Plain Radiography in Axial SpA: Getting the Basics and Subtleties Right Speaker: Monique Reijnierse (Netherlands)
10:55 - 11:20	Optimising MRI Interpretation in Early Axial SpA Speaker: Kay-Geert Hermann (Germany)
11:20 - 11:45	CT and Emerging Imaging Techniques in Axial SpA: What's Coming to Your Clinic Soon Speaker: Lennart Jans (Belgium)

EULAR Joint Sessions	Date: 05/06/2026
By the end of the session, delegates will be able to:	Room: George V Room 2

- Reflect on the challenges of managing RMDs in older age

10:30-11:45 BST

- Explore how to best target frailty

- Understand experiences of older adults and carers in daily life

- Discuss the importance of including older adults in RMD research

Rethinking care for brighter outcomes in older adults with RMDs

Chair:	Anne-Kathrin Rausch (Switzerland) José Antonio P. da Silva (Portugal)
10:30 - 10:45	Why would it make sense to adapt our disease management to older people? Speaker: Marta Novella-Navarro (Spain)
10:45 - 11:00	Understanding Frailty: From Identification to Intervention Speaker: Luise Lindgren (Denmark)
11:00 - 11:15	Voices of experience: What older adults with RMDs and their families need most Speaker: Dieter Wiek (Germany)
11:15 - 11:30	Underrepresented and overlooked: Older adults in RMD Research Speaker: Marloes van Onna (Netherlands)
11:30 - 11:45	Questions and Answers Speaker: José Antonio P. da Silva (Portugal) Co-Speaker: Anne-Kathrin Rausch / (Switzerland)

EULAR Debate

Date: 05/06/2026

- To understand the current role of renal biopsy for

Room: George V Room 3

the re-evaluation of patients with ANCA-Associated Vasculitis and kidney disease

10:30-11:45 BST

- To reassess the value of biopsy in the near future in the light of emerging humoral biomarkers and advanced imaging techniques.

- To discuss strategies to integrate biopsy, biomarkers, and imaging into a comprehensive follow-up approach.

To (Re)biopsy or Not to (Re)biopsy in ANCA-Associated Vasculitis: That Is Still the Question

Chair:	Sara Monti (Italy) Sabine Adler (Switzerland)
10:30 - 10:50	Pro - Renal biopsy is essential for re-assessment of patients with ANCA-associated vasculitis Speaker: David R. W. Jayne (United Kingdom)
10:50 - 11:10	Contra - Renal biopsy can be replaced by modern biomarkers and imaging Speaker: Alessandro Tomelleri (Italy)
11:10 - 11:20	Rebuttal - Renal biopsy is essential for re-assessment of patients with ANCA-associated vasculitis Speaker: David R. W. Jayne (United Kingdom)
11:20 - 11:30	Rebuttal - Renal biopsy can be replaced by modern biomarkers and imaging Speaker: Alessandro Tomelleri (Italy)
11:30 - 11:45	Questions and Answers Speaker: Sara Monti (Italy) Co-Speaker: Sabine Adler / (Aarau, Switzerland)

- Autoinflammatory diseases are often the consequence of abnormal innate immune activation.

Room: **George V Room 4**

10:30-11:45 BST

- Kinases regulate cellular processes, and mutated kinases can lead to immune dysregulation via complex pathways.

- STATs are transcription factors that are key to immune activation pathways. Loss or gain of function mutations can lead to variant phenotypes of rare inflammatory diseases.

- These are only few examples of diseases where immunodeficiency and autoinflammation can merge in the development of rare immune-mediated disorders with growing relevance.

Kinasopathies, STAT mutations and immune dysregulation

Chair:	Marco Gattorno (Italy) alexandre belot (France)
10:30 - 10:55	Immunoregulation driven by STAT GoF mutations Speaker: Catharina Schütz (Germany)
10:55 - 11:20	CDC42-associated disease Speaker: Jerome Delon (France)
11:20 - 11:45	IEI mimickers of rheumatic diseases Speaker: Sophie Hambleton (United Kingdom)

Innovation

Date: **05/06/2026**

By the end of this session, participants will:

Room: **Room 12**

- Understand the environmental impact of healthcare systems, with a focus on rheumatology.

10:30-11:45 BST

- Explore deprescribing and rational test ordering as tools to reduce the carbon footprint of clinical practice.
- Identify concrete strategies to implement sustainable practices in rheumatology departments and therapeutic pathways.

The carbon footprint of rheumatology: how can we reduce it?

Chair:	Nathalie Costedoat-Chalumeau (France) Patrick Gordon (United Kingdom)
10:30 - 10:55	The Environmental Impact of Healthcare and Where Rheumatology Fits In Speaker: Veronique Hentgen (France)
10:55 - 11:20	Deprescribing to Reduce the Environmental Burden of Rheumatology Speaker: Yann Nguyen (France)
11:20 - 11:45	Eco-responsibility in Rheumatology Departments Speaker: Tanja Stamm (Austria)

Hands-on Sessions

Date: **05/06/2026**

1. How to perform fast ultrasonography scans in daily clinical practice
2. Using handheld portable ultrasound devices.
3. Examples in different anatomical areas and pathologies using portable ultrasound devices.

Room: **Hands-on 1**

10:30-11:45 BST

Fast ultrasound protocols in Rheumatology: Point of Care

Chair:	Hilde Berner Hammer (Norway) Marion Kortekaas (Netherlands)
10:30 - 10:35	Point of Care lung scan in patients with suspected interstitial lung disease Speaker: ANDREA DELLE SEDIE (Italy)
10:35 - 10:40	Point of Care salivary gland scan in suspected sjögren's disease Speaker: Alojzija Hocevar (Slovenia)
10:40 - 10:45	Point of Care vessel scan in suspected vasculitis Speaker: Wolfgang Schmidt (Germany)
10:45 - 10:50	Point of Care joint scan in suspected arthritis Speaker: Carlo Perricone (Italy)
10:50 - 10:55	Questions and Answers Speaker: Hilde Berner Hammer (Norway) Co-Speaker: Marion Kortekaas / (Leiden, Netherlands)
10:55 - 11:35	Hands-on Stations Speaker: ANDREA DELLE SEDIE (Italy) Co-Speaker: Alojzija Hocevar / (LJUBLJANA, Slovenia), Wolfgang Schmidt / (Berlin, Germany), Carlo Perricone / (Perugia, Italy), Marion Kortekaas / (Leiden, Netherlands), Hilde Berner Hammer / (Oslo, Norway)

Hands-on Sessions

Date: **05/06/2026**

- Practice diagnostic reasoning in rheumatology.
- Compare clinical problem-solving with and without large language model (LLM) assistance.
- Reflect on benefits, limitations, and pitfalls of AI in clinical practice

Room: **Hands-on 2**

10:30-11:45 BST

You may wish to bring your own laptop for this session.

Clinical Case Solving in Rheumatology – With and Without AI Support

Chair:	Gerd R. Burmester (Germany) Thomas Hügle (Switzerland)
10:30 - 11:05	Clinical Decision Support with Live Prompting Speaker: Thomas Hügle (Switzerland)
11:05 - 11:40	Solve Difficult Cases! Who is the best? Speaker: Gerd R. Burmester (Germany)

EULAR Culture

Date: **05/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

10:30-12:30 BST

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	
--------	--

--	--

EULAR Culture

Date: **05/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

10:30-12:30 BST

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

How to Treat (HOT)

Date: **05/06/2026**

- To learn about recent EULAR management recommendations for these diseases

Room: **Plenary**

- To discuss recent trials and potential novel treatment options

11:15-12:00 BST

- To learn about prognostic factors and individualised treatment

Large vessel vasculitis and Polymyalgia rheumatica

Chair:	Frank Buttgereit (Germany) Maria C. Cid (Spain)
11:15 - 12:00	Large vessel vasculitis and Polymyalgia rheumatica Speaker: Chetan Mukhtyar (United Kingdom)

Health Professionals in Rheumatology (HPR)

Date: **05/06/2026**

The "HPR Move Together Session: Moving Science into Practice" at the EULAR 2026 Congress offers a unique and interactive experience for attendees to embed evidence-based practice in exercise and physical activity recommendations for rheumatic and musculoskeletal diseases (RMDs). This session is designed for both people with RMDs and all members of the multi-professional healthcare team. It aims to bridge the gap between scientific knowledge and practical strategies for promoting physical activity in rheumatology.

Room: **HPR Move Together**

12:15-13:15 BST

Attendees will participate in hands-on activities and learn how to integrate evidence-based exercise programmes into their daily lives and patient care. This will ultimately improve the understanding and management of RMDs.

This session will feature Therapeutic Exercise and Stretching

Mariana Carvalho is both a Physiotherapist and a

patient with inflammatory arthritis, and in this session, she will guide you through a sequence of movements that will work your strength, mobility, and flexibility

Martin is a rheumatology dietitian working for a UK charity, Arthritis Action. He is also qualified in strength and conditioning, utilising both of these skills in his clinical practice. In this session, Martin will present and demonstrate blood flow restriction (BFR) training. BFR has gained interest in elite athletes as well as people living with arthritis. Participants of Martin's session will be able to gain insight of this training regime and its implementation for people with RMDs.

EULAR HPR Move Together Session: Moving Science into Practice

Chair:	
12:15 - 13:15	EULAR HPR Move Together Co-Speaker: Martin Lau / (United Kingdom), Mariana Carvalho / (Lisbon, Portugal)

EULAR Culture

Date: **05/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest

12:30-14:30 BST

warriors for the most crucial mission in history:
finding the cure before it's too late.

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **05/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

12:30-14:30 BST

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

Hands-on Sessions

Date: **05/06/2026**

1. How to perform fast ultrasonography scans in daily clinical practice

Room: **Hands-on 1**

13:30-14:45 BST

2. Using handheld portable ultrasound devices.

3. Examples in different anatomical areas and pathologies using portable ultrasound devices.

Fast ultrasound protocols in Rheumatology: Point of Care

Chair:	Hilde Berner Hammer (Norway) Marion Kortekaas (Netherlands)
13:30 - 13:35	Point of Care lung scan in patients with suspected interstitial lung disease Speaker: ANDREA DELLE SEDIE (Italy)
13:35 - 13:40	Point of Care salivary gland scan in suspected sjögren's disease Speaker: Alojzija Hocevar (Slovenia)
13:40 - 13:45	Point of Care vessel scan in suspected vasculitis Speaker: Wolfgang Schmidt (Germany)

13:45 - 13:50	Point of Care joint scan in suspected arthritis Speaker: Carlo Perricone (Italy)
13:50 - 13:55	Questions and Answers Speaker: Hilde Berner Hammer (Norway) Co-Speaker: Marion Kortekaas / (Leiden, Netherlands)
13:55 - 14:45	Hands-on Workshop Speaker: Hilde Berner Hammer (Norway) Co-Speaker: Marion Kortekaas / (Leiden, Netherlands), ANDREA DELLE SEDIE / (Pisa, Italy), Alojzija Hocevar / (LJUBLJANA, Slovenia), Wolfgang Schmidt / (Berlin, Germany), Carlo Perricone / (Perugia, Italy)

Hands-on Sessions

Date: **05/06/2026**

This session will help delegates to know:

Room: **Hands-on 2**

13:30-14:45 BST

1. When to perform a synovial fluid analysis;
2. How to perform a synovial fluid analysis;
3. How to interpret a synovial fluid analysis.

Please note that there is a maximum capacity in this session. Delegates will be given access on a first come, first served basis.

This session is identical to the other 'Crystal Identification, synovial fluid analysis' session. Please do not attend more than one Hands-On Session of the same name.

Crystal identification, synovial fluid analysis

Chair:	Francesca Oliviero (Italy) Eleonora Norkuviene (Lithuania)
13:30 - 13:40	When should Synovial Fluid analysis be performed? Speaker: Abhishek Abhishek (United Kingdom)
13:40 - 13:50	Identifying crystals in synovial fluid Speaker: Anne-Kathrin Tausche (Germany)
13:50 - 14:45	Hands-on Workshop Speaker: Anne-Kathrin Tausche (Germany) Co-Speaker: Abhishek Abhishek / (Nottingham, United Kingdom), Francesca Oliviero / (Padova, Italy), Eleonora Norkuviene / (Kaunas, Lithuania)

PARE Meet the EULAR Expert

Date: 05/06/2026

To learn about the reasons surgery may be offered

Room: **Meet the EULAR Expert 1**

To share the risk factors and complications associated with joint surgery

13:30-14:00 BST

To spell out the options and alternatives to surgery

To educate on the prehab, surgery and rehab required for success

Is slicing too dicey? When is surgery the right choice? When is it the only option?

Chair:	
13:30 - 14:00	Is slicing too dicey? When is surgery the right choice? When is it the only option? Speaker: Anders Odgaard

Meet the EULAR ExpertDate: **05/06/2026**Room: **Meet the EULAR Expert 2****13:30-14:00 BST****Immunological impacts of our environment**

Chair:	
13:30 - 14:00	Immunological impacts of our environment Speaker: Eicke Latz (Germany)

Meet the EULAR ExpertDate: **05/06/2026**

What is the current state-of-the art strategy in the management of patients with JDM? What is the evidence for T2T strategies? What is the approach in light of the lack of approved drugs? What is the patient outcome?

Room: **Meet the EULAR Expert 3****13:30-14:00 BST****State-of-the-art in juvenile dermatomyositis**

Chair:	
13:30 - 14:00	State-of-the-art in juvenile dermatomyositis Speaker: Clarissa Pilkington (United Kingdom)

Meet the EULAR ExpertDate: **05/06/2026**Room: **Meet the EULAR Expert 4****13:30-14:00 BST**

Rheumatoid Arthritis

Chair:	
13:30 - 14:00	Rheumatoid Arthritis Speaker: Iain B. McInnes (United Kingdom)

Poster View Presentations

Date: **05/06/2026**

Room: **Poster View**

13:30-14:30 BST

Poster View VI

Chair:	
13:30 - 13:30	Performance of Artificial Intelligence-Based Salivary Gland Ultrasound in Sjögren Disease Speaker: Otto Olivas-Vergara (Spain)
13:30 - 13:30	Clinical Spectrum and Long-Term Outcomes of Childhood-Onset Sjögren's Disease Across Adulthood Speaker: Coziana Ciurtin (United Kingdom)
13:30 - 13:30	Novel Candidate Biomarkers for Monitoring Response to JAKi Treatment in Idiopathic Inflammatory Myopathy Speaker: Luke Tomlinson (United Kingdom)
13:30 - 13:30	Sequencing of HLA-A, -B,-C, -DRB1, -DQA1 genes in patients with Takayasu arteritis in the Kyrgyz and Russian populations Speaker: Altynai Bolotbekova (Kyrgyzstan)
13:30 - 13:30	Same, same, but different - ANCA-associated and large vessel vasculitis transcriptomes in whole blood Speaker: Jennifer Amsler (Switzerland)

13:30 - 13:30	Malignancy Patterns in Idiopathic Inflammatory Myopathies: Clinical and Serologic Risk Factors from a Nationwide Registry Speaker: Yonatan Shneor Patt (Israel)
13:30 - 13:30	TO EVALUATE THE ROLE OF ALTERNATIVE COMPLEMENT CASCADE IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS Speaker: Deepak Moka (India)
13:30 - 13:30	Small-Molecule Inhibitors of TNF Reduce Pro-inflammatory Disease Activity while Preserving TNFR2 Signaling, which Maintains Regulatory T Cell Activity and Prevents Aberrant T Cell Cytokine Production Speaker: Daniel DiRenzo (United States of America)
13:30 - 13:30	Serum M-CSF/TNF-α clustering stratifies renal prognosis in microscopic polyangiitis, reflecting an M-CSF-associated CD163-positive macrophage-driven pathomechanism of glomerulonephritis. Speaker: Shogo Matsuda (Japan)
13:30 - 13:30	Serum KL-6 and Lung Ultrasound B-lines: A Combined Non-invasive Model for Screening and Predicting Interstitial Lung Disease in Idiopathic Inflammatory Myopathy Speaker: Yukai Wang (China)
13:30 - 13:30	Changing treatment patterns and the impact on pulmonary outcomes in Sjögren's disease-associated interstitial lung disease: a multicentre European real-world study Speaker: Kastriot Kastrati (Austria)
13:30 - 13:30	Risk stratification model for severe infections after remission induction therapy in idiopathic inflammatory myopathy: A multicenter MYKO study Speaker: Mahiro Yamamoto (Japan)
13:30 - 13:30	Identification of Clonally Expanded Cytomegalovirus-specific Effector Memory GZMK+ CD8 T cells in ANCA-Associated Vasculitis Speaker: Laura S. van Dam (Netherlands)
13:30 - 13:30	Clinical heterogeneity and outcomes in patients with antisynthetase antibodies: influence of serological profile, age and sex Speaker: Maria del Carmen Carrasco Cubero (Spain)

13:30 - 13:30	Multi-Omics Profiling Reveals Molecular Overlap Between Sjögren's Disease and SLE and Identifies Candidate Biomarkers for Sjögren's Disease Speaker: Hanna Schebet (Germany)
13:30 - 13:30	Machine learning-guided prediction and prognostic stratification of cancer-associated myositis: a multicenter MYKO cohort study. Speaker: Katsumasa Oe (Japan)
13:30 - 13:30	Low concentrations of anti-C5aR1 antibodies are associated with early ischemic events in giant cell arteritis (GCA) Speaker: Sebastian Klapa (Germany)
13:30 - 13:30	Eosinophilic granulomatosis with polyangiitis (EGPA) and the long-term risk of cardiovascular disease: large-scale propensity-matched global retrospective cohort study Speaker: Sebastian Klapa (Germany)
13:30 - 13:30	Synovial tissue heterogeneity in rheumatoid arthritis: from histological pathotypes to spatial transcriptomics Speaker: Alice Terrett (Australia)
13:30 - 13:30	Molecular Signature Response Classifier Identifies Contribution of GLP-1 Therapy to TNF Inhibitor Response in Rheumatoid Arthritis Patients Speaker: Lixia Zhang (United States of America)
13:30 - 13:30	Cardiovascular Risk Stratification Using Chest CT in Idiopathic Inflammatory Myopathies Speaker: Kastriot Kastrati (Austria)
13:30 - 13:30	Spatial Proteomic-based Phenotyping of Muscle Stem Cells Reveals Heterogeneity of Muscle Stem Cell Niches and Perturbations in their Cellular Interaction Networks in Immune Mediated Inflammatory Myopathies Speaker: Bilgesu Safak Tumerdem (Germany)
13:30 - 13:30	Effectiveness and safety of upadacitinib versus Tacrolimus in anti-MDA5-positive clinically amyopathic dermatomyositis related rapidly interstitial lung disease : a single-centre, retrospective cohort study Speaker: Xudong Liu (China)

13:30 - 13:30	<p>Enhanced Fibrogenic Pathways Define Scleromyositis Within the Spectrum of ACR/EULAR Myositis Subsets Speaker: Margherita Giannini (France)</p>
13:30 - 13:30	<p>A mitochondrial gene signature to stratify juvenile dermatomyositis patient groups for more targeted treatment Speaker: Meredyth Wilkinson (United Kingdom)</p>
13:30 - 13:30	<p>Evaluation of HLA alleles and polygenic scores in predicting clinical progression among individuals at-risk for rheumatoid arthritis Speaker: Taiki Yamaguchi (Japan)</p>
13:30 - 13:30	<p>Pain is associated with disease activity in idiopathic inflammatory myopathies in a longitudinal 10-year follow-up single-centre study Speaker: Thanh Hien Bui (Sweden)</p>
13:30 - 13:30	<p>Risk of disease progression events in patients with anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease treated with and without initial triple-combination therapy: A Japanese retrospective multicenter registry study Speaker: Tomoaki Higuchi (Japan)</p>
13:30 - 13:30	<p>Causal networks offer insights into pathobiological pathways to flare in rheumatoid arthritis: analysis of the BIOlogical Factors that Limit sustained Remission (BIO-FLARE) study Speaker: Karina Patasova (United Kingdom)</p>
13:30 - 13:30	<p>Pulmonary Hypertension in Idiopathic Inflammatory Myopathies: Clinical Characteristics and Determinants from a Greek Tertiary Center Speaker: Vasiliki Syrmou (Greece)</p>
13:30 - 13:30	<p>Nearly a Decade of Structural Progression on Salivary Gland Ultrasonography in Primary Sjögren's Disease: Prognostic and Phenotypic Implications Speaker: Kyung Ann Lee (Korea, Republic of (South Korea))</p>
13:30 - 13:30	<p>CD74+ Fibroblasts Trigger the Inflammatory Microenvironment in Early Sjögren's Disease Speaker: Xinwei Zhang (China)</p>

13:30 - 13:30	Risk Stratification and Immunosuppressant Analysis for Respiratory Progression in Patients with Anti-MDA5 Interstitial Lung Disease without Initial Respiratory Failure: A Japanese-Taiwanese Study Speaker: Pei-Hsiung Lai (Taiwan)
13:30 - 13:30	ESCO2-Dependent Histone Lactylation Mediates Neutrophil Extracellular Trap-Induced Activation of Synovial Fibroblasts in Rheumatoid Arthritis Speaker: Hong Qi (China)
13:30 - 13:30	Excess Mortality and Disease-Specific Mortality Risks in ANCA-Associated Vasculitis: Insights from a Nationwide Cohort Speaker: Johanna Dahlqvist (Sweden)
13:30 - 13:30	Differentiating infection from relapse in ANCA-associated vasculitis; the role of common inflammatory indices Speaker: Servet Akar (Türkiye)
13:30 - 13:30	Plasma Protein Profiles as Predictors of Disease Activity and Organ-Specific Involvement in AAV Speaker: Johanna Dahlqvist (Sweden)
13:30 - 13:30	Pain levels and distribution in idiopathic inflammatory myopathies Speaker: Lekshmi Minikumari Rahulan (India)
13:30 - 13:30	Peripheral Blood Transcriptomics Reveals Interferon-Driven Innate Immune Networks Distinguishing MDA5-Positive Dermatomyositis Within Idiopathic Inflammatory Myopathies and Informing Rational Therapeutic Targeting Speaker: Yoshinobu Koyama (Japan)
13:30 - 13:30	Impact of environmental exposures on risk, phenotype and disease activity in idiopathic inflammatory myopathies: A scoping review Speaker: Rishi Balse (India)
13:30 - 13:30	HGF-MSCs alleviate joint and lung injury in RA-ILD mouse model Speaker: manling zhang (China)

13:30 - 13:30	<p>Comparison of clinical characteristics and outcomes in younger- and elderly-onset ANCA-associated vasculitis Speaker: Sopita Nuansuwan (Thailand)</p>
13:30 - 13:30	<p>Enhanced fibroblast signature in females with early Rheumatoid Arthritis highlights a potential basis for poorer treatment outcomes Speaker: Benedetta Monosi (Italy)</p>
13:30 - 13:30	<p>Multi-Ancestry Genome-Wide Association Analysis of Sjögren's Disease Identifies Novel Risk Loci Speaker: Christopher J Lessard (United States of America)</p>
13:30 - 13:30	<p>Early post-treatment interferon responses linked to dendritic cell activation are associated with reduced relapse in ANCA-associated vasculitis Speaker: Shuji Sumitomo (Japan)</p>
13:30 - 13:30	<p>Mortality Trends in Dermatomyositis/Polymyositis in the United States between 1999 and 2024 Based on CDC WONDER Speaker: Meryem Pamuk (United States of America)</p>
13:30 - 13:30	<p>Comparison of Progressive Pulmonary Fibrosis Definitions in Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Impact on 5-Year Transplant-Free Survival Speaker: Irada Choudhuri (United States of America)</p>
13:30 - 13:30	<p>Fatty acid binding protein 3 (FABP-3) is a potential mediator of muscle damage in inflammatory myopathies and its serum level decrease in response to an intensive combined exercise program Speaker: Léa Debrut (France)</p>
13:30 - 13:30	<p>GTPase-Dependent RNA Decapping Drives Persistent Inflammation and Relapse Susceptibility in Giant Cell Arteritis Speaker: Reza Gheitasi (Germany)</p>
13:30 - 13:30	<p>Isolated biological activity during follow-up defines a distinct intermediate disease phenotype in Sjögren's disease Speaker: Chiara Baldini (Italy)</p>

13:30 - 13:30	Advancement of 3-dimensional synovial tissue organoids into a personalized drug-testing platform for rheumatoid arthritis Speaker: Amber Dassen (Netherlands)
13:30 - 13:30	Stratification of AAV Patients According to PR3-specific Serum Immunoglobulin Isotype Associates with Disease Activity and Clinical Manifestations Speaker: Valeria Facchini (Italy)
13:30 - 13:30	Distribution patterns and predictive value of IgG, IgA, and IgM autoantibody isotype in anti-synthetase syndrome and interstitial lung disease Speaker: Antonella Notarnicola (Sweden)
13:30 - 13:30	Muscle Weakness Severity Predicts Mortality in Immune Checkpoint Inhibitor-Associated Myositis and Overlap Syndromes Speaker: Angeles Shunashy Galindo-Feria (Sweden)
13:30 - 13:30	Spatial Mapping of Dysregulated Interferon and Mitochondrial Pathways in Juvenile Dermatomyositis Muscle Tissue Speaker: Aris Eleftherios Syntakas (United Kingdom)
13:30 - 13:30	Beyond Inflammation: Subtype-Specific Patterns and Predictors of Accrued Damage in Idiopathic Inflammatory Myopathies — Insights from the MYOSPAIN Registry Speaker: Jose Luis Tandaipan (Spain)
13:30 - 13:30	Postthrombotic Vascular Remodeling in Behçet Syndrome Speaker: Tumay Ak (Türkiye)
13:30 - 13:30	Dissecting the immune response that underscores eosinophilic granulomatosis with polyangiitis and its therapy Speaker: Raquel Lorenzetti (Austria)
13:30 - 13:30	Deep learning-based assessment of CD90+ synovial fibroblast heterogeneity in a treatment-naïve rheumatoid arthritis cohort Speaker: Federico Abatecola (United Kingdom)
13:30 - 13:30	Renal Survival in ANCA-Associated Vasculitis: Performance of the ANCA Renal Risk Score Speaker: Mariano Alves (Argentina)

13:30 - 13:30	<p>Spatial Transcriptomics Reveals Glandular Cell Involvement in the Pathophysiology of Sjögren's Disease Speaker: Christopher J Lessard (United States of America)</p>
13:30 - 13:30	<p>Efficacy and Safety of Rituximab and IVIG in Anti-SRP Immune-Mediated Necrotizing Myopathy: Systematic Review of the Evidence Speaker: KHALED ALDHUAINA (Kuwait)</p>
13:30 - 13:30	<p>CD45RC Expression Correlates with Lymphocytic Infiltration in Salivary Glands: Proof-Of-Concept of Therapeutic and Biomarker Potential in Sjogren's Disease Speaker: Joke Deprez (Belgium)</p>
13:30 - 13:30	<p>Cardiovascular Disease Risk in Patients with ANCA-Associated Vasculitis and Their Siblings: A Nationwide Swedish Study Speaker: Hanna Lindberg (Sweden)</p>
13:30 - 13:30	<p>Combined intensive resistance and endurance exercise in low-disease activity inflammatory myopathies : A Hospital vs. Community-Based prospective study Speaker: QUENTIN TOUMAZEAU (France)</p>
13:30 - 13:30	<p>Unsupervised machine learning identifies distinct phenotypes of anti-CCP positive at risk individuals with different risks of progression to rheumatoid arthritis Speaker: Eleanor Bolton (United Kingdom)</p>
13:30 - 13:30	<p>Predictors of Mortality in Idiopathic Inflammatory Myopathy: A Nationwide Multicenter Cohort Study Speaker: Inês Sopa (Portugal)</p>
13:30 - 13:30	<p>Baseline fibrosis, male sex, and positivity for anti-PL-7, anti-PL-12, or anti-OJ predict mortality in antisynthetase syndrome. Speaker: Daphne Rivero Gallegos (Mexico)</p>
13:30 - 13:30	<p>Treatment Patterns in Kawasaki Disease: The Results from the JIR-CLiPS Network Speaker: Andzelika Slegeryte (Lithuania)</p>

Clinical Poster Tours: Novel Approaches in Rheumatoid Arthritis

Chair:	Rachel Knevel (Netherlands) Jacob M. van Laar (Netherlands)
13:30 - 13:36	Determinants of Methotrexate Polyglutamate Levels in Patients with Rheumatoid Arthritis: Real-World Data Speaker: Karolina Anderle (Austria)
13:36 - 13:42	Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi) Speaker: Jeffrey Curtis (United States of America)
13:42 - 13:48	Wearable-derived data and machine learning predict EQ-5D-based quality of life in patients with rheumatoid arthritis Speaker: Misako Higashida-Konishi (Japan)
13:48 - 13:54	Using an AI-powered Ultrasound-robot (ARTHUR) to detect patients with inflammatory arthropathies by an assistant physician in a preclinical real world triage setting Speaker: Philipp Sewerin (Germany)
13:54 - 14:00	Real-world electronic health record data platform with machine learning to emulate randomized controlled trials in rheumatoid arthritis evaluating treatments after methotrexate failure Speaker: Katherine Liao (United States of America)
14:00 - 14:06	Multimodal Phenotyping of B-Cell Depletion and Reconstitution Following CD19 CAR T-Cell Therapy with Mivocabtagene Autoleucel in ACPA-Positive, Treatment-Refractory, Active Rheumatoid Arthritis - Data from the Phase 1 of the Prospective, Interventional COMPARE Trial Speaker: Thanh Hang Le (Germany)
14:06 - 14:12	Risk Modeling and Stratification to Identify Rheumatoid Arthritis Patients Most Likely to Achieve Remission after Initiating Tofacitinib and Other Advanced Therapies Speaker: Jinoos Yazdany (United States of America)

14:12 - 14:18	Towards personalized medicine in rheumatoid arthritis: a randomized controlled trial of a tailor made approach vs routine care - results of the PRIMERA trial Speaker: Agnes E.M. Looijen (Netherlands)
14:18 - 14:24	Decoding the proteomic landscape of rheumatoid arthritis onset: from causal drivers to clinical prediction Speaker: Yang Pu (China)

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour II**

13:30-14:30 BST

Clinical Poster Tours: Novelties in Inflammatory Myopathies

Chair:	
13:30 - 13:36	Unveiling the "Local Stiffness, Global Differentiation" Metabolic Landscape: A Spatial Metabolomics Study for Precision Subtyping in Idiopathic Inflammatory Myopathies Speaker: Yinlan Wu (China)
13:36 - 13:42	The Long-Term Safety and Efficacy of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy: Results From the Phase 2 Randomized ALKIVIA and Open-Label Extension ALKIVIA+ Trials Speaker: Hector Chinoy (United Kingdom)
13:42 - 13:48	Idiopathic inflammatory myopathies subtypes have clear epidemiological differences across sex and ethnicity subgroups: A population-based cohort in England, 2002-2021 Speaker: Patrick Gordon (United Kingdom)
13:48 - 13:54	Determinants and Phenotypes of Fatigue in Idiopathic Inflammatory Myopathy: A Global Study Speaker: Meera Shah (India)

13:54 - 14:00	Brepocitinib Demonstrates Consistent Benefit on Combined Measures of Clinical Response and Sustained Corticosteroid Tapering in Dermatomyositis Patients at One Year Speaker: Julie Paik (United States of America)
14:00 - 14:06	Universal versus risk-factor based screening for interstitial lung disease in idiopathic inflammatory myopathy Speaker: Ho So (Hong Kong, China)
14:06 - 14:12	First results of the DRIMID study : a multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in idiopathic inflammatory myopathies Speaker: Merve Kocyigit (Netherlands)
14:12 - 14:18	EFFICACY, SAFETY and TOLERABILITY OF ORALLY ADMINISTERED GLPG3667 IN ADULTS WITH DERMATOMYOSITIS: THE GALARISSO STUDY Speaker: Rohit Aggarwal (United States of America)
14:18 - 14:24	Understanding Patient-Physician Discordance in IIM: A Longitudinal Analysis of Disease Activity and Functional Outcomes Speaker: Lekshmi Minikumari Rahulan (India)

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour III**

13:30-14:30 BST

Basic and Clinical Poster Tours: Across the vasculitis-verse

Chair:	Christos Koutsianas (Greece) Elisabeth Brouwer (Netherlands)
13:30 - 13:36	Sequential temporal artery biopsies reveal tissue-level persistence of neutrophilic and senescent inflammatory drivers in GCA patients following Tocilizumab treatment Speaker: Loukas Chatzis (Greece)

13:36 - 13:42	Single-cell Analysis Reveals a Highly Cytotoxic CD8+T-cell Subset Associated with Macrophage Interactions in Takayasu Arteritis Speaker: Kexin Xu
13:42 - 13:48	IL6+ fibroblasts drive the pathological remodeling of Takayasu arteritis vessels through a non-canonical FGF7–FGFR1 axis Speaker: Cong Wang (China)
13:48 - 13:54	IL1Bhi Macrophages Promote Angiogenesis and Participate in Takayasu Arteritis Inflammation Speaker: Zhang Yaxin (China)
13:54 - 14:00	Genetic biomarkers of clinical manifestations of giant cell arteritis define four clinically-relevant genetic subgroups Speaker: Gonzalo Borrego-Yaniz (Spain)
14:00 - 14:06	MULTI-MODAL AND LONGITUDINAL IMMUNE PROFILING UNCOVERS A DISTINCT MONOCYTES PHENOTYPE DISTRIBUTION AND FUNCTION IN KAWASAKI DISEASE Speaker: Giulio Olivieri (Italy)
14:06 - 14:12	Changes in Nasopharyngeal Microbiota Composition in Children with Kawasaki Disease: A Case-Control Study Speaker: Jordi Antón (Spain)
14:12 - 14:18	Respiratory Phenotyping in Eosinophilic Granulomatosis with Polyangiitis: Implications For Disease Prognostication Speaker: Ayman Faisal (United Kingdom)
14:18 - 14:24	Relationships between host and gut microbiome in Behçet's syndrome: results of the BEHCETBIOT matched case-control study. Speaker: Morgane Joubert (France)

Poster Tour Presentations

Date: 05/06/2026

Room: Poster Tour IV

13:30-14:30 BST

Clinical Poster Tours: Clinical outcomes and new targets in Sjögren's disease

Chair:	Chiara Baldini (Italy) Valerie Devauchelle-Pensec (France)
13:30 - 13:36	Phenotypic clustering in Sjögren's disease-associated interstitial lung disease: a multicentre European real-world study Speaker: Kastriot Kastrati (Austria)
13:36 - 13:42	Unsupervised cluster analysis of clinical-serological phenotypes and predictors of progression in Sjögren's disease-associated interstitial lung disease: multicentre data from the ISLAND and GRISS study groups Speaker: Gaetano La Rocca (Italy)
13:42 - 13:48	Progression of Systemic Activity, Organ Damage, and Symptom Burden in Sjögren's Disease: Results from the Prospective Multicenter SjögrenSER-PROS Registry. Speaker: Olga Rusinovich Lovgach (Spain)
13:48 - 13:54	Artificial Intelligence-Assisted Lymphocytic Focus Score of Labial Salivary Glands in Diagnosing Sjögren's Syndrome: A Multi-center Clinical Validation and Deployment Study Speaker: Ying-qian Mo (China)
13:54 - 14:00	Sex differences in patient-reported outcome measures and clinical parameters in patients with Sjögren's disease Speaker: Dagmar Rebel (Netherlands)
14:00 - 14:06	Clinical Safety and Pharmacodynamics of IBI355 in Patients with Sjögren's Disease: a Randomized, Phase 1, Placebo-Controlled, Double-Blind Trial Speaker: Xiaomei Li (China)
14:06 - 14:12	EVALUATION OF THE IANALUMAB TREATMENT EFFECTS ON PAROTID AND SUBMANDIBULAR GLANDS OF PATIENTS WITH SJÖGREN'S DISEASE BY MULTIMODAL ULTRASOUND: RESULTS FROM A PHASE 2 MECHANISTIC STUDY Speaker: Baptiste Quere (France)
14:12 - 14:18	Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjögren's Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study Speaker: Jacques-Eric Gottenberg (France)

14:18 - 14:24	Factors associated with mortality in patients with Sjögren disease: analysis of the ASSESS cohort Speaker: Elodie Portier (France)
---------------	--

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour V**

13:30-14:30 BST

Clinical Poster Tours: Advances in Psoriatic Arthritis management

Chair:	Oliver FitzGerald (Ireland) Fabian Proft (Germany)
13:30 - 13:36	Investigating plasma protease activity as a biomarker indicating a risk for progression to Psoriatic arthritis in Patients with Cutaneous Psoriasis: A pilot study Speaker: Gitanjali Wahengbam (India)
13:36 - 13:42	Efficacy and safety of deucravacitinib through week 52 in patients with active psoriatic arthritis: impact of concomitant methotrexate use in a pooled analysis of the pivotal phase 3 POETYK PsA trials Speaker: Joseph F Merola (United States of America)
13:42 - 13:48	Interferon Response Genes and Joint Damage in Psoriatic Arthritis: A Sex-Stratified Analysis Speaker: Darshini Ganatra (Canada)
13:48 - 13:54	Efficacy and safety of probiotic supplementation in psoriatic arthritis - a randomized controlled trial Speaker: Philipp Bosch (Austria)
13:54 - 14:00	Quantifying the Obesity-Psoriatic Arthritis Nexus: Prevalence, Incidence, and Comorbidities from 19.9 Million US Patients (2018-2024) Speaker: Jeffrey R Curtis (United States of America)

14:00 - 14:06	Neutrophil-to-Lymphocyte Ratio as a Biomarker of Disease Activity and Severity in Psoriatic Arthritis: Results from a Large Longitudinal Cohort Speaker: Fadi Kharouf (Israel)
14:06 - 14:12	Differential molecular profiles in psoriatic arthritis: the potential of metabolomics to predict treatment outcomes Speaker: Mieke L. M. Bentvelzen (Netherlands)
14:12 - 14:18	Defining Remission in Psoriatic Arthritis from the Patient Perspective: Findings from the RemiPPsA International Qualitative Study Speaker: Clementina López-Medina (Spain)

Poster Tour Presentations

Date: **05/06/2026**

Room: **PARE Poster Tour**

13:30-14:30 BST

PARE Poster Tour III: Work, Life and Well-Being

Chair:	Francesca Marchiori (Italy) Laura Athié (Mexico)
13:30 - 13:36	From Global Insights to Local Impact: Unveiling South Africa's Axial Spondyloarthritis Needs Through the Patient-Led SFAS Survey Speaker: Maranda van Dam (South Africa)
13:36 - 13:42	Girasoles en Camino. The Santiago's Way for People with Scleroderma Speaker: Mercè Piñero Vegas (Spain)
13:42 - 13:48	Impact of Autoimmune Arthritis Conditions on Work and Finances Speaker: Katie Brown (United Kingdom)
13:48 - 13:54	Supporting Sustainable Work Participation Among Young Adults with Rheumatic and Musculoskeletal Diseases: A Patient-Led Initiative Aligned with Inclusive Working Life Policies Speaker: Joachim Sagen (Norway)

13:54 - 14:00	Mapping mental health trajectories in lupus: patient-identified inflection points and support opportunities from a European patient panel Speaker: Alain Cornet (Belgium)
14:00 - 14:06	ParentZoom: A service to support parents and carers of children and young people living with JIA Speaker: Suruthi Gnanenthiran (United Kingdom)
14:06 - 14:12	Medical–vocational rehabilitation for young adults with juvenile idiopathic arthritis Speaker: Andrea Handschuh (Austria)
14:12 - 14:18	Association between family support and medication adherence in patients with rheumatic diseases: a patient-reported study Speaker: Wenyu Xu (China)
14:18 - 14:24	Co-designed resources to support rheumatology healthcare professionals to write clinic letters directly to patients: outputs from a UK mixed-methods study Speaker: Charlotte Sharp (United Kingdom)

EULAR Culture

Date: **05/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

14:30-16:30 BST

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **05/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

14:30-16:30 BST

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	
--------	--

--	--

What is New (WIN)

Date: **05/06/2026**

1. Explore the most recent evidence on treatment strategies for IIM with a focus on diverse clinical manifestations
2. Gain insights into the latest advancements in antibody research, highlighting their diagnostic and prognostic relevance in IIM
3. Review the role of diagnostic tools and understand their application in clinical practice
4. Understand the importance of a collaborative, multidisciplinary approach in the management of IIM

Room: **Plenary**

14:45-15:30 BST

Idiopathic Inflammatory Myopathies

Chair:	Helena Andersson (Norway) Kastriot Kastrati (Austria)
14:45 - 15:30	Idiopathic Inflammatory Myopathies Speaker: Hector Chinoy (United Kingdom)

Basic and Translational Science

Date: **05/06/2026**

1. Elucidate how cell–cell interactions drive and sustain inflammation
2. Define the relevance of synovial pathotypes in rheumatoid arthritis
3. Characterise the distribution of synovial tissue cell

Room: **Connaught Room 1 & 2**

14:45-16:00 BST

subsets in rheumatoid arthritis patients

How do cells build their home - structural immunity in RA

Chair:	Anne Trolborg (Denmark) Michael Bonelli (Austria)
14:45 - 15:00	Dendritic cells as gatekeepers of inflammation in Rheumatoid Arthritis Speaker: Lucy MacDonald (United Kingdom)
15:00 - 15:15	The dual role of TGF-beta in Rheumatoid Arthritis Speaker: Adam P. Croft (United Kingdom)
15:15 - 15:30	Synovial tissue macrophages in Rheumatoid Arthritis Speaker: Stefano Alivernini (Italy)
15:30 - 15:45	Epigenetic imprinting in synovial fibroblasts Speaker: Markus Hoffmann (Germany)
15:45 - 15:55	Optimised Antigen-Specific Immunotherapy Liposomes Enable Immune Regulation and Sustained Disease Control in Experimental Arthritis Speaker: Shehzahdi Moonshi (Australia)
15:55 - 16:00	Questions and Answers Speaker: Anne Trolborg (Denmark) Co-Speaker: Michael Bonelli / (Vienna, Austria)

Basic and Translational Science

Date: **05/06/2026**

Understand how monocytic cells interact with the synovial stroma to drive inflammation

Room: **Connaught Room 3 & 4**

Learn about macrophage extracellular traps

14:45-16:00 BST

Gain insight into how extracellular traps influence

macrophage activation and behavior

Understand memory mechanisms in monocytic cells
and how they influence effector functions

Macrophages in Motion: New Mechanistic Insights into Inflammation and Innate Memory in RA

Chair:	Myles Lewis (United Kingdom) Audrey Paoletti (France)
14:45 - 15:05	A Joint Venture: How Monocyte–Stromal Interactions Drive Synovial Inflammation Speaker: Ursula Fearon (Ireland)
15:05 - 15:25	How Extracellular Traps Trigger Macrophage-Driven Inflammation Speaker: Miriam Shelef (United States of America)
15:25 - 15:45	Monocyte Memory in RA: Innate Cells Turning Adaptive? Speaker: Kim Midwood (United Kingdom)
15:45 - 15:55	JAK inhibition reprograms macrophages toward immune tolerance but impairs tumor immune surveillance through CD47–SIRPα signaling Speaker: Audrey Paoletti (France)

Health Professionals in Rheumatology (HPR)

Date: **05/06/2026**

Delegates will be able to:

Room: **Victoria Room 1**

i) update delegates on advances in the understanding of pain

14:45-16:00 BST

ii) describe assessment techniques for pain in people with RMDs

iii) describe evidence based treatment options for people with pain and RMDs

iv) understand evidence based techniques for reducing opiate use in chronic pain

The forgotten pandemic: Chronic pain in RMDs

Chair:	NADIA MALLIOU (Greece) Agnes Kocher (Switzerland)
14:45 - 15:00	Chronic pain explained: what is it, why it persists, and how to assess it Speaker: Zoe Rutter-locher (United Kingdom)
15:00 - 15:15	Sleep and pain in RMDs Speaker: Yvonne Lee (United States of America)
15:15 - 15:30	Management of chronic pain in people with RMDs Speaker: Rinie Geenen (Netherlands)
15:30 - 15:40	The Epidemiology of Pain in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study Speaker: Brett Thombs (Canada)
15:40 - 15:55	Questions and Answers Speaker: Agnes Kocher (Switzerland) Co-Speaker: NADIA MALLIOU / (Thessaloniki, Greece)

PARE

Date: **05/06/2026**

To define the challenges faced by people living with an RMD and going through menopause

Room: **Victoria Room 2**

14:45-16:00 BST

To evaluate the risks and benefits of hormone replacement therapy in patients with rheumatic diseases.

To identify sex- and gender-specific differences (in disease prevalence, progression, and therapeutic response in aging populations).

Hormones and RMDs: How Aging Affects Health in Women and Men

Chair:	Andri Phoka (Cyprus) Nina Brodin (Sweden)
14:45 - 15:00	Menopause and RMDs: Understanding the overlooked impact across gender differences Speaker: Anja Strangfeld (Germany)
15:00 - 15:15	Bridging the gap: Menopause management in RMD care Speaker: Mary Gillespie (Ireland)
15:15 - 15:30	How does a patient association support people with RMDs through menopause? Speaker: Katy Antonopoulou (Greece)
15:30 - 15:45	More than just hot flashes: Supporting people with RMDs through menopause Speaker: Sharon Petford (United Kingdom)
15:45 - 16:00	Questions and Answers Speaker: Andri Phoka (Cyprus) Co-Speaker: Nina Brodin / (Stockholm, Sweden)

Basic and Translational Science

Date: **05/06/2026**

1. To illustrate the growing knowledge of metabolic pathways on immunologic functions and vice versa

Room: **Victoria Room 3**

2. To illustrate the role of the different players in this

14:45-16:00 BST

interaction

Immune System and Metabolism: The links get tighter

Chair:	Gerhard Krönke (Germany) Ingrid E. Lundberg (Sweden)
14:45 - 15:00	Introduction: Key players of metabolism Speaker: Andreas Schäffler (Germany)
15:00 - 15:20	Impact of metabolic pathways on T- and B-cell activity Speaker: Víctor Sánchez-Margalet (Spain)
15:20 - 15:40	Impact of metabolic pathways on regulation of bone turnover Speaker: Stephan Blüml (Austria)
15:40 - 16:00	Impact of metabolic pathways on proinflammatory mesenchymal cells Speaker: Ulf Müller-Ladner (Germany)

Clinical Science

Date: **05/06/2026**

To learn about current EULAR initiatives on classification of chronic non-bacterial osteitis in children;

Room: **Victoria Room 4**

14:45-16:00 BST

To learn about the consensus on management of CNO in adults;

To get insights into disease activity monitoring including imaging;

To learn about new insights into the pathophysiology of CNO

Can we treat CNO to target?

Chair:	Hermann Girschick Clara Malattia (Italy)
14:45 - 15:03	EULAR/ACR classification criteria paediatric for CNO Speaker: Seza Ozen (Türkiye)
15:03 - 15:22	Diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults Speaker: Elizabeth Winter (Netherlands)
15:22 - 15:41	Assessment of disease activity using composite scores Speaker: Christiane Reiser (Germany)
15:41 - 16:00	Insights into the pathogenesis of CNO Speaker: Christian M Hedrich (United Kingdom)

Clinical Science

Date: **05/06/2026**

- To provide the impact of obesity on clinical features of fibromyalgia

Room: **Victoria Room 5 & 6**

14:45-16:00 BST

- To discuss the neuroendocrine milieu underlying obesity and fibromyalgia

- To learn the effect of weight loss strategies in fibromyalgia

Fibromyalgia and obesity: the hidden link

Chair:	Valerie Aloush (Israel) Jacob Ablin (Israel)
--------	---

14:45 - 15:05	Prevalence and impact of obesity on fibromyalgia and its symptoms Speaker: Lars Arendt-Nielsen (Denmark)
15:05 - 15:25	Evaluating obesity in fibromyalgia from a neuroendocrine perspective Speaker: ERNEST CHOY (United Kingdom)
15:25 - 15:45	The effect of weight loss strategies in fibromyalgia Speaker: Francesco Ursini (Italy)
15:45 - 16:00	Questions and Answers Speaker: Jacob Ablin (Israel) Co-Speaker: Valerie Aloush / (Tel Aviv, Israel)

Clinical Science

Date: **05/06/2026**

Understand the evolution of axSpA classification and upcoming refinements.

Room: **N1**

14:45-16:00 BST

Recognise the clinical challenges and heterogeneity of peripheral SpA.

Appreciate differential responses to therapies across axial and peripheral manifestations.

Explore strategies to optimise patient management across the full spectrum of SpA.

Integrate current evidence into practical decision-making for both axial and peripheral SpA patients.

Spondyloarthritis - Axial and peripheral SpA at a crossroads

Chair:	Olivier FAKIH (France) Margot Van Mechelen (Belgium)
--------	---

14:45 - 15:05	Evolution of axSpA Classification: Past Lessons, New Criteria and Future Speaker: Martin Rudwaleit (Germany)
15:05 - 15:20	The Challenges of Peripheral SpA in Clinical Practice Speaker: Floris A. van Gaalen (Netherlands)
15:20 - 15:35	Looking Beyond the Spine: Peripheral Arthritis in Axial SpA Speaker: Dafne Capelusnik (Israel)
15:35 - 15:50	Treatment Effects in Axial and Peripheral SpA Speaker: Astrid van Tubergen (Netherlands)
15:50 - 16:00	Questions and Answers Speaker: Olivier FAKIH (France) Co-Speaker: Margot Van Mechelen / (Antwerp, Belgium)

EULAR Joint Sessions

Date: **05/06/2026**

By the end of this session, delegates will be able to:

Room: **N2**

- Understand the evidence supporting Public and Patient Involvement (PPI) in health professional education.

14:45-16:00 BST

- Identify practical approaches to co-educating with patients and families in academic and clinical settings.

- Explore institutional strategies to embed and evaluate PPI across curricula.

- Recognise the value of lived experience and informal caregiving in shaping healthcare education.

- Discuss challenges and facilitators to implementing sustainable and inclusive models of involvement.

Learning from the Real Experts: Patient and Public Voices in Health Professional Education

Chair:	Mwidimi Ndosi (United Kingdom) Caroline Kirsten (Germany)
14:45 - 15:00	Time to Learn from Patients? The Science Behind Public and Patient Involvement in Health Professional Education Speaker: Ricardo Ferreira (Portugal)
15:00 - 15:15	Patient Voices in the Classroom: Co-Education in Practice Speaker: Dante Mulder (Netherlands)
15:15 - 15:30	Families as Educators: What Healthcare Professionals Can Learn from Informal Care Speaker: Richard Beesley (United Kingdom)
15:30 - 15:40	Effet of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program on Disease Management Self-Efficacy: A Two-Arm Parallel Partially Nested Randomised Controlled Trial Speaker: Marie-Eve Carrier (Canada)
15:40 - 16:00	Questions and Answers Speaker: Mwidimi Ndosi (United Kingdom) Co-Speaker: Caroline Kirsten / (Frankfurt am Main, Germany)

Innovation

Date: **05/06/2026**

1. Artificial intelligence (AI) and digitalisation are reshaping communication, diagnostics, and treatment in healthcare, yet their implementation entails critical challenges.

Room: **N3**

14:45-16:00 BST

2. The development of AI-driven healthcare is largely influenced by economic and political interests, while the perspectives of patients, researchers, and clinical administrators remain underrepresented.

3. AI lacks the social capital inherent to human professionals, necessitating reconsideration of acceptable error thresholds due to persisting distrust.

4. Moreover, digitalisation presents a significant risk to the integrity of rheumatic and musculoskeletal disease (RMD) care, as the musculoskeletal system is increasingly prone to neglect in contemporary practice.

Digitalisation in Rheumatology – Potential and Blind Spots

Chair:	Bente Glintborg (Denmark) Paul Studenic (Austria)
14:45 - 14:50	Introduction Speaker: Paul Studenic (Austria) Co-Speaker: Bente Glintborg / (Copenhagen, Denmark)
14:50 - 15:05	AI - opportunities for people with lived and learnt experience Speaker: Anthony Woolf (United Kingdom)
15:05 - 15:20	The dark side of digitalisation Speaker: Oliver Hendricks (Denmark)
15:20 - 15:35	AI – the key to therapy integrating complex psychosocial patient data? Speaker: Christel PARIS-BICKING (Denmark)
15:35 - 15:50	AI in Rheumatological Imaging - current status and potentials Speaker: Mikael Boesen (Denmark)
15:50 - 16:00	Questions and Answers Speaker: Paul Studenic (Austria) Co-Speaker: Bente Glintborg / (Copenhagen, Denmark)

InnovationDate: **05/06/2026**

In the 4th edition of the EULAR's Annual Rheumatology quiz, you can test and consolidate knowledge of RMD diagnosis, classification, and management, EULAR recommendations, unusual RMD presentations, common diagnostic pitfalls and much more.

Room: **George V Room 1****14:45-16:00 BST****EULAR's Annual Rheumatology Quiz**

Chair:	Cristina Macia-Villa (Spain) Emre Bilgin (Türkiye)
14:45 - 15:10	Round 1 - Via app available to all the audience Speaker: Chris Wincup (United Kingdom)
15:10 - 15:35	Round 2 - Jeopardy Speaker: Christopher John Edwards (United Kingdom)
15:35 - 16:00	Round 3 - Finale Speaker: Christopher John Edwards (United Kingdom) Co-Speaker: Chris Wincup / (London, United Kingdom), Emre Bilgin / (Sakarya, Türkiye), Cristina Macia-Villa / (Madrid, Spain)

EULAR Joint SessionsDate: **05/06/2026**

Recognise early clinical (and imaging) signs of gout.

Room: **George V Room 2**

Differentiate gout flares from mimicking arthritides.

14:45-16:00 BST

Initiate and titrate urate-lowering therapy to reach target serum urate.

Identify barriers to long-term adherence (medication, lifestyle, beliefs).

Apply structured self-management plans for diet,

alcohol, weight and flare action.

Collaborate across disciplines to sustain remission and crystal clearance.

Learn about laboratory models of gout disease.

Understand disease pathogenesis and future perspectives for the clinic.

Gout - Let us cure it together

Chair:	Magda Osipyan (Armenia) Shalaleh Karkon (Ireland)
14:45 - 15:10	The beginning - Diagnostics, flares and ULT Speaker: Pascal Richette (France)
15:10 - 15:35	The end - Adherence and self-management Speaker: Annette de Thurah (Denmark)
15:35 - 16:00	The future - Laboratory models of gout and how understanding disease pathogenesis can improve clinical care Speaker: Alexander So (Switzerland)

From Bench to Bedside

Date: **05/06/2026**

- To learn new pathogenic advances on IL-1 β deregulation in leading the occurrence of an inflammatory disease

Room: **George V Room 3**

14:45-16:00 BST

- To discuss new clinical patient phenotypes driven by the deregulated activity of IL-1 β

- To provide the latest advances about targeting of IL-1 β and its signalling in inflammatory diseases

Interleukin-1 β mediated diseases: innovative pathogenic mechanisms, clinical phenotypes, and therapeutic opportunities

Chair:	Marija Jelusic (Croatia) Marco Gattorno (Italy)
14:45 - 15:10	The inflammatory properties of IL-1β, at the crossroad of deregulated innate and adaptive immune response Speaker: stephanie GRAFF-DUBOIS (France)
15:10 - 15:35	Expanding the clinical patient phenotypes driven by the deregulated activity of IL-1β Speaker: Joost Frenkel (Netherlands)
15:35 - 16:00	New therapeutic opportunities targeting IL-1β and its signalling in inflammatory diseases Speaker: Eicke Latz (Germany)

From Bench to Bedside

Date: **05/06/2026**

1. to understand the pathophysiological impact of genes encoded by X and Y chromosomes on pathogenesis of vasculitis

Room: **George V Room 4**

14:45-16:00 BST

2. to learn about differences in clinical presentation and outcomes in patients with systemic vasculitis

3. to discuss differences regarding the efficacy of traditional and novel drugs in vasculitis patients

The Gendered Vessel: Understanding Sex-Based Mechanisms in Vasculitis

Chair:	Georgina Espígol-Frigolé (Spain) Valentin S. Schäfer (Germany)
14:45 - 15:10	X-chromosome and hormones - pathophysiological implications in vasculitis Speaker: Elvis Hysa (Italy)

15:10 - 15:35	Differences in clinical presentation and outcomes according to sex in systemic vasculitis Speaker: Maria Sandovici (Netherlands)
15:35 - 16:00	Differences in efficacy and safety of drugs according to sex in drug trials Speaker: Jens Thiel (Austria)

EMEUNET Presents

Date: **05/06/2026**

Gain a comprehensive understanding of longitudinal cohorts in rheumatology, from design and launch to long-term sustainability and critical interpretation. Learn how cohort studies have advanced disease knowledge, shaped practice, and how to evaluate data quality, minimize bias, and apply advanced analytic approaches, including trial emulation, to real-world datasets.

Room: **Room 12**

14:45-16:00 BST

Methodology: Longitudinal Thinking, Designing Studies that Change Practice

Chair:	Alexandros Panagiotopoulos (Greece) Victoria Konzett (Austria)
14:45 - 15:00	What Longitudinal Cohorts Have Taught Us About Rheumatic Diseases Speaker: Diederik De Cock (Belgium)
15:00 - 15:15	From Idea to Infrastructure: Designing and Launching a Longitudinal Cohort Speaker: Merete Lund Hetland (Denmark)
15:15 - 15:30	The Long Game: Ensuring Sustainability and Data Quality in Long-Term Studies Speaker: Emilia Gvozdenovic (Belgium)
15:30 - 15:45	What You Need to Know to Interpret Studies in 2026: From Observational Data to Clinical Trials Speaker: Kimme Hyrich (United Kingdom)

15:45 - 16:00	Panel Discussion Speaker: Victoria Konzett (Austria) Co-Speaker: Alexandros Panagiotopoulos / (Athens, Greece)
---------------	---

How to Treat (HOT) 1. To learn about current treatment recommendations for rheumatoid arthritis associated interstitial lung disease 2. To explore new treatment options 3. To learn about prognostic factors and individualised treatment.	Date: 05/06/2026 Room: Plenary 15:30-16:15 BST
---	---

Rheumatoid Arthritis associated Interstitial Lung Disease

Chair:	Andreina Manfredi (Italy) Ana Catarina Duarte (Portugal)
15:30 - 16:15	RA-associated ILD Speaker: Philippe Dieudé (France)

Poster View Presentations	Date: 05/06/2026 Room: Poster View 16:00-17:00 BST
----------------------------------	---

Poster View VII

Chair:	
--------	--

16:00 - 16:00	<p>Disease outcomes and quality of life over the first 12 months following diagnosis in children and young people with Juvenile Idiopathic Arthritis: Association with ethnicity and socioeconomic position</p> <p>Speaker: Richard Beesley (United Kingdom)</p>
16:00 - 16:00	<p>Impact of Patient and Physician Reported Disease Activity Indices on Damage in Behçet Syndrome</p> <p>Speaker: Mert Oztas (Türkiye)</p>
16:00 - 16:00	<p>Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's Disease: Results from a Pooled Analysis of Two Prospective Trials</p> <p>Speaker: Fabrizio De Benedetti (Italy)</p>
16:00 - 16:00	<p>A Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Subcutaneous Injections of SHR-2173 in Patients with Systemic Lupus Erythematosus</p> <p>Speaker: Chunyan Zhang (China)</p>
16:00 - 16:00	<p>A new endpoint for SLE clinical trials: the Treatment Response Measure for Systemic Lupus Erythematosus clinical trials (TRM-SLE)</p> <p>Speaker: Kathryn Connelly (Australia)</p>
16:00 - 16:00	<p>Treat-to-target in DMARD naive juvenile idiopathic arthritis: 12-month clinical outcome of a randomised controlled trial comparing methotrexate monotherapy with polytherapy: the CHAMP study</p> <p>Speaker: Bastiaan T. van Dijk (Netherlands)</p>
16:00 - 16:00	<p>Three months of remote monitoring upon discharge vs usual care in patients with subacute or chronic low back pain (AVA-PREPA): a randomised, open-label, phase 3, multicentre, superiority trial</p> <p>Speaker: Thomas Davergne (France)</p>
16:00 - 16:00	<p>Updated exposure–safety analysis of emapalumab in patients with macrophage activation syndrome (MAS)</p> <p>Speaker: Patrick Brossard (Switzerland)</p>
16:00 - 16:00	<p>Occurrence of ophthalmology appointments, eye conditions, and complications in children, young people, and young adults with juvenile idiopathic arthritis (JIA)</p> <p>Speaker: Lianne Kearsley-Fleet (United Kingdom)</p>

16:00 - 16:00	Target trial emulation to estimate the effectiveness of biologics using real-world data from the UK Juvenile Idiopathic Arthritis Biologics Register Speaker: Lianne Kearsley-Fleet (United Kingdom)
16:00 - 16:00	Defining the natural history of systemic sclerosis-associated interstitial lung disease to predict the first episode of functional progression: a EUSTAR analysis (EUSTAR CP196) Speaker: Maria Iacovantuono (Italy)
16:00 - 16:00	Persistent Systemic Inflammation Defines a Distinct High-Risk Phenotype in Systemic Sclerosis: An EUSTAR registry analysis Speaker: Cristiana Sieiro Santos (United Kingdom)
16:00 - 16:00	Multimodal imaging uncovers concomitant lung and primary heart involvement in systemic sclerosis: data from a single center prospective study Speaker: Giacomo De Luca (Italy)
16:00 - 16:00	Juvenile Arthritis Book Share: An innovative way of raising awareness of Juvenile Idiopathic Arthritis (JIA) amongst the general public. Speaker: Michelle roman
16:00 - 16:00	Clinical Phenotypes and Treatment Exposure Associated with Time to Relapse After Autologous Stem Cell Transplantation in Systemic Sclerosis: A Single-Center Exploratory Analysis Speaker: Rachel Sauls (United States of America)
16:00 - 16:00	The effects of a 12-week exercise intervention on nailfold video capillaroscopy patterns in people with systemic sclerosis: A multi-centre randomised controlled trial. Speaker: Alexandros Mitropoulos (United Kingdom)
16:00 - 16:00	Updated population pharmacokinetic (popPK) model for emapalumab using data from four prospective clinical trials in patients with hemophagocytic lymphohistiocytosis/macrophage activation syndrome (MAS) Speaker: Patrick Brossard (Switzerland)
16:00 - 16:00	Effects of exercise-based interventions on clinical outcomes in pre-clinical and early rheumatoid arthritis: a systematic review and meta-analysis Speaker: Javier Courel Ibáñez (Spain)

16:00 - 16:00	Pregnancy Outcomes in Behcet's Disease: A Systematic Review Speaker: Ghaydaa Aldabie (Kuwait)
16:00 - 16:00	Juvenile Overlap Myositis: Distinct Clinical Phenotype but Shared Serological Features with JDM Speaker: Laura Scagnellato (Italy)
16:00 - 16:00	Subclinical myocardial tissue changes in Systemic Sclerosis associate with progressive nailfold capillaroscopy patterns Speaker: Cristiana Sieiro Santos (United Kingdom)
16:00 - 16:00	Prevalence and risk factors for escalation to systemic treatment following intra-articular steroid injection in patients with juvenile idiopathic arthritis Speaker: Alon Kalter (Israel)
16:00 - 16:00	Cluster Analysis of Systemic Sclerosis to Dissect Complex Disease Heterogeneity Speaker: Junsuk Ko (Singapore)
16:00 - 16:00	Systemic Sclerosis in the Elderly. Evaluation of Disease Manifestations, Comorbidities and Survival in Geriatric Systemic Sclerosis. Speaker: Sindhu R. Johnson (Canada)
16:00 - 16:00	Marked heterogeneity of small bowel motility in systemic sclerosis with gastrointestinal involvement: a pilot MR Enterography study Speaker: Marco Minerba (Italy)
16:00 - 16:00	Calcinosis Progression in Systemic Sclerosis: A Prospective Cohort Study Speaker: Catarina Silva (Portugal)
16:00 - 16:00	External validation of the ILD-RISC score in Greek patients with Systemic Sclerosis Speaker: Nikolaos Koletsos (Greece)
16:00 - 16:00	Early-Life Infections, Antibiotics and Gene-Environment Interactions in the Risk of Juvenile Idiopathic Arthritis: Evidence from two Scandinavian Birth Cohorts Speaker: Sigrid Valen Hestetun (Norway)

16:00 - 16:00	<p>Management of MucoCutaneous and Joint Involvement of Behçet's Syndrome: A Systematic Literature Review Informing the 2025 Update of the EULAR Recommendations</p> <p>Speaker: Sinem Nihal Esatoglu (Türkiye)</p>
16:00 - 16:00	<p>Concordance of Clinical Phenotypes, HLA-B51, and ERAP-1 Variations Among First-Degree Relatives with Behçet Syndrome</p> <p>Speaker: Sinem Nihal Esatoglu (Türkiye)</p>
16:00 - 16:00	<p>JAK Inhibition with Tofacitinib or Baricitinib for Juvenile Idiopathic Arthritis: Real-World Data from the BiKeR Registry</p> <p>Speaker: Angela Zimmer (Germany)</p>
16:00 - 16:00	<p>Performance of the Systemic lupus erythematosus disease activity score (SLE-DAS) in daily clinical practice: a prospective study of 125 patients in India.</p> <p>Speaker: Ritasman Baisya (India)</p>
16:00 - 16:00	<p>Clinical, Imaging and Histologic Predictors of Therapy Escalation in Children with Juvenile Idiopathic Arthritis</p> <p>Speaker: Patricia Vega-Fernandez (United States of America)</p>
16:00 - 16:00	<p>Modulation of gut microbiota by nutritional interventions in Behcet's Syndrome: the randomized, cross-over, open-label, controlled MAMBA trial</p> <p>Speaker: Alessandra Bettioli (Italy)</p>
16:00 - 16:00	<p>Beyond Skin and Joints: A Multicenter Observational Study on Real-World Effectiveness of Anifrolumab in Hematological Manifestations of Systemic Lupus Erythematosus</p> <p>Speaker: Chiara Cardelli (Italy)</p>
16:00 - 16:00	<p>Early Damage Burden in Systemic Lupus Erythematosus in Africa: Results from the KESLER Cohort</p> <p>Speaker: Sheilla Achieng (United Kingdom)</p>
16:00 - 16:00	<p>CC312, a novel CD19/CD3/CD28 tri-specific T cell engager, leads to rapid and deep B-cell depletion and has broad potential for development in autoimmune diseases</p> <p>Speaker: Yingfeng Huang (China)</p>

16:00 - 16:00	Long-term Outcomes of Lupus Nephritis with Low Proteinuria at Diagnosis Speaker: Yuri Sasaki (Japan)
16:00 - 16:00	Reduced neural efficiency and cognitive fatigue during cognitive processing in systemic lupus erythematosus: A combined fMRI and eye-tracking study Speaker: Michelle Barraclough (United Kingdom)
16:00 - 16:00	The use of digital health interventions to support work ability in people living with rheumatic and musculoskeletal diseases: a scoping review Speaker: Susan Somerville (Ireland)
16:00 - 16:00	Post-marketing Safety Signals of Anifrolumab: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Speaker: Ke Gan (China)
16:00 - 16:00	Cognitive Symptoms in SLE: Insights from the Subjective Perceived Deficit Questionnaire-20 and the Objective American College of Rheumatology Neuropsychological Battery (ACR-NB) Testing Speaker: Michelle Barraclough (United Kingdom)
16:00 - 16:00	Does Prior Belimumab Use Influence Response to Anifrolumab in Moderate-to-Severe SLE? Real-World Evidence Speaker: Vanesa Calvo-Río (Spain)
16:00 - 16:00	Patient Acceptable Symptom State (PASS) in systemic lupus erythematosus: associations with disease activity measures in the RELESSER registry Speaker: César Magro Checa (Netherlands)
16:00 - 16:00	Unsupervised Clustering of Clinical and Laboratory Features of Systemic Lupus Erythematosus: Insights from a Multicenter Cohort Speaker: Yuke Hou (China)
16:00 - 16:00	Belimumab step-down dose spacing in patients with Systemic Lupus Erythematosus in persistent clinical remission: experience from a multicentre cohort Speaker: Alice Bartoletti (Italy)

16:00 - 16:00	Remission Achievement in SLE: Real-World Evidence from the AZAHAR Study in Spain Speaker: Josefina Cortés-Hernández (Spain)
16:00 - 16:00	Synovial CD4+HLADR+ effectors resistance to regulation and inflammatory metabolic reprogramming in juvenile idiopathic arthritis Speaker: Jing Yao Leong (Singapore)
16:00 - 16:00	The “SLEntesis” study: prevalence of enthesitis in a monocentric cohort of patients with systemic lupus erythematosus Speaker: Cosimo Cigolini (Italy)
16:00 - 16:00	WHEN TREATMENT STALLS: CAREGIVER-RELATED BARRIERS TO OPTIMAL MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS Speaker: Mariel Metcalfe (United Kingdom)
16:00 - 16:00	A PATIENT EDUCATION APP AND A CLINICAL DECISION SUPPORT SYSTEM FOR PEOPLE WITH KNEE OSTEOARTHRITIS: THE OA-AID FEASIBILITY STUDY Speaker: Ingrid Nordmo (Norway)
16:00 - 16:00	Advancing arthritis assessment in SLE clinical trials: derivation, validation and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument. Speaker: Samuel Wood (United Kingdom)
16:00 - 16:00	From nail to lung: nail ultrasound as a window for detection of interstitial lung disease in systemic sclerosis Speaker: Xuesong Liu (China)
16:00 - 16:00	Barriers to Early Recognition of Hidradenitis Suppurativa: Insights from Focus Groups and Rapid-Cycle Polling Speaker: Seth Ginsberg (United States of America)
16:00 - 16:00	Blood protein-wide association study reveals novel proteins in juvenile idiopathic arthritis pathogenesis Speaker: Kai-Xin Yao (China)
16:00 - 16:00	Systemic Treatment Patterns in SLE: Associations with Disease Severity and Organ-specific Activity Across 5 Registries in the Lupus Federated Data Network (LupusNet) Speaker: Guillermo Pons-Estel (Argentina)

16:00 - 16:00	Treatment Patterns and Clinical Outcomes in Early and Late Onset Lupus Nephritis: A South Asian Single Centre Cohort Speaker: Anupama Kurup (India)
16:00 - 16:00	Evaluation of the Enhanced National Rheumatoid Arthritis Society (NRAS) Right Start Service: patient-reported benefits and feasibility of embedding into RA care pathways Speaker: Ailsa Bosworth (United Kingdom)
16:00 - 16:00	Maternal Weight Gain and Hypertensive Disorders of Pregnancy as Risk Factors for Juvenile Idiopathic Arthritis: A Prospective Population-Based Pregnancy Cohort Study Speaker: Vilde Øverlien Dåstøl (Norway)
16:00 - 16:00	Exposure to Harmful Substances during Pregnancy, Gene-Environment Interactions and Risk of Juvenile Idiopathic Arthritis (JIA): An Exploratory Analysis from The Norwegian Mother, Father and Child Cohort Study Speaker: Vilde Øverlien Dåstøl (Norway)
16:00 - 16:00	Disease activity according to adalimumab serum levels in Juvenile Idiopathic Arthritis: Results from the My-JIA trial Speaker: Ingrid Herder (Norway)
16:00 - 16:00	Risk factors for preterm birth in women with systemic lupus erythematosus using German nationwide pregnancy register Rhekiss Speaker: Tatjana Rudi (Germany)
16:00 - 16:00	Treatment of juvenile idiopathic arthritis associated uveitis in real life: focus on first-line TNF inhibitors from the ITHACA cohort Speaker: Achille Marino (Italy)
16:00 - 16:00	Evaluation of Gastrointestinal Microbiome in Patients with Systemic Sclerosis: Our Experience and Emerging Research Speaker: Amelia Spinella (Italy)

16:00 - 16:00	<p>Effects of Clinical Pilates Training on Physical, Functional and Psychosocial Outcomes in Individuals with Rheumatoid Arthritis: A Randomized Controlled Trial</p> <p>Speaker: Selin Bayram (Türkiye)</p>
16:00 - 16:00	<p>Severe nailfold capillary loss and avascular areas predict bilateral carotid atherosclerosis in Systemic Sclerosis: a single-center evidence.</p> <p>Speaker: Luca Clerici (Italy)</p>
16:00 - 16:00	<p>Preliminary Evidence for the Making it Work Program for Systemic Sclerosis (MiW-SS) on Self-efficacy Compared to Usual Care</p> <p>Speaker: Janet L Poole (United States of America)</p>
16:00 - 16:00	<p>Quantitative Assessment for Systemic Sclerosis Patients with Raynaud's Phenomenon using Advanced Ultrasound Imaging</p> <p>Speaker: Fabian A Mendoza (United States of America)</p>
16:00 - 16:00	<p>Artificial Intelligence for Early Diagnosis of Behçet's Syndrome Based on Initial Patient's Encounter</p> <p>Speaker: Fadi Hassan (Israel)</p>
16:00 - 16:00	<p>Evidence for Shared Genetic Risk between Infertility and Juvenile Idiopathic Arthritis: Results from Population-Based Pregnancy Cohorts</p> <p>Speaker: Kristine Løkås Haftorn (Norway)</p>
16:00 - 16:00	<p>A tailored training for the Systemic Sclerosis community</p> <p>Speaker: Ilaria Galetti (Italy)</p>
16:00 - 16:00	<p>Frailty and Its Association with Muscle Strength and Cumulative Disease Damage in Behçet's Disease</p> <p>Speaker: Gülay Alp (Türkiye)</p>
16:00 - 16:00	<p>⁶⁸Ga-DOTATOC PET/CT in systemic sclerosis: preliminary data from a prospective, single-centre pilot study</p> <p>Speaker: Kjersti Johnsrud (Norway)</p>
16:00 - 16:00	<p>Incremental Diagnostic Value of FLIP Planimetry in Systemic Sclerosis Patients With Normal High-Resolution Manometry</p> <p>Speaker: Carlos Marques-Gomes (Portugal)</p>

16:00 - 16:00	Hyoid dysfunction as an overlooked mechanism of dysphagia in Systemic Sclerosis from the early disease stages Speaker: Silvia Peretti (Italy)
16:00 - 16:00	Serum calprotectin as a biomarker for monitoring disease activity in juvenile idiopathic arthritis: a systematic review Speaker: Nuno Delgado (Portugal)
16:00 - 16:00	Association of Anti-RNA Polymerase III antibodies with Silicone Breast Implants in Systemic Sclerosis patients: update of a multicentre EUSTAR Case-Control Study Speaker: Maria Grazia Lazzaroni (Italy)
16:00 - 16:00	Repeated 18F-NaF PET CT scans as a potential method for assessing metabolic activity and lesion development in systemic sclerosis related subcutaneous calcinosis Speaker: Gergely Bodor (Hungary)
16:00 - 16:00	Performance of Four Nutritional Screening Tools to Detect Malnutrition According to GLIM Criteria in Systemic Sclerosis: Association with Accumulated Organ Damage Speaker: Fernando Ortiz-Márquez (Spain)
16:00 - 16:00	CLINICAL COURSE AND RADIOLOGICAL OUTCOMES OF PULMONARY ARTERY THROMBOSIS IN BEHÇET'S DISEASE: A COMPARATIVE STUDY WITH NON-BEHÇET PULMONARY THROMBOSIS Speaker: Aida Shikhaliyeva (Türkiye)
16:00 - 16:00	ARTIFICIAL INTELLIGENCE DRIVEN EVALUATION OF THE AIRWAYS IMPROVES PROGNOSTIC ACCURACY BEYOND STANDARD ASSESSMENT IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE Speaker: Enrico De Lorenzis (Italy)
16:00 - 16:00	Emotions, identity and situated agency in systemic lupus erythematosus: patient-reported outcomes from an adapted aquatic intervention Speaker: Laura Athié (Mexico)

HPR Poster Tour I: Emerging Insights in Epidemiology and Population Health Outcomes

Chair:	Simone Battista (United Kingdom) Valentin Ritschl (Austria)
16:15 - 16:21	Burden of Osteoarthritis Attributable to High Body Mass Index in the European Union, 1990–2023: Sex- and Region-Specific Patterns from the Global Burden of Disease Study 2023 Speaker: Wenting Wu (China)
16:21 - 16:27	The impact of time to diagnosis on health outcomes in people with axial spondyloarthritis: a systematic review Speaker: Jenni Buckley (United Kingdom)
16:27 - 16:33	Sociodemographic and Clinical Factors Associated with Non-Attendance at Rheumatology Outpatient Appointments Speaker: Andres Manuel Ortiz-Rios (Mexico)
16:33 - 16:39	Patterns of Cohort Participation Among People with Systemic Sclerosis in an Open Cohort: a Scleroderma Patient-centered Intervention Network Cohort Study Speaker: Meira Golberg (Canada)
16:39 - 16:45	Outcomes of a multisite pragmatic work-focused occupational therapy intervention for individuals with rheumatic and musculoskeletal disorders Speaker: Yvonne Codd (Ireland)
16:45 - 16:51	Factors associated with health literacy among people with systemic sclerosis Speaker: Claire Adams (Canada)
16:51 - 16:57	Pain severity matters in long-term rehabilitation trajectories of function and quality of life. Speaker: Anne-Lene Sand-Svartrud (Norway)

16:57 - 17:03	Health literacy perceptions and practices among European healthcare providers in rheumatology: a cross-sectional mixed methods survey-based study Speaker: Jelle Pergens (Belgium)
---------------	--

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour II**

16:00-17:00 BST

Clinical Poster Tours: Treating Lupus, Changing Outcomes

Chair:	Isabell Haase (Germany) Laurent Arnaud (France)
16:15 - 16:21	CLINICAL, CELLULAR KINETICS, PHARMACODYNAMICS AND BIOMARKER DATA UP TO 24 MONTHS AFTER RAPCABTAGENE AUTOLEUCEL (YTB323), A RAPIDLY MANUFACTURED CD19 CAR-T THERAPY, FROM AN OPEN-LABEL, PHASE 1/2 STUDY IN SEVERE REFRACTORY SLE Speaker: Zahir Amoura (France)
16:21 - 16:27	Macrophage activation syndrome in systemic lupus erythematosus and Still's disease: 'same but different' with therapeutic implications Speaker: Antonio Tonutti (Italy)
16:27 - 16:33	DORIS Remission and LLDAS Attainment in Patients With Systemic Lupus Erythematosus Treated With Subcutaneous Anifrolumab With and Without On-Study Immunosuppressant Use: Post Hoc Analysis of the TULIP-SC Trial Speaker: Catharina Lindholm (Sweden)
16:33 - 16:39	LUPRED: a clinical score to predict complete remission in lupus nephritis Speaker: Thomas Barba (France)
16:39 - 16:45	Achievement and Maintenance of Glucocorticoid Reduction without Increasing Flare Risk in Asian Patients with SLE treated with Anifrolumab: Post-hoc analysis of AZALEA trial Speaker: Jiuliang Zhao (China)

16:45 - 16:51	ARTERIAL STIFFNESS IN SYSTEMIC LUPUS ERYTHEMATOSUS VS RHEUMATOID ARTHRITIS, DIABETES MELLITUS, AND HEALTHY CONTROLS: THE IMPACT OF TRADITIONAL CARDIOVASCULAR RISK FACTOR BURDEN AND LOW DISEASE ACTIVITY Speaker: Antigoni Soufla (Greece)
16:51 - 16:57	Oral corticosteroid use and patterns in patients with systemic lupus erythematosus: a population-based study using the Greater Manchester Care Record Speaker: Sarah Dyball (United Kingdom)
16:57 - 17:03	ALLEGORY Phase III Trial in Systemic Lupus Erythematosus: Pharmacodynamic Effects of Obinutuzumab Speaker: Edward M. Vital (United Kingdom)
17:03 - 17:09	Spanish Multicenter Real-World Registry of Anifrolumab ANIFRO-Reu) in Systemic Lupus Erythematosus: Efficacy and Safety In patients undergoing up to 12 months of follow-up Speaker: Tarek Carlos Salman-Monte (Spain)

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour III**

16:00-17:00 BST

Basic Poster Tours: New actors and mechanisms at the origins of Sjögren's disease

Chair:	Gaetane Nocturne (France) Joel van Roon (Netherlands)
16:15 - 16:21	Expansion of Pro-inflammatory LAMP1+ MAIT Cells in Sjögren's Disease and Their Diagnostic Potential Speaker: Yiming Gao (China)
16:21 - 16:27	Endogenous Retroviruses Activation Drives Epithelial Necroptosis and Salivary Gland Dysfunction in Sjögren's Disease Speaker: Yuan Liu (China)

16:27 - 16:33	Peripheral lymphopenia in Sjögren's disease is driven by Type I interferon-mediated disruption of the IL-7/IL-7R signaling axis Speaker: Pavlina Javorova (Austria)
16:33 - 16:39	Minor Salivary Gland Proteomics Reveals Distinct Clinical and Molecular Subgroups in Sjögren's Disease Speaker: Neža Štucin (Slovenia)
16:39 - 16:45	Age-associated B cells exacerbate primary Sjögren disease through promoting follicular T helper cell differentiation by overexpressing PD-L1 Speaker: Tao Zhou (China)
16:45 - 16:51	Peripheral blood gene expression as a biomarker of sustained response to B-cell therapy in Sjögren's disease Speaker: Coziana Ciurtin (United Kingdom)
16:51 - 16:57	Parotid transcriptomics reveals modulation of gene expression linked to salivary function and inflammation in Sjögren's disease following leflunomide and hydroxychloroquine combination treatment Speaker: Wing-Yi Wong (Netherlands)
16:57 - 17:03	Cellular and Transcriptional Differences Across Early Sjögren's Disease Subphenotypes Speaker: Christopher J Lessard (United States of America)
17:03 - 17:09	Molecular characterization of anti-Ro positive and negative Sjögren's disease with single cell RNA sequencing of peripheral blood Speaker: Christopher J Lessard (United States of America)

Poster Tour Presentations

Date: **05/06/2026**

Room: **Poster Tour IV**

16:00-17:00 BST

Clinical Poster Tours: Taking care of Systemic Sclerosis

Chair:	Claudia Iannone (Italy) Veronica Batani (United Kingdom)
--------	---

16:15 - 16:21	Points to consider for reporting outcomes measures in systemic sclerosis interventional studies on digital ulcers: An initiative from the World Scleroderma Foundation digital ulcer ad hoc committee Speaker: Corrado Campochiaro (Italy)
16:21 - 16:27	Rapidly progressing versus stable phenotype in patients with Systemic Sclerosis - Associated Pulmonary Arterial Hypertension. Speaker: Katya Dolnikov (Israel)
16:27 - 16:33	Preliminary criteria for the definition of difficult-to-treat digital ulcers in systemic sclerosis: a Delphi consensus. Speaker: Gemma Lepri (Italy)
16:33 - 16:39	Systemic Sclerosis Post-Diagnosis: Real-World Data on Disease Evolution, Treatment Patterns, and Healthcare Resource Utilisation in the US Speaker: Elizabeth Volkmann (United States of America)
16:39 - 16:45	Multidimensional Approach to Predict disease Progression and prognosis in patients with Very Early Diagnosis Of Systemic Sclerosis (MAPPING VEDOSS) Speaker: Vincenzo Venerito (Italy)
16:45 - 16:51	Efgartigimod PH20 Subcutaneous in Adults With Systemic Sclerosis: Design of a Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study (eSScape) Speaker: Dinesh Khanna (United States of America)
16:51 - 16:57	A Phase III, Double-blind, Randomised, Placebo-controlled Trial Evaluating the Safety and Efficacy of Oral Nerandomilast Treatment on Halting Disease Progression in Systemic Sclerosis Speaker: Anna-Maria Hoffmann-Vold (Norway)
16:57 - 17:03	Phenotypic impact of diabetes mellitus on the course of systemic sclerosis: Insights from an international multicenter study Speaker: Gonçalo Boletto (Portugal)
17:03 - 17:09	Immunosuppressants prevent digital ulcers in systemic sclerosis: evidence from a EUSTAR effectiveness study Speaker: Cosimo Bruni (Switzerland)

Basic and Clinical Poster Tours: Novelties in Juvenile Idiopathic Arthritis

Chair:	Eve Smith (United Kingdom) Alessandro Consolaro (Italy)
16:15 - 16:21	Achievement of inactive disease in a large cohort of polyarticular juvenile idiopathic arthritis patients Speaker: Gerd Horneff (Germany)
16:21 - 16:27	SLAMF7 Orchestrates IFN-γ-Induced Neutrophil Extracellular Traps to Fuel Cytokine Storm in Still's Disease Speaker: Qiongyi Hu (China)
16:27 - 16:33	Changes in ultrasound findings of synovitis during TNFα inhibitor treatment in children with Juvenile Idiopathic Arthritis. Results from the My-JIA Trial Speaker: Karolina Lendowska (Norway)
16:33 - 16:39	Genetic Architecture of Juvenile Idiopathic Arthritis from a Large-Scale Genome-Wide Association Study Meta-Analysis Speaker: Srijana Bastakoti (Norway)
16:39 - 16:45	The "comparison of STep-up and step-down therapeutic strategies in childhood ARthritis" (STARS) trial: baseline characteristics of the patients Speaker: Alessandro Consolaro (Italy)
16:45 - 16:51	Risk of medically important infections upon TNF-α- or IL-17-inhibitors in juvenile idiopathic arthritis: a comparative analysis from the German BIKER registry Speaker: Jana Kipp (Germany)
16:51 - 16:57	Single-cell sequencing of bronchoalveolar cells from systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD) reveals alterations across the immune landscape Speaker: Grant Schulert (United States of America)

16:57 - 17:03	Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still's Disease: Results from a Pooled Analysis of Two Prospective Trials Speaker: Alexei Grom (United States of America)
17:03 - 17:09	Modelling Heterogeneity: Challenges in Linking Interferon Signatures to Clinical Trajectories in Juvenile Idiopathic Arthritis Speaker: Laura Scagnellato (Italy)

Hands-on Sessions

Date: **05/06/2026**

1. Discuss the value of point of care rheumatology ultrasound (POCRUS) in LVV and PMR
2. Learn how to perform POCRUS scans at large vessels using handheld portable devices
3. Learn how to perform POCRUS scans at shoulders using handheld portable devices

Room: **Hands-on 1**

16:15-17:30 BST

Point of care rheumatology ultrasound - large vessel vasculitis and polymyalgia rheumatica

Chair:	Niccolò Possemato (Italy) Stavros Chrysidis (Denmark)
16:15 - 16:20	LVV - Introduction 1 Speaker: Cristina Ponte (Portugal)
16:20 - 16:25	LVV - Introduction 2 Speaker: Bhaskar Dasgupta (United Kingdom)
16:25 - 16:30	PMR - Introduction 1 Speaker: Luca Seitz (Switzerland)

16:30 - 16:35	PMR - Introduction 2 Speaker: Berit Dalsgaard Nielsen (Denmark)
16:35 - 17:30	Hands-on Workshop Speaker: Niccolò Possemato (Italy) Co-Speaker: Stavros Chrysidis / (Vejle, Denmark), Bhaskar Dasgupta / (Westcliff, United Kingdom), Berit Dalsgaard Nielsen / (Aarhus, Denmark), Luca Seitz / (Biel / Bern, Switzerland), Cristina Ponte / (Lisbon, Portugal)

Hands-on Sessions

Date: **05/06/2026**

This session will help delegates to know:

Room: **Hands-on 2**

16:15-17:30 BST

1. When to perform a synovial fluid analysis;
2. How to perform a synovial fluid analysis;
3. How to interpret a synovial fluid analysis.

Please note that there is a maximum capacity in this session. Delegates will be given access on a first come, first served basis.

This session is identical to the other 'Crystal Identification, synovial fluid analysis' session. Please do not attend more than one Hands-On Session of the same name.

Crystal identification, synovial fluid analysis

Chair:	Francesca Oliviero (Italy) Eleonora Norkuviene (Lithuania)
--------	---

16:15 - 16:25	When should Synovial Fluid analysis be performed? Speaker: Abhishek Abhishek (United Kingdom)
16:25 - 16:35	Identifying crystals in synovial fluid Speaker: Anne-Kathrin Tausche (Germany)
16:35 - 17:30	Hands-on Workshop Speaker: Anne-Kathrin Tausche (Germany) Co-Speaker: Abhishek Abhishek / (Nottingham, United Kingdom), Francesca Oliviero / (Padova, Italy), Eleonora Norkuviene / (Kaunas, Lithuania)

Meet the EULAR Expert

Date: **05/06/2026**

Room: **Meet the EULAR Expert 1**

16:15-16:45 BST

Management of joint involvement in systemic lupus

Chair:	
16:15 - 16:45	Management of joint involvement in systemic lupus Speaker: Edward M. Vital (United Kingdom)

Meet the EULAR Expert

Date: **05/06/2026**

Room: **Meet the EULAR Expert 2**

16:15-16:45 BST

Scleroderma

Chair:	
--------	--

16:15 - 16:45	Scleroderma Speaker: Francesco Del Galdo (United Kingdom)
---------------	---

Meet the EULAR Expert

Date: **05/06/2026**

Room: **Meet the EULAR Expert 3**

16:15-16:45 BST

Difficult skin manifestations with myositis

Chair:	
16:15 - 16:45	Difficult skin manifestations with myositis Speaker: Hanna Brauner

HPR Meet the EULAR Expert

Date: **05/06/2026**

Delegates will be able to:

Room: **Meet the EULAR Expert 4**

ii) Discuss advances in the evidence based treatment of people with work instability

16:15-16:45 BST

iii) Consider how to apply this new evidence to practice

Work instability in people with inflammatory arthritis

Chair:	
16:15 - 16:45	How To Treat Work instability in people with IA Speaker: Yeliz Prior (United Kingdom)

EULAR Culture

Date: **05/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history: finding the cure before it's too late.

16:30-18:30 BST

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **05/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear

16:30-18:30 BST

separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

EULAR Culture

Date: **06/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

08:30-10:30 BST

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest

warriors for the most crucial mission in history:
finding the cure before it's too late.

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: **06/06/2026**

London Eye Syndrome

Room: **Escape Room 2**

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

08:30-10:30 BST

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

What is New (WIN)

Date: **06/06/2026**

Review Current and Emerging Treatment Strategies for PH in Rheumatic Diseases:

Room: **Plenary**

09:00-09:45 BST

1. Present evidence-based approaches for the medical management of PH in CTDs, including the use of endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogs.
2. Discuss combination therapy, timing of intervention, and management in resource-limited settings.

Pulmonary hypertension in CTD

Chair:	Annamaria Iagnocco (Italy) Mandana Nikpour (Australia)
09:00 - 09:45	Breaking the Pressure Barrier: Advances in Treating PH in CTD From pathogenesis to personalised care, what is next in rheumatology? Speaker: Yannick Allanore (France)

Basic and Translational Science

Date: **06/06/2026**

1. Explore how AI can simulate and visualise complex biological tissues

Room: **Connaught Room 1 & 2**

09:00-10:15 BST

2. Discover tools and techniques for enhancing biological interpretation through data integration.

3. Learn how computational models simulate cellular behaviour and structure.

From Data to Tissue: AI-Driven Insights into Biological Systems

Chair:	Caroline Ospelt (Switzerland) Costantino Pitzalis (United Kingdom)
09:00 - 09:25	Tools for the next generation of biological data analysis Speaker: Constantin Ahlmann-Eltze (United Kingdom)
09:25 - 09:50	Machine Learning for Spatial Omics Data Integration Speaker: Ricardo Omar Ramirez Flores (United Kingdom)
09:50 - 10:15	AI models for precision diagnostics Speaker: Myles Lewis (United Kingdom)

EULAR Projects

Date: **06/06/2026**

1. Describe current and emerging roles of artificial intelligence in medical and rheumatology education, across different contexts (undergraduate, postgraduate, and continuing professional development).

Room: **Connaught Room 3 & 4**

09:00-10:15 BST

2. Explain how AI-driven tools can support education in rheumatology

3. Critically appraise the opportunities and limitations

of AI in medical education.

4. Recognise the ethical, regulatory, and governance challenges associated with the use of AI in medical education within a European context.

5. Identify practical principles to guide the responsible and effective integration of AI into educational initiatives.

AI in Medical Education

Chair:	Simona Rednic (Romania) Francisca Sivera (Spain)
09:00 - 09:20	Augmenting Medical Education with AI: From Knowledge Delivery to Clinical Reasoning Speaker: Eric Hachulla
09:20 - 09:40	Safe, Ethical, and Trustworthy AI in Rheumatology: Navigating the Risks Speaker: Diego Benavent (Spain)
09:40 - 10:00	Bringing AI into the Classroom: Practical Integration in Undergraduate Medical Education Speaker: Helen Oram
10:00 - 10:10	EULAR 2026 Undergraduate Teaching Concept Award Speaker: Francisca Sivera (Spain)
10:10 - 10:15	Q&A Speaker: Francisca Sivera (Spain) Co-Speaker: Simona Rednic / (Cluj, Romania)

Health Professionals in Rheumatology (HPR)

Date: 06/06/2026

Delegates will:

Room: Victoria Room 1

- Understand the mental health burden in patients with RMDs and the role of psychologically informed care in improving outcomes.
- Review research on implementing psychologically informed care by healthcare and interdisciplinary teams.
- Explore the biopsychosocial rehabilitation model in multidisciplinary RMD care.
- Identify opportunities to deliver psychologically informed care via telehealth and digital platforms.
- Recognize the value of mental health care for people with RMDs from the patient perspective

09:00-10:15 BST

Mental health matters: Innovative and scalable treatment approaches for patient-centred RMD management

Chair:	Emma Dures (United Kingdom) Aileen Ledingham (United States of America)
09:00 - 09:15	Educate, empower, engage: A holistic strategy for better mental health Speaker: Rikke Helene Moe (Norway)
09:15 - 09:30	Telehealth delivery of psychologically informed care and exercise for musculoskeletal pain Speaker: Rebecca J. Cleveland (United States of America)
09:30 - 09:45	The use of digital health to promote resilience in rheumatic diseases and conditions Speaker: Afton Hassett (United States of America)
09:45 - 10:00	Seeing the whole patient: Why mental health deserves equal attention Speaker: Ilaria Bini (Italy)
10:00 - 10:15	Questions and Answers Speaker: Emma Dures (United Kingdom) Co-Speaker: Aileen Ledingham / (Cambridge, United States of America)

PAREDate: **06/06/2026**

1. Demystify CAR-T and other novel therapies by explaining their mechanisms and potential clinical applications to treat RMDs.

Room: **Victoria Room 2****09:00-10:15 BST**

2. Discuss how patients can get involved in shaping studies of novel therapies and their subsequent integration into treatment pathways.

3. Explore the promise and challenges of precision medicine, with an emphasis on equity of access.

Next-Gen Treatments: CAR-based Therapies and Beyond in RMDs

Chair:	Jeanette Andersen (Denmark) Ertugrul Cagri Bolek (Türkiye)
09:00 - 09:15	The Future of Precision Therapies in RMDs Speaker: John Isaacs (United Kingdom)
09:15 - 09:30	CAR-T Cells in RMDs: Precision Promise, Practical Realities Speaker: Russka Shumnaliev (Bulgaria)
09:30 - 09:45	New Therapies, New Responsibilities: What Patients Want and Need Speaker: Peter Böhm (Germany)
09:45 - 10:00	Navigating New Frontiers of Treatment from the Left Seat Speaker: Karen Cheng (Switzerland)
10:00 - 10:15	Questions and Answers Speaker: Jeanette Andersen (Denmark) Co-Speaker: Ertugrul Cagri Bolek / (Ankara, Türkiye)

Practical Skills Lecture

Date: **06/06/2026**

1. Identify Key Features of Immunodeficiencies
2. Enhance Diagnostic Skills on how to use and interpret immunological tests
3. Understand the relationship between immunodeficiency and autoimmune diseases and how they influence each other

Room: **Victoria Room 3**

09:00-10:15 BST

Understanding Immunodeficiency: A Comprehensive Guide for Rheumatologists

Chair:	Nils Venhoff (Germany) Felice Rivellese (United Kingdom)
09:00 - 09:05	Introduction Speaker: Felice Rivellese (United Kingdom) Co-Speaker: Nils Venhoff / (Freiburg, Germany)
09:05 - 09:25	Decoding Primary Immunodeficiencies: What Every Rheumatologist Should Know Speaker: Frédéric Rieux-Laucat (France)
09:25 - 09:45	Secondary Immunodeficiencies in Rheumatic Diseases: Diagnosis and Management Speaker: Reinhard Voll (Germany)
09:45 - 09:58	Immunodeficiency and Autoimmunity: Navigating the Overlap Speaker: FABIO CANDOTTI (Switzerland)
09:58 - 10:15	Immunodeficiency in paediatric patients Speaker: Maaïke Kusters (United Kingdom)

InnovationDate: **06/06/2026**

1. Challenges and innovations in diagnosis, treatment, and access to biologics in low- and middle-income countries; EULAR's role in global equity

Room: **Victoria Room 4****09:00-10:15 BST**

2. Impact of environmental changes on incidence, disease activity, and access to care; adaptation strategies.

3. Addressing workforce shortages; training and capacity building; EULAR's role in global rheumatology education

4. National and EU-level surveillance frameworks; integrating RMD data into WHO NCD (noncommunicable diseases) platforms

Advancing Global Health in Rheumatology: Building Capacity, Equity, and Resilience Across Borders

Chair:	Tore K. Kvien (Norway) Annelies Boonen (Belgium)
09:00 - 09:05	Introduction Speaker: Annelies Boonen (Belgium)
09:05 - 09:15	RMDs in Low-Resource Settings: Bridging the Care Gap Speaker: Latika Gupta (United Kingdom)
09:15 - 09:25	Climate Change and RMDs Speaker: Tamiko Katsumoto (United States of America)
09:25 - 09:35	Global Workforce for RMDs Speaker: Bruno Fautrel (France)

09:35 - 09:45	Surveillance of MSK Conditions at Population Level Speaker: Anthony Woolf (United Kingdom)
09:45 - 09:55	Inequities in global representation and transparency in transcriptomic studies of systemic lupus erythematosus: a systematic assessment of public datasets Speaker: Rodolfo Martinez-Canales (Mexico)
09:55 - 10:15	Questions and Answers

EULAR Projects

Date: **06/06/2026**

1. To gain insight into the activities of EULAR Research Committee

Room: **Victoria Room 5 & 6**

09:00-10:15 BST

2. To become familiarised with the main resources available for researchers through the EULAR Research Centre;

3. To understand how the individual researcher can contribute to the major projects currently underway at the EULAR Research Centre.

EULAR Projects: Research

Chair:	Anna Molto (France) Ronald F. van Vollenhoven (Netherlands)
09:00 - 09:10	Introduction Speaker: Anna Molto (France)
09:10 - 09:25	The EULAR Research Centre Projects: Advanced Tissue Analysis; joining forces in using breakthrough technologies Speaker: Rik Lories (Belgium)

09:25 - 09:40	The EULAR Research Centre Projects: ENTRI; bringing centers together to do outstanding clinical trials Speaker: Andrew Cope (United Kingdom)
09:40 - 09:55	The EULAR Research Centre Projects: RheumaFacts the EULAR repository of RMD indicators Speaker: Anna Molto (France)
09:55 - 10:10	The EULAR Research Centre Projects: the RMD Impact Patients Survey Speaker: Anja Strangfeld (Germany)

EULAR Joint Sessions

Date: **06/06/2026**

1. To address fear of movement in patients living with AxSpA. Does chronic pain influence the level of motivation? What can we do to help patients to take the first step towards exercise and lifestyle changes?

Room: **N1**

09:00-10:15 BST

2. To showcase the impact of exercise, lifestyle changes and diet on patients' lives

3. To present how patient organizations can help patients get motivated

From Pain to Progress: Encouraging Exercise and Healthy Living in AxSpA

Chair:	Lillann Wermskog (Norway) Simone Battista (United Kingdom)
09:00 - 09:20	Managing kinesiophobia in patients living with chronic pain: a physiotherapist's guide to restoring movement and confidence Speaker: Deniz Bayraktar (Iceland)
09:20 - 09:40	Are movement and pain inseparable in AxSpA? Rethinking the relationship" Speaker: NADIA MALLIOU (Greece)

09:40 - 10:00	From evidence to action: do exercise, diet, and behavioural change really help in AxSpA? Speaker: Alexandros Mitropoulos (United Kingdom)
10:00 - 10:15	Walking Together: Can an annual event motivate movement? Lessons learned from Cyprus Speaker: Andri Phoka (Cyprus)

Clinical Science

Date: **06/06/2026**

1. What are the most common clinical manifestations of primary heart involvement in systemic sclerosis

Room: **N2**

09:00-10:15 BST

2. How to diagnose primary heart involvement in systemic sclerosis

2. How to treat primary heart involvement in systemic sclerosis

Primary heart involvement in systemic sclerosis

Chair:	Alain Lescoat (France) Serena Guiducci (Italy)
09:00 - 09:15	Pathogenesis of primary heart involvement in systemic sclerosis Speaker: Andrea-Hermina Györfi (Germany)
09:15 - 09:30	All faces of primary heart involvement in systemic sclerosis Speaker: Carina Mihai (Switzerland)
09:30 - 09:45	How to screen and diagnose primary heart involvement in systemic sclerosis Speaker: Cosimo Bruni (Switzerland)

09:45 - 10:00	Treatment of primary heart involvement in systemic sclerosis Speaker: Ivan Castellví (Spain)
10:00 - 10:15	Questions and Answers Speaker: Serena Guiducci (Italy) Co-Speaker: Alain Lescoat / (Rennes , France)

EULAR Projects

Date: **06/06/2026**

- To evaluate the current evidence-based strategies for the diagnosis, treatment, and monitoring of polymyalgia rheumatica and large vessel vasculitis

Room: **N3**

09:00-10:15 BST

- To apply practical approaches for osteoporosis screening and management in patients with inflammatory rheumatic diseases.

- To integrate modern imaging modalities into the routine assessment of spondyloarthritides

- To interpret classification criteria for antisynthetase syndrome

EULAR Recommendations

Chair:	George E. Fragoulis (Greece) Alessia Alunno (Italy)
09:00 - 09:03	Introduction Speaker: Alessia Alunno (Italy) Co-Speaker: George E. Fragoulis / (Athens, Greece)
09:03 - 09:20	EULAR recommendations for the management of polymyalgia rheumatica and large vessels vasculitis Speaker: Chetan Mukhtyar (United Kingdom)

09:20 - 09:37	Update of recommendations for vaccination in patients with autoimmune rheumatic diseases Speaker: Ori Elkayam (Israel)
09:37 - 09:54	2025 Update of the EULAR Recommendation for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice Speaker: Peter Mandl (Austria)
09:54 - 10:11	2025 European Alliance of Associations for Rheumatology / American College of Rheumatology Classification Criteria for Anti-Synthetase Syndrome Speaker: Lorenzo Cavagna (Italy)
10:11 - 10:15	Closing Speaker: George E. Fragoulis (Greece) Co-Speaker: Annette van der Helm - van Mil / (Leiden, Netherlands)

Clinical Science

Date: **06/06/2026**

1. Understanding the role of iron in bone metabolism and development of arthropathy

Room: **George V Room 1**

09:00-10:15 BST

2. Translating the benefit of iron depletion on joint health

3. Learning clinical signs and symptoms and to base the differential diagnosis on different types of imaging

Hemochromatosis arthropathy

Chair:	Pascal Richette (France) Geraldine McCarthy (Ireland)
09:00 - 09:22	Role of iron in bone metabolism and the benefit of iron depletion on bone health Speaker: François ROBIN (France)

09:22 - 09:43	EULAR classification criteria on hemochromatosis Speaker: Patrick Kiely (United Kingdom)
09:43 - 10:05	Hemochromatosis arthropathy: how to evaluate clinical signs and symptoms in relation to imaging? Speaker: Stephanie Finzel (Germany)
10:05 - 10:15	Prevalence, risk factors and structural joint damage in HFE-related hemochromatosis arthropathy: the Iron Fist Study Speaker: David Haschka (Austria)

Clinical Science

Date: **06/06/2026**

- To learn how to improve the diagnosis of autoinflammatory diseases in adults with fever of unknown origin

Room: **George V Room 2**

09:00-10:15 BST

- To discuss the late-onset complications in adults with autoinflammatory diseases

- To provide the latest advances about the treatment of adults with autoinflammatory diseases

The clinical management of autoinflammatory diseases presenting with recurrent fevers among adults, from diagnosis to treatment

Chair:	Martin Krusche (Germany) Helen J. Lachmann (United Kingdom)
09:00 - 09:25	The challenge of recognising adult onset autoinflammatory disease Speaker: Serdal Ugurlu (Türkiye)

09:25 - 09:50	Assessing the occurrence of adult onset complications in autoinflammatory disease Speaker: Stéphane Mitrovic (France)
09:50 - 10:15	The treatment of adult autoinflammatory disease Speaker: Luca Cantarini (Italy)

Challenges in Clinical Practice

Date: 06/06/2026

To discuss:

Room: **George V Room 3**

1. Difficult situations in the management of paediatric sacroiliitis
2. Pitfalls in imaging with focus on MRI findings and interpretation;
3. Challenges in the clinical evaluation;
4. Therapeutic options and monitoring of disease including long-term complications.

09:00-10:14 BST

Pitfalls and tricks in paediatric Sacroiliitis

Chair:	Gerd Horneff (Germany) Sonia Melo Gomes
09:00 - 09:12	Case Study : MRI findings in paediatric sacroiliitis - what you see is what you get Speaker: Lieve Morbée (Belgium)
09:12 - 09:37	Case Discussion: MRI findings in paediatric sacroiliitis - what you see is what you get Speaker: Nele Herregods (Belgium)
09:37 - 09:49	Case Study: Paediatric sacroiliitis - Clinical challenges in Spondyloarthritis Speaker: Anita Heinkele (Germany)

09:49 - 10:14	Case Discussion: Paediatric sacroiliitis - Clinical challenges in Spondyloarthritis Speaker: Toni Hospach (Germany)
---------------	---

EULAR Debate

Date: **06/06/2026**

This debate will help participants critically assess whether PsA and pSpA are one disease or distinct entities, understand their similarities and differences, and appreciate how classification influences diagnosis, research, and treatment decisions.

Room: **George V Room 4**

09:00-10:15 BST

PsA vs pSpA: Two Faces of the Same Coin or Different Currencies?

Chair:	Gizem Ayan (Türkiye) Alla Ishchenko (Belgium)
09:00 - 09:20	PsA and pSpA are the same disease Speaker: Filip Van den Bosch (Belgium)
09:20 - 09:40	PsA and pSpA are not the same disease Speaker: Frank Behrens (Germany)
09:40 - 09:50	PsA and pSpA are the same disease Speaker: Filip Van den Bosch (Belgium)
09:50 - 10:00	PsA and pSpA are not the same disease Speaker: Frank Behrens (Germany)
10:00 - 10:15	Discussion Speaker: Frank Behrens (Germany) Co-Speaker: Filip Van den Bosch / (Ghent, Belgium), Gizem Ayan / (ANKARA, Türkiye), Alla Ishchenko / (Antwerp, Belgium)

InnovationDate: **06/06/2026**

- Explore how socioeconomic and environmental factors influence the pathogenesis, activity, and outcomes of RMDs.

Room: **Room 12****09:00-10:15 BST**

- Examine mechanistic links between environmental exposures and immune dysregulation, and assess how inequalities shape patient care and research priorities.

- Insights to integrate these determinants into clinical practice and to inform future research directions for improved disease management.

Environment and Inequality: Unpacking Socioeconomic and Environmental Drivers of RMD Pathogenesis, Disease Activity, and Research

Chair:	Milena Bond (Italy) Gagandeep Sukhija (United Kingdom)
09:00 - 09:15	Mapping the Invisible: Global Inequalities and Environmental Determinants in RMDs Speaker: Pedro Machado (United Kingdom)
09:15 - 09:30	From Pollutants to Pathways: How Environment and Socioeconomic Factors Shape Autoimmune Immunopathology Speaker: Elena Pontarini (United Kingdom)
09:30 - 09:45	Pollution, Poverty, and Pain: Environmental and Social Drivers of Inflammatory Arthropathies and Osteoarthritis Burden Speaker: Giovanni Adami (Italy)
09:45 - 10:00	From Dust to Disease: Environmental Exposures and Inequalities in Systemic Autoimmune Conditions Speaker: Diane van der Woude (Netherlands)

How to Treat (HOT)Date: **06/06/2026**

1. Understand the principles of the Treat-to-Target (T2T) strategy in systemic lupus erythematosus (SLE), focusing on achieving remission or low disease activity to minimise long-term organ damage.

Room: **Plenary**

09:45-10:30 BST

2. Recognise the ongoing importance of glucocorticoids and hydroxychloroquine (HCQ) as foundational therapies, alongside the role of immunosuppressive agents and emerging biologic treatments for moderate to severe disease

3. Gain up-to-date insight into the latest management approaches and evolving therapeutic strategies in SLE care.

How to treat systemic lupus erythematosus

Chair:	Marta Mosca (Italy) Laurent Arnaud (France)
09:45 - 10:30	Rebalancing the Immune System: New Insights into Lupus Therapy Speaker: George Bertias (Greece)

Hands-on Sessions

Date: **06/06/2026**

1. Discuss the value of point of care rheumatology ultrasound (POCRUS) in LVV and PMR

Room: **Hands-on 1**

10:15-11:30 BST

2. Learn how to perform POCRUS scans at large vessels using handheld portable devices

3. Learn how to perform POCRUS scans at shoulders using handheld portable devices

Point of care rheumatology ultrasound - large vessel vasculitis and polymyalgia rheumatica

Chair:	Niccolò Possemato (Italy) Stavros Chrysidis (Denmark)
10:15 - 10:20	LVV - Introduction 1 Speaker: Cristina Ponte (Portugal)
10:20 - 10:25	LVV - Introduction 2 Speaker: Bhaskar Dasgupta (United Kingdom)
10:25 - 10:30	PMR - Introduction 1 Speaker: Luca Seitz (Switzerland)
10:30 - 10:35	PMR - Introduction 2 Speaker: Berit Dalsgaard Nielsen (Denmark)
10:35 - 11:30	Hands-on Workshop Speaker: Niccolò Possemato (Italy) Co-Speaker: Stavros Chrysidis / (Vejle, Denmark), Bhaskar Dasgupta / (Westcliff, United Kingdom), Berit Dalsgaard Nielsen / (Aarhus, Denmark), Luca Seitz / (Biel / Bern, Switzerland), Cristina Ponte / (Lisbon, Portugal)

Hands-on Sessions

Date: **06/06/2026**

This session will help delegates to know:

Room: **Hands-on 2**

10:15-11:30 BST

1. When to perform a synovial fluid analysis;
2. How to perform a synovial fluid analysis;
3. How to interpret a synovial fluid analysis.

Please note that there is a maximum capacity in this session. Delegates will be given access on a first

come, first served basis.

This session is identical to the other 'Crystal Identification, synovial fluid analysis' session. Please do not attend more than one Hands-On Session of the same name.

Crystal identification, synovial fluid analysis

Chair:	Francesca Oliviero (Italy) Eleonora Norkuviene (Lithuania)
10:15 - 10:25	When should Synovial Fluid analysis be performed? Speaker: Abhishek Abhishek (United Kingdom)
10:25 - 10:35	Identifying crystals in synovial fluid Speaker: Anne-Kathrin Tausche (Germany)
10:35 - 11:30	Hands-on Workshop Speaker: Anne-Kathrin Tausche (Germany) Co-Speaker: Abhishek Abhishek / (Nottingham, United Kingdom), Francesca Oliviero / (Padova, Italy), Eleonora Norkuviene / (Kaunas, Lithuania)

Poster View Presentations

Date: **06/06/2026**

Room: **Poster View**

10:15-11:15 BST

Poster View VIII

Chair:	
10:15 - 10:15	Validation of Thoracic Ultrasound Criteria for Screening Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicentre Study Speaker: Bjørk Sofíudóttir (Denmark)

10:15 - 10:15	Cell-Free DNA Methylation and Fragmentation Signatures Enable Non-Invasive Detection and Monitoring of Active Lupus Nephritis Speaker: Qiang Li (Hong Kong, China)
10:15 - 10:15	Pathogenesis and biomarker validation in people at risk of rheumatic and musculoskeletal diseases: a transcriptomic and flow cytometric study reveals a transient increase in B cell interferon-response and differentiation precedes onset of rheumatic and musculoskeletal diseases Speaker: Han-Hua Yu (United Kingdom)
10:15 - 10:15	Do people with palindromic rheumatism develop erosions? A longitudinal ultrasound study from a large UK cohort. Speaker: Task Toyoda (United Kingdom)
10:15 - 10:15	Prevalence and risk factors for interstitial lung disease in patients with rheumatoid arthritis receiving treat-to-target therapy from disease onset: 10-year follow-up of the ARCTIC trial Speaker: Henrik Mangseth (Norway)
10:15 - 10:15	Effectiveness of patient-initiated follow-up supported by asynchronous telemedicine in spondyloarthritis: pre-specified subgroup analysis of a randomised controlled trial Speaker: Marius L. Smits (Netherlands)
10:15 - 10:15	Machine learning to predict remission between six and 24 months in rheumatoid arthritis: insights from the JAK-pot collaboration Speaker: Zubeyir Salis (France)
10:15 - 10:15	RheumaPredict: Externally Validated Ensemble Machine Learning Model for Predicting Rheumatoid Arthritis Flares in Latin American Populations Speaker: Juan Sebastian Theran Leon (Colombia)
10:15 - 10:15	Validation of the Clinical Arthritis Rule (CARE) Tool in Identifying Inflammatory Arthritis Risk Among U.S. Patients Presenting for Rheumatology Consultation Speaker: Karen Salomon-Escoto (United States of America)
10:15 - 10:15	Effectiveness of swapping vs. cycling in remission achievement in patients with rheumatoid arthritis after failing a first TNFi due to inefficacy: real-world study (RA-Mission) Speaker: Eduardo Dourado (Portugal)

10:15 - 10:15	Longitudinal Outcomes of Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis: Damage and Cardiovascular Risk in Adulthood Speaker: Coziana Ciurtin (United Kingdom)
10:15 - 10:15	Women and men with systemic lupus erythematosus report a wide range of disease burden: observational data from the German National database of the Collaborative Arthritis Centers Speaker: Johanna Callhoff (Germany)
10:15 - 10:15	Identification and characterization of systemic lupus erythematosus patient clusters through integrated analysis of the RELESSAR and RELESSER data registries. Speaker: Malena Viola (Argentina)
10:15 - 10:15	Systematic Literature Review of Management Considerations in Patients with Difficult-to-Treat Rheumatoid Arthritis Speaker: Golnaz Shams (Austria)
10:15 - 10:15	The Early Arthritis Recognition Clinic Screening for the Presence of Clinical Arthritis: A Large Longitudinal Study of Long-Term Effectiveness in Rheumatoid Arthritis Speaker: Simonetta R.G. van Griethuysen (Netherlands)
10:15 - 10:15	Involving people with arthritis in the decision-making of a research funding patient organisation, Arthritis UK Speaker: Gemma Winsor (United Kingdom)
10:15 - 10:15	Long-Term Risk of Malignancies with Upadacitinib in Comparison to Adalimumab in Rheumatoid Arthritis Up to 5 Years: Post Hoc Analysis of Six Clinical Trials Speaker: Jerome Avouac (France)
10:15 - 10:15	Real-World Radiographic Outcomes of Sarilumab in Rheumatoid Arthritis: A Multicenter Study of Structural Remission and Progression Speaker: Masahiro Tada (Japan)
10:15 - 10:15	Understanding Patient and Physician Global Assessments in Rheumatoid Arthritis: A Meta-Epidemiological Study of Core Outcome Set Performance Speaker: Philip Rask Lage-Hansen (Denmark)

10:15 - 10:15	<p>Safety of multitargeted therapy using two biologics or one biologic and one JAKi in refractory pediatric inflammatory disorders: a retrospective multicentric cohort</p> <p>Speaker: Clément Triaille (Belgium)</p>
10:15 - 10:15	<p>Peritendinitis of the abductor digitorum minimi, frequently observed in pre-RA patients, may be involved in the early development of bone erosion of the fifth metatarsal joint in RA</p> <p>Speaker: Takeshi Suzuki (Japan)</p>
10:15 - 10:15	<p>Open Access Clinic for Arthralgia: Patient Flow and Diagnostic Pathways</p> <p>Speaker: Stine Daugaard Pedersen (Denmark)</p>
10:15 - 10:15	<p>Non-melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin-6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study</p> <p>Speaker: Zixing Tian (United Kingdom)</p>
10:15 - 10:15	<p>Detecting efficacy while missing risks by design: external validity of pivotal Janus kinase inhibitor (JAKi) trials</p> <p>Speaker: Ghislaine Blum (Germany)</p>
10:15 - 10:15	<p>Trajectories of disease activity over time in patients with SLE: A Cohort study</p> <p>Speaker: Ahmed Saleh (United Kingdom)</p>
10:15 - 10:15	<p>Improvement of neurological symptoms and associated biomarkers with deucravacitinib in patients with systemic lupus erythematosus in the phase 2 PAISLEY SLE trial</p> <p>Speaker: Marilyn Pike (United States of America)</p>
10:15 - 10:15	<p>Antifibrotics in interstitial lung disease related to rheumatic and musculoskeletal diseases: a systematic review and meta-analysis</p> <p>Speaker: Ana Catarina Duarte (Portugal)</p>
10:15 - 10:15	<p>A Vision Transformer-based Transfer Learning Model to Infer Metacarpophalangeal Joint Swelling on Hand Photographs in Patients with Rheumatoid Arthritis</p> <p>Speaker: Asier García-Alija (Spain)</p>

10:15 - 10:15	Predictive factors for achieving glucocorticoid-free remission in lupus nephritis Speaker: Ryota Sakai (Japan)
10:15 - 10:15	Withdrawal of Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis: Primary findings from the randomised controlled ALOSTRA trial Speaker: Anne-Birgitte Garm Blavnsfeldt (Denmark)
10:15 - 10:15	Mental Health and Quality of Life During Pregnancy and Postpartum in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: Results from the Norwegian RevNatus Registry Speaker: Ingrid Rekaa Nilssen (Norway)
10:15 - 10:15	Rituximab-induced serum sickness: new insights on a rare side effect based on a multicenter study of 94 patients Speaker: Romain Braida (France)
10:15 - 10:15	Safety, Accuracy and Clinical Utility of AI-Generated Rheumatoid Arthritis Patient Education: A Blinded Head-to-Head Rheumatologist Evaluation Speaker: Sree Hari Reddy Gadekallu (India)
10:15 - 10:15	Chimeric antigen receptor-based cellular therapy in autoimmune diseases: A systematic review and meta-analysis of clinical, serological and safety outcomes Speaker: Hon Jen Wong (Singapore)
10:15 - 10:15	Association between serum MMP-3 levels and cognitive function in patients with rheumatoid arthritis Speaker: Masahiro Tada (Japan)
10:15 - 10:15	Macrophage activation syndrome in adults: a nationwide multicentre cohort study in Portugal. Speaker: Daniel Carvalho (Portugal)
10:15 - 10:15	Prevalence of bronchiectasis, emphysema and airflow obstruction in established rheumatoid arthritis patients receiving modern treatment from disease onset Speaker: Henrik Mangseth (Norway)

10:15 - 10:15	<p>Treat-to-target Strategies Without Pharmacologic Restrictions Are Feasible in Elderly-Onset Rheumatoid Arthritis Due to a Risk-Benefit Profile Comparable to Young-Onset Rheumatoid Arthritis</p> <p>Speaker: Hamit Harun Dag (Netherlands)</p>
10:15 - 10:15	<p>Steroids and Me (Sam): Development and Validation of a Patient-Centered Digital Platform for Glucocorticoid Education and Shared Decision-Making</p> <p>Speaker: Martha Stone (United States of America)</p>
10:15 - 10:15	<p>Trends in the treatment of osteoporosis and fragility fractures in England: a population-level analysis</p> <p>Speaker: Yi-Qian Lim (United Kingdom)</p>
10:15 - 10:15	<p>Unsupervised phenotypic clustering of cardiovascular risk profiles in systemic lupus erythematosus</p> <p>Speaker: Alexis Mathian (France)</p>
10:15 - 10:15	<p>The comorbidity burden in early axial spondyloarthritis (axSpA) may differ and may be associated with lower rates of metabolic syndrome than in established axSpA.</p> <p>Speaker: Hasan Kocaayan (Türkiye)</p>
10:15 - 10:15	<p>Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: A single-center randomised controlled trial</p> <p>Speaker: Yusuke Yoshida (Japan)</p>
10:15 - 10:15	<p>Maternal and neonatal outcomes following Tofacitinib exposure during pregnancy in inflammatory arthritis: a single-center case series</p> <p>Speaker: Bodhisatwa Choudhuri (India)</p>
10:15 - 10:15	<p>Lipid-rich coronary plaque improves cardiovascular risk prediction beyond calcium scoring in rheumatoid arthritis</p> <p>Speaker: George Karpouzas (United States of America)</p>
10:15 - 10:15	<p>Multi-Dimensional Analysis of the B Cell Compartment in Systemic Lupus Erythematosus Reveals Effector and Regulatory Perturbations</p> <p>Speaker: Rachel Cheong (Singapore)</p>

10:15 - 10:15	Difficult-to-manage axial spondyloarthritis in 18,083 patients from five Nordic registries – an analysis inspired by recent ASAS definitions Speaker: Bente Glintborg (Denmark)
10:15 - 10:15	Association of Accelerated Biological Aging with 20 Autoimmune Diseases: Insights from UK Biobank Participants Speaker: Weishu Wang (China)
10:15 - 10:15	Safety and adverse event profile of universal allogeneic CAR cell therapies for refractory autoimmune diseases: a prospective cohort study Speaker: Xiaobing Wang (China)
10:15 - 10:15	A masked and TGFβRIII-biased αCD3-TGF-β fusion protein promotes regulatory T cell induction and immune tolerance Speaker: Bing Hou (China)
10:15 - 10:15	Pericoronary adipose tissue as a biomarker of coronary atherosclerosis and cardiovascular risk in rheumatoid arthritis Speaker: George Karpouzas (United States of America)
10:15 - 10:15	Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of Phase 3 belimumab trial data. Speaker: Angela Lin (Australia)
10:15 - 10:15	Association between underweight and unfavorable clinical events in Japanese patients with rheumatoid arthritis: analysis of IORRA cohort Speaker: Tomoaki Higuchi (Japan)
10:15 - 10:15	The impact of achieving early remission for individuals with severe rheumatoid arthritis: a population-level cohort study in the National Early Inflammatory Autoimmune Diseases Audit Speaker: Mark Russell (United Kingdom)
10:15 - 10:15	Patients improve, patterns persist: temporal stability of RA subsets Speaker: Tjardo D. Maarseveen (Netherlands)
10:15 - 10:15	The RNP⁺Sm⁺ lupus endotype is associated with poor response to B-cell depletion and ferritin-marked interferon-myeloid inflammation Speaker: Muhammad RA Shipa (United Kingdom)

10:15 - 10:15	Three-Month Treatment Targets for Achieving Glucocorticoid-Free Remission at 12 Months in Late-Onset Rheumatoid Arthritis Speaker: Takahiko Sugihara (Japan)
10:15 - 10:15	Establishing a consultation service for women with inflammatory rheumatic and musculoskeletal disease (iRMD) during preconception, pregnancy and lactation: analysis of reasons for consultation Speaker: Diana Vossen (Germany)
10:15 - 10:15	Long-term Outcomes of Juvenile-onset Spondyloarthritis into Adulthood: A 17-Year Follow-up and Comparison with Late Adult-onset Disease (REGISPON-3 Substudy) Speaker: María Ángeles Puche-Larrubia (Spain)
10:15 - 10:15	Effect of denosumab on implant survival following total hip and knee arthroplasty in osteoarthritis patients: a registry-based data linkage study Speaker: Jacopo Ciaffi (Italy)
10:15 - 10:15	Pirfenidone Inhibits Renal Fibrosis in Murine Lupus Nephritis via Downregulating MXRA7: A Potential Therapeutic Strategy Speaker: XIANG LI (China)
10:15 - 10:15	Prevalence and risk factors of progressive pulmonary fibrosis in patients with connective tissue disease-associated interstitial lung disease: a single-centre retrospective cohort study Speaker: Paula Yang (Hong Kong, China)
10:15 - 10:15	Long-term outcomes in patients with rheumatoid arthritis treated according to treat-to-target recommendations: 10-year follow-up of the ARCTIC trial Speaker: Lena Nordberg (Norway)
10:15 - 10:15	Integrated Spatial Transcriptomics and Proteomics Reveals Aberrant Lymphoid Networks and Stromal Damage Patterns in Pediatrics Lupus Nephritis Speaker: Nicholas Hasle (United States of America)
10:15 - 10:15	Five-Year Treat-to-Target Outcomes in Early RA: Impact of a Temporary 6-Month Etanercept Course Based on Initial COBRA-Slim Response in the CareRA2020 Trial Speaker: Nicolas Degryse (Belgium)

10:15 - 10:15	Six1 activation is involved in glycolytic pathway and inflammatory injury in SLE mice model Speaker: yong jin (China)
10:15 - 10:15	Being the significant other of a person with rheumatoid arthritis – a qualitative study in a Swedish context Speaker: Maria Bergström (Sweden)
10:15 - 10:15	Treatment Patterns Before and During Pregnancy in Women with Sjögren's Disease, Systemic Lupus Erythematosus, or Rheumatoid Arthritis: A Nationwide Population-Based Register Study in Sweden Speaker: Rebecca Zaha (United States of America)
10:15 - 10:15	Subjective and objective dimensions of RA disease activity capture heterogeneity in treatment outcomes that DAS28 does not Speaker: Simon Steiger (Sweden)
10:15 - 10:15	Subcutaneous versus intravenous ultra-low dose rituximab in patients with rheumatoid arthritis: a randomised controlled non-inferiority trial Speaker: Pauline Bovens (Netherlands)
10:15 - 10:15	Prospective development and validation of Pune Vasculopathy Score to quantify the activity of the proliferative obliterative vasculopathy in connective tissue diseases Speaker: Varsha Bhatt (India)
10:15 - 10:15	EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia: Validation and Analysis of Additional Predictive Factors in the Reuma-Check Cohort Speaker: Rodrigo Garcia Salinas (Argentina)
10:15 - 10:15	“A Seed for Change”: Web-Based Interventions Supporting Self-Management in Rheumatic Diseases Speaker: Heta Rissanen (Finland)
10:15 - 10:15	Induction of Cure in Early Arthritis (I CEA): 1-year results of a randomized clinical trial comparing three treatment strategies in recent-onset undifferentiated arthritis Speaker: Sytske Anne Bergstra (Netherlands)

10:15 - 10:15	Spontaneous Pregnancy Success Rates among Rheumatoid Arthritis patients with Infertility: Comparing Treatment Strategies. Speaker: Irene Tan (United States of America)
10:15 - 10:15	Nebulized pirfenidone (AP01) for progressive pulmonary fibrosis in connective tissue disease-associated and other interstitial lung diseases: 4-year data from the ATLAS open label extension trial Speaker: Anna-Maria Hoffmann-Vold (Norway)
10:15 - 10:15	DAPIROLIZUMAB PEGOL TREATMENT AND IMPROVEMENT IN LABORATORY MARKERS OF DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: 48-WEEK RESULTS FROM A PHASE 3 TRIAL Speaker: Thomas Dörner (Germany)
10:15 - 10:15	Mechanistic and Translational Preclinical Evaluation of GenSci136, a Long-Acting Dual BAFF/APRIL Inhibitor, in Systemic Lupus Erythematosus Speaker: BO QU (China)
10:15 - 10:15	Consistent long-term safety of filgotinib in rheumatoid arthritis over a median of 4.8 years: Integrated evidence from seven clinical trials Speaker: Rene Westhovens (Belgium)
10:15 - 10:15	Carotid–Femoral Pulse Wave Velocity Outperforms SCORE2 in Cardiovascular Risk Prediction in Rheumatic Diseases: A 7-Year Follow-Up Study. Speaker: Konstantinos Triantafyllias (Germany)
10:15 - 10:15	Shift Work is Associated with an Increased Risk of Rheumatoid Arthritis in Women, but not in Men Speaker: Carl Turesson (Sweden)
10:15 - 10:15	Ethnic variation in comorbidities among people with rheumatoid arthritis: a cross-sectional study of 1.9 million participants from Our Future Health Speaker: Benjamin Zuckerman (United Kingdom)
10:15 - 10:15	The relationship of artery specific pericoronary fat attenuation with ipsilateral atherosclerosis and the influence of systemic inflammation in Rheumatoid Arthritis Speaker: George Karpouzas (United States of America)

10:15 - 10:15	<p>Outcomes of Lung Cancer Among Hospitalized Adults with Rheumatoid Arthritis: A National Inpatient Analysis Speaker: Srijani Thannir (United States of America)</p>
10:15 - 10:15	<p>Current Symptom-Based Detection of RA-ILD Results in Under-Detection, Advanced Disease and Excess Mortality: A Multicenter Norwegian Quality Assurance Audit Speaker: Eirik Ikdahl (Norway)</p>
10:15 - 10:15	<p>Treatment Intensity and Clinical Outcomes in Psoriatic vs Non-Psoriatic Peripheral SpA: A Propensity- Matched Analysis Speaker: Yesim Erez (Türkiye)</p>
10:15 - 10:15	<p>“ANA \geq1:640 with Negative Extractable Nuclear Antibodies: Are They a Warning Sign for the Development of Systemic Autoimmune Disease Within 5 Years?” Speaker: Cristina Rocamora-Gisbert (Spain)</p>
10:15 - 10:15	<p>Risk of Cancer Associated with bDMARDs and tsDMARDs in Patients with Rheumatoid Arthritis and a History of Cancer: Insights from the ARCA Registry Speaker: Juan Molina-Collada (Spain)</p>
10:15 - 10:15	<p>Acute Toxicity Profile and Inflammatory Risk Factors of CAR-T Cell Therapy in Refractory Autoimmune Diseases: A Real-World Cohort Study Speaker: Merav Lidar (Israel)</p>
10:15 - 10:15	<p>Clinical features and outcomes of patients with autoimmune rheumatic diseases admitted to the intensive care unit: a single-center Italian experience Speaker: Chiara Calabrese (Italy)</p>
10:15 - 10:15	<p>Gender influence on ultrasound-assessed therapeutic response in rheumatoid arthritis: Insights from the GENder on UltraSound (GENUS) study Speaker: Juan Molina-Collada (Spain)</p>
10:15 - 10:15	<p>Pulmonary fibrosis in rheumatoid arthritis: a multicentre observational real-world study Speaker: Evripidis Kaltsonoudis (Greece)</p>

10:15 - 10:15	Routine-care weight variation and longitudinal DAS28-CRP in rheumatoid arthritis with obesity, a real-world cohort study Speaker: Zubeyir Salis (France)
10:15 - 10:15	Baseline Low Creatinin Phosphokinase Levels and Their Increasing Changes Are Associated with the Better Clinical Outcomes of Jack Inhibitor Therapy Speaker: Kou Katayama (Japan)
10:15 - 10:15	Safety and Treatment Persistence of Filgotinib in Patients with Rheumatoid Arthritis: Results from the Multicentre SOFIA study (Observational Study on the Safety of Filgotinib in Rheumatoid Arthritis) Speaker: Anna Giorgia Osele (Italy)
10:15 - 10:15	Validation of a Corrected Axial Spondyloarthritis Metrology Index in 11 Randomized Clinical Trials. Speaker: Dafne Capelusnik (Israel)
10:15 - 10:15	Common Proteomic Biomarkers Associated With Systemic Sclerosis and Distinct Cardiac Phenotypes Speaker: Steven Scholfield (United Kingdom)
10:15 - 10:15	Association between air pollution and risk of rheumatoid arthritis. a systematic review and meta-analysis. Speaker: Rashad Mohamed (Egypt)
10:15 - 10:15	Comparison of efficacy and side effect profile of same day split versus twice a week split of oral methotrexate in rheumatoid arthritis: a randomized controlled study Speaker: Rajat gupta (India)
10:15 - 10:15	A systematic literature review informing the 2025 update of the EULAR recommendations for the use of imaging in the diagnosis and management of axial spondyloarthritis in clinical practice Speaker: Susanne Juhl Pedersen (Denmark)
10:15 - 10:15	Threshold dose of oral glucocorticoid therapy on risk of serious infection in patients with rheumatoid arthritis: a nested case-control analysis Speaker: Huan Meng (Hong Kong, China)

10:15 - 10:15	Romosozumab does not improve volumetric bone mineral density at distal radius but increases bone strength: a prospective study Speaker: Mariana Diz Lopes (Portugal)
10:15 - 10:15	The spectrum and relative risk of lung pathology in systemic autoimmune rheumatic diseases: a nationwide postmortem study. Speaker: Laura Ross (Australia)
10:15 - 10:15	Association between Wrist Bone Erosion Burden Assessed by High-resolution Peripheral Quantitative Computed Tomography and Disability in Patients with Rheumatoid Arthritis Speaker: Xianfeng Yan (Hong Kong, China)
10:15 - 10:15	Differentiation of Physiological from Pathological Bone Erosions in Rheumatoid Arthritis: an Eight-Year HR-pQCT Study of the Second Metacarpal Head Speaker: Xianfeng Yan (Hong Kong, China)
10:15 - 10:15	Limited predictability of second-line DMARD persistence after methotrexate failure in rheumatoid arthritis Speaker: Nils Steinz (Netherlands)
10:15 - 10:15	Xeligekimab improved enthesitis at Achilles tendon sites in patients with radiographic axial spondyloarthritis: 48-week results of a phase III randomized controlled trial Speaker: Hongsheng Sun (China)
10:15 - 10:15	Anti-mitofusin-1 autoantibodies are associated with erosive disease in seronegative rheumatoid arthritis: data from the ESPOIR cohort Speaker: Laurinda Carré (France)
10:15 - 10:15	Several JAK-STAT pathways are active in early, untreated rheumatoid arthritis and are only partially normalized by treatment with csDMARDs Speaker: Antti Kurttila (Finland)
10:15 - 10:15	Impact of TNF-inhibitor discontinuation on postpartum flare in rheumatoid arthritis: results from the Norwegian RevNatus Registry Speaker: Ingunn Sagberg (Norway)

10:15 - 10:15	Mapping the Changing Connections Between Health Issues Prior to Rheumatoid Arthritis: A Swedish Case-Control Study Speaker: Kayode Fowobaje (Sweden)
10:15 - 10:15	CNS diseases cerebrospinal fluid single-cell atlas reveals immune characteristics of neuropsychiatric systemic lupus erythematosus Speaker: Mengtao Li (China)
10:15 - 10:15	Safety of early tapering of biologic therapy in rheumatoid arthritis: a comparative study at 12 and 24 months Speaker: Paola Jauregui Rojas (Peru)
10:15 - 10:15	Immune checkpoint inhibitors-induced granulomatous uveitis for patients with cancer: a systematic literature review of reported cases identifying phenotypes of disease and outcomes Speaker: Nandini Bindal (United Kingdom)
10:15 - 10:15	Cardiorenal–Metabolic Comorbidity and Therapy Eligibility in Rheumatoid Arthritis: Real-World Data from the Ontario Best Practices Research Initiative (OBRI) Speaker: Bindee Kuriya (Canada)
10:15 - 10:15	Perspectives on Patient Research Partner Involvement in Rheumatology Research: A National Survey of Portuguese Researchers Speaker: Mariana Carvalho (Portugal)
10:15 - 10:15	TL1A and TL1A-driven Inflammatory Pathways are Upregulated in RA, PsA and axSpA Speaker: Heather Llewellyn (United States of America)
10:15 - 10:15	Ultra low dose Rituximab in Rheumatoid arthritis patient refractory or intolerant to csDMARDs or JAK inhibitors- a prospective pilot study from a tertiary care centre in northern india Speaker: ANJUM SIDDIQUI (India)
10:15 - 10:15	MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH GLUCOCORTICOIDS: A REAL-WORLD MULTICENTRE STUDY FROM ARTESER REGISTRY Speaker: Adrián Martín-Gutiérrez (Spain)

10:15 - 10:15	Safety Profile of Efgartigimod Across Multiple Global Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases With Emerging Data in Idiopathic Inflammatory Myopathy, Sjögren's Disease, and Lupus Nephritis Speaker: Hector Chinoy (United Kingdom)
10:15 - 10:15	Prescription Patterns, Safety, and Drug Survival of Targeted Therapies in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: Data from the BIOBADASER Registry. Speaker: Juan Sarmiento-Monroy (Spain)
10:15 - 10:15	Distinct IgM and IgG Autoantibody Architectures Characterize Incomplete and Classified Systemic Autoimmune Diseases Speaker: Rebecca Wood (United States of America)
10:15 - 10:15	Impact of glucocorticoid expose on mortality, hospitalization, and infection risk in patients with rheumatoid arthritis: a time-dependent analysis using the weighted cumulative index Speaker: Misaki Yoshida (Japan)
10:15 - 10:15	Safety, efficacy, and molecular mechanism of CD3×CD19 T-Cell-engager therapy in active systemic lupus erythematosus: a Phase I Investigator Initiated Trial Speaker: Jason Xu (United States of America)
10:15 - 10:15	Clinical Outcomes Following Withdrawal of Upadacitinib in Patients With Axial Spondyloarthritis Who Achieved Remission: Findings From the Phase 3, Placebo-Controlled, Double-Blind SELECT-AXIS 2 Trial Speaker: Atul Deodhar (United States of America)
10:15 - 10:15	Trends and In-Hospital Outcomes of Multiple Myeloma in Autoimmune Rheumatic Disease Hospitalizations: A National Inpatient Sample Analysis, 2016–2022 Speaker: Naina Kumari (United States of America)
10:15 - 10:15	Inhibition of Integrin $\alpha 5$ Ameliorates Renal Injury in MRL/lpr Mice: A Novel Therapeutic target in Lupus Nephritis Speaker: Tingting Ding (China)
10:15 - 10:15	Screening for transthyretin amyloid cardiomyopathy in patients with musculoskeletal (MSK) symptoms: a monocentric prospective exploratory study of MSK imaging utility Speaker: Thomas Bardin (France)

10:15 - 10:15	Understanding Trust, Awareness, and Readiness for Artificial Intelligence in Arthritis Care: Results From a National Patient Survey Speaker: Ellen Wang (Canada)
10:15 - 10:15	Efficacy and safety of filgotinib in patients with rheumatoid arthritis: Final results of the FINCH 4 long-term extension study Speaker: Yoshiya Tanaka (Japan)
10:15 - 10:15	Early versus late dose reduction of biological treatment in RA patients in stable remission: Results from part 2 of the randomized NORD-STAR trial Speaker: Marte S Heiberg (Norway)
10:15 - 10:15	Emerging Efficacy and Safety of Mivocabtagene Autoleucel, a Fully Human CD19 CAR T-Cell Therapy, in Severe Autoimmune Rheumatic Diseases Speaker: Fredrik N. Albach (Germany)
10:15 - 10:15	The impact of adiposity on the disease course of rheumatoid arthritis patients Speaker: Kim van Slingerland (Netherlands)
10:15 - 10:15	Targeting BCMA with the T Cell-Engaging Bispecific Antibody Teclistamab in Treatment-Refractory Autoimmune Diseases Speaker: Fredrik N. Albach (Germany)
10:15 - 10:15	Selecting the right score: how disease activity composite scores influence treatment outcomes with IL-6-inhibitors, JAK-inhibitors and TNF-inhibitors in rheumatoid arthritis – insight from the ‘JAK-pot’ collaboration Speaker: Ophelia Zimmermann (Switzerland)
10:15 - 10:15	Time-to-event risk of first-time arterial and venous thromboembolic events in patients with autoimmune inflammatory rheumatic diseases – a Danish nationwide cohort study Speaker: Dina Husum (Denmark)
10:15 - 10:15	Incidence of Parkinson's disease in patients with RA, axSpA and PsA, and possible protective effects of b/tsDMARD Speaker: Johan Askling (Sweden)

10:15 - 10:15	Discussing Sexual and Reproductive Health in a Rheumatology Outpatient Clinic: What Do Patients Need? Speaker: Tania Vargas (Netherlands)
10:15 - 10:15	Switching to Filgotinib is Non-inferior to Add-on Therapy for Improvement of Disease Activity at Week 24 in Methotrexate–Inadequate Responders with Rheumatoid Arthritis: The FAITHFUL Randomised Non-inferiority Trial Speaker: Mitsuhiro Akiyama (Japan)
10:15 - 10:15	High sensitivity flow cytometry incriminates memory B-cells in patients failing all licensed b/tsDMARD classes in poly-refractory rheumatoid arthritis: implications for therapy selection Speaker: Antonio Tonutti (Italy)
10:15 - 10:15	Assessing internal construct validity of SDAI and CDAI in rheumatoid arthritis: A study using confirmatory factor analysis, minimal clinically important difference and other psychometric tests Speaker: Jacob Brauner Jørgensen (Denmark)
10:15 - 10:15	Predicting long-term survival benefit of nerandomilast in patients with progressive pulmonary fibrosis (PPF) Speaker: Madhu Kanakapura (Germany)
10:15 - 10:15	Safety and tolerability of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial Speaker: Anna-Maria Hoffmann-Vold (Norway)
10:15 - 10:15	The rheumatologist’s expertise in estimating risk of developing rheumatoid arthritis in patients with clinically suspect arthralgia; what’s the value? Speaker: Stijn Claassen (Netherlands)
10:15 - 10:15	Clinical Pathway and Care Ecosystem for Connective Tissue Disease-Associated Interstitial Lung Diseases (CTD-ILD): Insights from the European FRAME Project Speaker: Harald E. Vonkeman (Netherlands)
10:15 - 10:15	Baseline cfDNA active chromatin profiles reflect synovial pathotype-associated programs that distinguish responders and non-responders to TNF inhibitors, JAK inhibitors, and abatacept in rheumatoid arthritis Speaker: Jeffrey R Curtis (United States of America)

10:15 - 10:15	<p>Risk of Multiple Lower Extremity Fractures in Methotrexate-Treated Patients: Evidence for 'Methotrexate Osteopathy'? Speaker: Judith Everts-Graber (Switzerland)</p>
10:15 - 10:15	<p>VALIDATION OF A DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS BASED ON 44 JOINTS (DAPSA44) USING DATA FROM PHASE 3 CLINICAL TRIALS OF BIMEKIZUMAB IN PSORIATIC ARTHRITIS Speaker: Sofia Ramiro (Netherlands)</p>
10:15 - 10:15	<p>Results in pregnancy follow up by a multidisciplinary unit in women with rheumatoid diseases, comparing those with inflammatory arthropathies and autoimmune diseases. Speaker: Julia Álvarez Noval (Spain)</p>
10:15 - 10:15	<p>LFD-200, an Immune-Targeted Glucocorticoid ADC, Demonstrates a Favorable Safety, PK, and PD Profile vs. Prednisone and Placebo in a First-in-Human Study Speaker: Matthew McClure (United States of America)</p>
10:15 - 10:15	<p>Artificial Intelligence-Enabled Opportunistic Screening to Close the Care Gap in Osteoporosis Speaker: Lesley Jackson (United States of America)</p>
10:15 - 10:15	<p>Association between DAS28-GGT and coronary atherosclerosis in patients with rheumatoid arthritis Speaker: Manon Lesturgie Talarek (France)</p>
10:15 - 10:15	<p>NKX019, an Allogeneic, Off-the-Shelf, CD19-Targeting, CAR NK-Cell Therapy, Induces Deep CD19+ B-Cell Depletion in Haematological Malignancy and Models of Autoimmune Disease Speaker: Mira Tohme (United States of America)</p>
10:15 - 10:15	<p>Pharmacodynamic and pharmacokinetic activity of zola-cel in autoimmune indications: translational data from the Phase 1 Breakfree-1 study Speaker: Melissa Harnois (United States of America)</p>
10:15 - 10:15	<p>Demyelinating events during exposure to TNF-inhibitors in patients with rheumatoid arthritis: results from the French National Healthcare Database Speaker: Joanna Kedra (France)</p>

10:15 - 10:15	Preclinical and Translational Assessment of Small Molecule IRF5 Inhibitors in Lupus-Relevant Systems Speaker: Nuruddeen Lewis (United States of America)
10:15 - 10:15	Polygenic burden of lupus enhances type I interferon signaling in healthy individuals Speaker: Hajime Inokuchi (Japan)
10:15 - 10:15	CAN CLUSTER ANALYSIS REDEFINE PHENOTYPES IN GIANT CELL ARTERITIS? DATA FROM THE ARTESER REGISTRY Speaker: Carmen Secada-Gómez (Spain)
10:15 - 10:15	Cross-Cohort International Validation of Treat-to-Target Endpoints in Childhood Lupus: Data from the UK JSLE Cohort Study, CARRA Registry and JIRcohort Speaker: Eve Smith (United Kingdom)
10:15 - 10:15	Autoantibodies and risk for subclinical rheumatoid arthritis-associated interstitial lung disease by visual inspection and quantitative computed tomography imaging Speaker: Rathnam Venkat (United States of America)
10:15 - 10:15	Human trophoblast organoid-endometrium on chip model reveals the impaired maternal-fetal interface in systemic lupus erythematosus Speaker: Dewei Liu
10:15 - 10:15	Efficacy and Safety of Janus Kinase Inhibitors vs. Abatacept in Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Retrospective Study Using Propensity Score Matching and Quantitative CT Speaker: Yukiko Takakuwa (Japan)
10:15 - 10:15	Support Needs and Non-Pharmacological Interventions for People with Hand Osteoarthritis: A Systematic Review Speaker: Julie Katrine Karstensen (Denmark)
10:15 - 10:15	Risk of Major Adverse Cardiovascular Events Associated with JAK Inhibitors versus TNF Inhibitors in Elderly Patients with Immune-Mediated Inflammatory Diseases: A Nationwide Population-based Cohort Study Speaker: Raphaëlle Curmin (France)

10:15 - 10:15	Immunomodulation with anti-TNF therapy, intralipid infusions and corticosteroids is associated with higher live-birth rates in women with recurrent pregnancy loss: a large observational cohort study Speaker: Noémie Abisror (France)
10:15 - 10:15	CEBPA-driven Abnormal Expansion of Bone Marrow Autoreactive CD11c+ pro-B Cells in Systemic Lupus Erythematosus Speaker: Zirui Yang (China)
10:15 - 10:15	Predicting Functional Performance in Knee Osteoarthritis: The Relative Contribution of Strength and Ultrasound-Based Morphology and Quality of Quadriceps and Hamstring Muscles Speaker: Beyza Tayfur (Türkiye)
10:15 - 10:15	High-throughput proteomic profiling reveals IL12B as a diagnostic biomarker in systemic lupus erythematosus Speaker: Carlos Perez-Sanchez (United Kingdom)
10:15 - 10:15	A Novel Mouse Model of Systemic Lupus Erythematosus for Efficacy Evaluation of CD3/BCMA T Cell Engagers Speaker: Juan Liang (China)
10:15 - 10:15	Escalated immunomodulation with adalimumab and/or intravenous immunoglobulin is associated with higher live-birth rates in chronic intervillositis of unknown etiology: a multicentre observational cohort Speaker: Noémie Abisror (France)
10:15 - 10:15	Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study Speaker: Arsene Mekinian (France)
10:15 - 10:15	High-grade Krenn synovitis score predicts clinical response to JAK inhibitors compared to non-TNF targeted biologics in difficult-to-treat rheumatoid arthritis Speaker: Mariangela Salvato (Italy)
10:15 - 10:15	The association of overweight and obesity with pain, fatigue, C-reactive protein, disease activity measures and ultrasound characteristics in early RA DMARD-naïve patients - 12-month follow-up data Speaker: Valeriia Melokhina (Ukraine)

10:15 - 10:15	Assessing bone fragility in systemic sclerosis: results of the "ScleroBone" Italian multicentre retrospective study Speaker: Giammarco De Mattia (Italy)
10:15 - 10:15	International Evaluation of Childhood Lupus Low Disease Activity State in Childhood Lupus: Sensitivity analyses from the UK JSLE Cohort Study, CARRA Registry and JIRcohort Speaker: Eve Smith (United Kingdom)
10:15 - 10:15	Nutritional quality, ultra-processed food and risk of rheumatoid arthritis : Results from the NutriNet-Santé cohort Speaker: Johanna Sigaux (France)
10:15 - 10:15	Long-Term Functional Trajectories and Treatment Retention with Nintedanib in IPF and Progressive SARD-ILD Speaker: Francesco Pollastri (Italy)
10:15 - 10:15	BIMEKIZUMAB-TREATED PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS REPORT LOW LONG-TERM UVEITIS RATES: UPDATED 3-YEAR RESULTS FROM POOLED PHASE 2B AND PHASE 3 STUDIES Speaker: Martin Rudwaleit (Germany)
10:15 - 10:15	Health literacy as the missing link between socio-economic vulnerability and poor health outcomes Speaker: Annelies Boonen (Belgium)
10:15 - 10:15	Proton Pump Inhibitors Exposure, Fracture and Mortality Risk in a Nationwide Matched Cohort: Results from the French OSIRIS Study. Speaker: Cécile Philippoteaux (France)
10:15 - 10:15	Elevated serum anti-CD27 antibodies are associated with disease activity and treatment response in patients with rheumatoid arthritis Speaker: Jing He (China)
10:15 - 10:15	Evolving patient profiling and safety outcomes of patients with Rheumatoid Arthritis treated with Janus kinase inhibitors after regulatory warnings Speaker: Cristina Garufi (Italy)

10:15 - 10:15	Increased Circulating Granzyme K+ CD8+ T Cells Correlate with Disease Activity and Therapeutic Response to TNF Inhibitors in Rheumatoid Arthritis Speaker: Yuetong Qi (China)
10:15 - 10:15	Identifying Unmet Informational and Support Needs Among People Living with Sjögren's Disease: A Patient Perspective Study Speaker: Seth Ginsberg (United States of America)
10:15 - 10:15	Beyond Hemodynamics: Eosinophil Ratios and Leukocyte Variability Predict Mortality in Asian Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Speaker: Pei Xuan Wang (Taiwan)
10:15 - 10:15	Performance of the 2025 ASAS SPARTAN Revised Classification Criteria for Axial Spondyloarthritis in a Canadian Multicenter Inception Cohort with Psoriasis, Uveitis, or Colitis, Presenting with Undiagnosed Back Pain Speaker: Stephanie Wichuk (Canada)
10:15 - 10:15	Comparative HbA1c Changes After Biologic and JAK Inhibitor Treatment in Rheumatoid Arthritis: Real-World Data from A Multicenter Cohort (ANSWER) Speaker: Masao Katsushima (Japan)
10:15 - 10:15	Risk of cancer between JAKi and other advanced treatment classes in rheumatoid arthritis: A systematic literature review and network meta-analysis Speaker: Mark Gibson (United Kingdom)
10:15 - 10:15	Splenic neuromodulation for difficult-to-treat rheumatoid arthritis as monotherapy and in combination with biologics or targeted synthetic DMARDs: a randomised early feasibility trial (ConsiderATE) Speaker: Sander Tas (Netherlands)
10:15 - 10:15	Kidney-Resident Cell–Immune Crosstalk Drives Persistent Inflammation in Lupus Nephritis Speaker: Cristina Solé-Marcé (Spain)
10:15 - 10:15	Communication gaps on sexual health in patients with rheumatic diseases. Speaker: Juan Pablo González-Morales (Mexico)

10:15 - 10:15	CLN-978, a bispecific CD19 x CD3 T cell engager, induces robust B cell depletion in patients with rheumatoid arthritis and systemic lupus erythematosus Speaker: Ricardo Grieshaber-Bouyer (Germany)
10:15 - 10:15	Sex differences in b/tsDMARDs safety in rheumatoid arthritis: results from the JAK-pot international collaboration Speaker: Lucia Otero Varela (Spain)
10:15 - 10:15	Clinical safety and evidence of tissue B-cell and plasma cell depletion with cizutamig, a BCMAxCD3 T-cell engager, in patients treated with autoimmune diseases Speaker: Peter Wung (United States of America)
10:15 - 10:15	Assessing the type I interferon signature in rheumatic diseases by flow cytometry Speaker: Patrick-Pascal Strunz (Germany)
10:15 - 10:15	Factors associated with methotrexate-related gastrointestinal intolerance and toxicity in rheumatoid arthritis and psoriatic arthritis Speaker: Mariana Pinheiro (Portugal)
10:15 - 10:15	Sexual function in premenopausal women with rheumatoid arthritis : A comparative study Speaker: Asma FARAH (Tunisia)
10:15 - 10:15	OBESITY AND RISK FRACTURE Speaker: Marta Ibáñez Martínez (Spain)
10:15 - 10:15	Enhanced Ultrasound Improvement of Enthesitis with IL-17 Inhibition in Psoriatic Arthritis: A Real-World Study Speaker: Seyyid Bilal acikgoz (Türkiye)
10:15 - 10:15	Long-term response trajectories and Treat-To-Target implementation after treatment modification in extrarenal SLE flares: a 24-month real life study Speaker: Giancarlo Cascarano (Italy)
10:15 - 10:15	INTRAVENOUS CYCLOPHOSPHAMIDE VERSUS MYCOPHENOLATE MOFETIL FOR INDUCTION THERAPY IN INCIDENT LUPUS NEPHRITIS: DATA FROM A MULTI-ETHNIC, MULTINATIONAL LATIN AMERICAN COHORT (GLADEL 2.0) Speaker: Victor R. Pimentel-Quiroz (Peru)

10:15 - 10:15	Baseline B-cell counts and inflammation markers predicting likelihood and severity of toxicity to CAR T-cell therapy in patients with autoimmune disease Speaker: Melanie Hagen (Germany)
10:15 - 10:15	Impact of systemic autoimmune diseases in maternal and fetal-neonatal outcomes Speaker: Mario Martín-Portugués (Spain)
10:15 - 10:15	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of S-4321, a Non-Depleting Bifunctional PD-1/FcγRIIb Agonist, in Healthy Participants Speaker: Julia Manasson (United States of America)
10:15 - 10:15	Robust and Durable Clinical Responses Observed Following Treatment with AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab in Patients with Severe Rheumatoid Arthritis and Inadequate Response to Multiple Prior Targeted Therapies Speaker: Guillermo Valenzuela (United States of America)
10:15 - 10:15	Treatment with LBL-051-S3, a CD3/CD19/BCMA trispecific antibody, leads to a complete loss of plasma cells and B cells with minimal cytokine release in non-human primates Speaker: Scott Plevy (United States of America)
10:15 - 10:15	Validation of EULAR targets at 3 and 6 months as predictors of complete renal response in Lupus Nephritis: Results from a real-life multicenter cohort Speaker: Maria Pappa (Greece)
10:15 - 10:15	Comparison of the risk of acute anterior uveitis flare between adalimumab and subcutaneous infliximab in patients with radiographic axial spondyloarthritis and prior acute anterior uveitis: a randomized controlled trial Speaker: Oh Chan Kwon (Korea, Republic of (South Korea))
10:15 - 10:15	Antibodies against TRIM72 Protein Compromise Membrane Repair in Lupus Patient Derived Organoids Speaker: Wael Jarjour (United States of America)

10:15 - 10:15	Is Bimekizumab Related to Increased Oral Candidiasis Incidence? A Cross-Indication Secondary Analysis of Randomized Controlled Trials Speaker: Gabriela Moreira (Brazil)
10:15 - 10:15	Exploring Bone marrow B cell resetting after CD19/BCMA CART therapy in Refractory Systemic Lupus Erythematosus Speaker: Xiaoming Zhang (China)
10:15 - 10:15	Prevalence of Cervical Intraepithelial Neoplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus: A Nationwide, Real World Analysis in Colombia Speaker: Diana Sandoval (Colombia)
10:15 - 10:15	Identification of systemic autoimmune rheumatic disease associated pulmonary arterial hypertension requiring immunosuppressive therapy Speaker: Yurina Nakanishi (Japan)
10:15 - 10:15	CD39 Immune Checkpoint Determines Disease Activity in Rheumatoid Arthritis Speaker: Selene Rubino (United States of America)
10:15 - 10:15	A CD19/BCMA DUAL-TARGETING T-CELL ENGAGER ENABLES DEEP B-CELL DEPLETION WITH LOW CYTOKINE RELEASE IN PRECLINICAL MODELS Speaker: Barry Duplantis (Canada)
10:15 - 10:15	Evolution of BMD and bone turnover markers after denosumab discontinuation with zoledronic acid in patients with spinal cord injury-induced osteoporosis Speaker: Francina Salabert-Carreras (Spain)
10:15 - 10:15	Flare after Achieving Sustained Drug-Free Remission in SLE: Higher Risk in Patients with High Prior Disease Activity, and in those with Renal and Mucocutaneous Involvement. Data from the SLICC (Systemic Lupus International Collaborating Clinics) Inception Cohort Speaker: Manuel Ugarte-Gil (Peru)
10:15 - 10:15	Does Upadacitinib Increase Cardiovascular Risk in SpA and IBD? A Meta-Analysis of Randomized Controlled Trials Speaker: Gabriela Moreira (Brazil)

10:15 - 10:15	Update of the EULAR Points to Consider for the Use of Artificial Intelligence and Big Data in Rheumatic and Musculoskeletal Diseases Speaker: Latika Gupta (United Kingdom)
10:15 - 10:15	Power Doppler Ultrasound in Clinically Active Rheumatoid Arthritis: Preventing Overtreatment through Imaging Speaker: Karina Bonfiglioli (Brazil)
10:15 - 10:15	Short-term effects of Filgotinib versus Adalimumab on bone microarchitecture in rheumatoid arthritis, 24-week results of a randomized clinical trial Speaker: Giovanni Adami (Italy)
10:15 - 10:15	ALBI score–defined hepatic dysfunction: does it predict early mortality in adult hemophagocytic lymphohistiocytosis? Speaker: Jinal Soni (India)
10:15 - 10:15	Demographic and serological predictors of mortality in rheumatoid arthritis: a large Romanian hospital cohort study Speaker: Andreea Minzararu (Romania)
10:15 - 10:15	The activating Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) exhibits inhibitory effects on stimulated B cells Speaker: Julia Grupa (Germany)
10:15 - 10:15	Mechanistic Study of the Antidepressant Agomelatine in Modulating STING Activity During the Pathogenesis of Systemic Lupus Erythematosus Speaker: Yunan Wang (China)
10:15 - 10:15	Therapeutic Role of Interleukin-2 in Lupus-Associated Diffuse Alveolar Hemorrhage via Modulating T cell Subsets Speaker: Xingyue Zeng (China)
10:15 - 10:15	Incremental Diagnostic Value of Oblique Sacroiliac Joint Radiographs Beyond Antero-Posterior Views: Validation Against Low-Dose CT Speaker: Kyung Ann Lee (Korea, Republic of (South Korea))
10:15 - 10:15	Development of a BAFFR×CD3 T cell engager for autoimmune diseases Speaker: Zhenping Zhu (United States of America)

10:15 - 10:15	Firts-in-Class Oral IR5 Degradar, KT-579, Demonstrates Selective and Potent In vitro and In vivo Activity in Human Cellular Assays and Mouse Models of Lupus Speaker: Veronica Campbell (United States of America)
10:15 - 10:15	Prevalence of spondyloarthritis in Inflammatory Bowel Disease: Data from the NIHR IBD BioResource database. Speaker: Jake Weddell (United Kingdom)
10:15 - 10:15	Human Tonsil Organoids and Immune Synapse Assays as Complementary Platforms for Mechanistic Profiling of Autoimmune Therapeutics Speaker: Lauren Schewitz-Bowers (United Kingdom)
10:15 - 10:15	The impact of vertebral fractures on pulmonary function tests in patients with interstitial lung disease. A cross-sectional study Speaker: Angelo Fassio (Italy)
10:15 - 10:15	Broad autoantibody profiles reveal novel diagnostic markers and HLA-linked self-reactivities in systemic lupus erythematosus Speaker: Denis Lagutkin (Sweden)
10:15 - 10:15	Impact of Disease Activity Improvements on Patient-Reported Outcomes in Patients With Systemic Lupus Erythematosus: Results From the Phase 2 SLEek Study Speaker: Chris Wincup (United Kingdom)
10:15 - 10:15	Mesenchymal Stem Cell-Derived Microvesicles Confer Protection Against Rheumatoid Arthritis-Associated Interstitial Lung Disease Speaker: Xiuping Liang (China)
10:15 - 10:15	A circular RNA-encoded CD19xCD3 T-Cell Engager: A Novel Off-the-Shelf Strategy for Deep B-Cell Depletion Therapy in Autoimmune Speaker: Rui Cao (China)
10:15 - 10:15	What is the effectiveness of a second IL-6 inhibitor after failing the first IL-6 inhibitor in rheumatoid arthritis? Results of a large retrospective cohort study. Speaker: Jelmar Delsing (Netherlands)
10:15 - 10:15	Serum and Urine NETosis Markers Differentiate Lupus Nephritis and Reflect Lupus Nephritis Activity Speaker: Gamze Kemec Türkmen (Türkiye)

10:15 - 10:15	<p>Functional response and survival in interstitial lung diseases treated with nintedanib: real-world clinical practice experience from a multidisciplinary committee.</p> <p>Speaker: Pilar Martínez Valles (Spain)</p>
10:15 - 10:15	<p>Deciphering the Shared Genetic Architecture and Molecular Bridges Between Physical Activity and Autoimmune Diseases: A Large-Scale Multi-Trait Analysis</p> <p>Speaker: Zhixiu Li (China)</p>
10:15 - 10:15	<p>Calcinosis in Juvenile Autoimmune Rheumatic Diseases – observation from one Pediatric Rheumatology Clinic</p> <p>Speaker: Anna Gwóźdz-Broczkowska (Poland)</p>
10:15 - 10:15	<p>GDF-15 levels are associated with kidney function and chronicity index in Lupus Nephritis</p> <p>Speaker: Enrico Fuzzi (Sweden)</p>
10:15 - 10:15	<p>Clinical significance of anti-IgG heavy chain/HLA-DR antibodies in patients with rheumatoid arthritis–associated interstitial lung disease</p> <p>Speaker: Iku Shirasugi (Japan)</p>
10:15 - 10:15	<p>Long-term analysis of lymphoma in Rheumatoid Arthritis - a Belgian case study.</p> <p>Speaker: Julie Lesenfants (Belgium)</p>
10:15 - 10:15	<p>Inflammatory burden across age-related carotid plaque groups in rheumatoid arthritis</p> <p>Speaker: Fernanda M. Garcia-Garcia (Mexico)</p>
10:15 - 10:15	<p>Novel Composite Metabolic Indicators for Cardiovascular Disease Risk Can Improve the Prediction in Patients with Rheumatoid Arthritis: A Prospective Cohort Study</p> <p>Speaker: Lie Dai (China)</p>
10:15 - 10:15	<p>Exploring the role of centrally augmented pain processing on disability in rheumatoid arthritis: data from the Central Aspects of Pain in Rheumatoid Arthritis (CAP-RA) study</p> <p>Speaker: Charlotte Ainsworth (United Kingdom)</p>

10:15 - 10:15	<p>ANTIFIBROTICS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE: COMPARATIVE STUDY OF NINTEDANIB VS PIRFENIDONE. NATIONAL MULTICENTER STUDY OF 107 PATIENTS</p> <p>Speaker: Ana Serrano-Combarro (Spain)</p>
10:15 - 10:15	<p>Frequency and Predictors of Discordance Between ANA Patterns and SSc-Specific Autoantibodies</p> <p>Speaker: Bárbara Fernandes Esteves (Portugal)</p>
10:15 - 10:15	<p>FIBROBLAST ACTIVATION AND INFLAMMATORY-FIBROTIC CROSSTALK IN CTD-ILD: CONTRIBUTION OF FAPI PET CT MOLECULAR IMAGING AND BRONCHOALVEOLAR LAVAGE ANALYSIS.</p> <p>Speaker: Valentina Boni (Italy)</p>
10:15 - 10:15	<p>Identifying gaps in the cardiovascular risk management of women with spondyloarthritis and rheumatoid arthritis: when lipid-lowering therapy falls short</p> <p>Speaker: Alessia Alunno (Italy)</p>
10:15 - 10:15	<p>Effectiveness of Trimethoprim-Sulfamethoxazole Prophylaxis in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Glucocorticoids and/or Immunosuppressants: Systematic Review and Meta-analysis</p> <p>Speaker: Wanruchada Katchamart (Thailand)</p>
10:15 - 10:15	<p>Risk Factors Associated with Major Cardiovascular Adverse Event and Heart Failure in Patients with Ankylosing Spondylitis: a Nationwide Nested Case-Control Study</p> <p>Speaker: Se Rim Choi (Korea, Republic of (South Korea))</p>
10:15 - 10:15	<p>Baseline Serum IgA2 anti-dsDNA as a theragnostic biomarker for low disease activity with belimumab after rituximab therapy in systemic lupus erythematosus</p> <p>Speaker: Muhammad RA Shipa (United Kingdom)</p>
10:15 - 10:15	<p>Long-term remission and difficult-to-treat disease in established rheumatoid arthritis with concomitant Sjögren's disease: results from a multicentric national registry</p> <p>Speaker: Florian Kim Kollert (Germany)</p>

10:15 - 10:15	Paradoxical effects of body mass index on coronary plaque redistribution to higher-risk segments in rheumatoid arthritis compared to controls Speaker: George Karpouzas (United States of America)
10:15 - 10:15	Early achievement of remission confers better outcomes than low disease activity in both seropositive and seronegative patients with new-onset rheumatoid arthritis Speaker: Clelia Zampaglione (Italy)
10:15 - 10:15	The use of belimumab in systemic lupus erythematosus in real life setting: analysis of drug discontinuation and flares from a multicentric, nationwide Italian cohort (BeRLiSS-JS 2.0) Speaker: Marisol Bracalenti (Italy)
10:15 - 10:15	Glucocorticoid withdrawal and flare risk during systemic lupus erythematosus remission: a propensity score–matched analysis. Speaker: Greta Hulej (Italy)
10:15 - 10:15	In utero exposure to TNF and IL-1 inhibitors does not impair hepatitis B immunization Speaker: Ufuk Ilgen (Türkiye)
10:15 - 10:15	Long-term kidney and patient outcomes in pure versus mixed lupus membranous nephritis Speaker: Martina Uzzo (Italy)
10:15 - 10:15	Opening the Black Box of Finger Ischemia: Very High-Resolution Ultrasound Reveals the Spectrum of Vascular Abnormalities in Secondary Raynaud's Phenomenon Speaker: Douwe J Mulder (Netherlands)
10:15 - 10:15	Mortality and Treatment Strategies in Rheumatoid Arthritis Patients with Nontuberculous Mycobacterial Disease: An Integrated Analysis of a Detailed Single-Center Cohort and Large-Scale Real-World Data Speaker: Keiichi Sakurai (Japan)
10:15 - 10:15	Periodontal Disease Burden Across SLE, SSc, PsA, and Psoriasis: A Comparative Clinical Study Speaker: GURU VIJAY CHAGALAKONDU (India)

10:15 - 10:15	Application of the 2023 Diagnostic Criteria for Hypophosphatasia Enables Efficient Genetic Testing Pre-Selection in Patients with Hypophosphatasemia: Results from the German COHIR Multicenter Study Speaker: Claus Juergen Bauer (Germany)
10:15 - 10:15	At the Point of Diagnosis: Examining Lupus Care Pathways at a Large Academic Health System in the Southeastern United States Speaker: Claire Timon (United States of America)
10:15 - 10:15	Real-world long-term persistence of advanced therapies after a first TNFi cessation in Rheumatoid Arthritis Speaker: Diederik De Cock (Belgium)
10:15 - 10:15	Efficacy and Safety of Upadacitinib Versus Adalimumab in Patients With Rheumatoid Arthritis Having Primary or Secondary Failure or Intolerance to a Tumor Necrosis Factor Inhibitor: Post Hoc Analysis of the SELECT-SWITCH Study Speaker: Eduardo Mysler (United States of America)
10:15 - 10:15	Patient-Perceived Symptom Burden, Psychological Distress, Quality of Life, and Frailty Risk in Systemic Lupus Erythematosus and Antiphospholipid Syndrome: Preliminary Findings from the PETAL Study Speaker: Sofia Magrin (Italy)
10:15 - 10:15	The prevalence and associations of interstitial lung disease in connective tissue disease patients at Kenyatta National Hospital Speaker: Paul Ekwom (Kenya)
10:15 - 10:15	Real-World Persistence of First-Line TNF and JAK inhibitors Following csDMARD Inadequate Response in Early RA: A Prospective Analysis of the Canadian Early Arthritis Cohort Speaker: Orit Schieir (Canada)
10:15 - 10:15	The DEUS Enthesitis index in axSpA :Bridging patient perception and imaging precision Speaker: Mai Morsy (Egypt)
10:15 - 10:15	Lupus Nexus: A Registry, Biorepository, and Data Exchange Platform to Foster Global Collaborations, Accelerate Research and Advance Precision Medicine Speaker: Teodora Staeva (United States of America)

10:15 - 10:15	Blue Soler Therapeutic Paddleboarding (SUP) Sports Program: A Patient-Led Clinical Trial to improve QoL in Adults with RMDs Speaker: Carolina Navalon-Martinez (Spain)
10:15 - 10:15	Predicting cumulative symptom burden and disease activity in anti-CCP positive individuals at risk of rheumatoid arthritis using machine learning frameworks Speaker: Kerem Abacar (United Kingdom)
10:15 - 10:15	A Nested, Encounter-Matched Case–Control Study of Sociodemographic and Clinical Correlates of Adverse Drug Events in Rheumatology Using Electronic Health Record Data Speaker: Ashley Lewis (United States of America)
10:15 - 10:15	Subclinical synovitis occurs in asymptomatic joints during flares of palindromic rheumatism Speaker: Helen-Jayne Sugden (United Kingdom)
10:15 - 10:15	Long-term Treatment Trajectories and Outcomes in 'Difficult-to-Manage' Axial Spondyloarthritis: A 15-Year Single-Center Retrospective Study Speaker: Semih Gulle (Türkiye)
10:15 - 10:15	Developing two distinct organoid-based models to study failing maternal-fetal tolerance in systemic lupus erythematosus Speaker: Wendy Dankers (Netherlands)
10:15 - 10:15	Bone health screening and osteoporosis in systemic lupus erythematosus: a real-world multicenter study Speaker: Daria Koliadenko (Ukraine)
10:15 - 10:15	PD-L1 related mechanisms distinguish CD4+ T cells in the pre-clinical and early stages of rheumatoid arthritis Speaker: Venkataragavan Chandrasekaran (Sweden)
10:15 - 10:15	Five year data on IL-6 inhibition with tocilizumab versus tumor necrosis factor-α inhibition in polyarticular juvenile idiopathic arthritis. A BIKER registry study. Speaker: Gerd Horneff (Germany)
10:15 - 10:15	Improvement in patient-reported outcomes (PROs) with filgotinib by prior advanced therapy in patents with rheumatoid arthritis: Interim results from the FILOSOPHY and PARROTFISH real-world studies Speaker: Patrick Durez (Belgium)

--	--

Poster Tour Presentations

Date: **06/06/2026**

Room: **Poster Tour I**

10:15-11:15 BST

HPR Poster Tour II: Emerging Approaches to Improve Rheumatology Care

Chair:	Bente Appel Esbensen (Denmark) Mwidimi Ndosu (United Kingdom)
10:15 - 10:21	Promoting healthy lifestyle habits in individuals with early knee osteoarthritis: A scoping review Speaker: Emelie Wiking (Sweden)
10:21 - 10:27	Higher patient expectations are associated with better outcomes after exercise therapy for knee osteoarthritis, results of the GLA:D program in the Netherlands Speaker: Adriana Konings-Pijnappels (Netherlands)
10:27 - 10:33	Demonstrating value in nurse-led care for newly diagnosed Axial Spondyloarthritis patients in a tertiary centre in Ireland Speaker: EILEEN SHINNERS (Ireland)
10:33 - 10:39	Patient-Reported Health Status Is Associated with Mortality in Early Systemic Sclerosis Across Key Disease Characteristics: Data from the Norwegian "NOSVAR" Registry Speaker: Marthe Mæhlen (Norway)
10:39 - 10:45	Development of the INSPIRE intervention: A complex intervention providing individualized support for informal caregivers of older adults with rheumatoid arthritis and frailty Speaker: Signe Marie Abild (Denmark)

10:45 - 10:51	Isolation and loneliness in rheumatology: A scoping review of factors influencing access, uptake, retention, and effects of social prescribing Speaker: Signe Marie Abild (Denmark)
10:51 - 10:57	Translating WORKWELL into a Digital Work Support Programme Speaker: Yeliz Prior (United Kingdom)
10:57 - 11:03	Improving Adherence to Fall Prevention Exercise in Older Adults with a History of Falls: A Cluster Randomised Trial of Brief Action Planning Training and Digital Support for Physiotherapists Speaker: Linda Li (Canada)

Poster Tour Presentations

Date: **06/06/2026**

Room: **Poster Tour II**

10:15-11:15 BST

Basic Poster Tours: Another one BITes the CAR-T

Chair:	Samuel Bitoun (France) Elena Pontarini (United Kingdom)
10:15 - 10:21	Integrating Rare Variant Burden and Polygenic Risk Scores Reveals a Complex Genetic Architecture among Systemic Autoimmune Rheumatic Diseases Speaker: Anastasia Madenidou (United Kingdom)
10:21 - 10:27	Synovial lining fibroblast molecular endotypes relate to divergent phenotypes in rheumatoid and psoriatic arthritis Speaker: Shing Law (United Kingdom)
10:27 - 10:33	Targeting BCMA using T-cell engager bispecifics in autoimmune diseases: Exploring the mechanism of circulating B-cell depletion and soluble BCMA as a biomarker of tissular plasma cells Speaker: JEANNE GAUTHIER (France)

10:33 - 10:39	Differential Inflammatory Signatures Across MIS-C, Kawasaki Disease, and Still Disease. Speaker: Tetyana Pidkova (Spain)
10:39 - 10:45	Phenotypic and genotypic characterization of peripheral B cell reconstitution following rese-cel (Resecabtagene Autoleucel) infusion and transient B cell depletion across the RESET- Myositis, RESET-SSc, and RESET-SLE trial Phase 1/2 Cohorts Speaker: Thomas Furmanak (United States of America)
10:45 - 10:51	Interstitial lung disease does not differ in patients with and without overlap syndrome in systemic sclerosis: single centre follow up study Speaker: Gábor Kumánovics (Hungary)
10:51 - 10:57	Characterization of AZD0120, a BCMA/CD19 Dual-Targeting Autologous CAR T-cell Therapy Generated from PBMCs of Patients with Rheumatologic Disease Speaker: Nicola Ferrari (United Kingdom)
10:57 - 11:03	A Targeted Nanobody-LNP Platform for Rapid, Durable, and Translatable In Vivo CAR-T Cell Generation Speaker: Xiangrong Song (China)
11:03 - 11:09	AB-101, an Allogeneic NK Cell Therapy, in Combination with Anti-CD20 Monoclonal Antibodies, Consistently Achieves Deep B-cell Depletion Comparable with CAR T Cell Therapies in Patients with Rheumatologic Diseases Speaker: Heather Raymon (United States of America)

Poster Tour Presentations

Date: **06/06/2026**

Room: **Poster Tour III**

10:15-11:15 BST

Clinical Poster Tours: Challenges in Rheumatoid Arthritis

Chair:	Andrea Di Matteo (United Kingdom) Ladislav Šenolt (Czechia)
--------	--

10:15 - 10:21	The association between depression and cardiovascular events in a nationwide early rheumatoid arthritis cohort Speaker: Kaiyang Song (United Kingdom)
10:21 - 10:27	Identification of muscle functional vulnerability phenotypes in older patients with rheumatoid arthritis using unsupervised machine learning Speaker: Diego Benavent (Spain)
10:27 - 10:33	Therapeutic Decisions, Not Mechanisms of Action, Drive Progression to Difficult-to-Treat RA: Insights From a 20-Year Real-World UCLouvain Brussels Cohort. Speaker: Cécile Van Mullem (Belgium)
10:33 - 10:39	CD19 CAR T-cell therapy for difficult-to-treat rheumatoid arthritis: Long-term follow-up Speaker: xinxin xu (China)
10:39 - 10:45	Physical function in older people with rheumatoid arthritis and population controls: A cross-sectional study of self-reported and performance-based measures Speaker: Saskia Truijen (Netherlands)
10:45 - 10:51	Difficult-to-Treat Rheumatoid Arthritis Is a Dynamic Condition: Longitudinal Patterns and Drivers of D2T Status Over Time Speaker: Francesco Natalucci (Belgium)
10:51 - 10:57	Incidence and Predictors of Frailty in Rheumatoid Arthritis: A Population-Based Cohort Study Speaker: Elena Myasoedova (United States of America)
10:57 - 11:03	Reconciling trial efficacy with real-world effectiveness in trial-ineligible rheumatoid arthritis patients Speaker: Satoshi Kubo (Japan)
11:03 - 11:09	Longitudinal Associations of Metabolic Syndrome, Body Mass Index, and Difficult-to-Treat Rheumatoid Arthritis Speaker: Misti L. Paudel (United States of America)

Basic and Clinical Poster Tours: Bone Health, New Directions

Chair:	Edgar Wiebe (Germany) Radmila Matijevic (Serbia)
10:15 - 10:21	Timing of glucocorticoid-induced bone damage and bisphosphonate protection assessed by dual X-ray absorptiometry (DXA) and high resolution peripheral quantitative computed tomography (HR-pQCT) Speaker: Olivier Malaise (Belgium)
10:21 - 10:27	Forecasted Economic Impact of Denosumab Biosimilars in European Markets: Cost-efficiencies and Opportunity for Expanded Patient Access Speaker: Kunal Shastri (United States of America)
10:27 - 10:33	Age-related bone loss inhibited by miR-146a is regulated via IRAK1 Speaker: Elisabeth Simader (Austria)
10:33 - 10:39	PEX5 acts as a negative regulator of RANKL-induced osteoclastogenesis in vitro and inflammatory calvarial bone destruction in vivo Speaker: Myeoung-su Lee (Korea, Republic of (South Korea))
10:39 - 10:45	Characterization of blood molecular signature of osteoporosis in systemic mastocytosis Speaker: Yannick Degboé (France)
10:45 - 10:51	Genetic variants in idiopathic osteoporosis in men Speaker: Joshua Peñafiel-Sam (Spain)
10:51 - 10:57	Impact of post-hip fracture anti-osteoporotic therapy and rheumatology follow-up on mid- term mortality: a real-world study. Speaker: Esther Monleón Acosta (Spain)

10:57 - 11:03	Real-World Attitudes Toward Treat-to-Target and Therapeutic Sequencing in Postmenopausal Osteoporosis Among Moroccan Rheumatologists Speaker: IMANE EL BINOUNE (Morocco)
11:03 - 11:09	Effect of short-course androgen deprivation therapy on bone mineral density in non-metastatic prostate cancer Speaker: Arthur Bouchut (France)

Poster Tour Presentations

Date: **06/06/2026**

Room: **Poster Tour V**

10:15-11:15 BST

Clinical Poster Tours: Crossing roads across diseases

Chair:	Pierre-Antoine Juge (France) Katerina Chatzidionysiou (Sweden)
10:15 - 10:21	First-in-Human Autologous Anti-CD19 E-CAR-T Therapy with a Novel CD3ε Domain Induces Deep Tissue Remission and Resident Memory Differentiation in Refractory Autoimmune Diseases Speaker: Xiaobing Wang (China)
10:21 - 10:27	Metabolic impact and cardiovascular safety of interleukin-17 inhibitors in psoriatic arthritis and axial spondyloarthritis: a real-world study in a tertiary referral hospital in southern Spain. Speaker: Javier Manzaneque Sánchez (Spain)
10:27 - 10:33	Immune response to recombinant herpes zoster vaccine in patients with inflammatory rheumatic musculoskeletal diseases - a prospective longitudinal study over 12 months Speaker: Uta Kiltz (Germany)
10:33 - 10:39	Shielding the Future: Development and Validation of a Purposeful Shared Decision-Making tool “the PRED-Shield Navigator” for Chronic Glucocorticoid Therapy Speaker: Ali El Miedany (United Kingdom)

10:39 - 10:45	Preclinical to clinical translation of ABO2203, a messenger RNA (mRNA) encoding a CD3 × CD19 T-cell engager (TCE), for refractory autoimmune diseases (AIDs): Preliminary results from the first-in-human clinical trial Speaker: Mengyan Wang (China)
10:45 - 10:51	Combination of nintedanib with dual immunosuppression in SSc-ILD and RA-ILD: A systematic review and pooled multicentre real-world cohort study Speaker: Anastasia Chioni (Greece)
10:51 - 10:57	Prevalence and in-hospital outcomes of autoimmune rheumatic diseases among patients with hemophagocytic lymphohistiocytosis: a national cohort study. Speaker: Murilo Bastos (United States of America)
10:57 - 11:03	Brief, Daily, Remote, Digital Cognitive Assessments in Immune-Mediated Inflammatory Disorders (IMIDs): Findings from a Large Longitudinal Multi-Cohort Study Speaker: Alex Kaula (United Kingdom)
11:03 - 11:09	Efficacy of nerandomilast in patients with autoimmune interstitial lung diseases and progressive pulmonary fibrosis in the FIBRONEER-ILD trial Speaker: Anna-Maria Hoffmann-Vold (Norway)

EULAR Culture

Date: **06/06/2026**

Year 3026 - The Last Hope

Room: **Escape Room 1**

The world has fallen into chaos. A relentless pandemic has spread across the globe, unleashing a virus that hijacks the immune system, causing a devastating, untreatable rheumatic disease. Pain dominates humanity. The streets are empty, the hospitals collapsed, and only a small fraction - 1% - has managed to remain uninfected. But a whisper of hope has emerged from the wasteland. A mysterious messenger has arrived at EULAR headquarters, bearing news that could change everything: a patient has miraculously recovered. This is where you come in. The EULAR High Council has summoned its finest warriors for the most crucial mission in history:

10:30-12:30 BST

finding the cure before it's too late.

Level: Intermediate

Target Audience: Clinicians, Researchers

Escape Room: Year 3026 - The Last Hope

Chair:	

EULAR Culture

Date: 06/06/2026

London Eye Syndrome

Room: Escape Room 2

Sometimes the whole picture only becomes visible when perspective changes. In *London Eye Syndrome*, nothing is revealed all at once. The clues appear separately, the patterns seem incomplete, and the meaning remains just out of reach. But as participants move through the room, details begin to connect, fragments start to align, and what first feels scattered slowly turns into something coherent. The experience unfolds through observation, teamwork, and the ability to look beyond one isolated piece in order to recognise the larger whole. In the end, the challenge is not simply to find clues, but to understand how they belong together.

10:30-12:30 BST

Level: Beginner, Intermediate

Target Audience: Everyone at EULAR 2026 including our PARE, PAED and HPR Communities

Escape Room: London Eye Syndrome

Chair:	

Health Professionals in Rheumatology (HPR)

Date: **06/06/2026**

The “EULAR Move Together Session: Moving Science into Practice” at the EULAR Congress 2026 provided by physio- and occupational therapists and sport scientists offers attendees a unique and interactive experience to implement evidence-based recommendations for exercise and physical activity in rheumatic and musculoskeletal diseases. This event is for everyone—people with rheumatic and musculoskeletal diseases (RMDs) and all members of the multi-professional healthcare team. The aim is to bridge the gap between scientific knowledge and practical strategies to promote physical activity in rheumatology.

Room: **HPR Move Together**

10:30-11:30 BST

Attendees will participate in hands-on activities and learn to integrate evidence-based exercise programmes into their daily lives and patient care. This will ultimately improve their well-being and the understanding and management of RMDs.

This session will include Yoga and Therapeutic Dance (R&B)

Ezgi Yasar is a physiotherapist who works on accessible and sustainable movement. In this workshop, she will share information about yoga forms and breathing practices that can be done with chair support.

EULAR HPR Move Together Session: Moving Science into Practice

Chair:	
10:30 - 11:30	EULAR HPR Move Together Co-Speaker: Devin Höfel / (Germany), Ezgi Yasar / (HILVERSUM, Netherlands)

PARE Meet the EULAR Expert

Date: 06/06/2026

1. Describe how AI tools, such as LupusGPT, are being used to deliver accurate, patient-centered information to individuals living with RMDs.

Room: **Meet the EULAR Expert 1**

10:45-11:15 BST

2. Evaluate the opportunities and limitations of AI-powered communication tools in promoting health literacy and shared decision-making.

3. Identify practical and ethical challenges in applying AI for patient support, including trust, transparency, data quality, bias, and accessibility.

AI as a Partner in Care: Empowering the RMD Community with Information

Chair:	
10:45 - 11:15	AI as a Partner in Care: Empowering the RMD Community with Information Speaker: Jeanette Andersen (Denmark)

HPR Meet the EULAR Expert

Date: 06/06/2026

Delegates will be able to:

Room: **Meet the EULAR Expert 2**

ii) Discuss advances in the evidence based treatment of people with work instability

10:45-11:15 BST

iii) Consider how to apply this new evidence to practice

Work instability in people with inflammatory arthritis

Chair:	
10:45 - 11:15	How To Treat Work instability in people with IA Speaker: Yeliz Prior (United Kingdom)

Meet the EULAR Expert

Date: **06/06/2026**

Room: **Meet the EULAR Expert 3**

10:45-11:15 BST

Management of joint involvement in systemic lupus

Chair:	
10:45 - 11:15	Management of joint involvement in systemic lupus Speaker: Edward M. Vital (United Kingdom)

Meet the EULAR Expert

Date: **06/06/2026**

Room: **Meet the EULAR Expert 4**

10:45-11:15 BST

Psoriatic Arthritis

Chair:	
--------	--

10:45 - 11:15	Psoriatic arthritis Speaker: Laura C. Coates (United Kingdom)
---------------	---

What is New (WIN) Date: **06/06/2026**

To learn about new imaging modalities applied to Rheumatoid Arthritis: Room: **Plenary**

11:45-12:30 BST

- PET immune imaging using tracers
- Whole-body MRI
- Dual-Energy Computed Tomography
- Microvascular imaging ultrasonography

What are the advantages and disadvantages. What we know so far. What the future might bring.

Imaging in Rheumatoid Arthritis: the future is now

Chair:	Sarah Ohrndorf (Germany) Conny J. van der Laken (Netherlands)
11:45 - 12:30	Imaging in Rheumatoid Arthritis: the future is now Speaker: Annamaria Iagnocco (Italy)

Basic and Translational Science Date: **06/06/2026**

- to understand the novel mechanisms of immunotolerance Room: **Connaught Room 1 & 2**

12:00-13:15 BST

- to identify important cellular and molecular players
- to present novel ways of intervention

New avenues and interventions in immunotolerance

Chair:	Zoltán Szekanecz (Hungary) Anastasia Madenidou (United Kingdom)
12:00 - 12:05	Introduction Speaker: Anastasia Madenidou (United Kingdom) Co-Speaker: Zoltán Szekanecz / (Debrecen, Hungary)
12:05 - 12:25	Immune checkpoint blockade and agonism Speaker: Marie Kostine (France)
12:25 - 12:45	Targeting T-cells for therapeutic tolerance Speaker: Lucienne CHATENOUD (France)
12:45 - 13:05	Tolerogenic dendritic cells Speaker: John Isaacs (United Kingdom)
13:05 - 13:15	Questions and Answers Speaker: Zoltán Szekanecz (Hungary) Co-Speaker: Anastasia Madenidou / (Manchester, United Kingdom)

Clinical Science

Date: **06/06/2026**

1. Implement targeted vaccination for immunosuppressed rheumatic patients; apply European guidance and monitor safety.

Room: **Connaught Room 3 & 4**

12:00-13:15 BST

2. Use registries to track incidence, treatment, and outcomes; inform policy and improve care.

3. Expand self-management programs on exercise, diet, and mental health; assess impact and integrate digital tools.

4. Highlight the social and economic burden of

rheumatic diseases; include musculoskeletal health in national strategies.

Public Health and Rheumatic Diseases

Chair:	Loreto Carmona (Spain) José A. Gomez-Puerta (Spain)
12:00 - 12:05	Introduction Speaker: José A. Gomez-Puerta (Spain)
12:05 - 12:15	Optimising Vaccination Strategies for Immunosuppressed RMD Populations Speaker: Natasa Toplak (Slovenia)
12:15 - 12:25	Leveraging National and International Registries to Monitor RMD Burden and Outcomes Speaker: Manuel Ugarte-Gil (Peru)
12:25 - 12:35	Implementing Evidence-Based Lifestyle and Self-Management Programs at the Population Level Speaker: Carter Thorne (Canada)
12:35 - 12:45	Translating Musculoskeletal Burden into Policy and Funding Decisions Speaker: Evelyn Hsieh
12:45 - 12:55	Sex-Specific Mortality and the Burden of Comorbidities in Rheumatoid Arthritis: Results from the Population-Based CAPTURED Study Speaker: José A. Gomez-Puerta (Spain)
12:55 - 13:05	Evaluating the uptake of pneumococcal vaccination and all-cause pneumonia outcomes in adults with rheumatic and musculoskeletal diseases: a retrospective cohort study in the West of Scotland, UK Speaker: Stefan Siebert (United Kingdom)

13:05 - 13:15	Question and Answers Speaker: Loreto Carmona (Spain)
---------------	--

Health Professionals in Rheumatology (HPR)

Date: **06/06/2026**

- Understand the significance and impact of sarcopenia in rheumatic and musculoskeletal diseases (RMDs)

Room: **Victoria Room 1**

12:00-13:15 BST

- Explore different methods to measure skeletal muscle fitness across RMDs and identify the most suitable tests for various contexts

- Learn how to effectively use skeletal muscle fitness assessment results to design and enhance strength training interventions for individuals with RMDs

- Discover the patient perspective on skeletal muscle fitness assessment and training in RMDs

Muscle Matters: Advancing Care Through Targeted Muscle Fitness

Chair:	Kristine Norden (Norway) Martin Lau (United Kingdom)
12:00 - 12:02	Introduction Speaker: Kristine Norden (Norway) Co-Speaker: Martin Lau / (United Kingdom)
12:02 - 12:17	The Hidden Burden: Sarcopenia in RMDs Speaker: Joshua Bennett (United Kingdom)
12:17 - 12:32	Tools of the Trade: Selecting Optimal Skeletal Muscle Fitness Measurements Speaker: Hamilton Roschel (Brazil)

12:32 - 12:47	From Assessment to Action: Translating Skeletal Muscle Fitness Data into Effective Interventions Speaker: Jasmin Ma (Canada)
12:47 - 13:02	Muscle Beyond Strength: Integrating Technology into Rehabilitation of RMDs Speaker: David Beckwée (Belgium)
13:02 - 13:12	Effectiveness of a 3-month, multicomponent, pedometer-driven physical activity behaviour change intervention initiated after total hip arthroplasty for hip osteoarthritis on daily step counts - a randomised controlled trial Speaker: Theresa Bieler (Denmark)
13:12 - 13:15	Closing Speaker: Kristine Norden (Norway) Co-Speaker: Martin Lau / (United Kingdom)

PARE	Date: 06/06/2026
The role of caregivers in supporting people living with RMDs	Room: Victoria Room 2
	12:00-13:15 BST
Identify strategies and tools to support and empower caregivers and involve them meaningfully in care planning.	
To highlight the emotional and financial burden caregivers face	

It Takes a Village: Strengthening the Support System for People With RMDs

Chair:	Tanita-Christina Wilhelmer (Switzerland) George E. Fragoulis (Greece)
--------	--

12:00 - 12:15	Why should partners of people with RMD be included and supported Speaker: Charlotte Werdal Hansen (Denmark)
12:15 - 12:30	Is caring for someone full-time a vocation or simply necessary due to current health systems? Speaker: Victoria Romero Pazos (Spain)
12:30 - 12:45	The silent partner: Understanding and supporting caregivers Speaker: Rosaria Talarico (Italy)
12:45 - 12:55	Racing for a cure for JIA: How Juvenile Arthritis Research brought together a community to connect, inspire and bring hope Speaker: Katherine Norris (United Kingdom)
12:55 - 13:15	Questions and Answers Speaker: Tanita-Christina Wilhelmer (Switzerland) Co-Speaker: George E. Fragoulis / (Athens, Greece)

EMEUNET Presents

Date: **06/06/2026**

The audience learns:

Room: **Victoria Room 3**

Why visuals matter (science of communication)

12:00-13:15 BST

How to make them (hands-on, AI-assisted)

How to present them (live presentation skills)

How to share them widely (digital platforms, ethics)

Visual Abstracts and Science Communication in Rheumatology using AI

Chair:	Elvis Hysa (Italy) Mary Lucy Marques (Portugal)
--------	--

12:00 - 12:15	Why Visuals Matter in Rheumatology: The Science of Attention and Retention Speaker: Luis Fernando Perez (Netherlands)
12:15 - 12:35	From Data to Design: Creating High-Impact Visual Abstracts (with AI?) Speaker: Kim Lauper (Switzerland)
12:35 - 12:55	Science on Stage: How to Present Complex Data Clearly and Persuasively Speaker: Felice Rivellese (United Kingdom)
12:55 - 13:15	Amplifying Your Research: Social Media, Digital Platforms, and Responsible Communication Speaker: Meghna Jani (United Kingdom)

From Bench to Bedside

Date: **06/06/2026**

- To provide the emerging mechanistic steps in leading to Sjogren's Disease

Room: **Victoria Room 4**

12:00-13:15 BST

- To learn the latest advances about possible new therapeutic targets in Sjogren's Disease

- To discuss how to improve the management of Sjogren's Disease from pathogenesis to treatment

From emerging pathogenic steps to new therapeutic strategies in Sjogren's Disease

Chair:	Frans G.M. Kroese (Netherlands) Saviana Gandolfo (Italy)
12:00 - 12:20	The implications of genetics and epigenetics for new therapeutic strategies Speaker: Athanasios Tzioufas (Greece)

12:20 - 12:40	Molecular signatures, patient subgroups, and targeted therapies Speaker: Divi Cornec (France)
12:40 - 13:00	JAK-STAT signalling pathway in pathogenesis and treatment Speaker: Blake M Warner (United States of America)
13:00 - 13:15	Questions and Answers Speaker: Frans G.M. Kroese (Netherlands) Co-Speaker: Saviana Gandolfo / (Naples, Italy)

Challenges in Clinical Practice

Date: **06/06/2026**

1. Discuss real-world cases to illustrate challenges encountered in clinical practice

Room: **Victoria Room 5 & 6**

12:00-13:15 BST

2. Analyse the common reasons for failure of CAR-T cell therapy in RMDs

3. Evaluate future research directions and strategies for managing and overcoming CAR-T failure

I failed CAR-T - what's next?

Chair:	David Simon (Germany) Russka Shumnalieva (Bulgaria)
12:00 - 12:15	Case Presentation: Failure of CAR-T: Learnings from Haemto Oncology Speaker: Andreas Wirsching (Germany)
12:15 - 12:35	Case Discussion: Failure of CAR-T: Learnings from Haemto Oncology Speaker: Ricardo Grieshaber-Bouyer (Germany)

12:35 - 12:50	Case Presentation: CAR-T failure - how to target the right population? Speaker: Fredrik N. Albach (Germany)
12:50 - 13:10	Case Discussion: CAR-T failure - how to target the right population? Speaker: Hans Ulrich Scherer (Netherlands)
13:10 - 13:15	Questions and Answers Speaker: David Simon (Germany) Co-Speaker: Jule Taubmann / (Germany)

Clinical Science

Date: **06/06/2026**

-Understand the challenges and opportunities in achieving early diagnosis of axial Spondyloarthritis in routine clinical practice.

Room: **N1**

12:00-13:15 BST

-Evaluate the evidence for whether early diagnosis meaningfully changes long-term outcomes in axSpA.

-Critically appraise the role of MRI in early axSpA detection, balancing its potential for timely diagnosis against the risk of overdiagnosis

Early axSpA: a race against time?

Chair:	Philipp Bosch (Austria) Krystel Aouad (Lebanon)
12:00 - 12:25	Can we diagnose axSpA early in daily clinical practice? Speaker: Marleen G.H. van de Sande (Netherlands)
12:25 - 12:50	Does Early treatment in early AxSpa change outcomes? Speaker: Raj Sengupta (United Kingdom)

12:50 - 13:15	The MRI revolution: facilitator of early diagnosis or gateway to overdiagnosis? Speaker: Gaëlle Varkas (Belgium)
---------------	--

EULAR Joint Sessions

Date: **06/06/2026**

Delegates will be able to:

Room: **N2**

- Identify contemporary evidence-based vocational interventions
- Highlight the patient perspective in the design and evaluation of work interventions programmes,
- Discuss current research supporting implementation of work interventions
- Consider process evaluation and feasibility of work interventions
- Consider context in the design and implementation of work programmes.

12:00-13:15 BST

Sustainable work in people with RMDs - how are we doing?

Chair:	Yeliz Prior (United Kingdom) Sofia Sotiria Marantidou (Greece)
12:00 - 12:20	Healthy and sustainable work participation - the importance of lifestyle and treatment Speaker: Annelies Boonen (Belgium)
12:20 - 12:35	The importance of work and barriers when living with arthritis Speaker: Francisco Javier Carreira Roca (Spain)
12:35 - 12:55	Sick leave and presenteeism in RMDs Speaker: Suzanne Verstappen (United Kingdom)

12:55 - 13:15	Vocational rehabilitation - what can we do to improve work ability? Speaker: Yvonne Codd (Ireland) Co-Speaker: Christina Merete Tvede Madsen / (Sønderborg, Denmark)
---------------	---

Basic and Translational Science Date: **06/06/2026**

Room: **N3**

12:00-13:15 BST

LATE BREAKING ABSTRACTS

Chair:	

Challenges in Clinical Practice Date: **06/06/2026**

Room: **George V Room 1**

12:00-13:15 BST

1. To understand the persistently increased cardiovascular risk in RMDs and translate it into treatment decisions by contextualising risk scores and integrating both antirheumatic and cardioprotective strategies;
2. To identify infection risks under immunosuppressive therapy, particularly in vasculitis and know appropriate preventive strategies, including vaccination and monitoring, in daily clinical practice;
3. manage challenging situations in patients with a history of cancer, active malignancy, or high cancer risk (e.g. heavy smokers) and how to adapt antirheumatic treatment in the context of checkpoint inhibitor therapies

4. To learn how to identify common psychiatric comorbidities in RMDs, such as depression and anxiety. And to learn how to apply screening approaches to detect psychiatric comorbidities early and understand their implications for disease outcomes and treatment adherence.

Keys for Better Outcomes - Let's talk about comorbidities!

Chair:	Claudia Iannone (Italy) Johan Askling (Sweden)
12:00 - 12:10	Case Presentation: Infections under immunosuppressive therapy in vasculitis: risk, prevention, and management Speaker: Ai Li Yeo (Australia)
12:10 - 12:30	Case Discussion: Infections under immunosuppressive therapy in vasculitis: risk, prevention, and management Speaker: Kevin L. Winthrop (United States of America)
12:30 - 12:40	Case Presentation: Psychiatric comorbidities - are they real? And how do we treat them? Speaker: Ashley Hawarden (United Kingdom)
12:40 - 13:00	Case Discussion: Psychiatric comorbidities - are they real? And how do we treat them? Speaker: Natasha Cox (United Kingdom)
13:00 - 13:10	Unmasking Ambulatory Hypertension and early cardiovascular remodelling in clinically Normotensive Children with Systemic Lupus Erythematosus Speaker: Mansi Varshney (India)
13:10 - 13:15	Closing Speaker: Claudia Iannone (Italy) Co-Speaker: Johan Askling / (Stockholm, Sweden)

1. How often are sarcopenia and osteoporosis associated in the elderly

Room: **George V Room 2**

12:00-13:15 BST

2. Prevalence and causes of malnutrition in the elderly

3. What are the specificities of treatment of sarcopenia and osteoporosis in the elderly

Difficult-to-treat gastrointestinal manifestations in systemic sclerosis

Chair:	Alain Lescoat (France) Muriel Elhai (Switzerland)
12:00 - 12:10	Case Presentation: Gastric antral vascular ectasia in systemic sclerosis Speaker: Artur Ejsmont (Poland)
12:10 - 12:30	Case discussion: Gastric antral vascular ectasia in systemic sclerosis Speaker: Otylia Kowal-Bielecka (Poland)
12:30 - 12:40	Case Presentation: Small intestinal bacterial overgrowth in systemic sclerosis Speaker: Marco Minerba (United Kingdom)
12:40 - 13:00	Case Discussion: Small intestinal bacterial overgrowth in systemic sclerosis Speaker: Francesco Del Galdo (United Kingdom)
13:00 - 13:05	Questions and Answers Speaker: Alain Lescoat (France) Co-Speaker: Muriel Elhai / (Zürich, Switzerland)

EULAR Joint Sessions

Date: **06/06/2026**

- Explore how Digital Health Technologies (DHT) can

Room: **George V Room 3**

help with the provision of better Rheumatology services

12:00-13:15 BST

- Explore the potential of DHT in facilitating the development of patient-centric therapies and other research

- Explore the limitations and barriers of using DHT in Rheumatology and future directions

Digital Health and Technology in Rheumatology - quo vadis?

Chair:	Rachel Knevel (Netherlands) Hanna Grasshoff (Germany)
12:00 - 12:05	Introduction Speaker: Chloe Hinchcliffe Co-Speaker: Rachel Knevel / (Leiden, Netherlands)
12:05 - 12:25	Rheumatology in the digital health era Speaker: Nina Osteras (Norway)
12:25 - 12:45	Can real world accelerometer data predict development of inflammatory arthritis Speaker: Dylan McGagh (United Kingdom)
12:45 - 13:05	Identify digital biomarkers of fatigue in rheumatic diseases Speaker: Wan-Fai Ng (United Kingdom)
13:05 - 13:15	Questions and Answers Speaker: Hanna Grasshoff (Germany) Co-Speaker: Rachel Knevel / (Leiden, Netherlands)

Practical Skills Lecture

Date: 06/06/2026

- To identify and differentiate the hallmark skin

Room: George V Room 4

manifestations of Myositis

12:00-13:15 BST

- To explore advanced diagnostic and monitoring tools including dermoscopy and biopsy, CDASI C
- To discover the latest therapeutic advancements for treating skin manifestations in
- To understand the importance of a multidisciplinary approach

Beyond the Muscle: Skin Manifestations in Myositis

Chair:	Jiri Vencovsky (Czechia) Antonella Notarnicola (Sweden)
12:00 - 12:20	Skin Manifestation in Myositis Challenges and Pitfalls Speaker: Victoria Werth (United States of America)
12:20 - 12:40	Advanced Assessment Techniques for Skin Manifestations in Myositis Speaker: Hanna Brauner
12:40 - 12:55	Quiz: Innovations in Therapeutics for Dermatomyositis Skin Disease
12:55 - 13:10	Quiz: Integrating Multidisciplinary Care for Optimal Skin Management
13:10 - 13:15	Questions and Answers Speaker: Jiri Vencovsky (Czechia) Co-Speaker: Antonella Notarnicola / (Stockholm, Sweden)

Innovation

Date: **06/06/2026**

Understand the current capabilities and limitations of

Room: **Room 12**

large language models (LLMs) relevant to rheumatology.

12:00-13:15 BST

1. Evaluate how LLMs may support clinical decision-making and enhance patient information and communication.
2. Identify key ethical challenges, including issues of bias, privacy, and regulatory requirements, in the use of AI in medicine.
3. Apply practical strategies to detect and prevent hallucinations or misinformation when using LLMs in clinical or research contexts.
4. Critically appraise the potential role of AI in the future of rheumatology, whether as a complement or (radically) possible substitute for human expertise.

Spotlight Consultation: AI vs The Doctor - (When) will AI replace the rheumatologist

Chair:	Diego Benavent (Spain) Augusta ORTOLAN (Italy)
12:00 - 12:15	Which AI tool do we have? - LLMs in medicine Speaker: Johannes Knitza (Germany)
12:15 - 12:30	AI in clinical decision making and patient information Speaker: Latika Gupta (United Kingdom)
12:30 - 12:45	Ethical Challenges and Regulatory Pathways for AI in Medicine Speaker: Vincenzo Venerito (Italy)

12:45 - 13:00	Avoiding Hallucinations of LLMs in Medicine Speaker: Gerd R. Burmester (Germany)
13:00 - 13:15	Panel Discussion Speaker: Diego Benavent (Spain)

How to Treat (HOT)

Date: **06/06/2026**

Managing rheumatoid arthritis (RA) is based on the treat-to-target (T2T) strategy aimed at achieving remission or low disease activity. The presentation will cover the core principle of early, aggressive treatment, followed by the timely escalation to biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs), such as JAK inhibitors, upon treatment failure. A key focus will be given to contemporary approach to difficult-to-treat RA (D2T RA), where a multidisciplinary assessment is crucial to identify and address non-inflammatory drivers of symptoms, followed by rational cycling or combination of different classes of advanced therapies to overcome resistance. Furthermore, the discussion emphasized the importance of patient-physician shared decision-making and continuous reassessment of therapeutic strategies to optimize long-term outcomes, focusing not only on joint symptoms but also on improving quality of life and managing comorbidities.

Room: **Plenary**

12:30-13:15 BST

Rheumatoid Arthritis

Chair:	Ladislav Šenolt (Czechia) Claire Immediato Daien (France)
12:30 - 13:15	The RA Paradigm Shift: New Insights into Pathogenesis and a Pipeline of Promise Speaker: Elena Nikiphorou (United Kingdom)

EULAR Projects

Date: **06/06/2026**

Room: **Plenary**

13:15-14:45 BST

EULAR 2026 Highlights

Chair:	Bimba Hoyer (Germany) Helga Lechner-Radner (Austria) Simon Stones (United Kingdom) Erika Mosor (Austria)
13:15 - 13:20	Introduction to the EULAR 2026 Congress Highlights Speaker: Bimba Hoyer (Germany)
13:20 - 13:35	Highlights from the PARE Sessions Speaker: Sara Badreh Wirström (Belgium)
13:35 - 13:50	Highlights from the HPR Sessions Speaker: Mwidimi Ndosì (United Kingdom)
13:50 - 14:10	Highlights from the Basic and Translational Sessions Speaker: Marie-Elise Truchetet (France)
14:10 - 14:40	Highlights from the Clinical Science Sessions Speaker: György Nagy (Hungary)
14:40 - 14:45	Closing of the EULAR 2026 Congress Highlights Speaker: Bimba Hoyer (Germany)